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Abstract
Hepatitis C virus (HCV) represents the leading cause of liver disease. Most of the 
patented potential anti-HCV agents are nucleosides. Usually, to be active, 
nucleosides need to be phosphorylated three times in order to generate the 
corresponding 5 ’-triphosphate inside cells. Our group has developed the 
phosphoramidate approach that bypasses the first phosphorylation step and releases 
the 5 ’-monophosphate intracellulary.
Part of the presented work was focused on the synthesis and the biological evaluation 
of phosphoramidates of novel 4 ’-modifed nucleosides (AZC, AZU, AZA, 
dipentanoyl-AZC  and ETU).
Phosphoramidates with different natural (L-alanine, L-valine, glycine, L-leucine, L- 
isoleucine, L-methionine, L-proline, L-valine and L-phenylalanine) and unnatural 
(cyclopentylglycine, dimethylglycine, /5-alanine, N-methylglycine, L-ethylaspartate 
and D-alanine) amino acid were synthesised.
Octyl, dodecyl (never synthesised before), methyl, ethyl, isopropyl, benzyl, 2-butyl, 
butyl and tert-butyl are all the variation on the ester part of the phosphoramidate 
structures synthesised.
a- and /5-naphthyl, 8-quinoline and different substituents on the phenyl ring (para- 
chloro, 3,4-dichloro, /?ara-methyl and ^ara-methoxy) are the major examples of aryl 
moiety variations applied to these nucleosides.
The protection of the 2 ’- and 3’-positions with cyclopentylidene and subsequent 
deprotection significantly increased the overall yield of these reactions.
The optimisation of the synthesis of AZA was achieved and it represents the first 
example of a 4 ’-modified ribo-purine nucleoside active against HCV. The 
application of our technology to AZA and AZU converted an inactive nucleoside 
into a sub-micromolar active phosphoramidate. The separation of the two 
diastereoisomers was achieved for some of the AZC phosphoramidates synthesised.
A series of novel phosphoramidates of 2 ’-methyl modified purine (adenosine and 
guanosine) were synthesised using the 2 ’-, 3 ’-protection previously optimised. The 
aryl moiety (a-naphthyl and phenyl) and ester (methyl, ethyl, tert-butyl, benzyl) 
variations were explored using L-alanine as amino acid. A general enhancement of 
activity was observed applying the phosphoramidate technology to these nucleosides.
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Chapter
Nucleoside analogues in the treatment of HCV infections
1.1 Hepatitis C Virus (HCV)
1.1.2 General characteristics of HCV
The Hepatitis C Virus (HCV) was identified for the first time in 1989 as a 
single-stranded positive sense RNA virus of the flaviviridae family.1
According to the WHO (World Health Organisation), more than 170 million 
people are chronically infected by this virus, which is the main cause of liver disease.2 
This includes over 4 million Americans, and is projected to cost a staggering $400 
billion or $100,000 per patient for lifetime healthcare maintenance (excluding liver 
transplantation costs). The Centre for Disease Control (CDC) estimates that HCV 
costs the United States more than $600 million annually. By 2015 as many as 40,000 
Americans are expected to die annually as a consequence of HCV-related 
complications; already the prevalence of HCV infections is four times greater than 
HIV in the United States and the death rate from hepatitis C is expected to surpass that 
of AIDS in the near future. WHO has estimated the percentage of people for each 
continent that are currently infected by HCV (Table l . l ) . 2
602 5.3 31.9
785 1.7 13.1
466 4.6 21.3
858 1.03 8.9
1500 2.15 32.2
1600 3.9 62.2
5811 3.1 169.7
Table 1.1. HCV estimated world infection prevalence2
Africa
Americas
Eastern
Mediterranean
Europe
South-East
Asia
Western
Pacific
Total
1
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The most reliable data suggests that 3.1% of the worldwide population is 
infected by HCV, with the highest percentage in Africa and Eastern Mediterranean 
countries (Table 1.1). Approximately 85% of individuals initially infected with this 
virus will become chronically infected, of which 20-30% progress onto liver cirrhosis. 
The other 15% of HCV infected individuals simply have an acute infection that 
resolves spontaneously in a few weeks or months.3,4 The major routes of transmission 
of this virus are injecting drug use, transfusion, occupational exposure and sexual 
transmission (G raph l . l ) . 5
OtherUnknown
Occupational
Transfusion
Injecting Drug 
Use
Graph 1.1. Sources of infection for people with HCV‘
2
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1.1.2 HCV structure
The structural components of HCV comprise the core, which contains the 
genome, and two heavily glycosylated envelope glycoproteins El and E2 (Figure 
l . l ).6*7
The envelope glycoprotein 1 (E l) and 2 (E2) are referred to as hypervariable 
regions 1 and 2 since they are susceptible to an extraordinarily high mutation rate.6
Envelope 
glycoprotein 2
RNA
genome
Nucleocapsid
proteins
Envelope 
glycoprotein 1
Lipidic
Envelope
Figure 1.1. HCV organisation 
http://www.rit.edu/~-Japfaa/infectious.html
In the HCV genome, which is composed of 9600 nucleotides,1 there are three 
different regions: regions encoding for structural and non-structural proteins, and the 
5’- and 3’- Non-Translated Regions (5’-NTR and 3’-NTR, Figure 1.2) at the 
extremities of the HCV genome.16,1
3
Plinio Pem one
5 -N T R  S tru c tu ra l P ro te in s N o n -S tru c tu ra l P ro te in s 3 - N T R
Nucleocapside
NS1■■■■1
E1 E2 NS2
Glycoproteins Membrane Binding Protein
NS3
Serine Protease/Helicase/NTPase 
NS4A NS4B
Cofactors
NS5A
IFN Resistance
NS5A
RdRp
Figure 1.2. HCV: genome organisation
The 5 ’NTR is also called the Internal Ribosome Entry Site (IRES) and it 
allows the transcription of the viral genome by the ribosome of the host cell.*7The 5’- 
NTR contains 341 nucleosides organised in different domains. The AUG triplet, 
present in the fifth domain, is structurally important because it is the initiator sequence 
for the interaction of the ribosome of the host cell.
The region encoding the polyprotein precursor is divided into different 
domains: C, El and E2 (which encode for structural proteins) and NS1, NS2, NS3, 
NS4A/B and NS5A/B (which encode for non-structural proteins).8,9
C, El and E2 have a hydrophobic C terminus. This feature is thought to be 
important for the membrane association and the cleavage from the polyprotein by the 
host signal peptidases. The C domain encodes for a non-glycosylated protein C that, 
complexed with genomic RNA, forms the nucleocapsid:8,9 this is also important as it 
represents a signal sequence that directs the E l and E2 to the lumen of the 
endoplasmic reticulum (ER). Adjacent to C, there are two domains El and E2 that 
code for the envelope glycoproteins El and E2.8,9 Once synthesised, E2 is modified 
by N-Iinked glycosylation in the ER.
The NS1 domain function is actually unknown, while the NS2 encodes for a 
membrane-binding protein.10
4
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The NS3 encodes for three different proteins:11,12,13 serine protease (located at 
the N-terminus),11, 12 helicase13 and nucleotide triphosphatase (located at the C- 
terminus).11, 12 The serine protease activity is responsible for the cleavage of 
polyproteins to release the NS3/4A, NS4A/B, NS4B/5A and NS5A/B.11,12 
Furthermore, helicase unwinds duplex RNA structures that are essential during the 
virus replication.11 12
The NS4 has two different domains: NS4A and NS4B. NS4A is an essential 
cofactor of the NS3 proteinase and is required for efficient polyprotein processing. 
The function of NS4B is not yet known. NS5A is a highly phosphorylated protein. 
The level of phosphorylation is influenced by NS4A via direct interaction with 
NS5A.21 The role that NS5A may play in RNA replication is so far unknown; 
presumably it is an important regulator of replication and is possibly responsible for 
interferon resistance.14,15
The last domain (NS5B) encodes for RNA-dependent RNA-polymerase 
(RdRp), which is very important during viral replication,16 and a key target of anti- 
HCV therapy. The RdRp has a molecular mass of 68 kDa.16
5
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1.1.3 HCV replication
The hypothetical model of HCV replication starts from the interaction between 
the viral envelope glycoprotein E2 and a protein of the host cell called CD81 (Figure
1.3) . 17,18,19
Translation
via host ribosomes
Processing
via host and viral proteases 
on ER membrane
ER lumen
Replication
of (♦) and (•) strand 
Viral RNA
Figure 13. HCV replication
http://www.genelabs.com/research/HCV_LifeCycle.jpg
CD-81 is a receptor expressed on hepatocytes and B lymphocytes. CD-81 is a 
membrane-associated protein in which there is a Large Extracellular Loop (LEL) that 
can bind to the HCV, but the mechanism of internalisation of the virus is unknown.18
The viral genome (plus-RNA) is then released into the cell and enters into the 
cytoplasm. Due to the presence of the 5 ’-NRT, the viral genomes can bind to the 
ribosomes and express the encoding polyprotein precursors.19 The result is the 
synthesis of a polyprotein that is cleaved by the viral serine protease (coded by NS3 
subunit) to release all the viral proteins that remain tightly associated with membranes 
of the endoplasmic reticulum.20,21
The plus-RNA is also used for the synthesis of minus-RNA by the replicase 
formed by a complex between NS3, NS4A and NS5B.21
6
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This new RNA strand is used as a template for the production (by RdRp) of an 
excess amount of positive strand (plus-RNA)21 that interacts with the structural 
proteins to be encapsidated.21
Viruses are encapsulated, by budding, into the lumen of the ER and then 
exported out of the host cells through transit in the Golgi complex.
1.1.4 Pathogenesis of HCV
The tendency of HCV to cause chronic infection is explained by the 
extraordinary ability of this virus (in contrast to most other viruses, including 
Hepatitis A) to avoid destruction by the immune system.3 This characteristic can be 
explained by considering the existence of what is called HCV quasispecies, as a result 
of mutation of RdRp.21
These viral quasispecies correspond to a very minor molecular variation with 
1-2% nucleotide heterogeneity. Based on molecular similarity, there are numerous 
genotypes. There are six distinct HCV genotypes with very large molecular 
differences at the nucleotide level, which coincides with a different geographic 
distribution (Table 1.2) . 21
Type 1 Japan/China/Russia/US
Type 2 Western Europe
Type 3 North America
Type 4 Central and North Africa/ Middle East
Type 5 South Africa
Type 6 South-East Asia
Table 1.2. HCV genotypes and their geographical distribution
Indeed, HCV like several other RNA viruses, does not circulate in infected 
individuals as a homogeneous population of identical viral entities, but as a pool of 
genetically distinct but closely related variants.21
7
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The principal effect of virus infection in humans is liver damage (cirrhosis and 
hepatocellular carcinoma) , 21,22 but the causes are not completely understood. The virus 
itself probably does not cause liver cell damage directly. Indeed, the level of the virus 
in the blood does not correlate with the actual liver damage seen in a liver biopsy .22
Liver damage in chronic HCV is probably caused by the interplay between the 
virus and the immune system, which includes cytotoxic lymphocytes and specific 
inflammatory messengers (cytokines) . 21
Several extra-hepatic conditions are associated with chronic Hepatitis C .23 
These conditions are not very common and their occurrence does not correlate with 
the severity of the underlying liver disease .23 The most widely described associated 
condition is cryoglobulinaemia .2 4 ,25 This condition is due to the presence of abnormal 
antibodies (cryoglobulins) produced by HCV stimulation of lymphocytes. These 
antibodies can deposit in small blood vessels, thereby causing inflammation of the 
vessels in tissues throughout the body . 24 25 26
Patients with cryoglobulinaemia can have quite a variety of symptoms. These 
symptoms may include weakness, joint pain or swelling (arthralgia or arthritis), a 
raised purple skin rash (palpable purpura) usually in the lower portion of the legs, 
swelling of the legs and feet due to loss of protein in the urine. 26
In addition, these patients may develop Raynaud's phenomenon, in which the 
fingers and toes change colour (white, then purple, then red) and become painful in 
cold temperatures . 26
8
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1.1.5 C u rren t trea tm en t
Until now, the only marketed treatment for patients with Hepatitis C are 
conventional interferon a-2b  (IFN), sometimes combined with ribavirin (1, Figure
1.4), pegylated interferon, and combined pegylated a-2b interferon and ribavirin.
By attaching the polyethylene glycol, the size of the interferon increases so it takes 
longer for the body to excrete. It also helps protect the interferon molecule from 
metabolism . 27 Previous studies have shown that pegylated alpha interferons are more 
effective in producing a sustained viral response in patients with chronic hepatitis C 
than their non-pegylated counterparts .27
Normally interferon stays in the body for about 24 hours; PEG-interferon will 
remain in the system for up to seven days at higher levels, permitting the drug to be 
injected only once a week. For this reason, pegylated alpha interferons significantly 
improve the quality of life for patients as the frequency of administration is 
dramatically reduced.
Pegylated interferon is used alone (monotherapy) or in some cases, in 
combination therapy when taken with an antiviral ribavirin (Rebetol ®). In both cases, 
it is administered intravenously since it is a protein, and needs to enter the 
bloodstream directly. Hepatitis C patients exhibit only a 20% response to treatment 
with alpha-interferon; though as many as 40 to 50% may initially respond, most will 
typically relapse . 27
IFN has been shown to possess direct antiviral, antiproliferative, and 
immunomodulatory activities .27 However, the exact mechanism of action of IFN in the 
treatment of chronic HCV infection is not known.
Our knowledge of the mechanism of action of ribavirin is no better than that of 
IFN. Ribavirin is not a potent direct antiviral agent in vitro, with an EC^ value in the 
high micromolar (/*mol/L) range against most viruses. When ribavirin is combined 
with interferon, published reports indicate that the response rate improves two to ten 
fold . 27 The mechanism of action of ribavirin is unknown but at present there are 4 
proposed mechanisms.
They can be divided into two groups. 27 The first group consists of two possible 
indirect mechanisms:
1. Enhancement of host T-cell-mediated immunity against viral infection through 
switching the T-cell phenotype from type 2 to type 1 and
9
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2. Inhibition of the host enzyme human inosine monophosphate dehydrogenase 
(IMPDH).
The second group consists of two other hypotheses for the direct inhibition of
HCV:
1. Inhibition of NS5B-encoded RNA-dependent RNA polymerase (RdRp) by 
ribavirin;
2. A RNA mutagen that drives a rapidly mutating RNA virus over the threshold to 
“error catastrophe”.21
a
O
HO I
OH OH
Interferon a-2b Ribavirin (1)
Figure 1.4. Structure of Interferon a-2b and Ribavirin 
http://www.stanford.edu/group/virus/flavi/2004gallo/drug.html
Therapy is initially effective in only a fraction of affected patients and it 
appears that eradication of infection is unusual in patients infected with the genotypes 
most common in the United States and most areas of Europe.3
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1.2 Rationale for the use of nucleoside analogues in antiviral therapy
In general, a virus can be defined as a non-cellular biological entity. Viruses 
consist of nucleic acid surrounded by protein; some animal viruses are also 
surrounded by a membrane. Inside the infected cell, the virus uses the synthetic 
capability of the host to produce progeny virus.28
All viruses are incapable of self-replication. Their life cycle strictly depends 
on the presence of a host cell capable of synthesising the viral proteins and replicating 
the viral genome.
In general, viruses can be divided into two major categories: RNA and DNA 
viruses. In both cases, the virus replication involves the synthesis of viral proteins 
implicated in the duplication of the viral genome, necessary for the synthesis of new 
virions.
In general terms, the DNA and RNA virus replication starts with the release of 
viral nucleic acid into the cytoplasm of the host cell. Once integrated into the host 
cells’ genome, the viral genome is used to synthesise viral proteins and other viral 
RNA or DNA necessary for the construction of new viral entities that can then be 
released outside the host cell.
The presence of nucleotides within the host cells in the form of triphosphates 
is essential.
Due to the fact that the replication of the viral nucleic acid is essential for viral 
reproduction, 50% of the antiviral drugs in current use or under development in the 
UK target enzymes involved in the viral replication and, in particular, viral 
RNA/DNA polymerases, which have been preferential targets for antiviral 
chemotherapy. One of the major antiviral classes is represented by nucleoside 
analogues. However to interact with these enzymes, nucleosides have to be converted 
to the corresponding triphosphate species by viral or human kinases.
A nucleoside triphosphate by itself is not a desirable drug candidate as its high 
charge content can preclude cell penetration. Thus, nucleoside analogues are used as 
prodrugs of the bioactive triphosphate form . 7
However, as a consequence of the structure similarity with the natural 
nucleosides, the possibility of direct interaction with cellular DNA replication can 
give rise to toxicity problems.
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These modified nucleosides can act in two different ways: chain terminators 
stopping the polymerisation of the viral genome (DNA or RNA) or enzyme inhibitors, 
where the major targets are the RNA/DNA polymerase or the viral protease, both 
mechanisms of action may coexist in the same nucleoside analogue.
1.3 Nucleoside analogues and their activation mechanism
Nucleoside analogues represent an important class of antiviral and anticancer 
drugs many of which have already been marketed (Figure 1.5).
Br NH
HO
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BVdU (2)
NH
HO O
NH;
ACT (3)
N
N ^ O
HO—I o
V i
OH F 
Gemcytabine (4)
HO'
< " I an ^ n^ nh2
Aciclovir (5)
NH
HO o
OH
IDU (6)
NH
HO O
OH
AraC (7)
Figure 1.5. Examples of marketed nucleosides
Generally, in order to be active, these nucleosides need to be phosphorylated 
three times. Although, there are example of nucleosides (e.g. AraC) in which the 
active form are represented by their diphosphate species. In general, nucleoside kinase 
(NK) is responsible for the first phosphorylation to give the 5 ’-monophosphate (5’- 
MP) and nucleoside monophosphate kinase (NMPK) for the second to give the 5’- 
diphosphate (5’-DP ) . 29 33
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The last phosphorylation is due to the presence of nucleoside diphosphate 
kinase (NDPK) to give the 5’-triphosphate (5’-TP), which represents the active 
species in most cases. Following intracellular conversion to the nucleoside analogue 
5'-TP, the compounds act by selectively inhibiting the RNA/DNA-polymerase of the 
virus (Figure 1.6) and/or incorporation into the growing nucleic acid chain and 
downstream disruption of function.34
Figure 1.6. Scheme of nucleoside activation
Due to the structural differences and the high selectivity of the substrate, the 
first phosphorylation of the modified nucleoside is often inefficient. Therefore 
administration of 5 ’-MP should bypass this limiting step. Unfortunately, because of 
the high polarity, these compounds (nucleoside 5 ’-monophosphates) are not able to 
easily penetrate the cellular membrane.
However, the phosphate moiety offers a suitable site to attach a degradable 
lipophilic carrier residue, which allows an increased level of penetration of the cell 
membrane or transfer across cell membrane.
Modified
Nucleoside
Modified
Nucleoside NDPK
Ant m i  a I Effect
|  5-Tripliosphate
5'-Mono phosph ale 
J  5' Diphosphate
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1.4 Nucleoside analogues with potential HCV activity
Many pharmaceutical companies are investing in the discovery of new 
approaches against HCV and the principal class of compounds are RNA- and DNA- 
polymerase inhibitors (Figure 1.7).
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z
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N
WO 02/069903
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Figure 1.7. Some nucleoside RNA-polymerase inhibitors currently under investigation
The reason to focus the research programme on nucleosides is due to a number 
of reasons: ( 1 ) they show good selectivity as antivirals, because their mechanism of 
action can cause the inhibition of RNA synthesis that provides the basis of HCV 
replication (2) the target for all these nucleoside analogues is RdRp, as this enzyme is 
essential for the HCV replication.
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1.5 Prodrug approach
The concept of prodrug was first introduced by Albert35 as a 
pharmacologically inactive derivative of an active drug which could be used to 
modify the properties of drugs. Numerous prodrugs have been designed and 
developed to overcome pharmaceutical and pharmacokinetics barriers in clinical drug 
application. A classical prodrug design often represents a non-specific chemical 
approach to mask undesirable drug properties such as limited bioavailability, lack of 
site specificity and chemical instability. According to Wermuth ,36 prodrugs can be 
divided into two main groups: bioprecursor and carrier-linked prodrugs.
In the case of bioprecursor prodrugs, molecules containing latent functionality 
can be converted into an active drug. A bioprecursor cannot be converted to the active 
drug by simple cleavage of the group: commonly the types of activation consist of 
oxidation (most common method), reduction and phosphorylation (antiviral agent).
In the case of carrier-linked prodrugs, drugs are attached through a 
metabolically labile chemical linkage to another molecule designated as the “pro- 
moiety”. The “pro-moiety” alters the physical properties of the drug. Carrier-linked 
prodrugs can be divided into bipartite, tripartite and mutual prodrugs.
A bipartite prodrug is a compound where the pro-moiety is a carrirer, acting 
like a “masking-group”, which liberates the active drug.
A tripartite prodrug is a drug modified by a two component “masking-group”; 
a carrier connected to a linker arm, which is connected to the drug itself. The 
mechanism of liberation involves first an enzymatic reaction to cleave the carrier. The 
remaining inactive compound undergoes a spontaneous cleavage of the linker to 
release the bioactive drug.
In a mutual prodrug, the carrier, released after the cleavage, is a bioactive drug
as well.
1.6 Protide approaches
The protide approach is a prodrug approach based on the concept that the 
modified nucleotide can be derivatised with certain masking groups to increase the 
lipophilicity; allowing the nucleotide prodrugs to efficiently cross the cell membrane. 
The masking groups used for the protide approach must be non-toxic and should be 
good leaving groups that can be enzymatically or chemically cleaved.
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Once inside the cell, the protide can be hydrolysed to release the 5’-MP, which 
can then be further converted to the active 5 ’-TP (Figure 1.8).
Modified
Nucleoside D D E
'ED
5'Moiw phosph ate 
5'-Diphospttate 
I 5' Triphosphate
Modified
Nucleoside
HYDROLYSIS
\ 7
Modified
Nucleoside
Modified
Nucleoside
Antiviral Effect
Figure 1.8. Protide approach for modified nucleotide
Several researchers, starting from these principles, have applied different 
pronucleotide (prodrug of nucleoside) approaches. Some recent successful approaches 
include: bis(pivaloxymethyl)-phosphotriester-nucleoside [Bis(POM)- (8)],3739
bis(isopropyloxycarbonyloxymethyl)-phosphotriester-nucleoside [Bis(POC)- (9) ] , 40141 
bis(S-(2-hydroxyethylsulfidyl]-2-thioethyl-phosphotriester-nucleoside (Bis(SDTE)- 
(10)] and bis(S-acyl-2-thioethyl)-phosphotriester-nucleoside IBis(SATE)- (12) ] , 42^ 5 
cyc/osaligenyl nucleoside [cyc/osal-nucleoside (11)],46-50 phosphoramidate diesters 
(13)51,52 and nucleoside aryl phosphoramidates (14) (Figure 1.9) . 5358
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Figure 1.9. Pronucleotide approaches
1.6.1 Bis(POM) approach
The Bis(POM) approach (8 ), developed by Farquhar et al . , 37'39 is one of the 
possible ways to deliver the 5 ’-monophosphate nucleoside into the cell. The general 
structure is a Bis(pivoxyl) nucleoside. The mechanism of release of 5 ’- 
monophosphate (5’-MP) is thought to follow an initial enzymatic reaction by an 
esterase that cleaves one of the two POM groups to give the hydroxymethyl analogue,
17
Plinio Perrone Chapter One
which spontaneously dissociates with elimination of formaldehyde to give the 
phosphodiester. Cleavage of the second POM group by cellular carboxyesterase 
regenerates the parent nucleoside 5 ’-monophosphate (5’MP).
This approach has been successfully applied in order to deliver the anti-cancer 
drug 5-fluoro-2’-deoxyuridinemonophosphate (5-FdUMP) and the anti-herpes and 
anti-HIV PMEA (9-(2-phosphomethoxypropyl)adenine).37'39
Preliminary in vitro studies on Bis(POM)-PMEA have shown a high increase 
of bioavailability. Moreover, studies with radiolabelled Bis(POM)-PMEA showed a 
considerable increase (100 fold) of cellular uptake of PMEA. PMEA was 
subsequently tested in vivo for oral bioavailability in monkeys: the results obtained 
showed a bioavailability greater then 40%. For this reason Bis(POM)-PMEA was 
selected for human clinical trials. A drawback of this approach is the requirement of a 
second identical activation reaction, because the intermediate phosphodiester is a 
poorer substrate for the activating carboxyesterase. Moreover, the delivery of one 
molecule of the nucleoside results in the liberation of two equivalents of potentially 
toxic formaldehyde and pivalinic acid.
Nevertheless, the Bis(POM)-PMEA has been approved for the treatment of 
HBV (Viread™).
1.6.2 Bis(POC) approach
The Bis(POC) approach (9) has been developed by Fridland et al.,40' 41 and it 
represents the possible solution of all the problems involved in the Bis(POM) 
approach (8). Using this protide approach, it is possible to deliver the monophosphate 
without liberation of potentially toxic substrates.
The mechanism of action is again a carboxyesterase-catalysed cleavage of the 
isopropyl ester to give isopropanol and the intermediate diester that fragments into 
carbon dioxide, formaldehyde and a mono-(POC)phosphate ester that is subsequently 
degraded to yield the corresponding nucleoside monophosphate. In contrast to the 
Bis(POM)-approach, this approach avoids the formation of two equivalents of 
pivalonic acid that can cause toxicity. The Bis(POC)-approach was applied to the anti- 
HIV PMPA and has shown 30% bioavailability in dogs in repeat 5-day dosage of 60 
mg/kg/day.40
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1.6.3 Bis(SATE) Bis(SDTE) approaches
Bis(SATE) and Bis(SDTE) approaches have been developed by Imbach and 
Gosselin.42"*5 In particular, the Bis(SDTE)-approach has been applied to PMEA and an 
in vitro study showed an enhancement of activity most probably due to an increase of 
bioavailability for these derivatives. Their mechanism of activation is similar to that 
shown for the Bis(POM) and Bis(POC)-approaches. It starts with the carboxyesterase 
catalyzed reaction for Bis(SATE) releasing pivalonic acid and the corresponding 
thioethylester. The product spontaneously eliminates episulfide to yield the 
intermediate phosphodiester. As in the case of Bis(POM)- and Bis(POC)- approaches, 
the Bis(SATE)- derivative requires a second identical enzyme-catalyzed activation 
step to release the corresponding 5 ’-monophosphate.
The Bis(SDTE)-nucleoside activation mechanism, on the other hand, starts 
with a reductase enzyme that cleaves the disulfide bond with the formation of 
thioethanol and thioethyltriester. From this point, the mechanism of activity is the 
same as that described for the Bis(SATE)-approach.
Bis(SDTE)- and Bis(SATE)-nucleoside approaches have been successfully 
applied to 5-FdUMP, PMEA, dduMP and AZTMP.42^ 5
1.6.4 CyclossA approach
The cyclosaX approach has been developed by Chris Meier et al., and is 
another possible way to improve the biological properties of nucleoside analogues. It 
has been applied to several nucleosides with variable results.
The phenyl ester bond should be the most labile while the concurrent cleavage 
of the benzyl ester in the cyc/osal structure to yield the 2-hydroxymethyl- 
phenylphosphodiester is unfavourable because the phosphate ester in the ortho 
position of the benzyl ester stabilises this bond.
The hydrolysis should proceed as follows: in the initial step the phenyl ester 
bond is cleaved selectively because the negative charge could be delocalised in the 
aromatic ring leading to the 2-hydroxy-benzylphosphodiester. As a consequence, the 
substituent ortho to the benzyl group switches from an acceptor (phosphate) to a 
donor (hydroxyl) group and this induces the cleavage of the diester and subsequently 
releases 5 ’-monophosphate nucleoside and the salicylic alcohol spontaneously.
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The main difference to the other mentioned prodrug approaches is that this 
concept requires only one activation step to deliver the corresponding monophosphate 
nucleoside. Moreover, compared to the Bis(POM)-, Bis(POC)-, Bis(SATE)- and 
Bis(SDTE)- approaches, this concept does not result in the formation and release of 
toxic intermediates such as formaldehyde, episulfide and pivalinic acid.
The cyclosdX approach has been applied to different nucleosides:46'50 d4T 
(stavudine), AZT, FdU, d4A (2’,3’-dideoxy-2’,3’-didehydroadenosine). One of the 
most important advantages of this approach is the water solubility of the cyclosal 
derivatives.
1.6.5 Phosphoramidate monoester approach
Phosphoramidate monoesters essentially developed by Wagner et a/.51,52 are a 
prodrug approach for nucleosides where only one of the phosphate charges is masked 
by an amino acid ester. This is an adaptation of the approach of McGuigan et a/..53 58 
Aromatic amino acid ester phosphoramidate monoesters of AZT 51 and FLT (3’- 
fluoro-dideoxythymidine)52 were synthesised and found to be potent, non toxic and 
water soluble anti-HIV-1 agents.
Due to the remaining charge, these compounds are considerably water soluble 
and indefinitely stable in human blood.51 52
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1.7 Aryl-phosphoramidate
1.7.1 G eneral characteristics
The aryl-phosphoramidate approach, developed by McGuigan et al., is one 
example of the protide approach and represents a route to the delivery of the 5 ’-mono­
phosphates of modified nucleosides.
The applications of our technology to nucleosides such as d4T53 57 and 
abacavir58 represent the most successful examples.
HO
d4T (15) 
Figure 1.10. d4T and Abacavir.
Y
NH
<'
N
N
HO—I
N
AN NH2
Abacavir (16)
1.7.2 Proposed mechanism  of activation
This prodrug approach allows the pronucleotide to penetrate the membrane by 
passive diffusion and, once in the cell, releases the active species (5’-MP). The 
putative activation mechanism of these compounds comprises three steps (Figure 
l . l l ) . 59
The activation is thought to follow an initial esterase-type catalysis, cleaving 
the ester.59 The esterase involved in this first step has not yet been identified but from 
3iP-NMR studies it has been possible to observe the activity of a pig liver esterase on a 
number of aryl-phosphoramidates.
The second step is an intramolecular nucleophilic attack of the carboxylic 
group on the phosphorus to give a cyclic intermediate (18). This intermediate has 
never been isolated due to its probable instability; it is presumably rapidly hydrolysed 
to the corresponding amino acyl phosphoramidate diester (19).
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Figure 1.11. Putative activation mechanism of aryl phosphoramidates
The final step is an enzymatic cleavage of the amino acid to give the 
nucleoside 5 ’-MP (20).
Results from in vitro antiviral tests found d4T-phosphoramidates to be 10 
times more potent than the parent nucleoside in wild-type CEM/O and MY-4 cells.54 
Most importantly, the d4TMP phosphoramidate completely retained the full biological 
activity in mutant thymidine kinase-deficient CEM-TK cells and suppressed HIV-1 
infection in natural peripheral blood lymphocytes. This result proved that d4TMP was 
delivered intracellulary making the observed activity of the compound entirely 
independent of thymidine kinase (TK) suggesting that phosphoramidate approach was 
successful as a TK-bypass. 54 The metabolism of d4T phosphoramidate was analysed 
by HPLC. The formation of compound 19 was observed proving the postulated 
phosphoramidate metabolism (Figure 1.11).
1.7.3 Previous successful examples
There is a variety of evidence that suggests the aryl-phosphoramidate approach 
is the key to increasing the activity of the modified nucleosides. For example, d4A 
phosphoramidate (21) has shown a 1000-fold boost in activity in HIV-2 CEM cells
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[TK7TK ] compared to the parent nucleoside (22) (Figure 1.12). Moreover, the same 
nucleoside (22) is inactive against Hepatitis B virus, while the phosphoramidate (21) 
is active at sub-//M levels.53
NH
HO
Figure 1.12. d4A and parent phosphoramidate
1.7.4 Possible modification sites
For the corresponding aryl-phosphoramidates of a particular nucleoside 
analogue, there are three possible modification sites that have been investigated and 
optimised the aryl moiety, ester and amino acid (Figure 1.13).
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Figure 1.13. Possible aryl phosphoramidate modification
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1.7.4.1 Amino acid variation
In the past, amino acid variations have been the subject of an intense study. 
The amino acid that has shown the broadest activity, for a variety of nucleosides and 
biological targets has been L-alanine (G raph 1.2).55
In particular, considering d4T phosphoramidates tested against HIV, the 
glycine phosphoramidate was less active (60-70 fold) than the corresponding L- 
alanine compound. The presence of a hydrophobic pocket to accommodate the L- 
amino acid side-chain site of the putative activating enzymes is one interpretation of 
these data.
L-amino acids, with larger and more hydrophobic sidechains (e.g. L-valine, L- 
isoleucine, L-leucine), displayed a remarkable reduction in activity: this might 
indicate that the suggested hydrophobic pocket may be sterically limited.55,56
G raph 12. SAR: amino acid variation
(data related to phosphoramidates of d4T and against HIV-1 in CEM cells)
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1.7.4.2 Aryl moiety variation
The second possible modification site is the aryl moiety. Studies exploring 
substitution in the para-position on d4T aryl-phosphoramidates showed that a chloro 
group enhanced the anti-HIV activity (G raph 1.3).56
200 
180 
f  160
^  140
8 120 
u j 100
*  80
M 60 «
5  40a.
20
0
G raph 13 . Comparison of /xjra-substitued aryl moieties (data related methyl-L-alanine 
phosphoramidates of d4T and against HIV-1 in CEM cells)
l a
It was notable that strongly electron withdrawing groups {para-CN, para- 
N02) led to a slight reduction in potency, whilst several substituents, such as the 
para-COOMe and, particularly para-C 1 groups led to significant potency. The chloro 
compound was also the most lipophilic unit studied. In conclusion, an enhancement of 
activity could be obtained in the presence of lipophilic and mildly electron- 
withdrawing groups in the para-position of the phenyl ring.59
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1.7.4.3 Ester variation
The ester of the amino acid provides another possible modification site. 
Previous work suggests the benzyl ester to be the best ester in many cases (Graph
1.4).57
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G raph 1.4. Comparison of different esters (date related to L-alanine-phosphoramidates of d4T 
against HIV-1 in CEM cells)57
The benzyl ester was noted to be highly potent. The rm-butyl ester analogue 
of d4T was >50 times less potent than the benzyl ester parent compound. This trend 
can be explained considering that the tert-butyl ester might be a poor substrate for the 
esterase involved in the activation mechanism of the phosphoramidates.5
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Chapter Two
Aim of the work
2.1 C ollaboration with Roche
In collaboration with Roche Bioscience, the phosphoramidate approach 
technology was applied to different 4 ’-modified ribo-nucleosides (Figure 2.1) in order 
to explore the structure activity relationship (SAR) of the three different modification 
sites (amino acid, ester and aryl moiety); the results of which are illustrated in this 
thesis.
NH;
H° ^N3 oh oh
AZC (23)
N
A .
NH
HO O
ara-AZU (26)
HO
N3 oh oh 
AZU (24)
N
N
HO O
OH OH
AZA (27)
N NH
N
HO O
OH OH
HOn ^ o k
4 / OH OH 
ETU (25)
NH
HO O
dipent-AZC (28)
AZI (29) 
Figure 2.1. Roche nucleosides
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The activity of 4’-azidocytidine (23) and 4 ’-azidouridine (24) and their 
corresponding 5’-triphosphate species were reported (Table 2.1).1
AZC 1.28 0.29
AZU (24) >100 0.22
Table 2.1. Activity of Roche nucleosides
E C ^  the molar concentration of nucleoside which produces 50% of the 
maximum possible response.
I C ^  the molar concentration of 5’-triphosphate which produces 50% of 
RdRp inhibition.
AZU was found to be completely inactive; in contrast the corresponding 5’- 
triphosphate showed good activity as an inhibitor of RdRp. This difference in 
behaviour was correlated with inefficient metabolism, required to convert the 
nucleoside into the corresponding active species (5’-triphosphate, see Chapter One). 
Moreover recent studies have demonstrated that AZC-monophosphate is incorporated 
into the RNA of HCV during its replication and the inhibition of further RNA 
elongation is the result of this process.1
2.2 /J-2’-methylnucleosides
The application of the phosphoramidate approach applied to different 2’- 
modified nucleosides will be illustrated. In the literature there are several examples of 
reported 2’-modified nucleosides.2 5
The active form of these modified nucleosides is represented by the corresponding 5’- 
triphosphate species that can interact with the viral RdRp. This interaction allows 
these species to be incorporated into the growing chain of viral RNA and 
consequently cease the HCV replication. Consequently, in order to be active, the 
modified nucleoside has two requisites: it should be a good substrate for RdRp to be 
incorporated into the viral RNA and simultaneously, it should be conformationally 
different than the natural substrate to affect the termination of the viral RNA. The aim 
of this project was the initial synthesis of 2’-methyladenosine and 2’-
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methylguanosine; subsequently, based on the previously explored SAR, the synthesis 
a series of phosphoramidates was planned.
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Chapter
Aryloxyphosphoramidates of cytidine analogues 
3.1. Roche nucleosides
3.1.1 Target enzymes
Within the HCV genome, the helicase, serine protease (encoded by NS3 
subunit) and RNA dependent RNA polymerase (RdRp encoded by NS5B) are 
essential in the virus replication.1 For this reason, they have to be considered possible 
target enzymes in the design of an anti-HCV drug.
The helicase unwinds stable structures in the RNA template, facilitating 
replication. The serine protease is responsible for the cleavage of polyproteins once 
they are synthesised. Inhibition of these enzymes can impede viral replication.
We focused our attention on RdRp: it acts on single stranded minus-RNA 
producing complementary strands starting from the nucleoside 5’-triphosphate, 
incorporating 5 ’-monophosphate species in the RNA structure and releasing a 
diphosphate molecule (Figure 3.1).
Nucleoside
Viral
RNA RdRp III
Incorporation
Triphosphate
Diphosphate
Figure 3.1. Scheme of RdRp activity
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The inhibition of RdRp will cease HCV replication. HCV encodes for a specific 
RdRp therefore, if successful, a new class of nucleoside can be effective against all of 
the 6 genotypes of HCV so far isolated.
3.1.2 Roche Biosciences D atabase
Roche Biosciences has patented and screened 4 ’-modified ribo-nucleosides 
that were designed as chain terminators of the growing RNA chain (Figure 3.2). The 
presence of a bulky group in the 4 ’-position might confer steric and/or conformational 
sugar modification and consequently it may impede the RNA elongation. Moreover, 
to be incorporated into viral RNA these nucleosides need to be phosphorylated to the 
corresponding 5 ’-triphosphosphate. A previous study demonstrated that the 
corresponding 2 ’-deoxy-nucleoside analogues (in particular 4 ’-azidothymidine) 
showed activity against mutant HIV in the same range of AZT, and they were found 
to be active at sub-micromolar level.3
NH;
N
N
Rl R2 R3
WO 02/100415 
GB 20905
NH2
A N ^ O
'—I X
R2 R3 
WO 02/18404
Roche Patent
Figure 3.2. Roche Biosciences patents
The groups introduced were alkynyl, azido, cyano, alkyl, alkenyl, allyl, and 
alkoxy. The majority (95%) of the compounds synthesised were inactive against 
HCV.4 The aim of the collaboration between our research group and Roche 
Biosciences was to apply the aryl-phosphoramidate approach to different Roche 4 ’- 
modified ribo-nucleosides
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3.2 Suggested synthetic pathway
The phosphoramidate synthesis is a three step reaction: first the synthesis of 
the aryldichlorophosphate (33) starting from the appropriate phenol/naphthol (31) and 
POCl3 (32), followed by the coupling of 33 with the corresponding amino acid ester 
(34). The obtained phosphochloridate (35) is then reacted with the appropriate 
nucleoside to give the desired arylphosphoramidate (36) (Figure 3.3). 6,7
O
11
OH CI-P-CI
O
34
N-P-Nucleoside 
H ' Nucleoside
NMI
Figure 3 3 . General synthetic pathway for the phosphoramidates
39
Plinio Perrone Chapter Three
3.3 Phenyl phosphoramidates of 4 ’-azidocytidine
As mentioned in C hap ter One, in the aryloxyphosphoramidates there are 
three possible modification sites: namely the aryl moiety, the lateral chain and the 
ester of the amino acid. In the first instance, we focused our attention on the amino
acid ester using phenyl as the aryl moiety. Some of the amino acid esters were not
commercially available. In this case were synthesised.
3.3.1 Synthesis of am ino acid esters
The synthesis of the amino acid esters not commercially available is outlined 
below. There are two possible synthetic routes: the first was used for high-boiling 
alcohols. In this case, the amino acid (37) and the appropriate alcohol (38), in the 
presence of p-toluene sulphonic acid (pTSA), were stirred at reflux overnight to give 
the corresponding amino acid ester tosylate salts (39) (Figure 3.4).
o
,
38  o
H’Nr c ' OH
R
R'OH , d-TSA-  A q .R' 
Dean and Stark Apparatus ^
37
Toluene, pTSA, reflux
39
Figure 3.4. General synthetic pathway for the synthesis of amino acid esters with high-boiling
alcohols (R== chain of the amino acid and R’= ester)
The second synthetic route was used for low-boiling alcohols: in this case the 
amino acid (37) was heated at reflux overnight with the appropriate alcohol in the 
presence of thionyl chloride to give the amino acid ester hydrochloride salts (40) 
(F igure 3.5).
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---------------------------------------------------------------------------------------------------------------------------
38
H2N I  _ K O H 1 SOCh c r  ^  I
I Reflux T
R R
37 40
Figure 3.5. General synthetic pathway for the synthesis of amino acid esters with low-boiling 
alcohols (R= chain of the amino acid and R’= ester)
Not all the esters synthesised gave a solid product: in these cases, the ester 
hydrochloride salt was used in the subsequent reaction as an oil. The yields of the 
obtained products are reported in the table below (Table 3.1).
41® cyclopentylgly benzyl tosylate 60%
42® cyclopentylgly ethyl hydrochloride 56%
43® cyclopentylgly isopropyl hydrochloride 56%
44 L-isoleucine ethyl hydrochloride 39%
459 D-alanine butyl tosylate 62%
4610 D-alanine dodecyl tosylate 67%
479 L-alanine butyl tosylate 67%
Table 3.1. Yields of amino acid esters synthesised
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3.3.2 Synthesis of phosphorylating agents for coupling with 4’-azidocytidine
The synthetic route for the synthesis of phosphochloridate (49) was developed 
by McGuigan et al., 6’ llf 12,13 and involved a coupling reaction between commercially 
available phenyl-dichlorophosphate (48) and the appropriate amino acid salt (39/40) 
in the presence of triethylamine (TEA) at -78 °C overnight (Figure 3.6).
O -P-C I
NH$ CI/pTSA"
TEA, DCM, -78 °C 
overnight
39/40
R= Amino acid 
R'= Ester
Figure 3.6. General synthetic pathway for the synthesis of phosphorylating agents
Due to the possible instability of the compounds (49) the purification involved 
a rapid flash column chromatography using EtOAc/Hexane (7:3) as eluent
This reaction was not stereoselective, so the result was the formation of two 
stereoisomers, in the case of chiral amino acids, the splitting of the 31P-NMR signal 
was noted. The observed chemical shifts were between 7.7 and 10.6 ppm (Table 3.2).
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Rv, H oN.n.CI
I
O
R= Amino acid 
R'= Ester
508 cyclopentylgly benzyl 7.72
518 cyclopentylgly ethyl 8.09
528 cyclopentylgly isopropyl 8.16
53 L-isoleucine ethyl 10.64, 10.01
548 D-alanine benzyl 9.29, 9.05
55 D-alanine tert-butyl 9.48, 9.30
56 D-alanine butyl 9.45, 9.29
57 D-alanine dodecyl 9.38, 9.15
58 L-alanine butyl 9.40, 9.19
59 L-ethyl-asp ethyl 9.78, 9.54
Table 32 . 31P Chemical shifts of phosphorochloridates synthesised
Compounds 50, 51 and 52 showed only one signal in the 31P-NMR as a 
consequence of the absence of a chiral centre in the a-position of the amino acid.
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3.3.3 Initial synthesis of arylphosphoram idates in the presence of NMI
As mentioned previously, the most common pathway for the synthesis of the 
arylphosphoramidates (60) comprised the use of A-methyl-imidazole (NMI) as 
activator of the phosphorochloridate (49) (Figure 3.7).6
NMI, THF
49 NH
R= Amino acid 
R -  Ester
N3 OH OH
Figure 3.7. Mechanism of activation of phosphorochloridate in the presence of NMI
Unfortunately using the standard procedure developed in our group,8’9 there 
was no evidence of the presence of the desired product.
To increase the reactivity of the nucleoside, the same procedure was tried with 
different equivalents of NMI (5-10 equivalents) and phosphorochloridate (P-Cl, 49) 
(3-8 equivalents) at -78 °C and room temperature, but in these cases also there was no 
evidence of the presence of phosphoramidates (60).
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4 ’-Azidocytidine (23) had a low solubility in THF (used as solvent for the 
reaction). In an attempt to increase the solubility, other solvents (acetonitrile, 
pyridine) were tried by other members of the group without satisfactory results.
4 ’-Azidocytidine (23) was synthesised as a monohydrate and as a 
consequence, the molecule of water might react with the phosphorochloridate before 
the nucleoside, to give the product of hydrolysis of the phosphorochloridate.
In order to have the nucleoside as dry as possible, 4 ’-azidocytidine was 
azeotroped with pyridine. Unfortunately, also in this case the reaction did not show 
any presence of product. The low reactivity observed may be a consequence of the 
presence of the azido group in the 4 ’-position, reducing easy access of the electrophile 
to the 5 ’-position.
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3.3.4 Alternative synthesis of phosphoramidates
A completely different approach was proposed, exploiting the higher reactivity 
of the phenyldichlorophosphate (P-C12) as a source of phosphate. It was planned as a 
one pot reaction: the first step was nucleophilic substitution of 4 ’ azidocytidine on P- 
Cl2 with the formation of an unstable intermediate (61) that was coupled with the 
corresponding amino acid ester to give the desired product (62) (Figure 3.8).
NHNH
O -P-C I
HO
Base, THF, -78 °C, 
after one hour OH OH3 OH OH
ii /
,C - 0THF, ovemighi
R= Am ino acid 
R'= Ester
3 OH OH
Figure 3.8. Proposed phosphoramidate synthetic route
Several conditions were tried but the desired product was not isolated (Table 
3.3). In all these attempts, the nucleophilic attack of 4 ’-azidocytidine (23) with P-C12 
was probably achieved. The 31P-NMR of the reaction showed the presence of a single 
peak at 4.2 ppm, instead of 3.5 ppm (chemical shift of P-C12).
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1 1 NMI 1.5 eq cyclopentylgly ethyl -78° C
1 3 NMI 3 eq cyclopentylgly ethyl r.t.
1 1 TEA 2 eq cyclopentylgly ethyl r.t
1 3 NMI 3 eq L-phenylalanine ethyl r.t.
Table 3 3 . Conditions tried with the new synthetic scheme
However, due to its possible instability, this intermediate (61) was not isolated 
and characterised and, without further purification, the amino acid ester was added to 
the reaction mixture, and stirred overnight Analysis of the crude product of the 
reaction (TLC and MS) did not show any evidence of the presence of the 
phosphoramidate. It was assumed that the chemical shift observed did not derive from 
the hypothesised nucleophilic substitution of the phenyl-dichlorophosphate with the 
nucleoside, but from the complex between P-C12 and NMI or TEA. With the 
challenges to clearly understand why this reaction was not working, this synthetic 
pathway was abandoned.
3.3.5 Synthesis of phenyl phosphoram idate in the presence of ‘BuMgCl
The method of Uchiyama was investigated next.13 This approach is based on 
the treatment of nucleoside with 1 equivalent of a strong organometallic base, such as 
a solution of /m-butylmagnesium chloride (tBuMgCl), to form the corresponding 
metal alkoxide (63) (Figure 3.9) followed by the coupling reaction with the 
appropriate phosphochloridate.13 Due to the presence of a ribo-sugar with 3 hydroxy 
groups in the 2’-, 3’- and 5’-positions possible regioselectivity problems might be 
encountered. In the first instance, 1.5 eq of Grignard reagent was used. Unfortunately, 
due to the really low yield, the desired product was only observed by MS.
Considering that 4 ’-azidocytidine (23) was synthesised as a monohydrate 
derivative, the same reaction was repeated in the presence of 2.5 eq of 'BuMgCl. In
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this case, from TLC, it was possible to identify the desired phosphoramidate which 
was isolated.
NH
63 |f
N
MgCI
N3 oh oh
7
o^h oh
R= Amino acid 
R'= Ester
f y 0-^ a
' = '  OH
Figure 3.9. Successful synthetic scheme for AZC phenyl-phosphoramidates
The general synthetic pathway started with the addition of 2.5 equivalents of 
'BuMgCl to a solution containing 1 equivalent of 4 ’-azidocytidine in THF. After 15 
minutes, the appropriate phenyl phosphorochloridate (49) was added and stirred 
overnight (Figure 3.9). The reaction was quenched by the addition of an aqueous 
solution of NH4C1. The phosphoramidates synthesised are reported in Table 3.4.
Nevertheless, the purification required at least one chromatography column 
and two preparative TLC plates to give the pure aryl phosphoramidate (62). The 
presence of a product caused by the hydrolysis of the phenylphosphochloridate was 
observed (64), isolated and fully characterised: by 31P-NMR it appears as a broad peak 
at 0.1 ppm.
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NH
13 OH OH
R= Amino Acid 
R’= Ester
65 cyclopentylgly benzyl 3.70, 367
66 cyclopentylgly ethyl 3.74
67 cyclopentylgly isopropyl 3.77, 3.75
68 L-isoleucine ethyl 5.55, 5.30
69 D-alanine benzyl 4.80, 4.26
70 D-alanine ferf-butyl 4.91, 4.45
71 D-alanine butyl 4.73, 4.55
72 D-alanine dodecyl 4.80, 4.33
73 L-ethyl-asp ethyl 4.67, 4.40
74 L-alanine butyl 4.82 4.32
Table 3.4. List of phenyl phosphoramidates synthesised
Due to the high number of purification steps, the initial yields were reasonably
low (5-10%).
The use of tBuMgCl as coupling agent might cause a non-regiospecific 
reaction with T-  and 3’- phosphorylation, forming side products. However after 
analysing ,3C-NMR spectra, the isolated product was the aryloxy-phosphoramidate in 
the 5’-position with no traces of other regioisomers.
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NH
w
'3 OH OH
♦o
Figure 3.10. Example of 13C-NMR of aryloxy-phosphoramidate
Only the CH2 group in the 5’ position (red) displayed 4 signals as a 
consequence of the presence of the two diastereoisomers and the coupling with the 
phosphorus. The CH in the 2’- (blue) and 3’-position (green) had only two signals 
each (Figure 3.10), due to the presence of the two diastereoi somers.
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3.3.6 Biological activity of phenyl phosphoramidates of 4’-azidocytidine
All the compounds synthesised were evaluated in vitro using a replicon assay 
by Sophie Le Pogam and Isabel Najera in the lab of Klaus Klumpp in Roche 
Biosciences (Palo Alto, California).
3.3.6.1 Replicon assay
The replicon assay used a subgenomic HCV replicon composed of the HCV 
5’-NTR, the gene encoding for renilla luciferase (Re-Luc, a protein obtained from 
Renilla), fused with neomycin phosphotransferase (NPTII) and a part of HCV 
replicon that is constituted by the subunits NS3, NS4B, NS5A and NS5B and the 
HCV 3’-NTR (Figure 3.11).14,15
5’-NTR Re-Luc NTPII NS4B NS5A NS5B 3’-NTR
Figure 3.11. Structure of the replicon for the assay
The cell line used for this assay was the human hepatoma cell (Huh-7).14,15 
This strand of RNA, after in vitro transcription, was incorporated into Huh-7, and 
neomycin (conferred by subunit NTPII) resistant colonies were isolated and expanded.
The activity of renilla luceferase expressed by the replicon, reflects its RNA 
level in the cells, so indirectly the IQo of aryl phosphoramidate was measured as 
inhibition of luciferase activity. The advantage of this kind of assay is that using this 
particular protein (luciferase) and only a part of HCV replicon, there is a high 
replication of the virus that could simulate the real behaviour of the virus in the host 
liver cells.
Different mutations have been inducted on the HCV subunits and in particular 
in the NS3, NS5A and NS5B to improve the activity of this method.14,15
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3.3.6.2 Biological activity of phenyl phosphoramidate of 4’-azidocytidine
All the compounds synthesised were evaluated against HCV in vitro. Table
3.5 displays all the reported data for the phenyl phosphoramidates.
NH
N3 OH OH
R= Amino Acid 
R’= Ester
65 cyclopentylgly benzyl 9.0 >100
66 cyclopentylgly ethyl <100 >100
67 cyclopentylgly isopropyl <100 >100
68 L-isoleucine ethyl >100 >100
69 D-alanine benzyl 0.9 >100
70 D-alanine ferf-butyl <100 >100
71 D-alanine dodecyl >100 >100
72 D-alanine butyl 0.92 >100
73 L-ethyl-asp ethyl <100 >100
74 L-alanine butyl 10.8 >100
23 4’-azidocytidine 1.28 >100
5 ’-triphosphate-AZC= 0.29 pM IC50
Table 3.5. Biological data of AZC phenyl phosphoramidates
100= The concentration of phosphoramidate, which produces 50% of the maximum 
possible effect
The concentration of phosphoramidate, which produces 50% of toxic effect
There is no significant difference in terms of activity comparing 4 ’- 
azidocytidine (23) and its corresponding most active synthesised phosphoramidate 
(69). This effect might indicate that, once in the cells, these phosphoramidates may be 
hydrolysed releasing the nucleoside and not the 5’-monophosphate, without any 
possibility to bypass the first phosphorylation. Another possible explanation might be 
related to the activation mechanism of the 4 ’-azidocytidine itself. The first
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phosphorylation might not be the limiting step for this nucleoside so its corresponding 
phosphoramidates, once inside the cells, release the 5’-monophosphate that is a poor 
substrate for the second or third phosphorylation.
3.3.6.3 Ester variation
The ester of the amino acid carries out an important role in the 
phosphoramidate metabolism; they have to be a good substrate for the “esterase” in 
order to be easily removed since their cleavage represents the first step in the 5’- 
monophosphate release (see C hapter One).
In collaboration with other researchers in our group, the ester variation has 
been explored in the L-alanine phosphoramidate series (G raph 3.1).
2.5
oin
ui 1.5
>  1
*  0.5
0
i
G raph 3.1. Ester variation for L-alanine AZC phosphoramidates
(ethyl, benzyl, 2-butyl, terf-butyl, isopropyl and methyl 
phosphoramidates were synthesized by other researchers of our group)
As previously observed,17 the presence of a good substrate for the esterase 
such as the ethyl and benzyl group increases the activity. More bulky esters such as 
butyl, isopropyl and tert-butyl decrease the activity. The presence of the 2-butyl ester
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does not significantly reduce the activity even though this group does not usually 
represent a good substrate for the esterase. Surprisingly the tert-butyl ester 
phosphoramidate showed reasonable activity in contrast with methyl and butyl ester 
derivatives that were poorly active.
3.3.6.4 Amino acid variation
Another important part in the phosphoramidate structure is represented by the 
amino acid. Also in this case the presence of a good substrate for the esterase can 
efficiently deliver the 5’-monophosphate. For the 4 ’-azidocytidine the amino acid 
variation has been investigated. The activity of different benzyl phosphoramidates is 
reported in G raph 3.2.
V 0.8
y 0 .4
O 0.2
G raph 3.2. Amino acid variation for AZC phosphoramidates
(all benzyl ester phosphoramidates, L-alanine, glycine, dimethylgycine, 
phenylalanine, leucine and valine were synthesised by other researcher 
in our group)
As predicted and observed in the past,18 it is clear that L-alanine is the most 
active amino acid.
54
Plinio Perrone Chapter Three
Of note was the inactivity of cyclopentylglycine, which was unexpected and 
not observed in previous projects. 18
In contrast with the data for d4T phosphoramidates,6 the D-alanine 
phosphoramidate showed similar activity to the corresponding L-isomer. A 3-5 fold 
reduction in activity was found on replacing L-alanine with glycine and 
dimethylglycine. This might indicate that the presence of the methyl group with the L- 
alanine configuration does not confer any advantage over the corresponding simple 
hydrogen of glycine or the D-alanine isomer. Moreover, L-amino acids, with larger 
and more hydrophobic side chains (e.g. L-valine, L-isoleucine, L-leucine), showed a 
remarkable reduction in activity: this might indicate the presence of a small 
hydrophobic pocket in the putative activating enzyme (“esterase” and 
“phosphoramidase”).
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3.4. Substituted phenyl phosphoramidates of 4 ’-azidocytidine
In previous work it was noticed that the presence of different substituents on 
the aryl moieties can modify the biological activity.11 In order clearly to define how 
the activity is influenced by the presence of a particular substituent the Topliss tree 
concept has been applied to ethyl L-leucine 4 ’-azidocytidine phosphoramidate.
The Topliss tree methodology has been reported as an operational scheme for 
analogue design that may help to find the best substituent and their corresponding 
relative position on the aryl moiety of an active compounds (Figure 3.12).20
4-a
4-OMe
L
Sm  right
L
4-CH.
L
3-NM», J-CH3 3-CFj
\  /  I
2 -0  3 ,5 -0 ,
4-NO,
4-F
3-NO,
M
• 3 ,4 -0 ,
4-CF,
2.4 -0-
4-NO,
M» Moreactv* 
E = Equtecfcve. 
L * La
3-C Fj-4 - 0
I
3-Cf ,-4 -N O ?
Figure 3.12. Topliss tree
The Topliss tree is based on the effect of electron-withdrawing and electron- 
releasing groups on the aryl moiety. In the first instance, the preparation of para- 
chloro on the phenyl ring is suggested. If this new compound is more active than the 
parent compound (M) this means that the electron-withdrawing effect can give an 
increase in activity; for this reason, it would be advantageous to synthesise the 3,4- 
dichloro, increasing the inductive effect on the ring.
If it is equally active (E) this means that the presence of this group does not 
affect the activity, and so it would be better to introduce the methyl group in the para 
position.
If it is less active (L) the choice is to synthesise the /?-methoxy, because, this 
means that the presence of an electron-withdrawing group can give a decrease in
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activity, so it is possible that the presence of an electron-releasing group can help the 
activity. The Topliss tree methodology was applied to the 4 ’-azidocytidine 
phosphoramidate with ethyl-L-leucine as the amino acid ester, which was previously 
synthesised by other member of our group and tested against HCV.
3.4.1 Synthesis of phosphorylating agent for coupling with am ino acids
In order to synthesise phosphoramidates with substituents on the aryl moiety, 
it was necessary to synthesise arylphosphorodichloridates that represented the starting 
materials for the couplings with the appropriate amino acid. The general synthetic 
pathway, used for the synthesis of aryldichlorophosphates, was developed by 
McGuigan et al.6'7 Phosphorus oxychloride (POCl3, 75) and the appropriate phenol 
derivative (76) were coupled in the presence of TEA to give the corresponding 
aryldichlorophosphate (77) (F igure 3.13).
75
POCI3
TEA, diethyl ether, -78 °C 
overnight
CI-P-CI
Figure 3.13. General synthetic pathway for the synthesis of aryldichlorophosphate 
(R and R’= substituents on the aryl moiety)
Because of the substantial instability of these compounds, the crude product of 
the reaction was quickly filtered to remove the triethylammonium salt. The reactions 
succeeded with reasonable yield and high purity. The observed chemical shifts in 31P- 
NMR spectra were between 4.8 and 5.5 ppm (Table 3.6).
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Yield
i
78s chloroO H 40% 5.00
R'
79 chloro chloro 45% 4.79
80 methyl H 72% 4.98R
8111 methoxy H 67% 5.45
Table 3.6. Yields for the aryl-dichlorophosphates synthesised
3.4.2 Synthesis of phosphorylating agents for coupling with 4’-azidocytidine
As mentioned in section 3.3.2 the synthetic route for the synthesis of 
phosphorylating agents for coupling with the modified nucleosides was developed by 
McGuigan et a l involving the coupling of the appropriate substituted 
phenylphosphorodichloridate with L-leucine ethyl ester hydrochloride in the presence 
of triethylamine (TEA) at -78 °C overnight. Due to the possible instability of the 
compounds the purification involved a filtration through a filtration funnel to remove 
the tri ethyl ammonium salt. As a result of the presence of two possible phosphorus 
configurations, it was possible to see signal splitting in the 31P-NMR spectra (Table
3.7).
O
M O
P (ppm)
82 chloro H 9.75, 9.73
83 chloro chloro 9.84,9.78
R
84 methyl H 10.06,9.63
85 methoxy H 10.54, 10.22
Table 3 .7 .3,P Chemical shifts of L-leucine ethyl ester phosphorochloridates
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3.4.3 Synthesis and biological activity of phosphoramidates of 4’-azidocytidine 
with substituents on the aryl moiety
Four compounds with different substituents present in the first row of the 
Topliss tree (p-chloro, 3,4 dichloro, ^-methyl and /?-methoxy) were synthesised 
simultaneously. The synthetic pathway used has been previously described (see 
section 3.3.5) and involved the synthesis of an alkoxide intermediate in the presence 
of an excess of tBuMgCl followed by coupling with the appropriate 
phosphorochloridate (Figure 3.14).
Figure 3.14. Synthesis of substituted phenyl AZC phosphoramidates
The phosphoramidates synthesised had yields between 3% and 14%. These 
compounds were tested in vitro in the replicon assay (see section 3.3.6.1) against 
HCV (Table 3.8).14 15
tBuMgCl, THF
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NH
OH OH
86 H H >100 >100
87 chloro H 2.52 >100
88 chloro chloro 2.32 >100
89 methyl H 4.3 >100
90 methoxy H 9.3 >100
23 4,-azidocytidine 1.28 >100
5’-triphosphate-AZC= 0.29 pM IC50
Table 3.8. Biological activity of AZC phenyl substituted phosphoramidates
IC5 o= The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
(compound 86 was synthesised by other researchers in the group)
For AZC conversion of an inactive unsubstituted phosphoramidate to 
substituted phosphoramidates active at the pM  level was achieved (Graph 3.3).
In particular, the effect of an inductive group such as para-chloro (87) and 3,4- 
dichloro (88) on the activity was higher when compared to the presence of an 
electron-donating group such as para-methyl (89) and para-methoxy (90). However, 
the difference of the effect between an electron-withdrawing (87, 88) or electron- 
donating group (89, 90) is not significant.
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~  0.8
S  0.6
w 0 .4
c 0.2
o 0.1
G raph 3 3 . Topliss tree applied to L-leucine ethyl ester phosphoramidates
Most importantly the activity of the parent nucleoside (4’-azidocytidine, 23) 
was higher compared to the substituted and unsubstituted phosphoramidates, that 
might be a direct consequence of the inefficient phosphoramidate metabolism to 
release the corresponding 5’-monophosphate.
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3.5 Naphthyl phosphoramidates of 4 ’-azidocytidine
Previous studies have shown that the presence of a naphthyl group instead of a 
phenyl group, in the phosphoramidate structures, increased the activity,1 suggesting 
that naphthyl phosphoramidates could be an attractive target. Moreover, it has been 
observed that the L-alanine benzyl ester was the most potent phosphoramidate 
synthesised for several nucleosides.6, 11 For this reason the synthesis of L-alanine 
benzyl phosphoramidates with a- and /3-naphthyl as the aryl moiety was planned. The 
synthetic route was slightly modified for this different aryl moiety.
3.5.1 Synthesis of phosphorylating agent for coupling with amino acids
In order to synthesise phosphoramidates with a- and /J-naphthyl as the aryl 
moiety, it was necessary to prepare the non-commercially available naphthyl- 
phosphorodichloridate.
The synthesis has been previously described in section 3.3.1: the same 
procedure was used, the only difference being that in this case the starting materials 
were a- and /3-naphthol. The purification methods required exactly the same 
procedure previously described.
The 31P-chemical shift and the yield of the synthesised phosphorodichloridates 
(91, 92) are reported in Table 3.9.
0ii
C I -P -C I1
01
Ar
Ar= Aryl moiety
Table 3.9. Yields of the synthesis of a-naphthyl and /2-naphthyl-phosphorodichloridates
3.5.2 Synthesis of phosphorylating agents for coupling with 4’-azidocytidine
For the synthesis of these intermediates, we applied the previously described 
procedure for the synthesis of phosphorochloridates (see section 3.3.2).
The purification method involved rapid column chromatography in the 
presence of a mixture of hexane/EtOAc (7:3) as eluent.
9119 a-naphthyl 90% 3.91
9219 /Lnaphthyl 87% 3.60
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Due to the non-regiospecific reaction, the synthesised products were a mixture 
of two diastereoi somers with a signal splitting observed in 31P-NMR spectra (Table
3.10).
H o
Y ' 0 ^ Y Nt cl
^  ?
Ar 9319 a-naphthyl 8.58, 8.25
Ar= Aryl moiety 9419 /?-naphthyl 8.32, 8.10
Table 3.10. a-Naphthyl and /S-naphthyl-phosphorochloridate
3.5.3 Synthesis of a-naphthyl 4’-azidocytidine phosphoramidates
In an attempt to increase the yield, the same phosphoramidate reaction was 
performed on 2 \3 ’-protected 4 ’-azidocytidine. Protection in the 2’- and 3’-positions, 
increased the solubility of the nucleoside in THF, therefore increasing its availability 
to react with the phosphorochloridate.
3.5.3.1 Synthesis of 2 \3 ’-protected a-naphthvl 4’-azidocytidine
phosphoramidates
In an attempt to increase the solubility of the nucleoside in THF and to reduce 
the number of chromatography columns required for the purification, the 2’- and 3’- 
positions were protected with cyclopentylidene. The corresponding 2’- and 3’-rptected 
nucleoside was provided by Roche.
The coupling of 2 \3 ’-cyclopentylidene 4-azidocytidine (96) was carried out 
using the Uchiyama procedure previously described (Figure 3.15).
The most important achievement was the complete solubilisation of the 
nucleoside in THF. The reaction was stirred overnight and the purification usually 
required just one chromatography column. As a consequence, the yields obtained were 
higher (72-85%) than those observed for the unprotected 4 ’-azidocytidine (3-14%).
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Figure 3.15. Synthesis of 2 ’,3’-cyclopentylidene a-naphthyl AZC phosphoramidates
3.5.3.2 Separation of 2’,3’-cyclopentylidene-AZC cr-naphthyl- 
phosphoram idate diastereoisom ers
The synthetic pathway used for the synthesis of the 4 ’-azidocytidine 
phosphoramidates was not stereospecific: and the product obtained was a mixture of 
compounds in which the P-centre had two possible configurations (two 
diastereoisomers). In order to explore the possibility of different activity between the 
two diastereoisomers, their separation was attempted using semi-preparative HPLC.
The mobile phase used was a mixture of acetonitrile and water in a ratio of 1:1. 
The analytical chromatogram obtained showed an almost complete separation of the 
two peaks (Figure 3.16).
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MORE POLAR LESS POLAR
5 •
I I
«
0 1 2  3 IS6 9 10 12 13 14S 7 8 114
Figure 3.16. Analytical HPLC for compounds 97.a/97.b
The two diastereoisomers (97.a/97.b) had retention times between 8 and 12 
minutes. Also in this case the UV spectra of the two peaks were absolutely identical. 
The same method was then adapted to the preparative column, in order to separate a 
reasonable quantity of material.
Figure 3.17 shows a region of the *H-NMR spectra of the separated 
diastereoisomers. An important observation is the presence of only one 
diastereoisomer in each fraction. In particular, the proton in the 5- and l ’-positions 
gives, in both cases, a doublet, due to the coupling, respectively, with the proton in the 
6- and 2’-position.
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LESS POLAR 
DIASTEREOISOMER
MORE POLAR 
DIASTEREOISOMER
Figure 3.17. Particular of the two 'H-NMR of the separated diastereoisomers (97.a/97.b)
Moreover, the CH2-protons in the 5’-position (orange), in the case of the less 
polar diastereoisomer the signal is a doublet of doublets that become a multiplet in the 
case of the more polar diastereoisomer (Figure 3.17). The same observation can be 
made with the benzylic protons (blue): in the first case (less polar diastereoisomer) the 
signal is an AB system; in contrast for the more polar compound it is a doublet of 
doublets (Figure 3.17). Consequently, the conformations of 5 ’-position and benzyl 
group might be affected by the different phosphorous configuration of the two 
diastereoisomers.
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3.5.3.3 D eprotection of the 2 ’,3’-positions
The cleavage of the acetal group in the 2 ’ and 3’-positions was performed in 
the presence of an 80% aqueous solution of formic acid. The reaction was stirred at 
room temperature for 4 hours (Figure 3.18).
NH NH
80% HCOOH
OH OH
97.a/97.b 98. a/98, b
Figure 3.18. Deprotection in 2 ’-3,’-position of a-naphthyl AZC phosphoramidates
The reaction produced the desired compound (98.a/98.b) and another more 
polar compound that might derive from the degradation of the phosphoramidate. The 
purification method required only one chromatography column with reasonably high 
yields (80% and 82%).
3.5.4 Synthesis and  H PLC  separation /?-naphthyl 4’-azidocytidine 
phosphoram idates
The yS-naphthyl phosphoramidate of L-alanine benzyl ester was synthesised 
using the Uchiyama procedure described in section 3.3.5. The yield for this reaction 
(5%) was comparable with that obtained for the phenyl phosphoramidate synthesis. 
Using the HPLC method optimised for the separation of a-naphthyl 
phosphoramidates, the two diastereoisomers were partially to separate. After HPLC,
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two main fractions were isolated with different ratios of diastereoisomers (Table
3.11).
Fraction 1 6.3 1 99.a
Fraction 2 1 7.8 99. b
Table 3.11. Ratio of the two fractions isolated
3.5.5 Biological activity of naphthyl phosphoramidates of 4’-azidocytidine
All the naphthyl phosphoramidates have been tested in vitro using a replicon 
assay (see section 3.3.6.1) against HCV (Table 3.12).11,12
Ar
O nh2
- A  A
-O  NH
0*0
N3 OH OH
Ar= Aryl moiety
98.a a-naphthyl 0.82 >100
98. b a-naphthyl 0.84 >100
99.a /5-naphthyl 2.86 >100
99.b ^-naphthyl 4.27 >100
23 4-azidocytidine 1.28 >100
5’-triphosphate-AZC= 0.29 pM IC50
Table 3.12. Biological activity of AZC naphthyl phosphoramidates
ICjcp The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
C C ^  The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
When the corresponding phenyl phosphoramidates of 4 ’-azidocytidine were 
compared to the nucleoside itself a reduction of 5-fold in activity was observed, that 
might be due to the poor interaction of the phenyl moiety with one of the enzymes 
involved in the release mechanism of the 5’-monophosphate (see section 1.7.2).
68
Plinio Perrone Chapter Three
1.4
1.2
^  1 
Oin 0.8 uIU
^ 0.6
c 0.4 0)
£ 0.2
l (
or' or' V '  ^
G raph 3.4. Biological activity of AZC-phosphoramidates with different aryl moieties 
a-naphthyl 1= less polar diasteroisomer 
a-naphthyl 2= more polar diasteroisomer 
^-naphthyl 1= fraction 1 
/3-naphthyI 2= fraction 2
The comparison between the phenyl and its corresponding a-naphthyl 
phosphoramidate shows a 7-fold increase in activity for the naphthyl analogue 
(G raph 3.4). This behaviour might be explained considering the phosphoramidate 
metabolism, in which the corresponding alkoxide of the aryl moiety is released as a 
side product (see section 1.7.2). Consequently the release of a more stabilised product 
such as the naphthol alkoxide might facilitate the entire process. Another possible 
explanation for the increase in activity is the increase of lipophilicity seen going from 
a phenyl group to a naphthyl-group. However, this cannot explain the different 
behaviour between a-and /S-naphthyl-phosphoramidates. It may be more likely that 
the active site of one of the enzymes involved in the metabolism of the 
phosphoramidate might have a lipophilic pocket capable of accommodating a phenyl 
group or a-naphthyl-group, while, the /S-naphthyl-group having a different orientation 
in space may be a poor substrate for these enzymes.
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3.6 dipentanoyl-AZC aryl phosphoramidates
Following the successful work done with protected AZC (see section 3.3.1), it 
was decided to synthesise phosphoramidates of a derivative of 4’-azidocytidine with a 
biologically cleavable protecting group. The presence of the pentanoyl group in the 
2’- and 3’-positions was suggested in order to increase the lipophilicity of the 
nucleoside and subsequently its availability in the reaction solvent (THF). Moreover 
this protecting group could be biologically cleaved inside the cells by esterase activity. 
A new class of phosphoramidates (100) derived from 2’,3’-dipentanoate 4 ’- 
azidocytidine was planned (Figure 3.19).
Figure 3.19. Scheme of dipentanoyl-AZC phosphoramidate synthesis
Using the usual synthetic pathway it was possible to synthesise the 
phosphoramidates reported in Table 3.13.
^uMgCI, THF
R= Amino acid 
Ar= Aryl moiety
28 100
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101 D-alanine phenyl 4.60, 4.13
102.a L-alanine a-naphthyl 3.55
102.b L-alanine a-naphthyl 3.54
103 L-alanine ^-naphthyl 3.32, 3.28
NH
R- Lateral chain 
Ar= Aryl Moiety
Table 3.13. dipentanoyl-AZC phosphoramidates synthesised
3.6.1 Separation of dipentanoyl- AZC a-naphthyl-phosphoram idates 
diastereoisom ers
The separation of 102.a/102.b was partially successful using HPLC and an 
isocratic solvent system: 57% acetonitrile 43% water. The analytical chromatogram 
showed a good separation between the two diastereoisomers (Figure 3.20).
LESS POLAR
MORE POLAR
1.300
1JOO IMPURITY
’.000
Figure 3.20. Analytical HPLC for compounds 102.a/102.b
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It was possible to distinguish the two diastereoisomers (retention time between 
18 and 19 minutes) and a third impurity (retention time 20 minutes). Starting from 
these promising results, the same method was applied to a preparative HPLC that 
allowed a separation of a larger quantity of compound (20 and 30 mg respectively). 
Analytical HPLC was performed on the two fractions separately (Figure 3.21).
FRACTION 1
FRACTION 2
R T C m ln l
5 5 6 6.5 7 7 5  8 6 5  9 95  10 105 11 11.5 12 12 5 13 135 14
Figure 3.21. Chromatogram of the two fractions separated by HPLC
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In both the chromatograms there is prevalence of one diastereoisomer. In the 
JH-NMR spectra of these two fractions there is a noted difference between the signals 
of the two diastereoisomers. In the first fraction the more shielded protons are 
predominant (blue), instead, in the second fraction the deshielded protons (red) have 
the highest intensity (Figure 3.22).
Moreover, the main signal of the benzylic protons is a doublet of doublets 
(blue) in the first fraction; for the diastereoisomers in the second one the main signal 
is an AB system (Figure 3.22). From this observation, it might be possible that the 
different phosphorus configuration of these two compounds affects also the 3D 
conformation of the rest of the molecule.
FRACTION 1
Blue= Shielded P-N
FRACTION 2
Red= Deshielded P-N
Figure 3.22. ‘H-NMR spectra of the two fractions separated by HPLC
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From the ‘H-NMR spectra integration, we determined the ratio between the 
two diastereoisomers in the two fractions (Table 3.14).
Fraction 1 3.4 1 102.a
Fraction 2 1 10 102.b
Table 3.14. Ratio of diastereoisomers in the two fractions isolated
3.6.2 Biological activity of phosphoramidates of dipentanoyl-49-azidocytidine
All the naphthyl phosphoramidates were tested in vitro using the replicon 
assay (see section 3.3.6.1) against HCV (Table 3.15).
NH
R= Lateral chain  
Ar= Aryl Moiety
101 D-alanine phenyl 1.2 >100
102.a L-alanine a-naphthyl 0.37 >100
102 .b L-alanine a-naphthyl 0.96 >100
103 L-alanine ^-naphthyl 0.47 >100
5’-triphosphate-AZC= 0.29 pM IC50
Table 3.15. Biological activity of pent-AZC phosphoramidates synthesised
I C ^  The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CCs p  The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
Comparing the two pure and separated dipentanoyl-4'-azidocytidine 
(102.a/102.b) phosphoramidate diastereoisomers and 4’-azidocytidine, there is no 
difference in terms of biological activity (98.a/98.b). Moreover, as observed for the a- 
naphthyl, the two diastereoisomers do not show a significant difference in terms of 
activity. Surprisingly the activity of the a-naphthyl (102.a/102.b) and the /J-naphthyl 
(103) derivatives are comparable and in the case of compound 102.b (pure a-naphthyl
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diastereoisomer) the activity is lower than compound 103. The biological activity of 
the L-alanine phenyl phosphoramidate of dipent-4 '-azidocytidine is 0.39 //M,18 only 3 
fold higher than the activity of the corresponding D-alanine derivative. The presence 
of a methyl group in the lateral chain of the amino acid may be important for the 
activity, but the enzyme involved in phosphoramidate metabolism does not appear to 
require a particular conformation in that position.
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Chapter
A ryloxyphosphoram idates o f uridine analogues 
4.1 4 ’-Azidouridine phenyl phosphoramidates
As illustrated in C hapter Two, the aim of the collaboration with Roche 
Biosciences was to apply the aryl-phosphoramidate technology to different 4’ 
modified nucleoside analogues. 4 ’-Azidouridine (24) was tested against HCV in the 
replicon assay and was found completely inactive, whereas the corresponding 5’- 
triphosphate had activity at 0.22 piM against RdRp.1 The activity of 4’-azidouridine 
triphosphate and the inactivity of the corresponding nucleoside might indicate that 4 ’- 
azidouridine (24) is poorly phosphorylated by the kinases (see Chapter One). One 
possibility to overcome this problem was the delivery into the cell of the 
corresponding 5’-monophosphate via phosphoramidate technology.
4.1.1 Synthesis of 4’-azidouridine phosphoramidates
Some of the chosen amino acid esters were not commercially available and 
needed to be synthesised.
4.1.1.1 Synthesis of amino acid esters
The synthesis of amino acid esters has been described in Chapter Three 
(Figure 3.4 and 3.5). All the amino acid esters reported as tosylate salts were 
synthesised using Dean Stark apparatus; while, all the hydrochloride amino acid esters 
were synthesised in the presence of thionyl chloride. In Table 4.1 the yields of the 
amino acid esters synthesised are reported.
YieldAmino acid
10414 D-alanine isopropyl Tosylate 64%
105 D-alanine 2-butyl tosylate 76%
106 D-alanine octyl tosylate 75%
Table 4.1. Yields of amino acid esters synthesised
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4.1.1.2 Synthesis of phosphorylating agents for coupling with 4’- 
azidouridine
This synthetic route has already been described in C hapter Three (Figure 
3.6): a reaction between the commercially available phenyldichlorophosphate and the 
appropriate amino acid salt.2 5 The 31P-NMR chemical shifts were observed between 
8.49 and 9.41 ppm (Table 4.2).
? H o
R,v V t ci
R O
6
R= Amino acid 
R'= Ester
Table 4 2 .31P Chemical shifts of phosphorochloridates synthesised
4.1.1.3 Synthesis of phenyl-AZU phosphoramidates
As the only successful access to 4 ’-azidocytidine aryloxyphosphoramidates 
was in the presence of tBuMgCl (see C hapter Three), a series of 4’-azidouridine 
phosphoramidates was synthesised using the same strategy (Figure 4.1).8
On comparison with the synthesis of 4 ’-azidocytidine phosphoramidates there 
were two substantial differences: due to its higher lipophilicity 4 ’-azidouridine was 
more soluble in THF and there were no traces after the first chromatography column 
of P-OH (64, product of hydrolysis of phosphorochloridate) and consequently the 
purification method was much easier.
10714 D-alanine isopropyl 9.41, 9.09
108 D-alanine 2-butyl 8.49
109 D-alanine octyl 9.20, 9.00
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NHNH
BuMgCI, THF
n 3 OH o h  
24
N3 o h  o h
R= Amino acid 
R'= Ester
HN
111
N3 o h  o h
Figure 4.1. Synthetic scheme for AZU phenyl-phosphoramidates
The yields observed using this nucleoside were between 10 and 20% with the 
synthesised phosphoramidates reported in Table 4.3.
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HN
3 OH OH
R= Amino acid 
R'= Ester
112 Cyclopentylgly benzyl 3.77, 3.74
113 Cyclopentylgly ethyl 3.85, 3.83
114 Cyclopentylgly isopropyl 3.87, 3.83
115 D-alanine benzyl 4.89, 4.29
116 D-alanine dodecyl 4.92, 4.38
117 D-alanine butyl 4.81,4.59
118 D-alanine 2 -butyl 4.97, 4.41
119 D-alanine octyl 4.35, 4.20
120 D-alanine isopropyl 4.97, 4.41
121 L-alanine butyl 4.91, 4.35
Table 4 3 .31P Chemical shifts of AZU phosphoramidates
4.1.2 Synthesis of phenyl phosphoram idates via protected 4’-azidouridine
In order to increase the solubility of the nucleosides and consequently the 
average yield of the phosphoramidates, the 2’- and 3’-positions were protected with an 
acetal group that could be easily cleaved in acid conditions. The corresponding T -  
and 3’-protected nucleoside was provided by Roche. In particular, the 
cyclopentylidene 4 ’-azidouridine was used to generate a second series of 4 ’- 
azidouridine phosphoramidates. Some of the chosen amino acid esters were not 
commercially available and therefore needed to be synthesised.
4.1.2.1 Synthesis of am ino acid esters
A second series of amino acid esters were synthesised using the previously 
described procedure (section 4.1.1). The amino acid esters generated are reported in 
Table 4.4.
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122s a,a-dimethylgly benzyl Tosylate 42%
123s a,a-dimethylgly ethyl hydrochloride 73%
1245 L-proline ethyl hydrochloride 77%
12514 /3-alanine ethyl hydrochloride 65%
126s N-methyl-glycine ethyl hydrochloride 78%
12714 L-alanine isopropyl hydrochloride 85%
Table 4.4. Amino acid esters synthesised
4.1.2.2 Synthesis of phosphorylating agents for coupling with protected 4’- 
azidouridine
The synthesis of phosphorochloridates involved a coupling reaction between 
the commercially available phenyldichlorophosphate and the corresponding amino 
acid ester in the presence of TEA at -78°C overnight. Due to the possible instability of 
these compounds, the purification method involved a rapid chromatography column 
using, as eluent, a mixture of EtOAc/hexane 3:7. The phosphorochloridates 
synthesised are reported in Table 4.5.25
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Cpd
no. 31P (ppm)
R= Amino acid 
R'= Ester
1285 L-alanine methyl 7.88
129s L-alanine ethyl 7.94
13014 L-alanine isopropyl 8.22
1317 L-alanine ferf-butyl 8.07
132s L-alanine benzyl 7.79, 7.75
13314 glycine benzyl 9.15
13414 L-valine benzyl 9.48, 8.95
135s a,a-dimethylgly benzyl 5.53
136s a,a-dimethylgly ethyl 5.58
13714 L-phenylalanine benzyl 7.91, 7.85
13814 L-phenylalanine ethyl 8.03, 7.95
139s L-leucine ethyl 8.46, 8.22
14014 L-proline ethyl 7.83, 7.76
141 L-methionine ethyl 8.70, 8.45
14214 /3-alanine ethyl 10.00
143s N-methyl-glycine ethyl 11.19
144 ethyl-aspartate ethyl 9.78, 9.54
Table 4 .5 .3,P Chemical shifts of phosphorochloridates synthesised
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4.1.2.3 Synthesis of phenyl phosphoramidates via protected 4’- 
azidouridine
The coupling of 2 \3 ’-cyclopentylidene 4’-azidouridine (145) with the 
corresponding phosphorochloridate was carried out using the Uchiyama procedure 
through an alkoxide intermediate to give the corresponding phosphoramidate (146).3,6 
As mentioned before (Chapter Three) the deprotection of the 2’- and 3’-position was 
performed in the presence of an aqueous solution of 80% formic acid to give the 
desired phenyl phosphoramidates of 4-azidouridine (147) (Figure 4.4).
NH HN
HO
146
145
80% HCOOH
R= Amino acid 
R -  Ester
HN
147 13 OH OH
Figure 4.4. Successful synthetic scheme applied to protected AZU
For both reactions (coupling and deprotection), the purification method 
required one chromatography column giving an overall yield between 70 and 80%. 
Table 4.6 reports the phosphoramidates synthesised using this synthetic pathway.
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o
HN
13 OH OH
R= Am ino acid  
R’= Ester
148 L-alanine methyl 3.50, 3.31
149 L-alanine ethyl 3.56, 3.35
150 L-alanine isopropyl 3.59, 3.38
151 L-alanine fe/T-butyl 3.63, 3.59
152 L-alanine benzyl 3.53, 3.28
153 glycine benzyl 3.53, 3.28
154 L-valine benzyl 4.45, 4.14
155 a,a-dimethylgly benzyl 1.86, 1.83
156 a,a-dimethylgly ethyl 1.90, 1.87
157 L-phenylalanine benzyl 3.21, 3.02
158 L-phenylalanine ethyl 3.28, 3.06
159 L-leucine ethyl 3.83, 3.47
160 L-proline ethyl 1.60, 1.25
161 L-methionine ethyl 3.81, 3.48
162 /3-alanine ethyl 3.33, 3.27
163 N-methyl-glycine ethyl 5.12, 4.93
164 ethyl-aspartate ethyl 3.66, 3.39
Table 4.6. Phosphoramidates synthesised via protected AZU
The presence of the cyclopentylidene group in the 2’- and 3’-positions 
significantly increased the solubility of 4 ’-azidouridine and consequently the 
concentration of the nucleoside in the reaction solvent (THF). The purification method 
required one chromatography column for each step (coupling and deprotection) and
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the yields observed were significantly higher compared to the same reaction 
performed with the unprotected 4’-azidouridine (24).
4.1.3 Biological activity of phenyl phosphoramidates of 4’-azidouridine
All the phosphoramidates synthesised were tested in vitro in the replicon assay 
(see section 3.3.6.1).9,10
4.1.3.1 Biological activity of L-alanine phenyl phosphoramidates of 4’- 
azidouridine
Historically, L-alanine phosphoramidates have in general shown the best 
antiviral and anticancer activity.11 In Chapter Three a similar result was shown for 
4 ’-azidocytidine. Starting from these promising results, L-alanine phosphoramidates 
with different substituents were prepared to explore the SAR in the ester position. In 
Table 4.7 the biological activities of the synthesised L-alanine phosphoramidates are 
reported.
3 OH OH
R= Ester
121 butyl 1.2 >100
148 methyl 2.5 >100
149 ethyl 1.3 >100
150 isopropyl 0.96 >100
151 ferf-butyl 5.1 >100
152 benzyl 0.61 >100
24 4’-azidouridine >100 >100
5’-triphosphate-AZU= 0.22 pM IC50
Table 4.7. Biological data of L-alanine AZU phenyl phosphoramidates
E C ^  The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CCso= The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
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The application of our phosphoramidate technology has converted an inactive 
nucleoside (4’-azidouridine, 24) into sub-^M active compounds.
As expected, the benzyl ester showed the best activity. The poor activity of 
rm-butyl derivative might be a direct consequence of the inefficiency of one or both 
of the enzymes (“esterase” and “phosphoramidase”) involved in the phosphoramidate 
metabolism.
Methyl, ethyl and isopropyl derivatives did not show a significant difference in 
potency (G raph 4.1).
1.8 
~  1.6
3. 1.4
a  i .2
0w 1
u  Al&J
^  0.8
u* 0 .6
1  0.4 o
“ ■ 0.2 
0
A * <e*
G raph 4.1. Activity of AZU L-alanine phosphoramidates
The 2-butyl phosphoramidate showed almost the same activity as the 
corresponding benzyl derivative, but interestingly, the L-alanine ethyl ester 
phosphoramidate showed poor activity.
The butyl derivative showed an activity similar to the isopropyl and ethyl 
analogues.
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4.1.3.2 Biological activity of D-alanine phenyl phosphoramidates of 4’- 
azidouridine
In previous published works, D-alanine phosphoramidates showed poor or at 
least modest activity, indicating a possible stereoselective metabolism of 
phosphoramidates.12 Initial biological results of 4’-azidocytidine phosphoramidates, in 
contrast, showed that L-alanine and D-alanine phosphoramidates had comparable 
activity; for this reason we decided to investigate the possible variation of the ester in 
a series of D-alanine phosphoramidates. The biological activities observed are 
reported in Table 4.8.
■ X  - A
NH
<A>
O '  'N  
O
N3 OH OH
R= Ester
115 benzyl 1.24 >100
116 dodecyl 16.3 >100
117 butyl >100 >100
118 2-butyl >100 >100
119 octyl 28.8 >100
120 isopropyl 100 >100
24 4’-azidouridine >100 >100
5’-triphosphate-AZU= 0 . 2 2  pM IC 5 0
Table 4.8. Biological data of D-alanine AZU phenyl phosphoramidates
EC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CCso= The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
From these data, the phosphoramidate bearing a benzyl ester showed the best 
activity possibly because the benzyl group might be a good substrate for the esterase 
enzyme involved in the activation mechanism of phosphoramidates (see Chapter 
Three).
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G raph 42.  Ester variation for D-alanine phosphoramidates
The dodecyl and octyl ester derivatives have never been made in the past 
(G raph 4.2). A long and lipophilic chain should represent a poor substrate for the 
enzyme involved in the phosphoramidate metabolism. The presence of modest activity 
might be an indication that the cleavage of the ester, by the corresponding enzyme 
was not the limiting step during the release of the 5’-monophosphate form. In the case 
of the D-alanine series the isopropyl and 2-butyl ester derivative showed poor activity, 
as a consequence of possible steric hindrance within the active site close to the ester 
bond.
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4.1.3.3 Biological activity of phenyl phosphoramidates of 4’-azidouridine
In order to investigate possible biological activity variations on changing the 
amino acid unit, a series of different amino acid ester phosphoramidates was 
synthesised and tested in the replicon assay (Table 4.9).
Cpd
no.
E C 5 0  C C 5 0  
(pM) (pM)
HN
3 OH OH
R= Amino acid 
R'= Ester
112 cyclopentylgly benzyl <100 >100
113 cyclopentylgly ethyl >100 >100
114 cyclopentylgly isopropyl 100 >100
153 glycine benzyl 1.6 >100
154 L-valine benzyl <100 >100
155 a,a-dimethylgly benzyl 3.4 >100
156 a,a-dimethylgly ethyl 10.3 >100
157 L-phenylalanine benzyl <100 >100
158 L-phenylalanine ethyl 1.37 >100
159 L-leucine ethyl 2.3 >100
160 L-proline ethyl 6.0 >100
161 L-methionine ethyl 14.0 >100
162 /3-alanine ethyl >100 >100
163 N-methyl-glycine ethyl >100 >100
164 ethylaspartate ethyl >100 >100
24 4’-azidouridine >100 >100
5’-triphosphate-AZU= 0.22 pM IC50
Table 4.9. Biological data of AZU phenyl phosphoramidates
E C ^  The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CCs p  The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
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The inactivity of phosphoramidates incorporating unnatural amino acids such 
as /J-alanine and A-methyl-glycine might indicate that the presence of an a-amino 
acid and a secondary amino group were prerequisites for the phosphoramidate 
metabolism. Also in this case all the cyclopentylglycine phosphoramidates are 
inactive, confirming a behaviour observed previously for the 4 ’-azidocytidine 
phosphoramidate (see C hapter Three).
Subsequently, the biological activities of different amino acid benzyl esters 
have been compared, for both 4’-azidouridine and 4 ’-azidocytidine phosphoramidates 
(G raph 4.3).
1.8 
£ 1.6
^  1.2 
Oin i
u  1ui
^  0.8
>  0.6
S 0.4 
O
Q- 0 .2
A  A  A  A  A  A
o  S
G raph 4 3 . Amino acid variation for AZU and AZC benzyl phosphoramidates
AZU-PN
AZC-PN
The D-alanine phosphoramidate was 2 fold less active than the corresponding 
L-isomer. Almost the same reduction in activity was found by replacing L-alanine 
with glycine and dimethylglycine. This indicates that the presence of the methyl group 
of the L-alanine unit does not confer any advantage over the glycine or D-alanine. 
Moreover, the fact that D-alanine and glycine are equipotent might indicate the
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presence of a non-stereospecific mechanism in the release of the 5’-monophosphate. 
Considering other L-amino acids with larger and more hydrophobic side chains (e.g. 
L-valine, L-isoleucine, L-leucine), a notable reduction of activity was observed: this 
might indicate the presence of a small hydrophobic pocket in the putative activating 
enzyme (“esterase” and “phosphoramidase”).
The possible correlation between the activity of the phosphoramidates and the 
lipophilicity of the amino acid present in these structures has been analysed and 
reported in G raph 4.4.
■  AZC-PN
■  1/ClogP
1/N o  of Carbon
0 .5
v
Graph 4.4. Correlation between AZU-PN activity ClogP and number of carbon (all the 
amino acids are benzyl ester)
ClogP expresses the value of lipophilicity of a molecule that might be 
correlated to the percentage of carbon in the molecules.
Substantial reduction in activity is observed when the ClogP reaches a value of 
~1. In this series of phosphoramidates (G raph 4.4) the variation of ClogP is owing to 
the lipophilicity of the lateral chain of the amino acid.
The trend of activity may result from size and length of the lateral chain of 
each amino acid. In G raph 4.4, the reciprocal of the number of the carbons in the
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lateral chain for each amino acid is indicated and is an expression of the value of the 
steric hindrance: more lipophilic amino acid (e.g. phenylalanine, leucine, valine) have 
a lower value compared to more hydrophilic amino acid (e.g. L- and D-alanine, 
glycine and dimethylglycine).
The trend of the activity and the reciprocal of the number of the carbons 
showed similar profile, indicating that the active site of one of the enzyme, involved 
in the release of the 5 ’-monophosphate might only tolerate small lateral chains such as 
the methyl of L- and D-alanine.
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4.2 Substituted phenyl phosphoramidates of 4 ’-azidouridine
In order to compare the effect of electon-donating and electron-withdrawing 
substituents on 4 ’-azidouridine and 4 ’-azidocytidine phosphoramidates, the Topliss 
tree concept has been applied to ethyl L-leucine 4 ’-azidouridine phosphoramidates.13
As mentioned in C hap ter Three, the Topliss tree is a methodology designed 
to find the best substituent that can be present on the aryl moiety of a general 
phosphoramidate system.13
4.2.1 Synthesis of phosphorylating agents fo r coupling with 4-azidouridine
In order to synthesise the appropriate phosphrochloridate required for the 
coupling with 4 ’-azidouridine, the compounds previously mentioned in C hap ter 
Three (see section 3.4.1 and 3.4.2) were resynthesised.
4.2.2 Synthesis and  biological activity of phosphoram idates of 4 ’-azidouridine 
with substituents on the ary l moiety
Four possible substituents present in the first row of the Topliss tree (p-chloro, 
3,4 di-chloro, p-methyl and p-methoxy) were synthesised. The synthesis as previously 
described (see section 3.3.5) was an application of the Uchiyama procedure in which 
the synthesis of the 5 ’-alkoxide of 4 ’-azidouridine was performed using an excess of 
tBuMgCl followed by coupling with the appropriate phosphorochloridate (Figure 
4.4).2'5
HNHN
O-P-N y  Ov ,NH
HO O tBuMgCl, THF
'3 OH OH'3 OH OH
Figure 4.4. Synthesis of substituted phenyl phosphoramidates of AZU
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All the compounds synthesised were tested in vitro in the replicon assay (see 
section 3.3.6.1) against HCV (Table 4.10).9 10
The unsubstituted phosphoramidates showed an E C ^  2.3 pM  which 
represents an activity superior to the substituted (electron-donating and electron- 
withdrawing groups) derivatives (Table 4.10).
OH OH
165 chloro H <100 >100
166 chloro chloro 15.1 >100
167 methyl H 2.1 >100
168 methoxy H <100 >100
159 H H 2.3 >100
24 4’-azidouridine 1.28 >100
5’-triphosphate-AZU= 0.22 pM IC50
Table 4.10. Biological activity of AZU phenyl substituted phosphoramidates
EQkp The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
In the case of para-chloro and para-methoxy the activity was totally absent 
(G raph 4.5). The presence of an inductive group (p-chloro and 3,4-dichloro) slightly 
reduced the observed activity. However, there is not a great difference, which 
indicates that the presence of an electron-withdrawing or electron-donating group 
might not influence the activity significantly.
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G raph 4.5. Topliss tree applied to AZU L-leucine ethyl ester phosphoramidates
A possible explanation might be correlated with the instability observed during 
the synthesis of the two unsubstituted phosphoramidates of 4 ’-azidocytidine and 4 ’- 
azidouridine. As a consequence of this instability, the phosphoramidates tested were 
already partially decomposed invalidating the biological results. For this reason the 
Topliss tree was not further investigated.
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4.3 Naphthyl and quinolinyl phosphoramidates of 4 ’-azidouridine
Previous studies have shown that the presence of a more lipophilic aryl moiety 
can increase the biological activity of phosphoramidates.14 For this reason we decided 
to synthesise a small series of phosphoramidates with a- and )8-naphthyl as the aryl 
moiety.
4.3.1 Synthesis of phosphorylating agent for coupling with amino acids
The synthesis of the phosphorylating agent for coupling with the amino acid 
was performed following the procedure already described in Chapter Three (see 
section 3.5.1)
4.3.2 Synthesis of phosphorylating agents for coupling with 4’-azidouridine
The previously described procedure for the synthesis of phosphorochloridate 
(see section 3.3.6) was applied .2'5
The instability of these compounds necessitated a rapid purification method by 
chromatography column using a mixture of hexane/EtOAc (7:3) as eluent.
Due to the non-stereospecific reaction, the synthesised products were a 
mixture of two diastereoisomers with a signal splitting in the 31P-NMR spectra (Table 
4.11).
Cpd Aryl
31P (PPm)
no. moiety
R'v H ON.n^ci
R= Amino acid 
R'= Ester
169 cyclopentylgly benzyl a-naphthyl 7.05
170 cyclopentylgly ethyl a-naphthyl 6.90
17114 D-alanine isopropyl a-naphthyl 7.88,7.37
17214 D-alanine benzyl a-naphthyl 7.40, 7.17
Table 4.11. Naphthyl phosphorochloridates synthesised
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4.3.3 Synthesis of a - and ^-naphthyl 4’-azidouridine phosphoramidates
The synthesis of naphthyl phosphoramidates of 4’-azidouridine was carried out 
using the Uchiyama procedure in the presence of an excess of tBuMgCl in THF (see 
section 3.3.5).3,6
In the first instance, L-alanine benzyl ester with a- and /^-naphthyl as the aryl 
moiety were synthesised, with yields of 9% and 5% respectively.
A r '° w NH O
N H
H O
'3 O H  O H3 O H  O H
24 Ar= Aryl mioety
Figure 4.7. Initial synthesis of naphthyl phosphoramidates of AZU
In an attempt to increase the yield, the same phosphoramidate reaction was 
performed with 2 \ 3’-protected 4 ’-azidouridine (145) and following the results 
obtained with the protection of 4 ’-azidocytidine, the cyclopentylidene group was 
utilised (Figure 4.8).
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i
NH
A r-O -P-N
HO
HN
145
80% HOCOOH
R= Amino acid 
R’ Ester
Ar= Aryl moiety HN
'3 OH OH
Figure 4.8. Synthesis of 2 \3 ’-cyclopentylidene 4 ’-azidouridine phosphoramidates
The reaction was stirred overnight and the purification usually required only 
one chromatography column with a significant increase in the overall yields.
The phosphoramidates synthesised using the protected and unprotected 4’- 
azidouridine are reported in Table 4.12.
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O o
P (ppm)
173 L-alanine benzyl a-naphthyl 3.94,3.76
174 L-alanine benzyl /?-naphthyl 3.78, 336
Ns OH OH
175 cyclopentylgly benzyl a-naphthyl 3.10,3.06
176 cyclopentylgly ethyl a-naphthyl 3.23,3.15
R= Amino acid 
R'= Ester 177 D-alanine isopropyl a-naphthyl 3.73, 360
173 D-alanine benzyl a-naphthyl 3.80, 360
Table 4.12. AZU naphthyl phosphoramidates synthesised and their JIP chemical shift
Due to the non-stereoselectivity of the coupling reaction, a mixture of two
and ‘H-NMR. The observed 31P-NMR chemical shifts were between 7.7 and 10.6 
ppm.
4.3.4 Synthesis of 8-quinolinyl phosphoramidate of 4’-azidouridine
The synthesis of a phosphoramidate with 8-hydroxy-quinoline as an aryl 
moiety was planned, because this group represents an isostere of the naphthol group 
and their calculated plC, values are similar (pKa~5). The pKg value is important in the 
phosphoramidate metabolism because one of the side products of this process is the 
corresponding phenolate of the aryl moiety: as a consequence a group with a similar 
plC, might have similar efficiency in the release of 5’-monophosphate.
In this case the first attempt was conducted using the standard procedure, but it 
was not possible to isolate the desired compound (179). Due to the possible high 
instability of the 8-hydroxy-quinolinyl group in the reaction conditions, the synthesis 
was performed using a modification to the standard procedure (Figure 4.9).
phosphate diastereoisomers was obtained as indicated by the splitting in the 31P-NMR
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OH + pocia EUN
0
c i- p - ci1o
180
° V NH O ^ H J
0,' ° ^
N» OH OH
179
1.
145
HO
NH
A .
EtsN
‘BuMgCI
2. HCOOH 80 %
O u ,'Y ^ nh3+ cr 
o
C ^ ° y ^ nX ci
o H o
181
Figure 4.9. Synthetic pathway for the synthesis of 8-quinolinyl phosphoramidate
Thus, the phosphorodichloridate (180) synthesis was carried out using the 
standard procedure described before with a yield of 75 %
The following coupling reaction with L-alanine benzyl ester hydrochloride 
was performed under the standard condition, and the phosphorochloridate (181), was 
used for the next step with 2,3’-cyclopentylidene 4-‘azidouridine (125) to give the 
corresponding phosphoramidate. The purification of this compound was carried out 
using HPLC.
The deprotection using the standard procedure (solution of 80% HCOOH) was 
performed. The desired product (179) was obtained in reasonable yield. For this 
compound the splitting of signals in 31P- (4.01, 3.95) and !H-NMR spectra was 
observed.
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4.3.5 Biological activity of naphthyl and 8-quinolinyl phosphoramidates of 4’- 
azidouridine
All the naphthyl and 8-quinolinyl phosphoramidates of 4 ’-azidouridine were 
tested in the replicon assay and the obtained data are reported in Table 4.13.9,10
NH
-Ox ,NH
13 OH OH
R= Amino acid 
R'= ester
173 L-alanine benzyl a-naphthyl 0.19 >100
174 L-alanine benzyl ^-naphthyl 3.5 >100
175 cyclopentylgly benzyl a-naphthyl 15.9 >100
176 cyclopentylgly ethyl a-naphthyl >100 >100
177 D-alanine isopropyl a-naphthyl >100 >100
178 D-alanine benzyl a-naphthyl 1.0 >100
179 L-alanine benzyl 8-quinolinyl 7.62 >100
24 4’-azidouridine >100 >100
5’-triphosphate-AZU= 0.22 pM IC50
Table 4.13. Biological results of AZU naphthyl and 8-quinoinyl phosphoramidates
The cyclopentylglycine phosphoramidates (175, 176) displayed poor activity, 
while for D-alanine derivatives, the isopropyl was found to be completely inactive, the 
benzyl ester showed an activity of 1.0 //M.
4.3.5.1 L-alanine naphthyl and 8-quinolinyl phosphoramidates of 4’- 
azidouridine
The /^-naphthyl phosphoramidate showed a considerable increase in 
activity compared to the inactive nucleoside (24), but most importantly the a-naphthyl 
derivative had an activity at 0.1 jiM  with an increase of >1000 fold compared to the 
corresponding nucleoside (4’-azidouridine, 24) (Graph 4.6).
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Nucleoside Phenyl 1-Naphthyl 2-Naphthyl 8-quinolinyl
G raph 4.6. Biological activity of AZU phosphoramidates with different aryl moiety
Comparing the a-naphthyl (173) and its corresponding phenyl 
phosphoramidate (152) the enhancement of the activity is 2.5-fold. This significant 
increase in activity has not been found for the /Tnaphthyl derivatives. An explanation 
for this different behaviour might be related to the nature of the active site of one of 
the enzymes (esterase) in which there might be a lipophilic pocket capable of 
interacting with a phenyl group or a-naphthyl-group ( jt- j i  interaction). The /3- 
naphthyl-group, on the other hands represents a poor substrate for the enzyme, due to 
its different orientation.
The biological data obtained for the 8-quinolinyl phosphoramidate (179) 
indicated that this compound is less active than the corresponding a-naphthyl and 
phenyl derivatives. Initially, the biological activity for this compound was expected to 
be comparable with the a-naphthyl derivative. However, the problems of instability 
encountered during the synthesis of this phosphoramidate (179) might have caused 
partial degradation during the test for the biological activity.
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4.4 4 ’-Ethynyluridine phosphoramidates
Another 4 ’-modification made by Roche was the introduction of an ethynyl 
group on the uridine structure (25). In the replicon assay 4 ’-ethynyluridine was found 
to be completely inactive. As explained for the 4 ’-azidouridine (24), the possible 
explanation for this involved the poor interaction between this nucleoside and the 
intracellular TK (see C hap ter One).1 If the first phosphorylation in particular, was the 
rate limiting step in this process, phosphoramidate methodology would represent a 
possible solution to efficiently deliver the 5 ’-monophosphate into the cells. The 
synthesis of the D-alanine benzyl ester phosphoramidates of 4 ’-ethynyluridine (180) 
was performed using the conditions already described for the 4 ’-azidocytidine (23) 
and the 4 ’-azidouridine (24) (Figure 4.10).
X  ' C H r 8 HN
HO O o
/  OH OH 
25
^  OH OH 
180
Figure 4.10. Synthesis of D-alanine benzyl ester of ETU
The procedure was the same used for the synthesis of 4 ’-azidocytidine (23) 
and 4 ’-azidouridine (24) phosphoramidates. The purification required one column and 
one preparative TLC without any traces of P-OH (64). The phosphoramidates were 
synthesised in reasonable yield. Preliminary biological data on the 4 ’-ethynyluridine 
phosphoramidates showed complete inactivity of these compounds; consequently 
other phosphoramidates were not synthesised. A possible explanation of this inactivity 
might be related to nucleoside activation to the corresponding 5 ’-triphosphate: in this 
case, the limiting step may not be the first but the second or the third phosphorylation; 
consequently the delivery of 5 ’-monophosphate through the phosphoramidate 
methodology does not bypass this limiting step.
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Chapter Five
Aryloxyphosphoramidates of adenosine analogues
5.1 Synthesis of 4 ’-azido-adenosine (AZA)
The synthesis of 4 ’-azidoadenosine was planned in order to apply the 
arylphosphoramidate approach to a purine nucleoside with the same structural 
modification as the previous examples (4’-azidocytidine 23, 4 ’-azidouridine 24 and 
4 ’-ethynyluridine 27).
5.1.1 Initial synthetic pathw ay for the synthesis of 4 ’-azido-adenosine
4 ’-Azidoadenosine represents the first example of a modified purine tested 
against HCV in this project. The proposed synthetic pathway is shown in Figure 5.1.1
nh2 
N N
HO
1 w l
OH OH 
181
nh2
N N
OH OH
27
nh2
OH OH 
182
N(Bz)2
N N
OBz OBz
185
N
N
O
OH OH
183
c.
NH2
<":u J
OH OH
184
a. Ph3P, l2l dioxane, pyridine; b. tBuOK, Pyridine; c. ICI, NaN3, DMF;
d. BzCI, Pyridine; e. 1. MCPBA, CH2CI2/H20; 2. MeONa, MeOH
Figure 5.1. Synthetic pathway for AZA
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5.1.2 Iodination of adenosine
The first attempt was performed using the same conditions as reported in 
literature.1 Due to a low solubility of the starting material (181) in dioxane-pyridine, 
the yield for this first reaction was 3%; for this reason other conditions were tried.2,3
The first alternative was to use triphenylphosphine, iodine and an excess of 
imidazole in NMP (yV-methyl-pyrrolidinone), which afforded 26% of an impure 
compound contaminated with triphenylphosphonium oxide.2
In order to use a different source of iodine, according to the literature, the 
iodination in the 5’-position was attempted using CI4 and triphenylphosphine in a 
solution of hexamethylphosphoric acid triamide (HMPT).3 Unfortunately, difficulty to 
remove the solvent and the formation of many product as indicated by TLC, were 
clear signs against a possible use of this reaction on a large scale.
Another attempt of the literature procedure was performed this time using 
pyridine as the solvent. In this case, after purification by column chromatography, the 
yield was 90%. Unfortunately, from the ‘H-NMR spectra the presence of 
triphenylphosponium oxide was observed.
The reaction was repeated on a larger scale starting from 15 g of adenosine. It 
afforded, after purification by column chromatography, a yield greater than 100%. 
The possible explanation was the presence, also in this case, of triphenylphosphonium 
oxide, confirmed by the presence of a signal at 25 ppm in the 31P-NMR spectra.
In order to avoid the use of a column for the purification, the first step was 
repeated, with the same conditions previously described, followed by an extraction 
(EtOAc/HzO). Due to the higher lipophilicity of triphenylphosphine, its percentage in 
the product was higher than before. Several attempts with crystallisation were tried 
with different solvents: ethanol, isopropanol, ethanol/chloroform, ethanol/ethyl acetate, 
ethanol/hexane, without any suitable results.
In order to overcome this problem, the same reaction was performed using 
triphenylphosphine supported on resin (polystyrene, PS-triphenylphosphine). In this 
case the desired product was obtained pure and in reasonable yield. Due to the high 
polarity of 5 ’-deoxy-5’-iodoadenosine (182) the use of large amounts of EtOAc was 
necessary to fully extract the compound. In order to make the protocol reliable on a 
larger scale, the same reaction was tried using as starting material the 2 ’,3’- 
isopropylidene protected adenosine (186) with PS-triphenylphosphine. In this case,
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the reaction proceeded at 50 °C (Figure 5.2). After purification by extraction, the pure 
desired product (187) was obtained in poor yield (13%). TLC indicated the formation 
of a polar compound that had been noticed in all the previous attempts; in the earlier 
cases it represented only a side product of the reaction and did not significantly affect 
the yield. This compound, isolated and fully characterised, was the product of 
intramolecular nucleophilic substitution at the 5 ’-position involving the nitrogen in the 
3-position (188).
NN
NN
HO OO Pyridine 
50° C
° x ?
13%
X
186
187 188
Figure 5.2. Synthesis of 5 ’-deoxy-5’-iodoadenosine using PS-Ph3P
This side product (188) has been reported in the literature for a compound 
having a good leaving group at the 5 ’-position (such as triphenylphosphonium oxide 
or tosylate).4,5,6
The reaction was repeated on a large scale using chromatography column as 
the purification method.
5.1.3 Elim ination of HI from  5’-deoxy-5’-iodoadenosine
The second step was the elimination in 4 ’-5’ position and it was performed 
using tBuOK in pyridine (Figure 5.1).2 Compared to the use of MeONa/MeOH, this 
method gave rise to an easier purification protocol. The main problem in this reaction 
was the unreliable yield (between 15% and 80%). By reducing the concentration of 
tBuOK, from 4.5 to 3.0 equivalents, and increasing the volume of pyridine, it was 
possible to avoid the formation of a black compound that contaminated the product 
and that was not easily removed by column chromatography. Nevertheless, in this
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way it was possible to obtain the desired product (183) in more reliable yield (70- 
80%).
5.1.4 Stereoselective and  regioselective addition of IN3
The key step in this synthesis was the regio- and stereo-selective addition of 
IN3 in the 4 ’- and 5 ’-positions (Figure 4.1), performed in situ by synthesis of IN3 
starting from NaN3 and IC1. In this preparation, iodine added preferentially to the p~ 
face of the double bond to give an iodonium intermediate which was opened on the a- 
side at the 4 ’-position by azide ion. There was no evidence of the presence of the 4 ’- 
epimer.
This step was successful only the first time that this reaction was attempted. In 
order to repeat this reaction again, the temperature was increased, unsuccessfully. 
New reagents were bought, but also in this case the TLC of the reaction did not show 
any presence of the desired product. The reason for the unreliability of this reaction 
(which was reasonably successful in the pyrimidine series) remains unclear.
5.1.5 Protection with benzoyl chloride
The fourth step was performed as reported in the literature.1 The lower yield 
may be correlated with the presence of salts impossible to detect by NMR that might 
reduce the actual weight of the starting material.
5.1.6 Displacement of iodine and deprotection of 2’,3’-hydroxy and 6- 
am ino benzoyl derivatives
The choice of meta-chloroperbenzoic acid (mCPBA)1 for the last step was 
made because the literature reported several studies about the displacement of iodine 
with subsequent deprotection with the more successful one employed using a one pot 
oxidation with mCPBA, followed by deprotection using NaOMe in MeOH.1
The presence of water, in the reaction enviroment, would oxidise the iodine to 
the corresponding hypervalent species improving the leaving group ability of iodine. 
In order to avoid the formation of several side products, the literature reported the 
displacement of the iodine and the subsequent deprotection as a one pot reaction.1 
Following this procedure, the overall yield of these two reactions combined was 50%
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and it gave enough AZA to synthesise one phosphoramidate and its corresponding 5 ’- 
monophosphate.
5.2 Alternative pathway for the synthesis of 4 ’-azidoadenosine
With the previous synthetic pathway it was possible to synthesise only one 
phosphoramidate and the corresponding 5’-monophosphate. In order to synthesise 
more AZA, an alternative synthetic pathway was proposed (Figure 5.3).
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a. 1. TBDMSCI, Im idazole; 2. TFA, H20 ,  THF; b. I2> P h3P, Pyridine; c. tBuOK, 
Pyridine; d. 1. DMDO; 2. TMSN3> SnCI4; e. TBAF, THF.
Figure S3.  Alternative synthetic pathway for the synthesis of AZA
The first step of this alternative synthetic pathway was the complete silylation 
of adenosine (in 2 ’-, 3’- and 5’-positions)7 followed by selective deprotection at the
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5 ’-position using a solution of TFA/H20/TH F 4 : l : l .8The reaction was attempted on a 
small scale, and gave a pure product with quantitative yield. The iodination was 
repeated twice. In the first attempt PS-Ph3P was used, and in second instance Ph3P was 
employed, in both cases, from TLC it was possible to see the presence of significant 
amounts of starting material.
5.2.1 M odified synthetic pathw ay for the synthesis of 4 ’-azidoadenosine
This alternative synthetic scheme was partially modified, with the iodination 
as first step followed by protection in the 2 ’,3’-positions (Figure 5.4).
n h 2nh
N
V *
X  V
N
< N
OH OH
N
H° ^  
OH OH
N
182181
190
NN
NN
HOHO OO
OH OH
- s i -- S i -
191192
a. I2, P h 3P, P yrid ine; b. TBDMSCI, Im idazole , P yrid ine; c . tB uO K , P yrid ine; 
d. 1. DMDO, 2. TMSN3> SnC I4; e . TBAF, THF.
Figure 5.4. Alternative synthetic pathway for the synthesis of AZA
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5.2.2 Iodination and  2’,3’-silylation of adenosine
The first step of this alternative synthetic pathway involved the selective 
iodination at the 5 ’-position of adenosine followed by protection at the 2 ’,3’-positions 
using the /erf-butyldimethylsilyl group.
In this case, the first purification method used was chromatography column 
which gave a product contaminated with triphenylphosphinum oxide. In order to 
avoid this problem, the first two steps (iodination of the 5 ’-position and protection in 
the 2 ’,3’-position) were combined together (Figure 5.5).
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HO O Pyridine
OH OH
181
NH
N
N
O
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182
N
N
O
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190 193
Figure 5.5. One pot reaction to give the 2 ’,3’-disiIyIate 5 ’-iodo derivative of adenosine
On a small scale this one pot procedure afforded the desired product (190) 
with an overall yield of 52% with the presence (13% yield) of the complete product of 
silylation in 2 ’-, 3 ’- and 6-position (193). In attempt to increase the yield, the tert-
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butyldimethyl silyl chloride was substituted with rm-buthyldimethylsilyltrifluoro 
methanesulfonate. This variation was applied successfully on a small scale and then 
repeated on a large scale with a significant increase in the overall yield.
5.2.3 Elim ination of HI from  5’-deoxy-5’-iodoadenosine
Following previously described methodology (see section 5.1.3) a pure white 
product was isolated in high yield. This reaction was attempted on a small scale and 
subsequently on a large scale affording, respectively, 88% and 70% yield (Figure 
5.4).
5.2.4 Epoxidation in the 4 ’-, 5’-position and  regio- and  stereo-selective 
ring opening
In the literature the synthesis of the epoxide followed by the regio- and stereo­
selective ring opening has been well reported for several nucleosides. 9
The synthesis of the epoxide derivative was performed using a 0.1 M solution 
of dimethyldioxirane (DMDO) in acetone.
The synthesis of DMDO was achieved starting from oxone® 
(monopersulphate compound) in the presence of water and acetone at basic pH. The 
DMDO was distilled as a 0.1 M solution of acetone.
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5.2.5 F u rth er modification on the 4’-azidoadenosine synthetic pathway
In an attempt to avoid the possible N6-oxidation of adenosine during the 
epoxidation reaction, the previous synthetic pathway was further modified with the 
protection of the 6-NH2 with a pivaloyl group (Figure 5.6). The reaction was 
attempted on a small and larger scale, affording respectively 95% and 93% (194).
HN HN
HO
- s i - - s i -
195191 194
HN HN
HO HO HO
OH OH
196
197198
a. Pivaloyl chloride, DIEA; b. 1. DMDO; 2. TMSN3, SnCI4; c. TBAF, 
THF; d. 1,1-dimethoxycyclopentane, pTSA; e. NH^MeOH
Figure 5.6. Further modification on the original AZA synthetic pathway
The subsequent epoxidation using DMDO afforded the desired product used in 
the next step. The regio- and stereo-selective ring opening was performed using azido- 
trimethilsylane and SnCl4. In the literature it has been reported that the use of other
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Lewis acids, such as TiCl4 or EtAlCl2, gave mainly the starting material with low 
yield.9 The work up for this reaction was the neutralisation of the Lewis acid using an 
aqueous solution of NaHC03, which resulted in an emulsion that was eliminated by 
filtration through a celite pad. Subsequent purification by chromatography column 
afforded the pure product (195) in an overall yield between 39 and 54%.
5.2.5.1 Deprotection of hydroxy groups in the 2’- and  3’-positions
The deprotection of the two hydroxy groups in the 2 ’- and 3’-positions 
(Figure 5.6) was performed using the standard procedure to cleave the silyl group: a 
solution of tetrabutylammonium fluoride (TBAF) in THF at room temperature. After 
purification by column the desired product (195) was obtained with 70% yield; 
however from the analysis of the *H-NMR spectra the presence of 
tetrabutylammonium protons were observed with a calculated percentage of 5% of the 
impurity.
5.2.5.2 Protection of hydroxy groups in the 2 ’- and 3’-positions
From previous work on AZC (23) and AZU (24) (see C hapter Three and 
C hapter Four), the protection of hydroxy groups in the 2 ’- and 3’-positions was 
important in order to obtain a higher yield and easier purification during the 
phosphoramidate synthesis. Considering the previous successful results, the 
cyclopentylidene group was chosen. The protection reaction was performed using 1,1- 
dimethoxycyclopentane as solvent and 1.5 equivalents of /?-toluene sulphonic acid 
(Figure 5.6). The purification method was chromatography column, which on a small 
and large scale gave the pure product (197) in yields of 71 and 67% respectively.
5.2.5.3 Deprotection of the 6-NH2
Due to the presence of the pivaloyl group, the last step of this synthesis was 
the deprotection of the 6-NH2. This reaction was performed in methanolic ammonia 
overnight (Figure 5.6).
Purification by chromatography column afforded the final product in 80% 
yield. Starting from 15 g of adenosine, 800 mg of the 2 ’,3’-protected 4 ’- 
azidoadenosine (198) was obtained.
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5.3 a-naphthyl 4 ’-azidoadenosine phosphoramidates
The 2 ’,3’-protected 4 ’-azidoadenosine represented the staring material for the 
synthesis of a small series of phosphoramidate.
OH C I - P - C I
POCI
Et3N
R' Y ^ NH*+
N
N
NH
VNH s .
N3 o h  o h
F ig u re  5.7. Proposed synthetic scheme for the synthesis of a-naphthyl AZA phosphoramidates
A series of 4 ’-azidoadenosine a-naphthyl phosphoramidates was targeted 
(Figure 5.7) using the Uchiyama procedure.10
5.3.1 Synthesis of phosphorylating agent for coupling with amino acids
The synthesis of the a-naphthyl dichlorophosphate was repeated following the 
conditions previously described in C hap ter Three and C hapter Four.
5.3.2 Synthesis of phosphorylating agents for coupling with 4’-azidocytidine
The SAR previously explored with 4 ’-azidocytidine and 4 ’-azidouridine 
phosphoramidates (see C hapter Three and C hap ter Four) showed that the presence 
of L-alanine as amino acid is an essential requisite in order to have good activity. For
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this reason a small series of 4 ’-azidoadenosine a-naphthyl phosphoramidates was 
planned.
The phosphorylating agents used for coupling with 4 ’-azidoadenosine (27) 
were synthesised using the same procedure as described in Chapter Three and 
Chapter Four.12* 13, 14 The synthesised phosphorochloridates are reported in Table 
5.1.
R " ° Y ^ N - P - C I  
U H '
R= Ester
Table 5.1. Phosphorochloridate synthesised
20011 ethyl 86% 8.42, 8.39
20111 ferf- butyl 89% 8.48, 8.19
5.3.3 Synthesis of a-naphthyl 4’-azidoadenosine phosphoramidates
In the first instance, the synthesis of naphthyl phosphoramidates of 4 ’- 
azidoadenosine (202) was performed in the presence of 4’-azidoadenosine, using the 
Uchiyama procedure using an excess of tBuMgCl in THF (see Chapter Three).10 
The first phosphoramidate synthesised was the a-naphthyl L-alanine benzyl ester 
(Figure 5.8).
NHNH
o h  o h
1 C ?
N3 o h  o h  
202
Figure 5.8. Initial synthesis of naphthyl phosphoramidates of AZA
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The major problem was the presence of what has been defined P-OH (64) after 
the first column (see Chapter Three). The full purification format required one 
chromatography column, one preparative TLC and one preparative HPLC. Due to the 
high number of purification steps, the yield of product was low (6%).
In an attempt to increase the yield and simplify the purification method, the 
same phosphoramidate reaction was performed with 2’,3’-protected 4 ’- 
azidoadenosine (198). Following the successful results obtained with the protection of 
4 ’-azidocytidine and 4 ’-azidouridine, cyclopentylidene was the group introduced in 
the 2’- and 3’-positions (Figure 5.9).
NH NH;
HO
198
80% HCOOH
R= Ester
NH
n 3 o h  o h
V°. ,n h
Figure 5.9. Synthesis of 2’,3’-cyclopentylidene AZA phosphoramidates
The reaction was stirred overnight and the purification usually required one 
chromatography column with good overall yields. The followed deprotection reaction 
was performed using an aqueous solution of formic acid (Figure 5.9).
The phosphoramidates synthesised are reported in Table 5.2.
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R X
o nh2
P (ppm)
203 ethyl 3.72, 3.68
N3 OH OH 204 ferf-butyl 3.85, 3.73
Table 5.2. a-Naphthyl phosphoramidates synthesised with 2 ’,3’-cyclopentylidene AZA
5.4 Phenyl 4 ’-azidoadenosine phosphoramidates
In order to compare the difference of activity between the presence of an a- 
naphthyl and phenyl unit as the aryl moiety, a series of phenyl 4 ’-azidoadenosine 
phosphoramidates was planned. Also in this case, L-alanine was used as the amino 
acid and benzyl, ethyl and /erf-butyl as esters.
5.4.1 Synthesis of phosphorylating agents for coupling with 4’-azidoadenosine
The non-commercially available phosphorochloridates were synthesised using 
the previously described procedure (see Chapter Three), in the presence of 
phenyldichlorophosphate, the appropriate amino acid ester and with an excess of 
triethylamine (Figure 5.12).
The phosphochloridates necessary for coupling with 4’-azidoadenosine were 
resynthesised using the procedure described in Chapter Three and Chapter Four. 12
5.4.2 Synthesis of protected AZA phosphoramidates
In order to avoid problems such as low solubility and difficult purification, the 
phenyl phosphoramidates of 4 ’-azidoadenosine were synthesised via the 
corresponding 2’,3’-cyclopentylidene nucleoside (Figure 5.10) using the Uchiyama 
procedure with an excess of tBuMgCl in THF (see Chapter Three and Chapter 
Four),10 It required only one chromatography column to obtain pure 2’,3’-protected 
4 ’-azidoadenosine phosphoramidates.
The deprotection was carried out with a 80% solution of HCOOH at room 
temperature for 4 hours (Figure 5.10).
14
120
Plinio Perrone Chapter Five
NHNH
HO
198
80% HCOOH
R= Ester
NH
OH OH
Figure 5.10. Synthesis of 2’,3’-cyclopentylidene AZA phosphoramidates
The purification of the deprotection reaction required only one column. The 
overall yield was around 70-80%. In this way it was possible to synthesise the 
phosphoramidates reported in Table 5.4.
NH
N
N
O
3 OH OH
206 benzyl 3.38, 3.21
207 ethyl 3.44, 3.28
208 ferf-butyl 3.42
Table 5.4. Phenyl Phosphoramidates synthesised using the 2 \ 3 ’-protected AZA
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5.5 Biological activity of aryloxy phosphoramidates of 4 ’- 
azidoadenosine
All the a-naphthyl and phenyl phosphoramidates have been tested in vitro 
using a replicon assay (see section 3.3.6.1) against HCV (Table 5.5).15,16
N
Ar'0._,NH \
nh2
I  J fN
OH OH
R= Ester 
Ar= Aryl moiety
202 benzyl a-naphthyl 0.22 >100
203 ethyl a-naphthyl 0.69 >100
204 ferf-butyl a-naphthyl >100 >100
206 benzyl phenyl 4.00 >100
207 ethyl phenyl 1.50 >100
208 ferf-butyl phenyl >100 >100
27 4’-azidoadenosine >100 >100
Table 5.5. Biological activity of AZA naphthyl phosphoramidates
EC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CCso= The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
The 4 ’-azidoadenosine (27) was found to be completely inactive and non­
toxic, indicating that this nucleoside might be a poor substrate for the kinases and 
consequently the concentration into the cell of its corresponding active form (5’- 
triphosphate) is very low.
The corresponding ethyl and benzyl ester phosphoramidates were active 
against HCV. These data confirm that the phosphoramidate approach is a valuable 
technology that allows the conversion of inactive nucleoside (27) into sub-piM active 
compounds (202, 203) bypassing the first phosphorylation that is often the rate 
limiting step in the activation mechanism of nucleosides.
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The comparison between phenyl and its corresponding a-naphthyl 
phosphoramidates shows a significant (18-fold) increase for the benzyl ester (202 and 
206) (Graph 5.1).
Z
3.
o  3 in u  iu
>ucV•M
S. i
Benzyl
Phenyl
a-Naphthyl
Ethyl tert-butyl
Graph 5.1. Biological activity of AZA phosphoramidates synthesised
This increase of activity might be the result of a decrease in the pIC, value and 
the increase in lipophilicity that might facilitate the passive diffusion of 
phosphoramidates. The two terf-butyl phosphoramidates synthesised, by way of 
contrast were not active as a consequence of being poor substrates for the esterase 
involved in the monophosphate release.
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Chapter Six
Aryloxyphosphoramidates of /7-2’-methylnucleosides
6.1 /?-2’-methylnucleosides
Several examples of modified nucleosides have been reported with potential 
anti-HCV activity. 12’3’4 In most cases, the modification was made at the 2 ’- or 3’- 
positions. The active forms of these nucleosides are represented by their 
corresponding 5 ’-triphosphate that (interacting with the active site of the RdRp) are 
incorporated into the growing chain of the viral RNA and consequently cease the 
HCV replication.
The 2 ’-methylpurines (adenosine and guanosine) have been demonstrated to 
be potent anti-HCV agents:1,2 /3-2’-methyladenosine showed I C ^  1.9 piM (inhibition 
of RdRp), E C ^  0.26 piM against HCV, and the detected level of its corresponding 5 ’- 
triphosphate was 105 Intracellular NTP/pmol per 106 cell. /J-2’-methylguanosine, 
instead, showed I C ^  0.13 piM (inhibition of RdRp), E C ^  3.5//M against HCV, but 
most importantly the detected level of its corresponding 5 ’-triphosphate was rather 
poor (Intracellular NTP/pmol per 106 cell= 0.2). This might be an indication that this 
nucleoside was a poor substrate for the kinases responsible for the conversion into its 
corresponding active species (5’-triphosphate). We decide to apply the 
aryloxyphosphoramidate approach to these two modified nucleosides in order to 
explore the possibility of further increasing their activity against H CV.1,2
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6.2 Synthesis of /?-2’-methyladenosine
The synthesis of fi-T -methyladenosine was planned following the reported 
procedure (Figure 6 .1).12
BzO
OBz OH
209
OBz a.
HO
OH OH
215
nh2
Bz0v ° T z
OBz O 
210
b. BzO—i n ?®z BzO—i Q°~ h i + l ^ | r ° H
OBz OH OBz OBz
211 212
c.
HN
BzO
OBz OBz
214
BzO
OBz OBz
213
OBz
a. Dess-Martin reagent, CH2CI2 dry; b. MeTiCI3; c. BzCI, DMAP, Et3N. d. 6-pivaloyladenine, DBU, 
TMS-triflate, CH3CN; d. MeOH/NH3
Figure 6.1. Synthesis of /J-2’-methyladenosine
6.2.1 Oxidation of the 2-position
The oxidation in the 2-position (Figure 6.1) of the starting material (209) was 
performed in the presence of the synthesised Dess-Martin reagent in anhydrous 
conditions overnight at room temperature to give a yield of 95%.5
6.2.2 Stereoselective addition of the methyl group a t the yS-2-position
The stereoselective addition of a methyl group in the ^-2-position (Figure 6.1) 
was performed in the presence of methyl titanium trichoride synthesised in situ from 
an anhydrous solution of titanium tetrachloride and methyl magnesium bromide in 
diethyl ether at -78° C. The keto-derivative (210) was added as a solution in diethyl 
ether. The purification method required one column chromatography to give a mixture 
of 211 and 212. The formation of 212 was due to an intramolecular trans-benzoylation 
to give a mixture of a- and ^derivatives (212). Compound 211 and 212 were isolated
127
Plinio Perrone Chapter Six
as a mixture and used for the next step without further purification. Also in this case 
the yield observed (70%) was in the same range reported in the literature.5
6.2.3 Benzoylation of tribenzoate /3-2-methyl ribosugar
In order to achieve a stereoselective coupling with the corresponding base (N6- 
pivaloyladenine) it was necessary to have a fully protected sugar. For this reason a 
benzoylation reaction was performed on the mixture of 211 and 212 (Figure 6.1) 
using benzoyl chloride triethylamine and DMAP as an activator in anhydrous 
conditions.5 The reaction was stirred overnight and the desired compound was 
obtained after purification by column chromatography. The yield (41%) observed was 
reasonably low relating to the presence of salts in the mixture of 211 and 212 that 
cannot be seen in the !H-NMR spectra.
6.2.4 Coupling reaction between 1,2,3,5-tetrabenzoate /3-2-methyl ribosugar and 
A^-protected adenine
In order to avoid problems of selectivity in N7- and A^-positions, the adenine 
was protected in Apposition with the pivaloyl group (217) using standard conditions 
(Figure 6.2).
Cl 
O
DIEA, DCM
216
Figure 6.2. Synthesis of pivaloyl adenine
HN
N
N
H
217
The following coupling reaction (Figure 6.1) to synthesise the fully protected 
nucleoside (214) was performed with l,8-diazabicyclo[5.4.0]undec-7-ene (DBU) and 
trimethylsilyl trifluoromethanesulfonate (TMS-triflate). DBU is a strong base and, in 
this case it was used to remove the proton in the A^-position of the corresponding
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adenine. TMS-triflate, instead, was used in order to increase the reactivity in the 1- 
position of 213. The reaction proceeded as described in the literature and the 
purification method required one chromatography column to give the pure nucleoside 
analogue (214) in reasonably high yield (49%).
Heteronuclear multiple bond correlation (HMBC) showed the correlation 
between C4 and H I’, confirming the presence of the A^-regioisomer.
Nuclear Overhauser Enhancement Spectroscopy (NOESY), instead, showed no 
correlation between the proton of H I ’ and the three protons of the methyl group in the 
2’-position confirming the presence of the ^-nucleoside; instead, the correlation 
between H2’ and the three protons of the methyl group in the 2 ’-position confirmed 
the presence of the methyl group in the ^-position.
6.2.5 Deprotection of A^-pivaloyl-2’,3’,5’-tetrabenzoate /?-2-methyladenosine
The final step was removal of the protecting groups using methanolic 
ammonia (Figure 6.1) at room temperature in a sealed tube overnight. The 
purification required one column chromatography to give the desired product (215) in 
72% yield.
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6.3 a-naphthyl /?-2’-methyladenosine phosphoramidates
Considering the previously explored SAR (C hapter Three, C hapter Four 
and C hap ter Five), a series of L-alanine a-naphthyl phosphoramidates of ft-2 ’- 
methyladenosine was planned.
6.3.1 Synthesis of 2’,3’-cyclopentylidene /?-2’-methyladenosine
In our previous work (C hapter Three, C hapter Four and C hapter Five) the 
presence of a protecting group in the 2’- and 3’-positions improved the selectivity of 
reaction in the 5 ’-position and increases the solubility of the nucleoside in THF. For 
this reason the synthesised /?-2’-methyladenosine was protected in the 2’- and 3’- 
position with the cyclopentylidene group. A6-pivaloyl-2’,3’,5’-tetrabenzoateyS-2’- 
methyladenosine (214) was selectively deprotected in the 2 ’- 3’- and 5 ’-positions 
whilst keeping the pivaloyl group in the ^-position. This reaction was performed in 
the presence of a 1 M solution of NaOH in ethanol and pyridine (Figure 6.3). The 
next step involved the introduction of the cyclopentylidene group in 2’- and 3’- 
positions in the presence of 1,1-dimethoxycyclopentane and a catalytic amount of p- 
TSA with a yield of 53% (Figure 6.3). The final step was the deprotection of the 6- 
amino group using methanolic ammonia (Figure 6.3) to give the desired product 
(220) in quantitative yield.
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HN HN
N
NBzO HO
OBz OBz OH OH
214 218
NH
HNN
N
N
NHO
HO
220
219
a. 1 M NaOH, ethanol, pyridine; b. 1,1-dimethoxypentane, p-TSA; c. MeOH/NH3
Figure 6.3. Synthesis of 2 ’,3’-protected £-2’-methyladenosine
6.3.2 Synthesis of phosphorylating agents for coupling with /?-2’-methyladenosine 
The SAR previously explored (Chapter Three, C hapter Four and C hapter 
Five) showed that the presence of L-alanine as the amino acid is essential to enhance 
biological activity. For this reason a small series of ^-2’-methyladenosine L-alanine 
a-naphthyl phosphoramidates was planned with variation on the ester of the amino 
acid. The phosphorochloridate were resynthesised using the same procedure described 
in C hapter Three, C hapter Four and C hapter Five.
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6 . 3 . 3  S y n t h e s i s  o f  a - n a p h t h y l  / ? - 2 ’ - m e t h y l a d e n o s i n e  p h o s p h o r a m i d a t e s
The synthesis of naphthyl phosphoramidates of /£-2’-methyladenosine ( 2 2 1 )  
was carried out using 2 \3 ’-cyclopentylidene-j8-2’-methyladenosine ( 2 2 0 )  using the 
Uchiyama procedure in the presence of an excess of tBuMgCl ( F i g u r e  6 . 6 ) . 9
The purification method required one column chromatography. The 
deprotection reaction was performed in the presence of a solution of 80% formic acid 
( F i g u r e  6 . 6 )  and the purification required one column chromatography.
o Rio
’BuMgCI, THF
220
80% HCOOH
RIO
R= Ester
OH OH
Figure 6.6. Synthesis of a-naphthyl /J-2’-methyladenosine phosphoramidates 221
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The a-naphthyl phosphoramidates synthesised are reported in Table 6.2.
222 benzyl 4.25, 4.14
223 ethyl 4.23, 4.20
224 tert- butyl 4.20, 4.08
Ri
NH
N
N
OH OH
R= Ester
Table 6.2. a-Naphthyl phosphoramidates synthesised with 2 ’,3’-cyclopentylidene /^2 ’-methyladenosine
6.3.4 Biological activity of a-naphthyl phosphoramidates of ft-2’-
methvladenosine
All the a-naphthyl phosphoramidates synthesised have been tested in vitro 
using a replicon assay (see section 3.3.6.1) against HCV (Table 6.3).10,11
222 benzyl 0.12 >100
223 ethyl 0.16 >100
224 ferf-butyl 2.36 >100
215 £-2’-methy lade nosi ne 0.071 >100
Ri
N
N
OH OH
Table 6.3. Biological activity of /J-2’-methyladenosine a-naphthyl phosphoramidates
E C ^  The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
The nucleoside itself (215) was shown to be a potent inhibitor of HCV with an 
activity of 71 nM. The corresponding a-naphthyl phosphoramidates were found to be 
less active. In particular the tert-butyl ester phosphoramidate (224) showed a rather 
poor activity (2.36 //M), confirming that this kind of ester is a poor substrate for the 
enzyme involved in the cleavage of the amino acid ester.
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The benzyl and ethyl ester, instead, were found to be active at sub-/*M level, 
indicating that these two ester were well tolerated by the esterase. A possible 
explanation of the lower activity of the phosphoramidates (222, 223, 224) compared 
to the nucleoside (215) might be related to the enzymes involved in the 
phosphoramidate metabolism; in particular the enzyme with phosphoramidase activity 
might not tolerate the presence of a methyl group in the 2 ’-position and as a 
consequence was not able to efficiently cleave the P-N bond.
0
benzyl ethyl tert-butyl 2'-methylA
Graph 6.1. Biological activity of 2’-methyladenosine phosphoramidates synthesised
Moreover, the observed intracellular level of nucleoside monophosphate 
(Intracellular NTP/pmol per 106 cell= 105)2 is reasonably high and it might be a 
consequence of an efficient first phosphorylation of yS-2 ’-methyladenosine (215) by 
the first kinases. In this case, therefore, it might be possible that the second or third 
phosphorylations are the limiting step of the activation mechanism of the nucleoside 
(215). As a consequence the administration of the corresponding phosphoramidates 
does not overcome the limiting step in this process.
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6.4 Synthesis of /?-2’-methylguanosine
The synthesis of /3-2'-methylguanosine (226) was subsequently planned, 
considering its high anti-HCV activity. The initial synthetic pathway started with the 
synthesis of ^-2-methyl ribosugar (213) followed by a coupling reaction with guanine 
and finally deprotection to give the desired product (Figure 6.7).
BzO
OBz OH
209
OBz
NH
HO~ \°y  »
OH OH 
226
NH;
BzO OBz b.
OBz N0 
210
tXJ!BzO—| o N ^ N ^ N H j h
OBz OBz
225
BzO—I n  OBz BzO—I n
OBz OH 
211
OBz OBz 
212
d. BzO~ l^ ° " | ^ OBz 
OBz OBz
213
a. Dess-Martin reagent, CH2CI2 dry; b. MeTiCI3; c. BzCI, DMAP, Et3N. d.Guanine, DBU, TMS-triflate, 
CH3CN; e. MeOH/NH3
Figure 6.7. Synthesis of /S-2’-methylguanosine
The synthesis of the ^-2-methyl ribosugar (213) was performed with the same 
procedures and yields described for the synthesis of /J-2’-methyladenosine (215). 
Considering what was observed during the synthesis of ^5-2’-methyladenosine (215), 
the free base (guanine) was used for the coupling reaction with /3-2-methyl ribosugar 
with the same conditions previously described . 1,2
The analysis of the HMBC and the NOESY confirmed that the synthesised 
nucleoside was /V9- and ^-structure. The !H-NMR of /3-2’-methylguanosine (226) have 
been reported (Figure 6 .8 ).
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a.3 7.0 4.5 4.0 35 3.0 2.5 1.5 ppm
Figure 6.8. ‘H-NMR of the A^-regioisomer
The reaction was repeated using the same conditions. Unfortunately in this case 
we isolated a fraction that from the ‘H-NMR showed the presence of at least two 
compounds, both of them with a signal compatible with a nucleoside structure 
suggesting the presence of a mixture of N9- and A^-regioisomers ( F i g u r e  6 . 9 ) .
NH
NH
NHHOHO NH
OH OHOH OH
Figure 6.9. ‘H-NMR of the A/9- and Af7-regioisomers mixture
The reasons for the different product ratio on repeating the reaction are 
unclear. Further research in the literature brought to our attention a paper in which the
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synthesis of yS-2 ’-methylguanosine (226) was performed under regioselective 
conditions. 12
In this case the reaction was performed in two steps: the first was the synthesis 
of the totally silylated acetylguanine followed by the coupling reaction in the presence 
of the previously synthesised 2 -methyl ribosugar (213) and trimethylsilyl 
trifluoromethanesulfonate (TMS-triflate) using para-xylene as solvent (Figure 6.10).
HMDS, TMS-triflate, p-xylene
OBz OBz
228
229
MeOH/NH3
O
NH
BzO
OBz OBz
226
Figure 6.10. Alternative scheme for the synthesis of /J-2’-methylguanosine
After purification by column chromatography, the A^-regioisomer (229) in 
63% yield was isolated without any traces of A7-regioisomer. The final step was 
deprotection with methanolic ammonia to give the desired product (226) in 
quantitative yield.
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6.5 a-naphthyl /?-2’-methylguanosine phosphoramidates
Considering previously explored SAR (C hapter Three and C hapter Four) a 
series of L-alanine a-naphthyl phosphoramidates of /T2’-methylguanosine was 
planned.
6.5.1 Synthesis of 2’,3’-isopropylidene /?-2’-methyladenosine
In previous work (C hapter Three, C hapter Four and C hapter Five) the 
increase of solubility of the nucleoside in THF in the presence of a protecting group in 
2 ’- and 3’-positions was noticed. For this reason the 2 ’,3’-protected version of /?-2’- 
methylguanosine was planned. The introduction of the cyclopentylidene group in the 
2 ’- and 3’-positions was attempted. Unfortunately this attempt was unsuccessful and 
consequently the use isopropylidene as the protecting group was considered. The 
synthesis was performed in the presence of /?-2 ’-methyladenosine (226) and a 
catalytic amount of perchloric acid in a solution of dry acetone (Figure 6.11).
N NH
HO
OH OH
HCIOi
Acetone
226
230
Figure 6.11. Synthesis of 2 ’,3’-isopropylidene yS-2’-methylguanosine
N NH
NHO
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6 . 5 . 2  S y n t h e s i s  o f  p h o s p h o r y l a t i n g  a g e n t s  f o r  c o u p l i n g  w i t h  p- 2’- 
m e t h y l g u a n o s i n e
T h e  s y n t h e s i s  o f  p h o s p h o d i c h l o r i d a t e  a n d  s u b s e q u e n t l y  L - a l a n i n e  
p h o s p h o c h l o r i d a t e  w e r e  r e p e a t e d  u s i n g  t h e  s a m e  c o n d i t i o n s  p r e v i o u s l y  d e s c r i b e d  
( C h a p t e r  T h r e e ,  C h a p t e r  F o u r  a n d  C h a p t e r  F i v e ) .
6 . 5 . 3  S y n t h e s i s  o f  a - n a p h t h y l  / ? - 2 ’ - m e t h y l g u a n o s i n e  p h o s p h o r a m i d a t e s
T h e  s y n t h e s i s  o f  n a p h t h y l  p h o s p h o r a m i d a t e s  o f  / 2 - 2 ’ - m e t h y l g u a n o s i n e  ( 2 3 2 )  
w a s  p e r f o r m e d  i n  t h e  p r e s e n c e  o f  2 ’ , 3 ’ - i s o p r o p y l i d e n e  fi-T - m e t h y l g u a n o s i n e  ( 2 3 0 )  
a n d  a n  e x c e s s  o f  t B u M g C l  ( F i g u r e  6 . 1 3 ) .  9 T h e  p u r i f i c a t i o n  m e t h o d  r e q u i r e d  o n e  
c o l u m n  c h r o m a t o g r a p h y .
1C V
°X°
2 3 0
Cl £ 
tBuMgCI, THF
O NH
60% CH3COOH
R= Ester
RIO
NHM X°>'NH < I X
OH OH
NH2
Figure €.13. Synthesis of a-naphthyl f$-2'-methylguanosine phosphoramidates
2 3 2
T h e  d e p r o t e c t i o n  w a s  p e r f o r m e d  w i t h  6 0 %  o f  a c e t i c  a c i d  a t  9 0 °  C  o v e r n i g h t  
( F i g u r e  6 . 1 3 )  a n d  i n  m o s t  c a s e s ,  t h e  p u r i f i c a t i o n  r e q u i r e d  o n e  c o l u m n
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chromatography and one semi-preparative HPLC. The a-naphthyl phosphoramidates 
synthesised are reported in Table 6.5.
233 benzyl 4.25, 4.14
234 ethyl 4.25, 4.14
235 terf-butyl 4.23, 4.10
236 methyl 4.35, 4.26
Ri
N N H
N N H
O H  O H
Table 6.5. a-Naphthyl phosphoramidates synthesised with 2’,3’-isopropylidene /J-2’-methylguanosine
6.5.4 Biological activity of a-naphthyl phosphoramidates of /J-2’- 
methylguanosine
All the a-naphthyl phosphoramidates synthesised have been tested in vitro 
using a replicon assay (see section 3.3.6.1) against HCV (Table 6 .6 ) . 1011
233 benzyl 0.08 >100
234 ethyl 0.17 >100
235 terf-butyl >50 >100
236 methyl 0.063 >100
226 /J-2’-methylguanosine 4.0 >100
Ri
N N H
N N H
O H  O H
Table 6.6. Biological activity of /3-2’-methylguanosine a-naphthyl phosphoramidates
ECX= The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
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The most active phosphoramidates (233 and 236) showed a significant 
increase in activity (Graph 6.2).
25
0
Graph 6.2. Biological activity of 2’-methylguanosine phosphoramidates synthesised
Considering the low intracellular level of nucleoside triphosphate observed 
(NTP/pmol per 106 cell= 0.2) and the boost of activity observed it is reasonable to 
suggest that the limiting step in the activation mechanism of p-2 '-methylguanosine 
(226) is the first phosphorylation by the kinases. This problem has been overcome by 
synthesising the corresponding a-naphthyl phosphoramidates (233, 234 and 236).
The rm-butyl phosphoramidate (235) showed an activity comparable to its 
corresponding nucleoside (226) a direct consequence of poor activity of the enzyme 
(“esterase”) responsible for the cleavage of this ester. The other esters are all roughly 
equivalent.
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6.6 Phenyl /?-2’-methylguanosine phosphoramidates
In 2006 Merck® published and patented a new series of fi-2'-methylguanosine 
phenyl phosphoramidates. In order to compare the patented derivatives with our 
corresponding a-naphthyl compounds, a series of L-alanine phenyl phosphoramidates 
(methyl and benzyl) was planned.
6.6.1 Synthesis of phenyl /J-2’-methylguanosine phosphoramidates
The phosphorylating agents (205) were resynthesised using the same 
procedure as previously described (Chapter Three, Chapter Four and Chapter 
Five).6,7,8 The synthesis of phenyl phosphoramidates of -methylguanosine (237) 
was performed using the Uchiyama procedure in the presence of 2’,3,-isopropylidene 
fi-2y-methylguanosine (230) and an excess of tBuMgCl (Figure 6.15). 9 The 
purification method required one column chromatography.
o
/ V S *  /= Y _  " H U
0 ^ 0  ‘BuMgCI, THF
R1
' V o  N i  
( V y NH < x T
°X°
230
60% CH3COOH
R= Ester
R1
' V o  N X  
f y ° > ' NH «•i r
0"'oX ! ^  H!
OH OH
Figure 6.13. Synthesis of phenyl /3-2’-methylguanosine phosphoramidates
237
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Also in this case, deprotection was carried out in presence of a solution 60% of 
acetic acid at 90° C overnight (Figure 6.13) and in most cases, the purification 
required one column chromatography and one semi-preparative HPLC. The phenyl 
phosphoramidates synthesised are reported in Table 6 .8 .
Ri
O
f  V°vNH 
0*0 „  N ^ N^ NH2
OH OH
R= Ester
238 benzyl 4.23, 4.10
239 methyl 4.35, 4.26
Table 6.8. Phenyl phosphoramidates synthesised with 2 \3 ’-isopropylidene /3-2’-methylguanosine
6.6.2 Biological activity of phenyl phosphoramidates of /?-2’-methylguanosine
All the phenyl phosphoramidates synthesised have been tested in vitro using a 
replicon assay (see section 3.3.6.1) against HCV (Table 6.9) . 10,11
238 Benzyl 36 >100
239 Methyl 0.88 >100
226 /J-2’-methylguanosine 4.0 >100
O
N NH
N
OH OH
Table 6.9. Biological activity of £-2’-methylguanosine phenyl phosphoramidates
EC5 o= The concentration of phosphoramidate which produces the 50% of the maximum 
possible effect
CC5 0 = The concentration of phosphoramidate which produces the 50% of the maximum 
toxic effect
The obtained data were unclear; in fact the benzyl ester phosphoramidate (238) 
was shown to be poorly active and less active than the corresponding nucleoside 
(226), whilst, the corresponding methyl ester phosphoramidate (239) was found to be 
more active than the corresponding nucleoside (226) with a 4-fold increase of activity.
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Although, compared to their corresponding a-naphthyl phosphoramidates (233 and 
236), the two phenyl phosphoramidates synthesised were shown to be less active. The 
unclear behaviour observed for the benzyl and methyl ester cannot be easily 
explained. The phenyl phosphoramidate with the benzyl ester showed a poor activity 
that might be a consequence of the simultaneous presence of a phenyl group and a 
benzyl group that might drastically reduce the activity of one of the enzymes involved 
in the phosphoramidate metabolism. Another plausible explanation might be that 
compound 238 is actively removed from the cell because of its favourable interaction 
with Pgp (P-glycoprotein, present in the cell). In conclusion, we have increased the 
activity of the patented phenyl phosphoramidate (239) particularly in the benzyl series 
by synthesising the corresponding a-naphthyl phosphoramidates.
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Chapter Seven
Experimental Procedures
7.1 General Methods
Thin Layer Chromatography
Thin layer chromatography (TLC) was performed on commercially available 
Merck Kieselgel plates and separated components were visualised using ultraviolet 
light (245 and 366 nm).
Column Chromatography
Column chromatography was performed using Fluka silica (35-70 /tm) as 
stationary phase. Glass columns were slurry packed in the appropriate eluent under 
gravity. Samples were applied as a concentrated solution in the same eluent, or pre­
absorbed onto silica gel. Fractions containing the product were identified by TLC, 
pooled and the solvent removed in vacuo.
NMR Spectroscopy
lH, I3C, 3,P and 19F were recorded on a Bruker Avance 500 spectrometer with 
operating frequencies of 500, 125, 202 and 470 MHz respectively. 31P-NMR are 
reported in units of 6  relative to 85% phosphoric acid as the external standard, positive 
shifts are downfield. The following abbreviations are used in the assignment of NMR 
signals: s (singlet), d (doublet), t (triplet), m (multiplet).
Mass Spectrometry
Low resolution mass spectra were run on a VG Platform II Fisons instrument 
(Fisons, Altrincham, UK) (atmospheric pressure ionisation, electrospray mass 
spectroscopy) in either positive or negative mode. High resolution mass spectrometry 
was performed as a service by Birmingham University, using fast atom bombardment 
(FAB).
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Solvents and Reagents.
All solvents used were anhydrous and used as purchased from Aldrich. All 
reagents were used as received. All glassware was oven dried at 130 °C for several 
hours or overnight and allowed to cool under dry nitrogen.
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7.2 Standard Procedures
For convenience, standard procedures have been given for reactions 
concerning the synthesis of precursors and derivatives of protides. Variations from 
these procedures and individual purification methods are given in the main text.
S t a n d a r d  p r o c e d u r e  A l :  Preparation of amino acid ester hydrochloride
salts
Thionyl chloride (2.0 mol. equivalents) was added dropwise to a stirred 
solution of the appropriate alcohol (15.0 mol equivalent) at 0 °C under nitrogen. The 
mixture was stirred at 0°C for 30 minutes and then slowly allowed to warm to room 
temperature. The appropriate amino acid (1.0 mol. equivalent) was added and the 
mixture was heated at reflux overnight. The solvent was removed under reduced 
pressure (last traces of solvent removed by co-evaporation with increasingly volatile 
solvents) to give the crude product as the solid hydrochloride salt.
S t a n d a r d  p r o c e d u r e  A 2 :  Preparation ofL-amino acid ester sulfonate salts
A mixture of the appropriate amino acid (1.0 mol. equivalent), the appropriate 
alcohol (15 mol. equivalent) and para-toluene sulfonic acid (p-TSA) monohydrate 
(1.1 mol equivalent) in toluene was heated at reflux overnight, using Dean-Stark 
apparatus. The solvent was removed under reduced pressure (last traces of solvent 
removed by co-evaporation with increasingly volatile solvents) to give the crude 
product as the solid p-toluene sulfonate salt.
S t a n d a r d  p r o c e d u r e  B :  P r e p a r a t i o n  o f  p h o s p h o r o d i c h l o r i d a t e  s p e c i e s
Most of the phosphorochloridate species (exept for the D-alanine dodecyl ester 
and D-alanine octyl ester phosphorchloridates) were synthesised using the previously 
reported standard procedure. 1 Phenylphosphorodichloridate (1.0 mol. equivalent) and 
the appropriate amino ester ( 1 . 0  mol. equivalent) were suspended in anhydrous 
dichloromethane (DCM, 123 mol. equivalent). Anhydrous triethylamine (2.0 mol. 
equivalent) was added dropwise at -78°C and after 1 hour, the reaction was left to rise 
to room temperature and stirred overnight. The solvent was removed under reduced 
pressure and the crude residue was purified by rapid column chromatography (using
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7:3 ethyl acetate/hexane as eluent). All phosphorochloridates were used as solutions in 
dry THF for subsequent reactions.
Standard procedure Bl: Preparation of Phosphorodichloridate species
Phosphorus oxychloride (1.0 mol equivalent) and the appropriate substituted 
phenol (1.0 mol equivalent) were stirred in anhydrous diethyl ether (31 mol. 
equivalent). Anhydrous triethylamine was added (1.0 mol. equivalent) at -78°C and 
the solution was allowed to warm to room temperature after 25 minutes. The 
triethylamine hydrochloride salt was filtered off and the solvent removed under 
reduced pressure to give a clear liquid.
Standard procedure C: Preparation of 4’-azidonucleoside
phosphoramidates
‘BuMgCl (2.5 mol. equivalent) and 4 ’-azido-nucleoside (1.0 mol. equivalent) 
were dissolved in dry THF (31 mol. equivalent) and stirred for 15 minutes. Then a 1M 
solution of the appropriate phosphorochloridate (2.5 mol. equivalent) in dry THF was 
added dropwise, after 20 minutes, and then stirred overnight. A saturated solution of 
NH4C1 was added and the solvent was removed under reduced pressure to give a 
yellow solid, which was subsequently purified.
Standard procedure Cl: Preparation of 4 ’-azido-2’, 3 ’-dipentanoatecytidine 
phosphoramidates
‘BuMgCl (2.5 mol. equivalent) and 2’,3’-dipentanoate-4’-azidocytidine (1.0 
mol. equivalent) were dissolved in dry THF (31 mol. equivalent) and stirred for 15 
minutes. Then a 1M solution of the appropriate phosphorochloridate (2.5 mol. 
equivalent) in dry THF was added dropwise, then stirred overnight. A saturated 
solution of NH4C1 was added and the solvent was removed under reduced pressure to 
give a yellow solid, which was subsequently purified.
Standard procedure C2: Preparation of 2 ’, 3 ’-protected modified 
nucleoside phosphoramidates
‘BuMgCl (2.0 mol. equivalent) and 2 ’,3’-protected modified nucleosides (1.0 
mol. equivalent) were dissolved in dry THF (31 mol. equivalent) and stirred for 15 
minutes. Then a 1M solution of the appropriate phosphorochloridate (2.0 mol.
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equivalent) in dry THF was added dropwise, then stirred overnight. A saturated 
solution of NH4CI was added and the solvent was removed under reduced pressure to 
give a yellow solid, which was subsequently purified.
S t a n d a r d  p r o c e d u r e  C 3 :  Preparation of phosphoramidates of modified 
nucleoside
2’, 3’-Cyclopentylidene modified nucleoside phosphoramidates were dissolved 
in a solution of 80% formic acid in water for 4 hours. The solvent was removed under 
reduced pressure to give a a white solid that was subsequently purified.
S t a n d a r d  p r o c e d u r e  C 4 :  Preparation of phosphoramidates of modified 
nucleoside
2’, 3’-Isopropylidene modified nucleoside phosphoramidates were dissolved 
in a solution of 60% of acetic acid in water at 90 °C overnight. The solvent was 
removed under reduced pressure to give a white solid that was subsequently purified.
S t a n d a r d  p r o c e d u r e  D :  Preparation of 4’-azidouridine phosphoramidates
‘BuMgCl (2.0 mol. equivalent) and 4 ’-azidouridine (1.0 mol. equivalent) were 
dissolved in dry THF (30 mol. equivalent) and stirred for 15 minutes. Then a 1M 
solution of the appropriate phosphorochloridate (2.0 mol. equivalent) in dry THF was 
added dropwise, over 20 minutes, and the mixture stirred overnight. A solution of 
NH4CI was added and the solvent was removed under reduced pressure to give a 
yellow solid, which was subsequently purified.
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7.3 Synthesis of amino acid esters.
Synthesis of cyclopentylglycine benzyl ester /7-toluene sulfonate salt (41)2
0  Prepared according to Standard procedure A2, from
NH3 Tos-  cyc,°Penty1g1ycine (S-O g> 39.0 mmol), /7-TSA- 
monohydrate (8.159 g, 42.9 mmol), benzyl alcohol 
(20.4 mL, 194 mmol) and toluene (50 mL). The 
product was isolated as a white solid (9.15 g, 60%)
6 h (<i4-CH3OH): 8.56 (3H, s, NH3+-amino acid ester) (7.72 (2H, d, 2 CH-tosylate, J=
9.0 Hz), 7.4 (2H, m, CH-phenyl), 7.35-7.30 (3H, m, CH-phenyl), 7.25 (2H, d, CH- 
tosylate, J= 9.0 Hz), 5.28 (2H, s, CH2-benzyl), 2.37 (3H, s, CH3-tosylate), 2.33 (2H,
m, CH2-cyclopentyl), 1.93 (2H, m, CH2-cyclopentyl), 1.89 (4H, m, CH2-cyclopentyl).
Synthesis of cyclopentylglycine ethyl ester hydrochloride salt (42)8
Prepared according to Standard Procedure A l, from
p  cyclopentylglycine (5.0 g, 38.7 mmol), thionyl chloride (6.0 
[ \  mL, 77.4 mmol) and ethanol (34.10 mL). The product was
obtained as a white solid (2.25 g, 56%).
6 h (cZ6-DMSO): 8.82 (3H, s, NH3+-amino acid ester), 4.19 (2H, m, CH2-ethyl, J= 7.1 
Hz), 2.08 (2H, m, CH2-cyclopentyl), 1.96 (2H, m, CH2-cyclopentyl), 1.89 (2H, m, 
CH2-cyclopentyl), 1.72 (2H, m, CH2-cyclopentyl), 1.23 (3H, t, CH3-ethyl, J= 7.1 Hz).
Synthesis of cyclopentylglycine isopropyl ester hydrochloride salt (43)8
Prepared according to Standard Procedure A l, from
P  cyclopentylglycine (2.5 g, 19.4 mmol), thionyl chloride (2.83
°  mL, 38.8 mmol) and isopropanol (50 mL). The product was
obtained as a white solid (2.25 g, 56%).
6 „ (d6-DMSO): 8.75 (3H, s, NH3+-amino acid ester), 4.97 (1H, m, CH-isopropyl, J=
6.3 Hz), 2.51 (2H, m, CH2-cyclopentyl), 2.09 (4H, m, CH2-cyclopentyl), 1.79 (2H, m, 
CH2-cyclopentyl), 1.25 (6 H, d, CH3 isopropyl, J= 6.3 Hz).
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Synthesis of L-isoleucine ethyl ester hydrochloride salt (44)
Prepared according to Standard Procedure A l, from L- 
isoleucine (5.0 g, 38.1 mmol), thionyl chloride (8.3 mL, 11.44 
NH3 c r  mmoi) ancj ethanol (33.54 mL). The product was obtained as a 
clear oil (2.5 g, 39%).
6 h (CDCI3): 8.71 (3H, s, NH3+-amino acid ester), 4.21 (2H, m, CH2-ethyl), 3.97 (1H, 
m, CHa), 2.15 (1H, m, CH-lateral chain), 1.48 (2H, m, CH2-lateral chain) 1.25 (3H, s, 
CH3-ethyI), 1.04 (3H, s, CH3-lateral chain), 0.90 (3H, s, CH3-lateral chain).
Synthesis of D-alanine -butyl ester p-toluene sulfonate salt (45)3
Q Prepared according to Standard procedure A2, from D-
Tos. alanine (5.0 g, 56.1 mmol), /?-TSA-monohydrate (11.74
= g, 61.7 mmol), butanol (26 mL) and toluene (50 mL).
The product was isolated as a white solid (11.0 g, 62%)
6 h (^-C H 3OH): 8.18 (3H, s, NH3+-amino acid ester), 7.78 (2H, d, CH-tosylate, J= 8.0 
Hz), 7.16 (2H, d, CH-tosylate, J= 8.0 Hz), 4.11-4.00 (3H, m, CH a, CH2-butyl), 2.38 
(3H, s, CH3-tosylate), 1.56-1.51 (2H, m, CH2-butyl), 1.47 (3H, d, CH3-alanine, J= 7.2 
Hz), 1.39-1.25 (2H, m, CH2-butyl), 0.89 (3H, m, CH3-butyl).
Synthesis of D-alanine dodecyl ester /7-toluene sulfonate salt (46)4
0  Prepared according to Standard
Tos. procedure A2, from D-alanine
= (2.5 g, 28.0 mmol), p-TSA-
monohydrate (5.87 g, 30.9 mmol), dodecyl alcohol (13.0 g, 280 mmol) and toluene 
(50 mL). The product was isolated as a white solid (7.92 g, 6 6 %)
6 h (<i4-CH3OH): 8.45 (3H, s, NH3+-amino acid ester), 7.82 (2H, d, CH-tosylate, J= 8.1 
Hz), 7.19 (2H, d, CH-tosylate, J= 8.1 Hz), 4.16-4.00 (3H, m, CHa, CH2-dodecyl), 
2.40 (3H, s, CH3-tosylate), 1.49 (3H, d, CH3-alanine, J= 7.2 Hz), 1.30 (22H, m, CH2- 
dodecyl), 0.94 (3H, t, CH3-dodecyl, J= 6.3 Hz).
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Synthesis of L-alanine -butyl ester p-toluene sulfonate salt (48)3
0  Prepared according to Standard procedure A2, from L-
NH3 Tos. alanine (2.5 g, 28 mmol), /?-TSA-monohydrate (5.86 g, 
30.8 mmol), butanol (14 mL) and toluene (50 mL). The 
product was isolated as a white solid (5.70 g, 65%)
6 „ 6 /4-CH3OH): 8.42 (3H, s, NH3+-amino acid ester), 7.59 (2H, d, CH-tosylate, J= 8.0 
Hz), 7.18 (2H, d, CH-tosylate, J= 8.0 Hz), 4.21-4.09 (3H, m, CHa, CH2-butyl), 2.33 
(3H, s, CH3-tosylate), 1.65-1.56 (2H, m, CH2-butyl), 1.44 (3H, d, CH3-alanine, J= 7.2 
Hz), 1.42-1.28 (2H, m, CH2-butyl), 0.92 (3H, m, CH3-butyl).
Synthesis of D-alanine isopropyl ester hydrochloride salt (104)*
q Prepared according to Standard Procedure A l, from D-alanine
(7.0 g, 78.6 mmol), thionyl chloride (11.42 mL, 157.2 mmol) 
= and isopropanol (90 mL). The product was obtained as a white
solid (8.30 g, 64%).
6 h (4rDMSO): 8.70 (3H, s, NH3+-amino acid ester), 4.87 (1H, m, CH-isopropyl, J=
6.3 Hz), 3.95 (1H, d, CHa, J=  6.7 Hz), 1.54 (3H, m, CH3-alanine), 1.25 (6 H, d, CH3- 
isopropyl, J= 6.3 Hz).
Synthesis of D-alanine 2-butyl ester p-toluene sulfonate salt (105)
q  Prepared according to Standard procedure A2, from D-
Tos. alanine (5.0 g, 56.1 mmol), p-TSA-monohydrate (11.74 g,
z 61.7 mmol), 2-butanol (26 mL, 280 mmol) and toluene
(50 mL). The product was isolated as a white solid (12.44 g, 70%)
6 h (d4-CH3OH): 8.49 (3H, s, NH3+-amino acid ester), 7.85 (2H, d, CH-tosylate, J= 8.0 
Hz), 7.15 (2H, d, CH-tosylate, J= 8.0 Hz), 4.20-4.00 (2H, m, CHa, CH-2-butyl), 2.42 
(3H, s, CH3-tosylate), 1.49 (3H, d, CH3-alanine, J= 9.0 Hz), 1.24-1.20 (5H, m, CH2-2- 
butyl, CH3-2-butyl), 0.94 (3H, m, CH3-2-butyI).
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Synthesis of D-alanine -octyl ester p-toluene sulfonate salt (106)
Prepared according to Standard procedure
O
J ] ^ ^ N h + Tos-  r^om ^-alanine (2.5 g, 56.1 mmol), p- 
i TSA-monohydrate (5.86 g, 30.8 mmol),
butanol (24 mL, 154 mmol) and toluene (50 mL). The product was isolated as a white
solid (7.90 g, 70%).
6 „ (^-C H 3OH): 8.40 (3H, s, NH3+-amino acid ester), 7.58 (2H, d, CH-tosylate, J= 8.0 
Hz), 7.16 (2H, d, CH-tosylate, J=  8.0 Hz), 4.20-4.09 (3H, m, CHa, CH2-octyl), 2.33 
(3H, s, CH3-tosylate), 1.65-1.58 (2H, m, CH2-octyl), 1.44 (3H, d, CH3-alanine, J= 7.16 
Hz), 1.29 (12H, m, CH2-octyl), 0.90 (3H, m, CH3-octyl).
Synthesis of L-alanine isopropyl ester hydrochloride salt (127)6
Prepared according to Standard Procedure A l, from L-alanine 
Nl-fJ c r  (5.0 g, 56.0 mmol), thionyl chloride (8.2 mL, 112.0 mmol) and
isopropanol (65 mL,). The product was obtained as a white
solid (8.0 g, 85%).
6 h 64-DMSO): 8.73 (3H, s, NH3+-amino acid ester), 4.96 (1H, m, CH-isopropyl, J=
5.0 Hz), 3.92 (1H, d, CHa, 7= 6.9 Hz), 1.40 (3H, d, CH3-alanine, J= 6.9 Hz), 1.20 
(6 H, d, CH3-isopropyl, J= 4.5 Hz).
Synthesis of a,a-dimethylglycine ethyl ester hydrochloride salt (123)2
Prepared according to Standard Procedure A l, from a,a- 
dimethylglycine (5.0 g, 48.0 mmol), thionyl chloride (7.0 mL,
96.5 mmol) and ethanol (42 mL). The product was obtained as a 
white solid (5.3 g, 73%).
6 h (76-DMSO): 8.85 (3H, s, NH3+-amino acid ester), 4.18 (2H, d, CH2-ethyl, J= 7.1 
Hz), 1.49 (6 H, s, CH3-a,a-dimethylglycine), 1.22 (3H, t, CH3-ethyl, J= 7.1 Hz).
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Synthesis of a,a-dimethylglycine benzyl ester p -toluene sulfonate salt (122)2
Q Prepared according to Standard procedure A2, from
Tos~ a «a ~dimethylglycine (5.0 g, 48.0 mmol), p-TSA- 
monohydrate (10 g, 53.1 mmol), benzyl alcohol (74 
mL, 720 mmol) and toluene (60 mL). The product was isolated as a white solid (7.60 
g, 42%).
6 h (4tDM SO): 8.47 (3H, s, NH3+-amino acid ester), 7.51 (2H, d, CH-tosylate, J= 7.7 
Hz), 7.41-7.32 (5H, m, CH-benzyl), 7.13 (2H, d, CH- tosylate, J= 7.7 Hz), 5.25 (2H, 
s, CH2-benzyl), 2.30 (3H, s, CH3-p-toluene sulfonate), 1.49 (6 H, s, CH3-a ,a -  
dimethylglycine).
Synthesis of L-proline ethyl ester hydrochloride salt (124)2
Prepared according to Standard Procedure A l, from L-proline
O
  // Ho _ (5.0 g, 43.0 mmol), thionyl chloride (6.5 mL, 86.0 mmol) and
Cl
1 y  ethanol (38 mL). The product was obtained as yellow liquid
(6.0 g, 77%).
6 h (d6-DMSO): 9.29 (2H, s, NH2+-amino acid ester), 4.31 (1H, t, CHa, J= 8.1 Hz), 
4.20 (2H, q, CH2-ethyl, J= 7.0 Hz), 3.24-3.16 (1H, m, CHa), 2.26-2.21 (2H, m, CH2- 
proline), 1.99-1.93 (2H, m, CH2-proline), 1.90 (2H, t, CH2-proline, J= 6 . 8  Hz), 1.23 
(3H, t, CH3-ethyl, J= 7.0 Hz).
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7.4 Synthesis of aryl-dichlorophosphates.
Synthesis of p-chlorophenyl dichlorophosphate (78)2
f O Prepared according to Standard Procedure E, from p-
C,“ “A / r ° ~ pr cy chlorophenol (3.0 g, 23.0 mmol), phosphorus oxychloride 
N '  Cl
(2.17 mL, 23.0 mmol) and triethylamine (3.25 mL, 23.0 
mmol), dry diethylether (25 mL). The product was obtained as a yellow clear oil (4.15 
g, 40%) used without further purification for the following reaction. 
d P (CDC13): 5.00; d„ (CDCI3): 7.44 (2H, m, CH-phenyl), 7.30 (2H, m, CH-phenyl).
Synthesis of 3,4-dichlorophenyl dichlorophosphate (79)
Prepared according to Standard Procedure E, from 3,4-
y = \  9  dichlorophenol (3.79 g, 23.0 mmol), phosphorus oxychloride
Cl—C /V -O -P-CI
^  v  (2.17 mL, 23.0 mmol), triethylamine (3.25 mL, 23.0 mmol)
and dry diethylether (25 mL). The product was obtained as a yellow clear oil (2.93 g,
45%) used without further purification for the following reaction.
6 P (CDCI3): 4.79; dH (CDCI3): 7.41 (1H, m, CH-phenyl), 7.38 (1H, m, CH-phenyl),
7.33 (1H, m, CH-phenyl).
Synthesis of p-methylphenyl dichlorophosphate (80)
Q Prepared according to Standard Procedure E, from /?-cresol
— L  V -  O -P-CI (4.00 g, 37.0 mmol), phosphorus oxychloride (3.45 mL, 37.0
—  Cl mmol), triethylamine (5.15 mL, 37.0 mmol) and dry 
diethylether (25 mL). The product was obtained as a yellow clear oil (7.91 g, 72%) 
used without further purification for the following reaction.
dp (CHCI3): 4.98; d„ (CHCI3): 7.22 (4H, m, CH-phenyl), 2.39 (3H, s, CH3-p-cresol).
Synthesis of p-methoxyphenyl dichlorophosphate (81)s
O Prepared according to Standard Procedure E, from p-
/ °  rnethoxyphenol (4.00 g, 32.0 mmol), phosphorus oxychloride
Cl
(3.00 mL, 32.0 mmol), triethylamine (4.49 mL, 32.0 mmol) 
and dry diethylether (25 mL). The product was obtained as a yellow clear oil (5.16 g,
67%) used without further purification for the following reaction.
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6 p (CHCI3): 5.45; 6 h (CHC13): 7.10 (2H, d, CH-phenyl, J= 9.1 Hz), 6.80 (2H, d, CH- 
phenyl, J= 9.1 Hz), 3.69 (3H, s, CH30-p-methoxyphenol).
Synthesis of a-naphthyl dichloro phosphate (91)*
Prepared according to Standard Procedure E, from a-naphthol (5.00 g,
0
C|_ p _ C| 34.7 mmol), phosphorus oxychloride (3.23 mL, 34.7 mmol),
1
O triethylamine (4.84 mL, 34.7 mmol) and dry diethylether (25 mL). The
product was obtained as a yellow clear oil (8.15 g, 90%) used without 
further purification for the following reaction.
6 p (CHC13): 3.91; 6 h (CHC13): 7.92 (1H, d, CH-naphthyl, J= 8.4 Hz), 7.68 (1H, s, CH- 
naphthyl), 7.58 (1H, d, CH-naphthyl, J= 8.4 Hz), 7.40-7.35 (3H, m, CH-naphthyl),
7.23 (1H, t, CH-naphthyl, 7= 7.9 Hz).
Synthesis of /J-naphthyl dichloro phosphate (92)*
q Prepared according to Standard Procedure E, from /?-naphthol
n
(5.00 g, 34.7 mmol), phosphorus oxychloride (3.23 mL, 34.7 mol)
[I I J ^1 and triethylamine (4.84 mL, 34.7 mol) and dry diethylether (25 
mL). The product was obtained as a yellow clear oil (7.85 g, 87%) used without 
further purification for the following reaction.
6 p (CHC13): 3.60; d H (CHC13): 7.73-7.66 (3H, m, CH-naphthyl), 7.61 (1H, m, CH- 
naphthyl), 7.40-7.30 (2H, m, CH-naphthyl), 7.25-7.23 (1H, m, CH-naphthyl).
Synthesis of 8-quinolinyl dichloro phosphate (180)
Prepared according to Standard Procedure E, from 8 -quinoline (4.00 g,
27.5 mmol), phosphorus oxychloride (2.57 mL, 27.5 mmol) and 
triethylamine (3.83 mL, 27.5 mmol) and dry diethylether (35 mL). The 
product was obtained as a yellow clear oil (5.38 g, 75%) used without 
further purification for the following reaction.
6 p (CHC13): 4.65; 6 H (CHC13): 8.91 (1H, m, CH-quinolinyl), 8.00 (1H, d, CH- 
quinolinyl, J= 8.3 Hz), 7.67 (1H, m, CH-quinolinyl), 7.61 (1H, m, CH-quinolinyl), 
7.45-7.39 (2H, m, CH-quinolinyl).
CI-P-C I
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7.5 Synthesis of aryl-phosphochloridates.
Synthesis of phenyl(benzyl-cyclopentylglycinyl) phosphorochloridate (50)2 
,— O O Prepared according to Standard Procedure B,
\  / ~ °  from phenyl dichlorophosphate (1.56 mL, 7.67
\— /  mmol), cyclopentylglycine benzyl ester tosylate
salt (41, 3.0 g, 7.67 mmol), dry triethylamine (2.13 mL, 15.34 mmol) and dry DCM 
(15 mL). The product was obtained as a clear yellow oil (2.57 g, 85%). 
d P (CDC13): 7.90; 6 „ (CDCI3): 7.96 (2H, d, CH-phenyl, J= 8.4 Hz), 7.44 (2H, m, CH- 
benzyl), 7.39 (4H, m, CH-phenyl, CH-benzyl), 7.27 (2H, d, CH-benzyl, J= 8.4 Hz),
5.24 (2H, s, CH2-benzyl), 4.65 (1H, s, NH), 2.43 (4H, m, CH2-cyclopentyl), 1.98 (4H, 
m, CH2-cyclopentyl).
Synthesis of phenyl(ethyl-cyclopentylglycinyl) phosphorochloridate (51)2
Prepared according to Standard Procedure B, from
O
phenyl dichlorophosphate (2.64 mL, 12.9 mmol), 
\ / cyclopentylglycine ethyl ester hydrochloride salt (42,
2.5 g, 12.9 mmol), dry triethylamine (3.60 mL, 25.8
mmol) and dry DCM (15 mL). The product was obtained as a clear white solid (3.37 
g, 79%).
6 p (CDCI3): 8.09; 6 „ (CDC13): 7.47 (1H, m, CH-phenyl), 7.34 (2H, m, CH-phenyl), 
7.30 (2H, m, CH-phenyl), 4.74 (1H, s, NH), 4.27 (2H, m, CH2-ethyl, J= 6.7 Hz), 2.30 
(4H, m, CH2-cyclopentyl), 1.92 (2H, m, CH2-cyclopentyl), 1.87 (2H, m, CH2- 
cyclopentyl), 1.35 (3H, t, CH3-ethyl, J= 6.7 Hz).
Synthesis of phenyl(isopropyl-cyclopentylglycinyl) phosphorochloridate (52)2
Prepared according to Standard Procedure B, from 
o  phenyl dichlorophosphate (1.08 mL, 7.2 mmol),
Cl \  /  cyclopentylglycine isopropyl ester hydrochloride salt
(43, 1.5 g, 7.2 mmol), dry triethylamine (2.00 mL, 14.4 mmol) and dry DCM 25 mL. 
The product was obtained as a clear yellow oil (2.11 g, 85 %).
6 P (CDCI3): 8.16; 6 h (CDCI3): 7.45 (2H, m, CH-phenyl), 7.30 (1H, m, CH-phenyl), 
6.85 (2H, m, CH-phenyl), 5.09 (1H, m, NH), 5.04 (1H, m, CH-isopropyl), 2.19 (2H,
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m, CH2-cyclopentyl), 2.18 (2H, m, CH2-cyclopentyl), 1.89 (2H, m, CH2-cyclopentyl), 
1.81 (2H, m, CH2-cyclopentyl), 1.27 (6 H, m, CH3-isopropyl).
Synthesis of phenyl(ethyl-L-isoleucinyl) phosphorochloridate (53)
q  q Prepared according to Standard Procedure B, from
\  phenyl dichlorophosphate (1.00 mL, 6.76 mmol), L-
Cl i
isoleucine ethyl ester hydrochloride salt (44, 1.4 g, 
6.76 mmol), dry triethylamine (1.88 mL, 13.52 mmol) 
and dry DCM (15 mL). The product was obtained as a clear white solid (1.6 g, 71%). 
&p (CDC13): 10.64, 10.01; 6 „ (CDC13): 7.26 (1H, m, CH-phenyl), 7.19 (2H, m, CH- 
phenyl), 7.16 (2H, m, CH-phenyl), 7.28 (1H, m, CH-phenyl), 4.76 (1H, m, NH), 4.15 
(2H, m, CH2-ethyl, J= 7.08 Hz), 3.89 (1H, m, CHa), 1.82 (1H, m, CH-lateral chain), 
1.43 (2H, m, CH2-lateral chain), 1.16 (3H, m, CH3-ethyl), 0.87-0.86 (6 H, CH3-lateral 
chain).
Synthesis of phenyl(benzyl-D-alaninyl) phosphorochloridate (54) 2
Prepared according to Standard Procedure B, 
/} ^  9  9\ from phenyl dichlorophosphate (0.64 mL, 4.27
C V o - p- nh . A
\ = /  ci T II 1 mm° 0 > D-alanine benzyl ester tosylate salt (0.9
g, 4.27 mmol), dry triethylamine (1.19 mL, 8.54 
mmol) and dry DCM (15 mL). The product was obtained as a clear oil (1.15 g, 76%). 
d P (CDC13): 9.29, 9.05; 6 H (CDC13): 7.41 (6 H, m, CH-phenyl, CH-benzyl), 7.32-7.30 
(4H, m, CH-benzyl), 5.26 (2H, d, CH2-benzyl), 4.66 (1H, m, NH), 4.34 (1H, m, CHa),
1.57 (3H, m, CH3-alanine).
Synthesis of phenyl(terf-butyl-D-alaninyl) phosphorochloridate (55)
Prepared according to Standard Procedure B, from 
phenyl dichlorophosphate (1.64 mL, 11.00 mmol), D- 
alanine rm-butyl ester hydrochloride salt (2 . 0  g,
11.00 mmol), dry triethylamine (1.61 mL, 22.00 mmol) and dry DCM (15 mL). The 
product was obtained as a clear oil (1.43 g, 41%).
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6 P (CDCI3): 9.48, 9.30; d H (CDC13): 7.37-7.12 (5H, m, CH-phenyl), 4.84 (1H, m, NH), 
4.80 (1H, m, CHa), 1.93 (9H, s, CH3-terf-butyl), 1.39 (3H, d, CH3-alanine, J= 4.2 
Hz).
Synthesis of phenyl(isopropyl-D-alaninyl) phosphorochloridate (107)6
Prepared according to Standard Procedure B, from phenyl 
$  Cl dichlorophosphate (1.79 mL, 12.0 mmol), D-alanine isopropyl 
0  i ^  ester hydrochloride salt (104, 2.0 g, 12.0 mmol), dry 
triethylamine (3.34 mL, 24.0 mmol) and dry DCM 25 mL. The 
product was obtained as a clear yellow oil (0.77 g, 21%).
6 P (CDC13): 9.41, 9.09; d H (CDC13): 7.43 (2H, m, CH-phenyl), 7.25 (1H, m, CH- 
phenyl), 6.80 (2H, m, CH-phenyl), 5.00 (1H, m, NH), 4.97 (1H, m, CH-isopropyl, 
CH-a), 1.48 (3H, m, CH3-alanine), 1.27 (6 H, m, CH3-isopropyl).
Synthesis of phenyl(2-butyl-D-alaninyl) phosphorochloridate (108)
Prepared according to Standard Procedure B, from phenyl 
dichlorophosphate (1.40 mL, 9.45 mmol), D-alanine 2-butyl 
ester tosylate salt (105, 3.0 g, 9.45 mmol), dry triethylamine 
(2.63 mL, 18.90 mmol) and dry DCM (15 mL). The product 
was obtained as a clear oil (2.70 g, 72%). 
dp (CDC13): 9.51, 9.32; d„ (CDC13): 7.37-7.12 (5H, m, CH-phenyl), 4.96-4.76 (1H, m, 
NH, CHa), 4.05 (1H, m, CH-2-butyl), 1.41 (3H, d, CH3-alanine), 1.24-1.19 (5H, m, 
CH2-2-butyl, CH3-alanine), 0.92 (3H, m, CH3-2-butyl).
Synthesis of phenyl(dodecilyl-D-alaninyl) phosphorochloridate (57)
Prepared according to Standard
H ON.h^ci Procedure B, from phenyl 
dichlorophosphate (0.52 mL, 3.49 
mmol), D-alanine dodecyl ester 
tosylate salt (46, 1.5 g, 3.49 mmol), 
dry triethylamine (0.96 mL, 6 . 8 8  mmol) and dry DCM (15 mL). The product was 
obtained as a clear oil (1.00 g, 67%).
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6 P (CDCI3): 9.38, 9.15; 6 „ (CDC13): 7.41-7.19 (5H, m, CH-phenyl), 4.78 (1H, m, NH), 
4.25-4.00 (3H, m, CHa, CH2-dodecyl), 1.54 (3H, m, CH3-alanine), 1.28 (22H, m, 
CH2-dodecyl), 0.91 (3H, t, CH3-dodecyl, J= 6.3 Hz).
Synthesis of phenyl(butyl-D-alaninyl) phosphorochloridate (56)
O Prepared according to Standard Procedure B, from phenyl
II H O
dichlorophosphate (1.90 mL, 12.7 mmol), D-alanine butyl 
ester tosylate salt (45, 4.0 g, 12.7 mmol), dry triethylamine 
(3.50 mL, 25.40 mmol) and dry DCM (15 mL). The 
product was obtained as a clear oil (2.37 g, 58%).
5 P (CDC13): 9.45, 9.29; 6 „ (CDC13): 7.35-7.15 (5H, m, CH-phenyl), 4.95-4.72 (1H, m, 
NH, CHa), 4.15 (2H, m, CH2-butyl), 1.54-1.50 (2H, m, CH2-butyl), 1.45 (3H, d, CH3- 
alanine), 1.42-1.20 (2H, m, CH2-butyl), 1.05-0.89 (3H, m, CH3-butyl).
Synthesis of phenyl(octyl-D-alaninyl) phosphorochloridate (109)
Prepared according to Standard Procedure B, 
from phenyl dichlorophosphate (1.01 mL, 6.76 
= O mmol), D-alanine octyl ester tosylate salt (106,
4.0 g, 12.7 mmol), dry triethylamine (1.86 mL, 
13.52 mmol) and dry DCM (15 mL). The 
product was obtained as a clear oil (2.54 g, 60%).
6 P (CDC13): 9.43, 9.27; 6 „ (CDC13): 7.38-7.17 (5H, m, CH-phenyl), 4.92-4.65 (1H, m, 
NH, CHa), 4.10 (2H, m, CH2-octyl), 1.54-1.45 (2H, m, CH2-octyl), 1.43 (3H, d, CH3- 
alanine), 1.39-1.15 (10H, m, CH2-octyl), 1.05-0.89 (3H, m, CH3-octyl).
Synthesis of phenyl(benzyl-L-alaninyl) phosphorochloridate (132)2
Prepared according to Standard Procedure B, 
from phenyl dichlorophosphate (0.70 mL, 4.63 
mmol), L-alanine benzyl ester hydrochloride salt 
(1.0 g, 4.63 mmol), dry triethylamine (1.30 mL, 9.26 mmol) and dry DCM (20 mL). 
The product was obtained as a clear oil (1.21 g, 90%).
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5 , (CDCI3): 7.79, 7.75; 8 „ (CDCI3): 7.25 (7H, m, CH-phenyl, CH-benzyl), 7.17-7.08 
(3H, m, CH-benzyl), 5.11 (2H, d, CH2-benzyl), 4.51 (1H, m, NH), 4.15 (1H, m, CHa),
1.42 (3H, m, CH3-alanine).
Synthesis of phenyl(ethyl-L-alaninyl) phosphorochloridate (129)2
O O Prepared according to Standard Procedure B, from
<^ = J > - o - p - nh> A o ^ phenyl dichlorophosphate (0.97 mL, 6.5 mmol), L- 
alanine ethyl ester hydrochloride salt ( 1 . 0  g, 6 . 5  
mmol), dry triethylamine (1.80 mL, 13.0 mmol) and dry DCM (20 mL). The product 
was obtained as a clear oil (1.55 g, 82%).
6 P (CDC13): 8.16, 7.94; 6 „ (CDC13): 7.28-7.20 (2H, m, CH-phenyl), 7.18-7.14 (3H, m, 
CH-phenyl), 4.17 (1H, m, NH), 4.13 (1H, m, CHa), 3.39 (2H, m, CH2-ethyl), 1.42 
(3H, m, CH3-alanine), 1.12 (3H, m, CH3-ethyl).
Synthesis of phenyl(methyl-L-alaninyl) phosphorochloridate (128)2
Prepared according to Standard Procedure B, from 
phenyl dichlorophosphate (0.53 mL, 3.58 mmol), L-
* C l  ^= alanine methyl ester hydrochloride salt (0.50 g, 3.58
mmol), dry triethylamine (0.99 mL, 7.16 mmol) and dry DCM (20 mL). The product 
was obtained as a clear oil (0.85 g, 8 6 %).
6 P (CDC13): 8.01, 7.88; 8 „ (CDC13): 7.30-7.27 (2H, m, CH-phenyl), 7.18-7.11 (3H, m, 
CH-phenyl), 4.63 (1H, m, NH), 4.11 (1H, m, CHa), 3.69 (3H, s, CH3-methyl), 1.43 
(3H, m, CH3-alanine).
Synthesis of phenyl(isopropyl-L-alaninyl) phosphorochloridate (130)6
Prepared according to Standard Procedure B, from
^ V o - p - n h ^ A  1  phenyl dichlorophosphate (0.45 mL, 2.98 mmol), L-
' ' Cl ^= alanine isopropyl ester hydrochloride salt (127, 0.50
g, 2.98 mmol), dry triethylamine (0.83 mL, 5.96 mmol) and dry DCM (20 mL). The 
product was obtained as a clear oil (0.58 g, 64%).
6 P (CDC13): 8.36, 8.22; 6 H (CDC13): 7.23-7.20 (2H, m, CH-phenyl), 7.16-7.05 (3H, m, 
3 CH-phenyl), 4.98-4.93 (2H, m, NH, CHa), 4.00 (1H, m, CH-isopropyl), 1.37 (3H, t, 
CH3-alanine, J= 3.7 Hz), 1.15 (6 H, m, CH3-isopropyl).
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Synthesis of phenyl(te/f-butyl-L-alaninyl) phosphorochloridate (131)7
O O Prepared according to Standard Procedure B, from
\ _ y _0 " P " NH\ ^ 0 J<C phenyl dichlorophosphate (0.83 mL, 5.5 mmol), L- 
N—' ci i
alanine tert-butyl ester hydrochloride salt (1.0 g, 5.5 
mmol), dry triethylamine (1.5 mL, 11.0 mmol) and dry DCM (20 mL). The product 
was obtained as a clear oil (1.71 g, 97%).
5 P (CDC13): 8.27, 8.07; 6 H (CDC13): 7.28-7.26 (2H, m, CH-phenyl), 7.22-7.14 (3H, m, 
CH-phenyl), 4.47 (1H, m, NH), 3.96 (1H, m, CHa), 1.40 (12H, m, CH3-alanine, CH3- 
tert- butyl).
Synthesis of phenyl(butyl-L-alaninyl) phosphorochloridate (58)
Prepared according to Standard Procedure B, from phenyl
H O
hLj^CI dichlorophosphate (1.90 mL, 12.7 mmol), L-alanine butyl 
O ester tosylate salt (47, 4.00 g, 12.7 mmol), dry 
triethylamine (3.54 mL, 25.40 mmol) and dry DCM (15 
mL). The product was obtained as a clear oil (2.67 g, 
65%).
6 P (CDC13): 9.40, 9.19; 6 „ (CDC13): 7.40-7.22 (5H, m, CH-phenyl), 4.82-4.66 (1H, m, 
NH, CHa), 4.38-4.30 (2H, m, CH2-butyl), 1.69-1.61 (2H, m, CH2-butyl), 1.42-1.39 
(3H, m, CH3-alanine), 1.37-1.32 (2H, m, CH2-butyl), 1.00-0.90 (3H, m, CH3-butyl).
Synthesis of phenyl(benzyl-L-valinyl) phosphorochloridate (134)6
Prepared according to Standard Procedure B, 
from phenyl dichlorophosphate (0.40 mL, 2.64 
mmol), L-valine benzyl ester tosylate salt (1.00 
g, 2.64 mmol), dry triethylamine (0.73 mL, 5.28 mmol) and dry DCM (15 mL). The 
product was obtained as a clear oil (0.84 g, 99%).
6 P (CDC13): 9.48, 8.95; 6 „ (CDC13): 7.27 (6 H, m, CH-phenyl, CH-benzyl), 7.24-7.14 
(4H, m, CH-benzyl), 5.12 (2H, d, CH2-benzyl), 4.25 (1H, m, NH), 3.91 (1H, m, CHa), 
0.93 (3H, m, CH3-lateral chain), 0.82 (3H, m, CH3-lateral chain).
O
A
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Synthesis of phenyl(ethyl-L-prolinyl) phosphorochloridate (140)6
Prepared according to Standard Procedure B, from
O.
q /  ° \ ^ _  Phenyl dichlorophosphate (0.41 mL, 2.78 mmol), L-
\  /  O-P—N v proline ethyl ester hydrochloride salt (124, 0.50 g, 2.78
Cl L _/
mmol), dry triethylamine (0.77 mL, 5.56 mmol) and dry 
DCM (20 mL). The product was obtained as a clear oil (0.65 g, 74%).
6 P (CDC13): 7.83, 7.76; 6 H (CDC13): 7.29-7.21 (2H, m, CH-phenyl), 7.17-7.13 (3H, m, 
CH-phenyl), 4.39 (1H, m, CH a), 4.12 (2H, m, CH2-ethyl), 3.49-3.44 (2H, m, CH2- 
proline), 2.18-2.14 (1H, m, CH-proline), 2.08-2.05 (1H, m, CH-proline), 1.94 (2H, m, 
CH2-proline), 1.19 (3H, m, CH3-ethyl).
Synthesis of phenyl(ethyl-L-leucinyl) phosphorochloridate (139)2
Prepared according to Standard Procedure B, from 
O -P -N H ^ ^ A  phenyl dichlorophosphate (0.38 mL, 2.55 mmol), L-
0 1  - leucine ethyl ester hydrochloride salt (0.50 g, 2.55
mmol), dry triethylamine (0.71 mL, 5.10 mmol) and 
dry DCM (15 mL). The product was obtained as a clear oil (0.83 g, 82%).
6 P (CDC13): 8.46, 8.22; 6 H (CDC13): 7.30-7.28 (2H, m, CH-phenyl), 7.19-7.14 (3H, m, 
CH-phenyl), 4.15 (1H, m, NH), 4.05 (2H, m, CH2-ethyl), 3.39 (1H, m, CHa), 1.78-
1.62 (1H, m, CH-lateral chain), 1.55 (2H, m, CH2-lateral chain), 1.24-1.18 (3H, m, 
CH3-ethyl), 0.88 (6 H, t, CH3-lateral chain, J= 3.6 Hz).
Synthesis of phenyl(ethyl-L-methioninyl) phosphorochloridate (141)
Prepared according to Standard Procedure B, from 
$  10  ?  N H ^ ^ A  phenyl dichlorophosphate (0.35 mL, 2.34 mmol), L-
\= = / q | : 0  methionine ethyl ester hydrochloride salt (0.50. g,
2.34 mmol), dry triethylamine (0.65 mL, 4.68 mmol) 
and dry DCM (20 mL). The product was obtained as a clear oil (0.81 g, 98%).
Sp (CDC13): 8.70, 8.45; 8 „ (CDC13): 7.27 (2H, m, CH-phenyl), 7.22-7.13 (3H, m, CH- 
phenyl), 4.94 (1H, m, NH), 4.19-4.12 (3H, m, CHa, CH2-ethyl), 2.50 (2H, m, CH2- 
lateral chain), 2.07-1.95 (5H, m, CH2-lateral chain, CH3-lateral chain), 1.42 (3H, m, 
CH3-lateral chain), 1.11 (3H, m, CH3-ethyl).
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Synthesis of phenyl(benzyl-glycinyl) phosphorochloridate (133)6
Prepared according to Standard Procedure B, 
from phenyl dichlorophosphate (0.44 mL, 2.96 
mmol), glycine benzyl ester tosylate salt ( 1 . 0 0  g, 
2.96 mmol), dry triethylamine (0.83 mL, 5.92 mmol) and dry DCM (15 mL). The 
product was obtained as a clear oil (0.65 g, 79%).
6 P (CDC13): 9.15; 8„ (CDCI3): 7.25 (6 H, m, CH-phenyl, CH-benzyl), 7.17-7.10 (4H, 
m, CH-benzyl), 5.11 (2H, d, CH2-benzyl), 4.54 (1H, m, NH), 3.84 (2H, m, CH2- 
glycine).
Synthesis of phenyl(ethyl-Af-methyl-glycinyl) phosphorochloridate (143)8
Prepared according to Standard Procedure B, from 
phenyl dichlorophosphate (0.48 mL, 3.25 mmol), N- 
methyl-glycine ethyl ester hydrochloride salt (126, 0.5 
g, 3.25 mmol), dry triethylamine (0.90 mL, 6.50 mmol) and dry DCM (20 mL). The 
product was obtained as a clear oil (0.94 g, 99%).
5 P (CDCI3): 11.19; 6 „ (CDCI3): 6.55-6.42 (2H, m, CH-phenyl), 6.38-6.25 (3H, m, 
CH-phenyl), 3.33-3.30 (2H, m, CH2-glycine), 3.16 (2H, m, CH2-ethyl), 2.02 (3H, s, 
CH3-N), 1.38 (3H, m, CH3-ethyl).
Synthesis of phenyl(benzyl-a,a-dim ethylglycinyl) phosphorochloridate (135)
Prepared according to Standard Procedure B, 
from phenyl dichlorophosphate (0.39 mL, 2.61 
mmol), a,a-dimethylglycine benzyl ester 
tosylate salt (122, 1.00 g, 2.61 mmol), dry triethylamine (0.73 mL, 5.22 mmol) and 
dry DCM (20 mL). The product was obtained as a clear oil (0.54 g, 56%).
6 P (CDCI3): 5.53; 5„ (CDC13): 7.26 (6 H, m, CH-phenyl, CH-benzyl), 7.23-7.12 (4H, 
m, CH-benzyl), 5.12 (2H, s, CH2-benzyl), 4.67 (1H, b, NH), 1.61 (6 H, d, CH3-a ,a -  
dimethylglycine).
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Synthesis of phenyl(ethyl-a,a-dimethylglycinyl) phosphorochloridate (136)
r—* O O Prepared according to Standard Procedure B, from
v y-  0 —P~NH /v
\ — /  ' phenyl dichlorophosphate (0.44 mL, 2.98 mmol),Cl
a, a-di methyl glycine ethyl ester hydrochloride salt 
(123, 0.50 g, 2.98 mmol), dry triethylamine (0.83 mL, 5.96 mmol) and dry DCM (20 
mL). The product was obtained as a clear oil (0.84 g, 92%).
6 P (CDC13): 5.58; S„ (CDC13): 7.29 (1H, m, CH-phenyl, J= 1.4 Hz), 7.20-7.14 (4H, m, 
CH-phenyl), 4.68 (1H, b, NH), 4.18 (2H, m, CH2-ethyl), 1.61 (6 H, d, CH3-a ,a -  
dimethylglycine), 1.13 (3H, m, CH3-ethyl).
Synthesis of phenyl(diethyl-L-aspartyl) phosphorochloridate (59)
O Prepared according to Standard Procedure B, from phenyl
U o dichlorophosphate (0.67 mL, 4.49 mmol), L-ethylasparatate 
O ethyl ester hydrochloride salt (1.0 g, 4.49 mmol), dry
O f ^ l l  triethylamine (1.25 mL, 8.98 mmol) and dry DCM (15 mL).
The product was obtained as a clear oil (1.14 g, 70%).
6 P (CDC13): 9.78, 9.54; 6 H (CDC13): 7.31-7.06 (5H, m, CH-phenyl), 4.86 (1H, m, NH), 
4.25-4.00 (5H, m, CHa, CH2-ethyl, CH2-ethyl lateral chain), 2.78 (2H, m, CH2-lateral 
chain), 1.23 (6 H, m, CH3-ethyl, CH3-ethyl lateral chain).
Synthesis of phenyl(benzyl-L-phenylalaninyl) phosphorochloridate (137)
Prepared according to Standard Procedure B, 
^  from phenyl dichlorophosphate (0.26 mL, 1.71
Cl z II I mmoi)j L-phenylalanine benzyl ester
hydrochloride salt (0.5 g, 1.71 mmol), dry 
triethylamine (0.48 mL, 3.42 mmol) and dry DCM (15 mL). The product was obtained 
as a clear oil (0.68 g, 92%).
6 P (CDC13): 7.91, 7.85; 6 „ (CDC13): 7.37-7.21 (7H, m, CH-phenyl, CH-benzyl), 7.17- 
6.92 (8 H, m, CH-benzyl, CH-lateral chain), 5.08 (2H, d, CH2-benzyl), 4.38 (1H, m, 
NH), 4.13-4.08 (1H, m, CHa), 3.06 (2H, m, CH2-lateral chain).
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Synthesis of phenyl(ethyl-L-phenylalaninyl) phosphorochloridate (138)
Prepared according to Standard Procedure B, from
/—  ^ O O
( /  >\ _ 0 _ p _ NH^ J | ^  phenyl dichlorophosphate (0.32 mL, 2.18 mmol), L-
Cl i  phenylalanine ethyl ester hydrochloride salt (0.5 g,
2.18 mmol), dry triethylamine (0.60, 4.36 mmol) and 
dry DCM (20 mL). The product was obtained as a 
clear oil (0.72 g, 1.96 mmol, 90%).
6 P (CDC13): 8.03, 7.95; 6 „ (CDC13): 7.35-7.20 (2H, m, CH-phenyl), 7.15-6.91 (8 H, m, 
CH-phenyl, CH-lateral chain), 4.36 (1H, m, CHa), 4.09 (1H, m, NH), 3.40 (2H, m, 
CH2-ethyl), 3.08-3.02 (2H, m, CH2-lateral chain), 1.12 (3H, t, CH3-ethyl, J= 6 . 6  Hz).
Synthesis of phenyl(ethyl-yS-alaninyl) phosphorochloridate (142)
q  Prepared according to Standard Procedure B, from
phenyl dichlorophosphate (0.48 mL, 3.25 mmol),
—  Cl O /5-alanine ethyl ester hydrochloride salt (125, 0.5 g,
3.25 mmol), dry triethylamine (0.90 mL, 6.50 mmol) and dry DCM (20 mL). The 
product was obtained as a clear oil (0.91 g, 96%).
6 P (CDC13): 10.00; 6 „ (CDC13): 7.32-7.27 (2H, m, CH-phenyl), 7.19-7.10 (3H, m, 
CH-phenyl), 4.54 (1H, b, NH), 4.09 (2H, m, CH2-ethyl), 3.33 (2H, m, CH2-/3-alanine), 
2.54 (2H, t, CH2-/5-alanine, J= 5.9 Hz), 1.18 (3H, t, CH3-ethyl, J= 7.0 Hz).
Synthesis of p-chloro-phenyl(ethyl-L-leucinyl) phosphorochloridate (82)
Prepared according to Standard Procedure B, from p-chloro- 
' J J - 'C I  Phenyl dichlorophosphate ( 7 8 ,  1.88 g, 7.66 mmol), L-leucine 
\  S  O ethyl ester hydrochloride salt (1.5 g, 7.66 mmol), dry 
triethylamine (2.14 mL, 15.32 mmol) and dry DCM (15 mL). 
The product was obtained as a clear oil (2.16 g, 77%). 
c » 6 P (CDC13): 9.75, 9.73; 6 „ (CDC13): 7.23 (2H, m, CH-phenyl), 
7.12 (2H, m, CH-phenyl), 4.37 (1H, m, NH), 4.13 (2H, m, CH2-ethyl), 3.99 (lH,m, 
CH-a), 1.78 (1H, m, CH-lateral chain), 1.53 (2H, m, CH2-lateral chain), 1.16 (6 H, m, 
CH3-lateral chain), 0.82 (3H, m, CH3-ethyl).
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Synthesis of 3,4-dichloro-phenyl(ethyl-L-leucinyl) phosphorochloridate (83)
Prepared according to Standard Procedure B, from a solution
H ON'p ^ c * 3,4-dichloro-phenyl dichlorophosphate (79, 2.14 g, 7.66
mmol), L-leucine ethyl ester hydrochloride salt (1.5 g, 7.66 
mmol), dry triethylamine (2.14 mL, 15.32 mmol) and dry 
qi DCM (15 mL). The product was obtained as a clear oil (2.28 
Cl g, 75%).
8 r (CDClj): 9.84, 9.78; 8 „ (CDC13): 7.41 (1H, m, CH-phenyl), 7.38 (1H, m, CH- 
phenyl), 7.33 (1H, m, CH-phenyl), 4.59 (1H, m, NH), 4.28 (1H, m, CHa), 4.09 (2H, 
m, CH2-ethyl), 1.70 (1H, m, CH-lateral chain), 1.45 (2H, m, CH2-lateral chain), 1.03 
(6 H, m, CH3-lateral chain), 0.78 (3H, m, CH3-ethyl).
Synthesis of p-methyl-phenyl(ethyl-L-leucinyl) phosphorochloridate (84)
Prepared according to Standard Procedure B, from p-methyl- 
phenyl dichloro phosphate (80, 1.72 g, 7.66 mmol), L-leucine 
ethyl ester hydrochloride salt (1.5 g, 7.66 mmol), dry 
triethylamine (2.14 mL, 15.32 mmol) and dry DCM (15 mL). 
The product was obtained as a clear oil (2.28 g, 75%).
6 h (CHC13): 10.06, 9.63; 6 „ (CHC13): 7.05 (2H, d, CH-phenyl),
7.00 (2H, m, CH-phenyl), 4.67 (1H, m, NH), 4.26 (1H, m, CHa), 4.12 (2H, m, CH2- 
ethyl), 1.87 (1H, m, CH-lateral chain), 1.69 (2H, m, CH2-lateral chain), 1.45 (3H, m, 
CH3-ethyl), 1.32 (3H, m, CH3-lateral chain), 1.02 (3H, m, CH3-lateral chain).
Synthesis of p-methoxy-phenyl(ethyl-L-leucinyl) phosphorochloridate (85)
Prepared according to Standard Procedure B, from p-methoxy- 
N S.C, phenyl dichlorophosphate (81, 1.85 g, 7.66 mmol), L-leucine 
ethyl ester hydrochloride salt (1.5 g, 7.66 mmol), dry 
triethylamine (2.14 mL, 15.32 mmol) and dry DCM (15 mL). 
The product was obtained as a clear oil (1.71 g, 61%).
, 0  6 p (CHC13): 10.54, 10.22; 6 „ (CHC13): 7.12 (2H, d, CH-phenyl, 
J= 9.0 Hz), 6.85 (2H, d, phenyl, J= 9.0 Hz), 4.46 (1H, m, NH), 4.28 (1H, m, CHa),
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3.85 (3H, s, CH30-/?-phenyl), 1.86 (1H, m, CH-lateral chain),1.65 (2H, m, CH2-lateral 
chain), 1.37 (3H, m, CH3-ethyl), 1.32 (3H, m, CH3-lateral chain), 0.96 (3H, m, CH3- 
lateral chain).
Synthesis of a-naphthyl(benzyl-L-alaninyl) phosphorochloridate (93) 6
Prepared according to Standard Procedure B, 
from a-naphthyl dichlorophosphate (91, 2.22 g, 
8.53 mmol), L-alanine benzyl ester 
hydrochloride salt (3.0 g, 8.53 mmol), dry 
triethylamine (2.38 mL, 17.07 mmol) and dry DCM (15 mL). The product was 
obtained as a clear oil (1.62 g, 47%).
SP (CDC13): 8.25, 8.58; 6 H (CDC13): 7.97 (1H, m, CH-naphthyl), 7.73-7.09 (11H, m, 
CH-naphthyl, CH-benzyl), 5.09 (2H, s, CH2-benzyl), 4.81 (1H, m, NH), 4.23 (1H, m, 
CHa), 1.42 (3H, m, CH3-alanine).
Synthesis of /3-naphthyl(benzyl-L-alaninyl) phosphorochloridate (94) 6
Prepared according to Standard Procedure
O O B, from ^5-naphthyl dichlorophosphate (92,
\s Q - p —NH i l
,— /  ^  ^  2.22 g, 8.53 mmol), L-alanine benzyl ester
hydrochloride salt (3.0 g, 8.53 mmol), dry 
triethylamine (2.38 mL, 17.07 mmol) and dry DCM (15 mL). The product was 
obtained as a clear oil (2.29g, 6 6 %).
6 P (CDC13): 8.32, 8.10; 6 „ (CDC13): 7.85-7.62 (4H, m, 3 CH-naphthyl, CH-benzyl), 
7.48-7.37 (3H, m, 3 CH-naphthyl), 7.27-7.18 (5H, m, CH-naphthyl, 4 CH-benzyl),
5.15 (2H, s, CH2-benzyl), 5.10 (1H, m, NH), 4.20 (1H, m, CHa), 1.47 (3H, m, CH3- 
alanine).
Synthesis of a-naphthyl(benzyl-cyclopentylglycinyl) phosphorochloridate (169)
Prepared according to Standard Procedure B,
y   O O
( /  \ _ n _ p _ NH JL ^  ^  from a-naphthyl dichlorophosphate (90, 1.33 g,
5.11 mmol), cyclopentylglycine benzyl ester 
tosylate salt (41, 2.0 g, 5.11 mmol), dry
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triethylamine (1.42 mL, 10.22 mmol) and dry DCM (15 mL). The product was 
obtained as a clear yellow oil (1.41 g, 62%).
6 P (CDC13): 7.05; 6 „ (CDC13): 8.00 (1H, m, CH-naphthyl), 7.72 (1H, m, CH- 
naphthyl), 7.56 (1H, d, CH-naphthyl, J= 8.4 Hz), 7.47 (1H, d, CH-naphthyl, J= 8.4 
Hz), 7.37 (1H, m, CH-naphthyl), 7.26 (1H, t, CH-naphthyl, J= 7.5 Hz), 7.24-7.13 (6 H, 
m, CH-phenyl, CH-naphthyl), 5.07 (2H, s, CH2-benzyl), 4.57 (1H, s, NH), 2.20-2.02 
(4H, m, CH2-cyclopentyl), 1.87-1.69 (4H, CH2-cyclopentyl).
Synthesis of cr-naphthyl(ethyl-cyclopentylglycinyl) phosphorochloridate (170)
Prepared according to Standard Procedure B, from a- 
V  naphthyl dichlorophosphate (90, 2.7 g, 10.33 mmol),
Cl \  j  cyclopentylglycine ethyl ester hydrochloride salt (42,
2.0 g, 10.33 mmol), dry triethylamine (2.9 mL, 20.65 
mmol) and dry DCM (15 mL). The product was obtained as a clear a white solid (3.40 
g, 8 6 %).
6 p (CDCI3): 6.90; 5„ (CDC13): 8.04 (1H, d, CH-naphthyl, J= 8.1 Hz), 7.79 (1H, d, CH- 
naphthyl, 7= 7.4 Hz), 7.65 (1H, d, CH-naphthyl, J= 8.3 Hz), 7.54-7.44 (3H, m, CH- 
naphthyl), 7.36 (1H, t, CH-naphthyl, J= 8.1 Hz), 4.25 (1H, s, NH), 4.16 (2H, m, CH2- 
ethyl, J= 7.0 Hz), 2.22-2.12 (4H, m, CH2-cyclopentyl), 1.86-1.73 (4H, m, CH2- 
cyclopentyl), 1.13 (3H, t, CH3-ethyl, J= 7.0 Hz).
Synthesis of a-naphthyl(isopropyl-D-alaninyl) phosphorochloridate (171)6
Prepared according to Standard Procedure B, from a- 
naphthyl dichlorophosphate (90, 2.70 g, 10.33 mmol), D- 
alanine isopropyl ester hydrochloride salt (104, 1.4 g, 10.33 
mmol), dry triethylamine (2.88 mL, 20.65 mmol) and dry 
DCM (15 mL). The product was obtained as a clear oil 
(2.55 g, 6 8 %).
6 P (CDCI3): 7.88, 7.37; 6 „ (CDC13): 7.97 (1H, m, CH-naphthyl), 7.23 (1H, m, CH- 
naphthyl), 7.01 (1H, m, CH-naphthyl), 6.80-6.40 (4H, m, CH-naphthyl), 4.50 (1H, m, 
NH), 4.02 (1H, m, CHa), 3.79 (1H, m, CH-isopropyl), 1.48 (6 H, d, CH3-isopropyl, J=
6.2 Hz), 1.42 (3H, m, CH3-alanine).
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Synthesis of a-naphthyl(benzyl-D-alaninyl) phosphorochloridate (172)6
Prepared according to Standard Procedure B, from a- 
naphthyl dichlorophosphate (90, 2.70 g, 10.33 mmol), 
D-alanine benzyl ester hydrochloride salt (3.6 g, 10.33 
mmol), dry triethylamine (2.88 mL, 20.65 mmol) and 
dry DCM (15 mL). The product was obtained as a 
clear oil (1.23 g, 29%).
5 P (CDC13): 7.40, 7.17; 6 „ (CDC13): 7.17 (1H, m, CH-naphthyl), 6.99-6.28 (11H, m, 
CH-naphthyl, CH-benzyl), 4.30-4.21 (2H, m, CH2-benzyl), 3.79 (1H, m, NH), 3.46 
(1H, m, CHa), 1.45 (3H, m, CH3-alanine).
N " X I
Synthesis of phenyl(methyl-L-alaninyl) phosphorochloridate (231)6
  Prepared according to Standard Procedure B, from a-
\ __ /  q  q  naphthyl dichlorophosphate (90, 2.54 g, 9.76 mmol), L-
(  Vo-P—NHv^ A /  alanine methyl ester hydrochloride salt (1.36 g, 9.76 
Cl mmol), dry triethylamine (2.70 mL, 19.52 mmol) and 
dry DCM (15 mL). The product was obtained as a clear oil (2.49 g, 78%).
6 P (CDC13): 8.25, 8.02; d H (CDC13): 8.10 (1H, t, CH-naphthyl), 7.88 (1H, d, CH- 
naphthyl, J= 7.6 Hz), 7.74 (1H, d, CH-naphthyl, J= 8.3 Hz), 7.62-7.55 (3H, m, CH- 
naphthyl), 7.45 (1H, t, CH-naphthyl, J= 7.9 Hz), 4.65 (1H, m, NH), 4.16-4.12 (1H, m, 
CHa), 3.82, 3.77 (3H, d, CH3-methyl), 1.27 (3H, t, CH3-alanine, J= 7.1 Hz).
Synthesis of a-naphthyl(ethyl-L-alaninyl) phosphorochloridate (207)6
Prepared according to Standard Procedure B, from a-
& naphthyl dichlorophosphate (90, 2.54 g, 9.76 mmol),O OO -p -n h  J L  L-alanine ethyl ester hydrochloride salt (1.5 g, 9.76
Cl i mmol), dry triethylamine (2.70 mL, 19.52 mmol) and
dry DCM (15 mL). The product was obtained as a clear oil (2.87 g, 8 6 %). 
d P (CDC13): 8.42, 8.25; d H (CDC13): 8.00 (1H, m, CH-naphthyl), 7.75 (1H, m, CH- 
naphthyl), 7.62-7.28 (5H, m, CH-naphthyl), 4.83 (1H, m, NH), 4.21-3.98 (3H, m, 
CHa, CH2-ethyl), 1.10 (3H, m, CH3-ethyl), 1.22 (3H, d, CH3-alanine, J= 4.2 Hz).
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Synthesis of a-naphthyl(terf-butyl-L-alaninyl) phosphorochloridate (208)6 
y  Prepared according to Standard Procedure B, from a-
naphthyl dichloro phosphate (90, 2.15 g, 8.25 mmol),
L-alanine terf-butyl ester hydrochloride salt (1.5 g,
8.25 mmol), dry triethylamine (2.30 mL, 16.50 mmol) 
and dry DCM (15 mL). The product was obtained as a clear oil (2.73 g, 89%). 
d P (CDC13): 8.48, 8.19; 6 „ (CDC13): 8.04 (1H, m, CH-naphthyl), 7.78 (1H, m, CH- 
naphthyl), 7.64-7.30 (5H, m, 5 CH-naphthyl), 4.50 (1H, m, NH), 4.08 (1H, m, CHa),
1.43 (9H, s, 3 CH3-terf-butyl), 1.38 (3H, m, CH3-alanine).
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7.6 Synthesis of cytidine analogue phosphoramidates.
Synthesis of 4 ’-azidocytidine 5’-0-[phenyl(benzyl-cyclopentylglycinyl)]
phosphate (65)
NH
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.986 mmol), 'BuMgCl (2.46 mL, 1M solution in THF, 2.46 mmol) and 
phenyl(benzyl-cyclopentylglycinyl) phosphorochloridate (50, 2.46 mL of solution 1M 
in THF, 2.46 mmol). The crude product was purified twice by column 
chromatography, using as eluent for the first CHCl3/MeOH (95:5) and for the second 
CHCl3/MeOH (80:20) then a preparative TLC using as eluent CHCl3/MeOH (9:1). 
The pure product was a white solid (30 mg, 5%).
SP (<4-CH3OH): 3.70, 3.67; d H (^-C H 3OH): 7.55 (1H, m, H6 -cytidine, J= 7.3 Hz),
7.24 (7H, m, CH-phenyl, CH-benzyl), 7.13 (3H, m, CH-phenyl, CH-benzyl), 6.07 
(1H, m, H l’-cytidine), 5.75 (1H, m, H5-cytidine, J= 7.3 Hz), 5.05 (2H, s, CH2- 
benzyl), 4.23 (1H, m, H2’-cytidine), 4.15 (1H, m, H3’-cytidine), 4.10 (2H, m, H5’- 
cytidine), 2.00 (2H, m, CH2-cyclopentyl), 1.92 (2H, m, CH2-cyclopentyl), 1.63 (2H, 
m, CH2-cyclopentyl), 1.55 (2H, m, CH2-cyclopentyl); 6 C (d4-CW3OW)\ 176.82 (1C, 
C =0 ester), 167.99 (1C, C4-cytidine), 158.56 (1C, C2-cytidine), 152.49, 152.42 (1C, 
C-phenyl), 143.48, 143.36 (1C, C6 -cytidine), 137.74, 137.73 (1C, C-benzyl), 131.73, 
131.55, 131.20 (2C, CH-phenyl, CH-benzyl), 130.20, 129.98 (1C, CH-phenyl), 
129.73, 129.71, 129.71, 129.69 (2C, CH-phenyl, CH-benzyl), 129.59, 129.45 (1C, 
CH-benzyl), 127.37, 126.70 (2C, CH-phenyl, CH-benzyl), 122.05, 121.99, 121.92 
(2C, CH-phenyl, CH-benzyl), 99.16, 99.04, 99.02 (1C, C5-cytidine), 97.24 (1C, C4’- 
cytidine), 93.87, 93.75 (1C, C l ’-cytidine), 74.88, 74.84 (1C, C3’-cytidine), 73.79, 
73.70 (1C, C2’-cytidine), 69.16, 69.07, 68.99, 68.76 (1C, C5’-cytidine), 68.72 (1C, C- 
cyclopentyl), 68.61 (1C, CH2-benzyl), 40.34, 40.23, 40.16, 40.05 (1C, CH2-
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cyclopentyl), 39.62, 39.56, 39.50 (1C, CH2-cyclopentyl), 25.10, 25.00 (1C, CH2- 
cyclopentyl), 24.98 (1C, CH2-cyclopentyl).
Synthesis of 4 ’-azidocytidine 5 ’-(7-[phenyI(ethyl-cyclopentylglycinyl)] phosphate
(66)
V ° .  , nh
'3 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.986 mmol), 'BuMgCl (2.46 mL 1M solution in THF, 2.46 mmol) and phenyl(ethyl- 
cyclopentylglycinyl) phosphorochloridate (51, 2.46 mL 1M solution of THF, 2.46 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH (85:15). 
The pure product was a white solid (100 mg, 18%).
5 P (^-C H 3OH): 3.74; 6 H (d4-CH3OH): 7.70 (1H, m, H6 -cytidine, J= 7.6 Hz), 7.38 
(2H, m, CH-phenyl), 7.36 (1H, m, CH-phenyl), 7.25 (2H, m, CH-phenyl), 6.19 (1H, 
m, H l’-cytidine), 5.87 (1H, m, H2-cytidine, J= 7.6 Hz), 4.37 (2H, m, CH2-ethyl), 4.28 
(1H, m, H2’-cytidine), 4.26 (1H, m, H3’-cytidine), 4.15 (2H, m, H5’-cytidine), 2.00 
(2H, m, CH2-cyclopentyl), 1.92 (2H, m, CH2-cyclopentyl), 1.63 (2H, m, CH2- 
cyclopentyl), 1.55 (2H, m, CH2-cyclopentyl), 1.25 (3H, m, CH3-ethyl); 6 C (d4- 
CH3OH): 177.05 (1C, C =0 ester), 168.05 (1C, C4-cytidine), 158.62 (1C, C2-
cytidine), 152.52, 152.43 (1C, C-phenyl), 143.51, 143.43 (1C, C6 -cytidine), 131.00 
(2C, CH-phenyl), 126.70 (1C, CH-phenyl), 122.07, 122.00, 121.93 (2C, CH-phenyl),
99.22, 99.19, 99.09, 99.05 (1C, C5-cytidine), 97.21 (1C, C4’-cytidine), 93.86, 93.79 
(1C, C l ’-cytidine), 74.86 (1C, C3’-cytidine), 73.87, 73.79 (1C, C2’-cytidine), 69.20, 
69.12, 69.05 (1C, C5’-cytidine), 68.72, 68.69 (1C, C-cyclopentyl), 62.93 (1C, CH2- 
ethyl), 40.35, 40.23 (1C, CH2-cyclopentyl), 40.10, 39.54 (1C, CH2-cyclopentyl), 
25.11, 25.00 (1C, CH2-cyclopenty1), 24.98 (1C, CH2-cyclopentyl), 14.86 (1C, CH3- 
ethyl).
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Synthesis of 4’-azidocytidine 5’-0-[phenyl(isopropyl-cyclopentylglycinyl)]
phosphate (67)
NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.986 mmol), ‘BuMgCl (2.46 mL of solution 1M in THF, 2.46 mmol) and 
phenyl(isopropyl-cyclopentylglycinyl)phosphorochloridate (52, 2.46 mL, 1M solution 
in THF, 2.46 mmol). The crude product was purified twice by column 
chromatography, using as eluent for the first CHCl3/MeOH (85:15) and for the second 
column CHCl3/MeOH (80:20) then a preparative TLC using as eluent CHCl3/MeOH 
(9:1). The pure product was a white solid (25 mg, 5%).
d P (^-C H 3OH): 3.77, 3.75; 6 „ (</4-CH3OH): 7.69 (1H, m, H6 -cytidine, J= 10.59 Hz), 
7.39 (2H, m, CH-phenyl), 7.27 (1H, m, CH-phenyl), 7.23 (2H, m, CH-phenyl), 6.20 
(1H, t, H l’-cytidine), 5.89 (1H, m, H5-cytidine, J= 10.59 Hz), 5.01 (1H, m, CH- 
isopropyl, J= 3.3 Hz), 4.40 (1H, m, H2’-cytidine), 4.36 (1H, m, H3’-cytidine), 4.28 
(2H, m, H5’-cytidine), 2.12 (2H, m, CH2-cyclopentyl), 1.97 (2H, m, CH2- 
cyclopentyl), 1.74 (2H, m, CH2-cyclopentyl), 1.66 (2H, m, CH2-cyclopentyl), 1.25 
(6 H, t, 2 CH3-isopropyl, J= 3.3 Hz).
Synthesis of 4’-azidocytidine 5’-0-[phenyl(ethyl-L-isoleucinyl)] phosphate (6 8 )
NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.986 mmol), ‘BuMgCl (2.46 mL 1M solution of THF, 2.46 mmol) and phenyl(ethyl- 
L-isoleucinyl) phosphorochloridate (53, 2.46 mL of solution 1M in THF, 2.46 mmol). 
The crude product was purified by column chromatography, using as eluent
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CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH (85:15). 
The pure product was a white solid (20 mg, 3%).
6 P (d4-CU3OU): 5.55, 5.30; 6 „ (rf4-CH3OH): 7.62 (1H, m, H6 -cytidine, J= 7.7 Hz),
7.34 (2H, m, CH-phenyl), 7.23 (1H, m, CH-phenyl), 7.17 (2H, m, CH-phenyl), 6.14 
(1H, m, H I’-cytidine, J= 9.51 Hz), 5.83 (1H, m, H5-cytidine, J= 7.7 Hz), 4.31 (2H, 
m, CH2-ethyl), 4.19 (1H, m, H2’-cytidine), 4.13 (1H, m, H3’-cytidine), 4.08 (2H, m, 
H5’-cytidine), 3.71 (1H, m, CH a), 1.74 (1H, m, CH-lateral chain), 1.45 (2H, m, CH2- 
lateral chain) 1.15 (3H, m, CH3-ethyl), 0.85-0.82 (6 H, m, CH3-lateral chain).
Synthesis of 4 ,-azidocytidine 5’-0-[phenyl(benzyl-D-alaninyl)] phosphate (69)
NH
'3 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.986 mmol), ‘BuMgCl (2.46 mL 1M solution of THF, 2.46 mmol) and 
phenyl(benzyl-D-alanine) phosphorochloridate (54, 2.46 mL of solution 1M in THF, 
2.46 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5), followed by a preparative TLC using as eluent 
CHCl3/MeOH (85:15) and at the end it was purified using semi-preparative HPLC. 
The pure product was a white solid (20 mg, 3%).
6 P (^-C H 3OH): 4.80, 4.26; 6 „ (</4-CH3OH): 7.63 (1H, m, H6 -cytidine, J= 7.6 Hz),
7.35 (6 H, m, CH-phenyl, CH-benzyl), 7.23 (4H, m, CH-benzyl), 6.15 (1H, m, H l’- 
cytidine), 5.89 (1H, m, H5-cytidine, J= 7.6 Hz), 5.16 (2H, s, CH2-benzyl), 4.35 (2H, 
m, H5’-cytidine), 4.26 (1H, m, H2’-cytidine), 4.23 (1H, m, H3’-cytidine), 4.16 (1H, 
m, CHa), 1.34 (3H, m, CH3-alanine).
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Synthesis of 4’-azidocytidine 5 ’ -0-[phenyl(te/t-butyl-D-alaninyl) ] phosphate (70)
NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 250 mg, 
0.821 mmol), ‘BuMgCl (2.0 mL 1M solution of THF, 2.054 mmol) and phenyl(tert- 
butyl-D-alaninyl) phosphorochloridate (55, 2.05 mL of solution 1M in THF, 2.054 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5), followed by a preparative TLC using as eluent CHCl3/MeOH 
(85:15). The pure product was a white solid (3.5 mg, 1%).
6 P (^-C H 3OH): 4.91, 4.45; 6 H (^-C H 3OH): 7.67 (1H, m, H6 -cytidine, J= 7.5 Hz), 
7.45 (5H, m, CH-phenyl), 6.17 (1H, m, H I’-cytidine), 5.92 (1H, m, H5-cytidine, J= 
7.5 Hz), 4.40-4.18 (2H, m, H2’-cytidine, H3’-cytidine, H5’-cytidine), 3.85 (1H, m, 
CHa), 1.45 (9, s, CH3-terf-butyl), 1.37 (3H, m, CH3-alanine).
MS (ES) m/e: 590 (MNa+, 100%); Accurate mass: C22H30N7O9NaP required 590.1761, 
found 590.1740.
Synthesis of 4’-azidocytidine 5 ’-CMphenyl(butyl-D-alaninyl)] phosphate (71)
•t,
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.924 mmol), ‘BuMgCl (1.85 mL 1M solution of THF, 1.850 mmol) and 
phenyl(butyl-D-alaninyl) phosphorochloridate (56, 1.85 mL of solution 1M in THF, 
1.850 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5), followed by a preparative TLC using as eluent 
CHCl3/MeOH (85:15). The pure product was a white solid (16 mg, 3%).
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6 P (^-C H 3OH): 4.73, 4.55; S„ (^-C H 3OH): 7.65 (1H, m, H6 -cytidine), 7.44-7.26 
(5H, m, CH-phenyl), 6.20 (1H, m, H I’-cytidine, J= 5.0 Hz), 5.94 (1H, m, H5- 
cytidine), 4.42-4.22 (2H, m, H2’-cytidine, H3’-cytidine), 4.25-3.98 (5H, m, CHa, 
H5’-cytidine, CH2-butyl), 1.73-1.59 (3H, m, CH3-alanine), 1.43-1.18 (4H, m, CH2- 
butyl), 0.96 (3H, m, CH3-butyl).
MS (ES) m/e: 591.0 (MNa+, 100%); Accurate mass: C22H29N6O10NaP required
590.1749, found 590.1740.
Synthesis of 4’-azidocytidine 5’-0-[phenyl(dodecyl-D-alaninyl)] phosphate (72)
NH2
3 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 200 mg, 
0.657 mmol), ‘BuMgCl (1.64 mL 1M solution of THF, 1.640 mmol) and 
phenyl(dodecyl -D-alaninyl) phosphorochloridate (57, 1.64 mL of solution 1M in 
THF, 1.640 mmol). The crude product was purified by column chromatography, using 
as eluent CHCl3/MeOH (95:5), followed by a preparative TLC using as eluent 
CHCl3/MeOH (85:15). The pure product was a white solid (23 mg, 5%).
6 P (^-C H 3OH): 4.80, 4.33; 6 H (rf4-CH3OH): 7.65 (1H, m, H6 -cytidine, J= 9.0 Hz), 
7.42-7.18 (5H, m, CH-phenyl), 6.18 (1H, m, H I’-cytidine), 5.90 (1H, m, H5-cytidine),
4.40-3.95 (7H, m, H2’-cytidine, H3’-cytidine, H5’-cytidine, CHa, CH2-dodecyl), 1.54 
(3H, m, CH3-alanine), 1.30 (22H, m, CH2-dodecyl), 0.92 (3H, t, CH3-dodecyl, J= 6.5 
Hz).
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Synthesis of 4’-azidocytidine 5’-0-[phenyl(ethyl-L-ethylaspartyl)] phosphate (73)
NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azido-cytidine (23, 300 mg, 
0.986 mmol), ‘BuMgCl (1.97 mL 1M solution of THF, 1.972 mmol) and phenyl(ethyl- 
L-ethylaspartyl) phosphorochloridate (59, 1.97 mL of solution 1M in THF, 1.972 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5), followed by a preparative TLC using as eluent CHCl3/MeOH 
(85:15). The pure product was a white solid (30 mg, 5%).
6 P (^-C H 3OH): 4.67, 4.40; 6 „ (rf4-CH3OH): 7.70 (1H, m, H6 -cytidine), 7.40-7.16 
(5H, m, CH-phenyl), 6.16 (1H, m, H l’-cytidine), 5.85 (1H, m, H5-cytidine), 4.40-4.00 
(9H, m, H2’-cytidine, H3’-cytidine, H5’-cytidine, CHa, CH2-ethyl, CH2-ethyl lateral 
chain), 2.78 (2H, m, CH2-lateral chain), 1.23 (6 H, m, CH3-ethyl, CH3-ethyl lateral 
chain).
MS (ES) m/e: 634.1 (MNa+, 100%); Accurate mass: C^H^NyOnNaP required 
634.1639, found 634.1624.
Synthesis of 4 ’-azidocytidine 5’-0-[phenyl(butyl-L-alaninyl)] phosphate (74)
NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 300 mg, 
0.924 mmol), ‘BuMgCl (1.8 mL 1M solution of THF, 1.849 mmol) and phenyl(butyl- 
L-alaninyl) phosphorochloridate (58, 1.8 mL of solution 1M in THF, 1.849 mmol). 
The crude product was purified by column chromatography, using as eluent
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CHCl3/MeOH (95:5), followed by a preparative TLC using as eluent CHCl3/MeOH 
(85:15). The pure product was a white solid (11 mg, 2%).
6 P (^-C H 3OH): 4.82, 4.32; 6 H (4,-CH3OH): 7.67 (1H, m, H6 -cytidine, J= 7.3 Hz), 
7.41-7.21 (5H, m, CH-phenyl), 6.18 (1H, m, H l’-cytidine, J= 4.0 Hz), 5.78 (1H, m, 
H5-cytidine, J= 7.3 Hz), 4.39-4.27 (2H, m, H2’-cytidine, H3’-cytidine), 4.25-4.09 
(5H, m, CHa, H5’-cytidine, CH2-butyl), 1.63-1.58 (3H, m, CH3-alanine), 1.41-1.23 
(4H, m, CH2-butyl), 0.95 (3H, m, CH3-butyl).
MS (ES) m/e: 590.3 (M N a\ 100%); Accurate mass: C^H^NsO^NaP required
590.1749, found 590.1740.
Synthesis of 4’-azidocytidine 5’-0-[p-chloro-phenyl(ethyI-L-leucinyl)] phosphate
(87)
NH
Cl
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 350 mg, 1.15 
mmol), ‘BuMgCl (2.88 mL 1M solution of THF, 2.88 mmol) and p-chloro- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (82, 2.88 mL of 1M solution in THF,
2.88 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10). The pure product was a white solid (100 mg, 14%).
SP (^-C H 3OH): 5.19, 4.92; 6 H M rC H 3OH): 7.74 ( 1 H, m, H6 -cytidine, J= 7A  Hz), 
7.36 (2H, m, CH-phenyl), 7.24 (2H, m, CH-phenyl), 6.15 (1H, m, H l’cytidine), 5.96 
(1H, m, H5-cytidine, J= 7.4 Hz), 4.37 (1H, m, H2’-cytidine), 4.25 (1H, m, H3’- 
cytidine), 4.15 (2H, m, CH2-ethyI), 4.13 (2H, m, H5’-cytidine), 3.88 (1H, m, CH-a), 
1.73 (1H, m, CH-lateral chain), 1.55 (2H, m, CH2-lateral chain), 1.25 (3H, m, CH3- 
lateral chain), 1.19 (3H, m, CH3-lateral chain), 0.90 (3H, m, CH3-ethyl).
MS (ES) m/e: 638.1 (MNa+, 100%); Accurate mass: C23H31N70 9NaPCl required 
638.1495, found 638.1507.
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Synthesis of 4’-azidocytidine 5’-0-[3,4-dichloro-phenyl(ethyl-L-leucinyl)]
phosphate (88)
NH
Cl
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 350 mg, 1.15 
mmol), ‘BuMgCl (2.88 mL 1M solution of THF, 2.88 mmol) and 3,4-dichloro- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (83, 2.88 mL of solution 1M in THF,
2.88 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10) The pure product was a white solid (40 mg, 5%).
5 P (^-C H 3OH): 5.27, 4.99; 6 H (^-C H 3OH): 7.70 (1H, m, H6 -cytidine, J= 7.5 Hz), 
7.54_7.48 (2H, m, CH-phenyl), 7.25, 7.18 (1H, m, CH-phenyl), 6.13 (1H, m, 
H l’cytidine), 5.93 (1H, t, H5-cytidine, J= 7.5 Hz), 4.39 (1H, m, H2’-cytidine), 4.28 
(1H, m, H3’-cytidine), 4.13 (2H, m, CH2-ethyl), 4.11 (2H, m, H5’-cytidine), 3.89 (1H, 
m, CH-a), 1.74 (1H, m, CH-lateral chain), 1.56 (2H, m, CH2-lateral chain), 1.28 (3H, 
m, CH3-lateral chain), 0.90 (3H, m, CH3-ethyl); 6 C (^-C H 3OH): 175.19 (1C, C =0 
ester), 168.05 (1C, C4-cytidine), 156.62 (1C, C2-cytidine), 151.31 (1C, C-phenyl), 
143.96, 143.49 (1C, C6 -cytidine), 132.70 (2C, CH-phenyl), 131.85 (1C, C-phenyl), 
124.17, 124.10 (1C, C-phenyl), 122.32, 122.13, 122.06 (1C, CH-phenyl), 98.96, 98.83 
(1C, C5-cytidine), 97.35, 97.23 (1C, C4’-cytidine), 94.14 (1C, C l ’-cytidine), 74.84,
74.55 (1C, C3’-cytidine), 73.94, 73.81 (1C, C2’-cytidine), 69.65, 69.58 (1C, C5’- 
cytidine), 62.87, 62.78 (1C, CH2-ethyl), 55.05, 54.98 (1C, CH-a), 44.38, 44.29 (1C, 
CH2-lateral chain), 26.04, 25.91 (1C, CH-lateral chain), 23.68, 23.62, 23.52 (1C, CH3- 
lateral chain), 22.23, 21.84 (1C, CH3-lateral chain), 14.86 (1C, CH3-ethyl).
MS (ES) m/e: 672.1 (MNa+, 100%); Accurate mass: C ^ H ^ N ^ N a P C ^  required 
672.1101, found 672.1117.
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Synthesis of 4’-azidocytidine 5’-6>-[p-methyl-phenyl(ethyl-L-leucinyl)] phosphate
(89)
NH
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 350 mg, 1.15 
mmol), ‘BuMgCl (2.88 mL 1M solution of THF, 2.88 mmol) and p-methyl- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (84, 2.88 mL of 1M solution in THF,
2.88 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (85:15) and a preparative TLC using as eluent CHCl3/MeOH 
(85:15). The pure product was a white solid (14 mg, 4%).
SP (^-C H 3OH): 5.24, 4.90; 6 „ (^-C H 3OH): 7.65 (1H, m, H6 -cytidine, J= 7.5 Hz),
7.15 (2H, m, CH-phenyl), 7.06 (2H, m, CH-phenyl), 6.20 (1H, m, H l’cytidine), 5.89 
(1H, t, H5-cytidine, J= 7.5 Hz), 4.32 (1H, m, H2’-cytidine), 4.23 (1H, m, H3’- 
cytidine), 4.17 (2H, m, CH2-ethyl), 4.11 (2H, m, H5’-cytidine), 4.07 (1H, m, CH-a),
2.26 (3H, s, CH3-p-methylphenyl), 1.72 (1H, m, CH-lateral chain), 1.55 (2H, m, CH2- 
lateral chain), 1.25 (3H, m, CH3-lateral chain), 1.18 (3H, m, CH3-lateral chain), 0.91 
(3H, m, CH3-ethyl); 5 C (4,-CH3OH): 175.31 (1C, C =0 ester), 167.97 (1C, C4- 
cytidine), 150.11 (1C, C2-cytidine), 143.31, 143.08 (1C, C6 -cytidine), 131.65, 131.60 
(1C, C-phenyl), 130.86 (2C, CH-phenyl), 121.65, 121.59 (1C, C-phenyl), 121.47, 
121.41 (2C, CH-phenyl), 98.92 (1C, C5-cytidine), 97.35 (1C, C4’-cytidine), 93.89 
(1C, C l ’-cytidine), 75.03, 74.83 (1C, C3’-cytidine), 73.89 (1C, C2’-cytidine), 69.26,
69.07 (1C, C5’-cytidine), 62.78, 62.72 (1C, CH2-ethyl), 54.96 (1C, CHa), 44.54 (1C, 
CH2-lateral chain), 26.03, 25.81 (1C, CH-lateral chain), 23.65, 23.56, 23.44 (1C, CH3, 
lateral chain), 23.18, 22.39 (1C, CH3, lateral chain), 14.67, 14.45 (1C, CH3-ethyl).
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Synthesis of 4’-azidocytidine 5’-0-[p-methoxy-phenyl(ethyl-L-leucinyl)]
phosphate (90)
NH
\ O
'3 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 350 mg, 1.15 
mmol), 'BuMgCl (2.88 mL 1M solution of THF, 2.88 mmol) and p-methoxy- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (85, 2.88 mL of 1M solution in THF,
2.88 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10) and then a preparative TLC using as eluent 
CHCl3/MeOH (85:15). The pure product was a white solid (20 mg, 3%).
6 P (d4-CU3OU): 5.59, 5.22; 6 „ (^-C H 3OH): 7.71 (1H, m, H6 -cytidine, J= 7.6 Hz), 
7.17 (2H, m, CH-phenyl), 6.91 (2H, m, CH-phenyl), 6.22 (1H, m, H l’cytidine), 5.96 
(1H, m, H2-cytidine, J= 7.6 Hz), 4.36 (1H, m, H2’-cytidine), 4.34 (1H, m, H3’- 
cytidine), 4.17 (2H, m, CH2-ethyl), 4.10 (2H, m, H5’-cytidine), 3.91 (1H, m, CH-a), 
3.79 (3H, s, CH30-phenyl), 1.74 (1H, m, CH-lateral chain), 1.56 (2H, m, CH2-lateral 
chain), 1.27 (3H, m, CH3-lateral chain), 1.21 (3H, m, CH3-lateral chain), 0.92 (3H, m, 
CH3-ethyl); 6 C (^-C H 3OH): 175.33 (1C, C=0 ester), 167.50 (1C, C4-cytidine), 
158.99 (1C, C2-cytidine), 145.85, 145.76 (1C, C-phenyl), 143.64, 143.42 (1C, C6 - 
cytidine), 122.85, 122.79 (1C, C-phenyl), 122.67, 122.61 (2C, CH-phenyl), 157.11 
(1C, C-phenyl), 99.30, 99.10, 98.97 (1C, C5-cytidine), 97.47, 97.39 (1C, C4’- 
cytidine), 93.90 (1C, C l ’-cytidine), 74.99, 74.75,74.05 (1C, C3’-cytidine), 73.90 (1C, 
C2’-cytidine), 69.22, 69.15 (1C, C5’-cytidine), 62.80, 62.73, 62.23 (1C, CH2-ethyl), 
56.53, 56.44 (1C, CH30-phenyl), 55.10, 54.96 (1C, CHa), 44.55, 44.45 (1C, CH2- 
lateral chain), 26.04, 25.81 (1C, CH-lateral chain), 23.69, 23.59, 23.46, 23.23 (1C, 
CH3, lateral chain), 22.41, 21.97 (1C, CH3, lateral chain), 14.78, 14.56 (1C, CH3- 
ethyl).
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Synthesis of 2 ’ ,3 ’ - 0,O-cy clopentylidene-4 ’-azidocy tidine 5
naphthyl(benzyl-L-alaninyl)] phosphate (97.a/97.b)
Prepared according to Standard Procedure C2, from 
2 ’ ,3 ’ ■-O, O-cyclopenty lidene-4’ -azidocytidine (95,
200 mg, 0.570 mmol), ‘BuMgCl (1.1 mL of 1M 
solution in THF, 1.14 mmol) and a- 
naphthyl(benzyl-L-alaninyl) phosphorochloridate 
(93, 1.1 mL of solution 1M in THF, 1.14 mmol).
The crude product was purified by column
chromatography, using as eluent CHCl3/MeOH 
(95:5) and preparative HPLC to separate the 2 
diastereoisomers. The pure product was a white solid (50 mg of the more polar 
diastereoisomer 97.a, 40 mg of the less polar diastereoisomer 97.b, overall 347 mg of 
mixture, 85%).
M ore Polar Diasteroisomer: 6 P (d^-CRjOH): 3.45; 6 H (d4-CH3OH): 7.94 (1H, d, CH- 
naphthyl, J= 7.4 Hz), 7.67 (1H, m, CH-naphthyl), 7.49 (1H, d, H6 -cytidine, J= 8.1 
Hz), 7.34-7.30 (3H, m, CH-naphthyl, CH-phenyl), 7.27 (1H, d, CH-naphthyl, J= 7.7 
Hz), 7.18 (1H, t, CH-naphthyl, J~  8.0 Hz), 7.08-7.05 (6 H, CH-naphthyl, CH-phenyl) 
5.69 (1H, d, H I’-cytidine, J= 1.7 Hz), 5.59 (1H, d, H5-cytidine, J= 7.4 Hz), 4.84 (2H, 
m, CH2-benzyl), 4.76 (H, m, H3’-cytidine, J= 6.3 Hz), 4.69 (1H, d, H2’-cytidine, J=
1.7 Hz), 4.10 (2H, m, H5’-cytidine), 3.87 (1H, m, CHa), 1.96 (2H, m, CH2-
cyclopentyl), 1.53-1.49 (6 H, m, CH2-cyclopentyl), 1.14 (3H, d, CH3-alanine, 7= 0.9 
Hz).
Less Polar Diasteroisomer: 6 P 04-CH3OH): 3.41; 6 „ (74-CH3OH): 7.92 (1H, m, CH- 
naphthyl), 7.72 (1H, d, H6 -cytidine, J= 7.3 Hz), 7.56-7.50 (4H, m, CH-naphthyl, CH- 
phenyl), 7.42 (1H, t, CH-naphthyl, J= 8.0 Hz), 7.35-7.31 (6 H, CH-naphthyl, CH- 
phenyl) 5.87 (1H, d, H l’-cytidine, J= 1.6 Hz), 5.79 (1H, d, H5-cytidine, J= 7.3 Hz),
5.12 (2H, m, CH2-benzyl), 5.00 (H, d, H3’-cytidine, J= 6.4 Hz), 4.97 (1H, d, H2’- 
cytidine, J= 1.6 Hz), 4.35 (2H, m, H5’-cytidine), 4.29 (1H, m, CHa), 2.25 (2H, m, 
CH2-cyclopentyl), 1.76-1.72 (6 H, m, CH2-cyclopentyl), 1.37 (3H, d, CH3-alanine, J= 
0.6 Hz).
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Synthesis of 4’-azidocytidine 5’-CM a-naphthyl (benzyl-L-alaninyl) phosphate
(98.a/98.b)
3 OH OH
Prepared according to Standard Procedure C3, 2 ’,3’-0,0-cyclopentylidene-4’- 
azidocytidine 5 ’-0-[a-naphthyl(benzyl-L-alaninyl)] phosphate (50 mg more polar 
97.a, 0.077 mmol, 40 mg less polar diastereoisomer 97.b, 0.056 mmol), and 10 mL of 
a solution 80% of HCOOH in water. The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a white 
solid (40 mg of the more polar diastereoisomer 98.a, 80%, 30 mg of the less polar 
diastereoisomer 98.b, 82%).
M ore Polar Diasteroisomer: 6 P (J4-CH3OH): 3.75; 6 H (<i4-CH3OH): 8.18 (1H, m, 
CH-naphthyl), 7.90 (1H, m, CH-naphthyl), 7.72 (1H, d, H6 -cytidine, J= 8.2 Hz), 
7.58-7.51 (4H, m, CH-naphthyl, CH-phenyl), 7.41 (1H, t, CH-naphthyl, J= 7.8 Hz),
7.33-7.28 (5H, m, CH-naphthyl, CH-phenyl), 6.11 (1H, d, H l’-cytidine, J= 4.5 Hz),
5.43 (1H, d, H5-cytidine, J= 8.2 Hz), 5.09 (2H, m, CH2-benzyl), 4.38 (1H, d, H3’- 
cytidine, J= 5.9 Hz), 4.31-4.22 (3H, m, H2’-cytidine, H5’-cytidine), 4.10 (1H, m, 
CHa), 1.34 (3H, d, CH3-alanine, J= 7.1 Hz).
MS (ES) m/e: 674.2 (MNa+, 100%); Accurate mass: C29H30N7O9NaP required
674.1740, found 674.1751.
Less Polar Diasteroisomer: 6 P (^4-CH3OH): 3.87; 6 „ (^-C H 3OH): 8.06 (1H, m, CH- 
naphthyl), 7.78 (1H, m, CH-naphthyl), 7.65 (1H, d, H6 -cytidine, J= 7.5 Hz), 7.45-
7.35 (4H, m, CH-naphthyl, CH-phenyl), 7.25 (1H, t, CH-naphthyl, J= 7.8 Hz), 7.21-
7.12 (5H, m, CH-naphthyl, CH-phenyl), 6.03 (1H, d, H l’-cytidine, J= 3.4 Hz), 5.65 
(1H, d, H5-cytidine, J= 7.5 Hz), 4.94 (2H, m, CH2-benzyl), 4.27 (1H, d, H3’-cytidine, 
J -  4.8 Hz), 4.20-4.12 (3H, m, H2’-cytidine, H5’-cytidine), 3.96 (1H, m, CHa), 1.23 
(3H, d, CH3-alanine, J= 6 . 8  Hz).
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MS (ES) m/e: 674.2 (MNa+, 100%); Accurate mass: C^Hgo^OgNaP required
674.1740, found 674.1725.
Synthesis of 4 ’-azidocytidine 5’-0-[/J-naphthyl(benzyl-L-alaninyl)] phosphate
(99.a/99.b)
NH
V 0  ^ -NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidocytidine (23, 200 mg, 
0.657 mmol), ‘BuMgCl (1.7 mL, 1M solution in THF, 1.64 mmol) and /$- 
naphthyl(benzyl-L-alaninyl) phosphorochloridate (94, 1.7 mL of solution 1M in THF, 
1.64 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5) and preparative HPLC to separate the 2 diastereoisomers. 
The pure product was a white solid (10 mg of the more polar diastereoisomer 99.a, 15 
mg of the less polar diastereoisomer 99.b, with an overall yield of 5%)
M ore Polar Diasteroisomer: 6 P (<^-CH3OH): 3.62; 5„ (<i4-CH3OH): 7.88-7.64 (5H, 
m, H6 -cytidine, CH-naphthyl), 7.52-7.47 (2H, m, CH-naphthyl, CH-phenyl), 7.38-
7.31 (6 H, m, CH-naphthyl, CH-phenyl), 6.16 (1H, d, H l’-cytidine, J= 4.6 Hz), 5.83 
(1H, d, H5-cytidine, J= 7.4 Hz), 5.13 (2H, m, CH2-benzyl), 4.38 (1H, d, H3’-cytidine, 
J -  5.8 Hz), 4.31-4.26 (3H, m, H2’-cytidine, H5’-cytidine), 4.12 (1H, m, CHa), 1.37 
(3H, d, CH3-alanine, J= 7.1 Hz).
Less Polar Diasteroisomer: 6 P (d4-CH3OH): 3.50; SH (<i4-CH3OH): 7.88 (2H, d, 2 
CH-naphthyl, J= 8.7 Hz), 7.81 (1H, d, CH-naphthyl, J= 8.0 Hz), 7.62 (1H, d, H6 - 
cytidine, J= 7.5 Hz), 7.52-7.48 (2H, m, CH-naphthyl, CH-phenyl), 7.37 (1H, m, CH- 
phenyl), 7.31 (6 H, m, CH-naphthyl, CH-phenyl), 6.13 (1H, d, H l’-cytidine, J= 5.5 
Hz), 5.78 (1H, d, H5-cytidine, J= 7.5 Hz), 5.09 (2H, m, CH2-benzyl), 4.39 (1H, d, 
H3’-cytidine, J= 5.9 Hz), 4.32 (1H, d, H2’-cytidine), 4.27-4.22 (2H, m, H5’-cytidine),
4.12 (1H, m, CHa), 1.38 (3H, d, CH3-alanine, J= 7.1 Hz).
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Synthesis of,4 ’-azido-2 ’ ,3 ’-dipentanoatecytidine 5 ’ -0-[phenyl(benzyl-D-alaninyl)]
phosphate (1 0 1 )
Prepared according to Standard Procedure C l, from 4 ’-azido-2’,3’- 
dipentanoatecytidine (28, 250 mg, 0.570 mmol), ‘BuMgCl (1.1 mL 1M solution of 
THF, 1.140 mmol) and phenyl(benzyl-D-alanine) phosphorochloridate (54, 1.1 mL of 
solution 1M in THF, 1.140 mmol). The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (95:5). The pure product was a white 
solid (320 mg, 72%).
5 P (^-C H 3OH): 4.60, 4.13; 5„ (rf4-CH3OH): 7.59 (1H, m, H6 -cytidine, J= 7.5 Hz),
7.34-7.18 (10H, m, CH-phenyl, CH-benzyl), 6.15 (1H, m, H l’-cytidine, J= 4.0 Hz), 
5.89-5.81 (2H, m, H5-cytidine, H2’-cytidine), 5.63-5.59 (1H, m, H3’-cytidine), 5.14 
(2H, s, CH2-benzyl), 4.37-4.29 (2H, m, H5’-cytidine), 4.05 (1H, m, CHa), 2.40 (4H, t, 
CH2-dipentanoate, J= 7.2 Hz), 1.61 (4H, m, CH2-dipentanoate), 1.40-1.34 (7H, m, 
CH3-alanine, CH2-dipentanoate), 0.93 (6 H, t, CH3-dipentanoate, J= 7.3 Hz); 6 C (<d4- 
CH3OH): 175.31, 175.26 (1C, C = 0  ester), 175.06, 174.99 (1C, C =0 dipentanoate), 
173.59, 173.56 (1C, C =0 dipentanoate), 168.29 (1C, C4-cytidine), 158.00 (1C, C2- 
cytidine), 152.42, 152.37, 152.33, 152.28 (1C, C-phenyl), 144.61, 144.41 (1C, C6 - 
cytidine), 137.61 (1C, C-phenyl), 131.27 (2C, 2 CH-phenyl), 130.14 (2C, 2 CH- 
phenyl), 129.75, 129.70 (2C, 2 CH-phenyl), 126.77, 126.69 (1C, CH-phenyl), 122.05, 
121.99, 121.92 (1C, CH-phenyl), 98.06, 97.92 (1C, C5-cytidine), 97.41 (1C, C4’- 
cytidine), 94.23, 93.73 (1C, C l’-cytidine), 74.03 (1C, C3’-cytidine), 72.95, 72.62 (1C, 
C2’-cytidine), 69.34, 69.28, 6 8 .8 6 , 68.80 (1C, C5’-cytidine), 68.51, 68.45 (1C, CH2- 
benzyl), 52.14, 52.90 (1C, CHa), 34.85, 34.70 (2C, 2 CH2-dipentanoate), 28.41, 28.36
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(2C, CH2-dipentanoate), 23.64 (2C, CH2-dipentanoate), 20.92, 20.84, 20.79, 20.69 
(1C, CH3-alanine), 14.55 (2C, CH3-dipentanoate).
MS (ES) m/e: 792.2 (MNa+, 100%); Accurate mass: QsH^NvOnNaP required 
792.2729, found 792.2734.
Synthesis of, 4’-azido-2’,3’-dipentanoatecytidine 5’-(9-[a-naphthyl(benzyl-L-
alaninyl)] phosphate (1 0 2 .a/1 0 2 .b)
Prepared according to Standard Procedure C l, from 4 ’-azido-2’,3’- 
dipentanoatecytidine (28, 150 mg, 0.342 mmol), ‘BuMgCl (0.7 mL 1M solution of 
THF, 0.684 mmol) and a-naphthyl(benzyl-L-alanine) phosphorochloridate (93, 0.69 
mL of solution 1M in THF, 0.684 mmol). The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (95:5). The pure product was a white 
solid (224 mg, 80%).
6 P (^-C H 3OH): 3.55, 3.54; 6 „ (^-C H 3OH): 7.93 (1H, m, CH-naphthyl), 7.64 (1H, m, 
H6 -cytidine), 7.46 (1H, m, CH-naphthyl), 7.30-7.03 (10H, CH-naphthyl, CH-benzyl), 
5.84 (1H, m, H l’-cytidine, J -  3.8 Hz), 5.66 (1H, m, H5-cytidine, 7= 6 . 6  Hz), 5.56 
(1H, m H3’-cytidine), 5.39 (1H, m H2’-cytidine), 4.84 (2H, m, CH2-benzyl), 4.17 
(2H, m, H5’-cytidine), 3.86 (1H, m, CHa), 2.18-2.09 (4H, m, CH2-dipentanoate), 1.63 
(3H, m, CH3-alanine), 1.38-1.32 (4H, m, CH2-dipentanoate), 1.17-1.02 (4H, m, CH2- 
dipenatanoate), 0.71-0.63 (6 H, t, CH3-dipentanoate).
MS (ES) m/e: 842.4 (MNa+, 100%); Accurate mass: C^H^N-jOnNaP required 
842.2891, found 842.2913.
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Synthesis of 4’-azido-2 ’ ,3 ’ -dipentanoatecytidine 5’-0-[jS-naphthyl(benzyl-L-
alaninyl)] phosphate (103)
NH
Prepared according to Standard Procedure C l, from 4 ’-azido-2’,3’- 
dipentanoatecytidine (28, 200 mg, 0.570 mmol), ‘BuMgCl (1.14 mL 1M solution of 
THF, 1.140 mmol) and ^-naphthyl(benzyl-L-alanine) phosphorochloridate (94, 1.14 
mL of solution 1M in THF, 1.140 mmol). The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (95:5). The pure product was a white 
solid ( 1 2 0  mg, 26%).
SP (^-C H 3OH): 3.32, 3.28; 6 „ (^-C H 3OH): 7.87-7.29 (13H, m, CH-phenyl, CH- 
naphthyl, H6 -cytidine), 6.11 (1H, d, H l’-cytidine, J= 4.0 Hz), 5.90-5.84 (2H, m, H5- 
cytidine, H2’-cytidine), 5.63-5.59 (1H, m, H3’-cytidine), 5.11 (2H, m, CH2-benzyl),
4.40-4.35 (2H, m, H5’-cytidine), 4.12 (1H, m, CHa), 2.39 (4H, m, CH2-dipentanoate), 
1.61 (4H, m, CH2-dipentanoate), 1.41-1.33 (7H, m, CH3-alanine, CH2-dipentanoate), 
0.93 (6 H, m, CH3-dipentanoate); 6 C (d4-CH3OH): 174.57 (1C, C =0 ester), 173.93,
173.88 (1C, C =0 dipentanoate), 173.21, 173.16 (1C, C =0 dipentanoate), 167.94, 
167.86 (1C, C4-cytidine), 157.64, 157.60 (1C, C2-cytidine), 149.54 (1C, C-naphtyl), 
144.20, 143.97 (1C, C6 -cytidine), 137.24, 137.21 (1C, C-phenyl), 135.33 (2C, C- 
naphthyl), 132.52 (2C, CH-phenyl), 131.04, 130.98 (2C, CH-phenyl), 129.58, 129.30,
129.26 (3C, CH-naphthyl), 128.84, 128.82, 128.60, 128.55 (2C, CH-naphthyl), 
127.93, 127.92 (1C, CH-phenyl), 126.74, 126.70 (1C, CH-naphthyl), 121.42, 121.38,
121.31 (1C, CH-phenyl), 117.93, 117.89, 117.84, 117.80 (2C, CH-naphthyl), 97.71, 
97.65, 97.58 (1C, C5-cytidine), 96.97, 96.93 (1C, C4’-cytidine), 93.80, 93.54 (1C, 
C l ’-cytidine), 73.66, 73.62 (1C, C3’-cytidine), 72.81, 72.62 (1C, C2’-cytidine), 69.05,
69.02 (1C, C5’-cytidine), 6 8 .8 8 , 68.08, 68.02 (1C, CH2-benzyl), 51.79, 51.72 (1C,
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CHa), 34.43, 34.27 (2C, CH2-dipentanoate), 27.99, 27.95 (2C, CH2-dipentanoate),
23.22, 23.20 (2C, CH2-dipentanoate), 20.47, 20.42, 20.35, 20.29 (1C, CH3-alanine), 
14.06 (2C, CH3-dipentanoate).
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7.7 Synthesis of uridine analogue phosphoramidates.
Synthesis of 4’-azidouridine S’-O-fphenyKbenzyl-cyclopentylglycinyl)] phosphate
(112)
NH
13 OH OH
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 300 mg, 1.052 
mmol), 'BuMgCl (2.10 mL of solution 1M in THF, 2.10 mmol) and phenyl(benzyl- 
cyclopentylglycinyl) phosphorochloridate (51, 2.10 mL of solution 1M in THF, 2.10 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH (9:1). The 
pure product was a white solid (130 mg, 20%).
6 P (^-C H 3OH): 3.77, 3.74; 6 H (^-C H 3OH): 7.58 (1H, m, H6 -uridine, J= 8.13 Hz),
7.28 (7H, m, CH-phenyl, CH-benzyl), 7.15 (3H, m, CH-benzyl), 6.09 (1H, m, H l’- 
uridine), 5.55 (1H, m, H5-uridine, J= 8.13 Hz), 5.08 (2H, s, CH2-phenyl), 4.29 (1H, 
m, H2’-uridine), 4.24 (1H, m, H3’-uridine), 4.09 (2H, m, H5’-uridine), 2.04 (2H, m, 
CH2-cyclopentyl), 1.98 (2H, m, CH2-cyclopentyl), 1.64 (2H, m, CH2-cyclopentyl),
1.55 (2H, m, CH2-cyclopentyl); 6 C (d*-CH3OH): 176.83 (1C, C =0 ester), 166.20 (1C, 
C4-uridine), 152.62, 152.48, 152.39 (1C, C2-uridine), 143.00, 142.88 (1C, C6 - 
uridine), 137.75, 137.73 (1C, C-phenyl), 131.22 (2C, CH-phenyl), 129.98 (1C, C- 
benzyl), 129.73 (2C, CH-phenyl), 129.69 (1C, CH-phenyl), 126.74 (2C, CH-benzyl),
122.00 (1C, CH-benzyl), 121.98, 121.93 (2C, CH-benzyl), 103.99, 103.96 (1C, C5- 
uridine), 99.23, 99.20, 99.06 (1C, C4’-uridine), 92.32, 92.13 (1C, C l ’-uridine), 74.86 
(1C, C3’-uridine), 69.32 (1C, C2’-uridine), 69.25, 68.79, (1C, C5’-urdine), 68.75,
68.62 (1C, CH2-benzyl), 40.35, 40.24 (1C, CH2-cyclopentyl), 40.07, 39.55 (1C, CH2- 
cyclopentyl), 25.10 (1C, CH2-cyclopentyl), 24.99 (1C, CH2-cyclopentyl).
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Synthesis of 4’-azidouridine 5’-O- [phenyl(ethyl-cyclopentylglyciny 1)] phosphate
( 1 1 3 )
NH
13 OH OH
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 300 mg, 1.052 
mmol), ‘BuMgCl (2.10 mL of solution 1M in THF, 2.10 mmol) and phenyl(ethyl- 
cyclopentylglycinyl) phosphorochloridate (52, 2.10 mL of solution 1M in THF, 2.10 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH (9:1). The 
pure product was a white solid ( 1 0 0  mg, 16%).
d P (^-C H 3OH): 3.85, 3.83; 6 „ (^-C H 3OH): 7.69 (1H, m, H6 -uridine, J= 8.1 Hz), 
7.38 (2H, m, CH-phenyl), 7.27 (1H, m, CH-phenyl), 7.23 (2H, m, CH-phenyl), 6.18 
(1H, m, H l’-uridine), 5.87 (1H, m, H5-uridine, J= 8.1 Hz), 4.40 (2H, m, CH2-ethyl)
4.35 (1H, m, H2’-uridine), 4.22 (1H, m, H3’-uridine), 4.17 (2H, m, H5’-uridine), 2.11 
(2H, m, CH2-cyclopentyl), 1.97 (2H, m, CH2-cyclopentyl), 1.73 (2H, m, CH2- 
cyclopentyl), 1.64 (2H, m, CH2-cyclopentyl), 1.25 (3H, m, CH3-ethyl); 6 C (d4- 
CH3OH): 177.05 (1C, C =0 ester), 166.22 (1C, C4-uridine), 152.63, 152.51, 152.42 
(1C, C2-uridine), 143.06, 142.94 (1C, C6 -uridine), 131.23 (2C, CH-phenyl), 126.75 
(1C, CH-phenyl), 122.05, 121.99, 121.93 (2C, CH-phenyl), 103.94 (1C, C5-uridine), 
99.29, 99.24, 99.15, 99.10 (1C, C4’-uridine), 92.23, 92.14 (1C, C l ’-uridine), 74.30,
74.24 (1C, C3’-uridine), 69.34 (1C, C2’-uridine), 68.75 (1C, C5’-uridine), 62.95 (1C, 
C-cyclopentyl), 55.20 (1C, CH2-ethyl), 40.37, 40.25 (1C, CH2-cyclopentyl), 40.12, 
39.52, 39.47 (1C, CH2-cyclopentyl), 25.10, (1C, CH2-cyclopentyl), 24.99 (1C, CH2- 
cyclopentyl), 14.85 (1C, CH3-ethyl).
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Synthesis of 4’-azidouridine 5’-0-[phenyl(isopropyl-cyclopentylglycinyl)]
phosphate (114)
NH
13 OH OH
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 300 mg, 1.052 
mmol), ‘BuMgCl (2.10 mL of solution 1M in THF, 2.10 mmol) and phenyl(isopropyl- 
cyclopentylglycinyl) phosphorochloridate (53, 2.10 mL, 1M solution in THF, 2.10 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH (9:1). The 
pure product was a white solid ( 1 1 0  mg, 12%).
d P (^-C H 3OH): 3.87, 3.83; SH (^-C H 3OH): 7.69 (1H, m, H6 -uridine, J= 8.1 Hz),
7.37 (2H, m, CH-phenyl), 7.27 (1H, m, CH-phenyl), 7.24 (2H, m, CH-phenyl), 6.18 
(1H, m, H l’-uridine), 5.66 (1H, m, H5-uridine, J= 8.1 Hz), 5.01 (1H, m, CH- 
isopropyl, J= 3.4 Hz), 4.40 (1H, m, H2’-uridine), 4.35 (1H, m, H3’-uridine), 4.24 
(2H, m, H5’-uridine), 2.10 (2H, m, CH2-cyclopentyl), 2.02 (2H, m, CH2-cyclopentyl), 
1.73 (2H, m, CH2-cyclopentyl), 1.67 (2H, m, CH2-cyclopentyl), 1.24 (6 H, d, CH3- 
isopropyl, J= 3.4 Hz); 8 C (</4-CH3OH): 176.58 (1C, C =0 ester), 166.20 (1C, C4- 
uridine), 152.64 (1C, C2-uridine), 152.52, 152.43 (1C, C4-uridine), 143.10, 142.95 
(1C, C6 -uridine), 131.26 (1C, CH-phenyl), 126.76 (1C, C-phenyl), 122.07, 122.08, 
121.95 (1C, C-phenyl), 104.00, 103.95 (1C, C5-uridine), 99.26, 99.17, 99.12 (1C, 
C4’-uridine), 92.35, 92.15 (1C, C l ’-uridine), 74.86 (1C, C3’-uridine), 70.65 (1C, C2’- 
uridine), 69.37, 69.30, 68.76 (1C, C5’-urdine), 67.31 (1C, C-cyclopentyl), 40.35,
40.24 (1C, CH2-cyclopentyl), 39.51 (1C, CH2-cyclopentyl), 25.19 (1C, CH2- 
cyclopentyl), 25.10 (1C, CH2-cyclopentyl), 22.35 (2C, CH3-isopropyl).
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Synthesis of 4’-azidouridine 5’-0-[phenyl(benzyl-D-alaninyl)] phosphate (115)
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 200 mg, 0.701 
mmol), 'BuMgCl (1.40 mL of solution 1M in THF, 1.40 mmol) and phenyl(benzyl-D- 
alaninyl) phosphorochloridate (55, 2.10 mL of solution 1M in THF, 2.10 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5) then a preparative TLC using as eluent CHCl3/MeOH (9:1). The pure product 
was a white solid ( 1 0 0  mg, 16%).
SP (^-C H 3OH): 4.89, 4.29; 6 „ (^-C H 3OH): 7.61 (1H, m, H6 -uridine), 7.36 (7H, m, 
CH-phenyl, CH-benzyl), 7.25 (3H, m, CH-phenyl), 6.15 (1H, m, H l’-uridine), 5.68 
(1H, m, H5-uridine), 5.17 (2H, s, CH2-benzyl), 4.38 (1H, m, H3’-uridine), 4.32 (1H, 
m, H2’-uridine), 4.23 (2H, m, H5’-uridine), 4.05 (1H, m, CHa), 1.36 (3H, m, CH3- 
alanine); 6 C (</4-CH3OH): 175.34, 175.29, 175.07, 175.01 (1C, C =0 ester), 166.22 
(1C, C4-uridine), 152.65, 152.56, 152.40, 152.36, 152.31, 152.27 (1C, C2-uridine), 
142.94, 142.86 (1C, C6 -uridine), 137.60, 137.54 (1C, C-phenyl), 131.31 (1C, C- 
benzyl), 130.00, 129.79 (2C, CH-phenyl), 129.76, 129.72 (2C, CH-benzyl), 126.79 
(2C, CH-benzyl), 121.83, 121.77, 121.71, 121.64 (2C, CH-phenyl), 104.03,103.99 
(1C, C5-uridine), 99.11, 98.98 (1C, C4’-uridine), 92.69, 92.43 (1C, C l ’-uridine), 
74.22, 74.16 (1C, C3’-uridine), 74.13, 73.93 (1C, C2’-uridine), 69.28, 69.21 (1C, 
CH2-benzyl), 68.71, 68.65, 68.54, 68.48 (1C, C5’-uridine), 52.17, 51.92 (1C, CHa), 
20.80, 20.70, 20.59 (1C, CH3-lateral chain).
MS (ES) m/e: 625.1 (MNa+, 100%); Accurate mass: C25H27N6O 10NaP required
625.1424, found 625.1424.
Anal. Calc, for C^H^NgO^P: C 49.84%, H 4.52%, N 13.95%. Found: C 50.30%, H 
4.32%, N 14.03%.
N3 oh oh
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Synthesis of 4’-azidouridine 5’-0-[phenyl(dodecyl-D-alaninyI)] phosphate (116)
NH
3 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 200 mg, 0.701 
mmol), 'BuMgCl (1.40 mL 1M solution of THF, 1.402 mmol) and phenyl(dodecyl -D- 
alaninyl) phosphorochloridate (58, 1.40 mL of solution 1M in THF, 1.402 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5), followed by a preparative TLC using as eluent CHCl3/MeOH (85:15). The 
pure product was a white solid (19 mg, 4%).
SP (<4-CH3OH): 4.92, 4.38; 5 H M rCH 3OH): 7.67 (1H, m, H6 -uridine, /=  8.7 Hz),
7.42-7.22 (5H, m, CH-phenyl), 6.15 (1H, m, H l’-uridine), 5.73 (1H, m, H5-uridine, 
J= 8.7 Hz), 4.40-3.95 (7H, m, H2’-uridine, H3’-uridine, H5’-uridine, CHa, CH2- 
dodecyl), 1.64 (3H, m, CH3-alanine), 1.30 (22H, m, CH2-dodecyl), 0.92 (3H, t, CH3- 
dodecyl).
Synthesis of 4’-azidouridine 5’-0-[phenyl(butyl-D-alaninyl)] phosphate (117)
NH
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 300 mg, 0.986 
mmol), 'BuMgCl (2.46 mL 1M solution of THF, 2.46 mmol) and phenyl(butyl-D- 
alaninyl) phosphorochloridate (57, 2.46 mL of solution 1M in THF, 2.46 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5), followed by a preparative TLC using as eluent CHCl3/MeOH (85:15). The 
pure product was a white solid (22 mg, 4%).
5 P (^-C H 3OH): 4.81, 4.59; 6 „ (^-C H 3OH): 7.60 (1H, m, H6 -uridine), 7.38-7.18 (5H, 
m, CH-phenyl), 6.11 (1H, m, H l’-uridine), 5.66 (1H, m, H5-uridine), 4.33-4.30 (2H,
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m, H2’-uridine, H3’-uridine), 4.17-4.04 (5H, m, CHa, H5’-uridine, CH2-butyl), 1.59
(3H, m, CH3-butyl).
MS (ES) m/e: 591.4 (MNa+, 100%); Accurate mass: C22H29N6O10NaP required 
591.1577, found 591.1580.
Synthesis of 4’-azidouridine 5’-0-[phenyl(2-butyl-D-alaninyl)] phosphate (118)
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 200 mg, 0.701 
mmol), ‘BuMgCl (1.40 mL 1M solution of THF, 1.40 mmol) and phenyl(2-butyl-D- 
alaninyl) phosphorochloridate (108, 1.40 mL of solution 1M in THF, 1.40 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5), followed by a preparative TLC using as eluent CHCl3/MeOH (85:15). The 
pure product was a white solid (18 mg, 5%).
6 P (<i4-CH3OH): 4.97, 4.41; 6 „ (rf4-CH3OH): 7.70 (1H, m, H6 -uridine, J= 10.0 Hz),
7.42-7.21 (5H, m, CH-phenyl), 6.15 (1H, m, H l’-uridine), 5.72 (1H, m, H5-uridine, 
J= 10.0 Hz), 4.40-4.15 (4H, m, H2’-uridine, H3’-uridine, H5’-uridine), 3.91 (1H, m, 
CHa), 1.61 (3H, d, CH3-alanine), 1.40-1.19 (5H, m, CH2-2-butyl, CH3-2-butyl), 0.91 
(3H, m, CH3-2-butyl); 6 C dept (d4-CH3OH): 143.03, 142.94 (1C, C6 -uridine), 131.32 
(1C, CH-phenyl), 121.86, 121.79 (2C, CH-phenyl), 121.72, 121.66 (2C, CH-phenyl),
104.05 (1C, C5-cytidine), 92.60-92.43 (1C, C l ’-uridine), 75.30, 74.84 (1C, C3’- 
uridine), 74.27, 74.15, 74.09, 74.04 (1C, C2’-uridine), 69.26 (1C, C5’-uridine), 6 8 . 8 6  
(1C, CH-2-butyl), 52.01 (1C, CH-a), 30.20, 30.16 (1C, CH2-2-butyl), 20.53, 20.47 
(1C, CH3-lateral chain), 20.18, 20.14 (1C, CH3-2-butyl), 20.05, 14.45 (1C, CH3-2-
(3H, m, CH3-alanine), 1.55 (2H, m, CH2-butyl), 1.36-1.25 (2H, m, CH2butyl), 0.95 
Ns OH OH
butyl).
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Synthesis of 4’-azidouridine 5’-(?-[phenyl(octyl-D-alaninyl)] phosphate (119)
NH
3 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 300 mg, 0.986 
mmol), 'BuMgCl (2.46 mL 1M solution of THF, 2.46 mmol) and phenyl(octyl-D- 
alaninyl) phosphorochloridate (109, 2.46 mL of solution 1M in THF, 2.46 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5), followed by a preparative TLC using as eluent CHCl3/MeOH (85:15). The 
pure product was a white solid (15 mg, 3%).
6 P (<i4-CH3OH): 4.93, 4.65; 6 „ (d4-CU3OU): 7.62 (1H, m, H6 -uridine), 7.38-7.18 (5H, 
m, CH-phenyl), 6.15 (1H, m, H l’-uridine), 5.64 (1H, m, H5-uridine), 4.38-4.34 (2H, 
m, H2’-uridine, H3’-uridine), 4.17-4.00 (5H, m, CHa, H5’-uridine, CH2-octyl), 1.55 
(3H, m, CH3-alanine), 1.52 (2H, m, CH2-octyl), 1.36-1.20 (10H, m, CH2-octyl), 0.95 
(3H, m, CH3-octyl).
Synthesis of 4 ’-azidouridine 5 ’-0-[phenyl(isopropyl-D-alaninyl)] phosphate (121)
NH
13 OH OH
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 200 mg, 0.701 
mmol), ‘BuMgCl (1.05 mL of solution 1M in THF, 1.05 mmol) and phenyl- 
(isopropyly-D-alaninyl) phosphorochloridate (107, 1.05 mL, 1M solution in THF,
1.05 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH 
(9:1). The pure product was a white solid (20 mg, 4%).
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SP (^-C H 3OH): 4.97, 4.41; 5„ (^-C H 3OH): 7.71 (1H, m, H6 -uridine), 7.30 (2H, m, 
CH-phenyl), 7.27 (1H, m, CH-phenyl), 7.20 (2H, m, CH-phenyl), 6.18 (1H, m, H l’- 
uridine), 5.66 (1H, m, H5-uridine), 4.98 (1H, m, CH-isopropyl, J= 3.4 Hz), 4.42 (1H, 
m, H2’-uridine), 4.37 (1H, m, H3’-uridine), 4.24 (2H, m, H5’-uridine), 1.45 (3H, m, 
CH3-alanine), 1.24 (6 H, d, CH3-isopropyl, J= 3.4 Hz).
Synthesis of 4’-azidouridine 5 ’-0-[p-chloro-phenyl(ethyl-L-leucinyl)] phosphate
(165)
NH
V ° N ,NH
Cl
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 250 mg, 0.876 
mmol), ‘BuMgCl (1.75 mL 1M solution of THF, 1.753 mmol) and /?-chloro- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (82, 1.75 mL of 1M solution in THF,
1.75 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10) and a preparative TLC using the same eluent. The pure 
product was a white solid (100 mg, 14%).
6 P (^-C H 3OH): 3.76, 3.46; 6 „ (^-C H 3OH): 7.67 (1H, m, H6 -uridine, J= 10.4 Hz),
7.38 (2H, d, CH-phenyl, J= 9.0 Hz), 7.26 (2H, d, CH-phenyl, J= 9.0 Hz), 6.15 (1H, 
m, H l’-uridine), 5.72 (1H, m, H5-uridine, J= 10.4 Hz), 4.38 (1H, m, H2’-uridine),
4.36 (1H, m, H3’-uridine), 4.17 (2H, m, CH2-ethyl), 4.13 (2H, m, H5’-uridine), 3.89 
(1H, m, CH-a), 1.73 (1H, m, CH-Iateral chain), 1.55 (2H, m, CH2-lateral chain), 1.26 
(3H, m, CH3-lateral chain), 1.23 (3H, m, CH3-lateral chain), 0.91 (3H, m, CH3-ethyl). 
MS (ES) m/e: 639.1 (M Na\ 100%); Accurate mass: C ^H ^N ^N aP C l required 
639.1348, found 639.1347.
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Synthesis of 4’-azidouridine 5’-0-[3,4-dichloro-phenyl(ethyl-L-leucinyl)]
phosphate (166)
NH
V ° s  ,nh
Cl
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 250 mg, 1.753 
mmol), 'BuMgCl (1.75 mL 1M solution of THF, 1.75 mmol) and 3,4-dichloro- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (83, 1.75 mL of 1M solution in THF,
1.75 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10) and then a preparative TLC using the same eluent. The 
pure product was a white solid (40 mg, 5%).
6 P (^-C H 3OH): 3.84, 3.52; 6 H (^-C H 3OH): 7.67 (1H, m, H6 -uridine, J= 12.0 Hz),
7.53 (1H, d, CH-phenyl, J= 9.0 Hz), 7.48 (1H, m, CH-phenyl), 7.22 (1H, d, CH- 
phenyl, J= 9.0 Hz), 6.12 (1H, m, H l ’-uridine), 5.72 (1H, m, H5-uridine, J= 12.0 Hz),
4.39 (1H, m, H2’-uridine), 4.36 (1H, m, H3’-uridine), 4.22 (2H, m, CH2-ethyl), 4.12 
(2H, m, H5’-uridine), 3.88 (1H, m, CH-a), 1.72 (1H, m, CH-lateral chain), 1.55 (2H, 
m, CH2-lateral chain), 1.30 (3H, m, CH3-lateral chain), 1.25 (3H, m, CH3-lateral 
chain), 0.92 (3H, m, CH3-ethyl); 6 C dept (^-CH 3OH): 141.92 (1C, C6 -uridine), 
131.19 (1C, C5-uridine), 122.61, 122.55 (1C, CH-phenyl), 120.56, 120.49 (1C, CH- 
phenyl), 102.44 (1C, CH-phenyl), 98.65 (1C, C5-uridine), 92.03 (1C, C l ’-uridine), 
72.77, 72.66 (1C, C3’-uridine), 72.56, 72.41 (1C, C2’-uridine), 68.15 (1C, C5’- 
uridine), 61.26 (1C, CH2-ethyl), 53.44 (1C, CH-a), 42.85, 42.76 (1C, CH2-lateral 
chain), 24.53 (1C, CH-lateral chain), 22.15, 22.08 (1C, CH3-lateral chain), 20.68,
20.28 (1C, CH3-lateral chain), 13.32 (1C, CH3-ethyl).
MS (ES) m/e: 673.1 (M Na\ 100%); Accurate mass: C^H^N-AjNaPC^ required 
673.0968, found 673.0958.
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Synthesis of 4’-azidouridine 5’ -0-[p-methyl-phenyl(ethyl-L-leucinyl) phosphate
(167)
NH
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 250 mg, 1.753 
mmol), ‘BuMgCl (1.75 mL 1M solution of THF, 1.75 mmol) and p-methyl- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (84, 1.75 mL of 1M solution in THF,
1.75 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10). The pure product was a white solid (50 mg, 5%).
6 P (</4-CH3OH): 5.63, 5.22; 6 „ (d4-CU3OU): 7.55 (1H, m, H6 -uridine), 7.08 (2H, m, 
CH-phenyl), 7.04 (2H, m, CH-phenyl), 6.08 (1H, m, H l’-uridine), 5.60 (1H, m, H5- 
uridine), 4.25 (1H, m, H2’-uridine), 4.23 (1H, m, H3’-uridine), 4.08 (2H, m, CH2- 
ethyl), 4.04 (2H, m, H5’-uridine), 3.79 (1H, m, CH-a), 2.23 (3H, s, CH3-/?-methyl- 
phenyl), 1.64 (1H, m, CH-lateral chain), 1.47 (2H, m, CH2-lateral chain), 1.15 (3H, m, 
CH3-lateral chain), 1.13 (3H, m, CH3-lateral chain), 0.80 (3H, m, CH3-ethyl); 6 C (d4- 
CH3OH): 175.34 (1C, C=0 ester), 166.19 (1C, C4-uridine), 152.71, 152.59 (1C, C2- 
uridine), 142.95, 142.66 (1C, C6 -uridine), 131.68, 131.63 (2C, CH-phenyl), 121.65 
(1C, C-phenyl), 121.59 (1C, C-phenyl), 121.43, 121.36 (2C, CH-phenyl), 99.29, 
99.04, 98.91 (1C, C5-uridine), 92.52 (1C, C4’-uridine), 91.76 (1C, C l’-uridine), 
7 4 .4 5 , 7 4 . 3 6  (1C, C3’-uridine), 74.19, 74.13 (1C, C2’-uridine), 69.33, 69.26 (1C, C5’- 
uridine), 62.81, 62.76, 62.66 (1C, CH2-ethyl), 55.07, 54.93 (1C, CHa), 44.53, 44.44 
(1C, CH2-lateral chain), 44.10, 43.99 (1C, CH3-/?-methyl-phenyl), 26.22, 26.04, 25.82 
(1C, CH2-lateral chain), 23.67, 23.58, 23.46 (1C, CH3, lateral chain), 22.87, 22.39, 
21.99, 21.17 (1C, CH3, lateral chain), 14.93, 14.87 (1C, CH3-ethyl).
MS (ES) m/e: 619.1 (MNa=, 100%); Accurate mass: C24H34N70 9NaP required 
619.1891, found 619.1893.
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Synthesis of 4’-azidouridine 5’-0-[p-methoxy-phenyl(ethyl-L-leucinyl)]
phosphate (168)
NH
\ O
13 OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 250 mg, 1.753 
mmol), ‘BuMgCl (1.75 mL 1M solution of THF, 1.75 mmol) and /?-methoxy- 
phenyl(ethyl-L-leucinyl) phosphorochloridate (85, 1.75 mL of 1M solution in THF,
1.75 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10). The pure product was a white solid (42 mg, 4%). 
d P (^-C H 3OH): 5.64, 5.23; 6 „ (4,-CH3OH): 7.65 (1H, m, Hl-uridine, J= 16 Hz), 7.18 
(2H, m, CH-phenyl), 6.91 (2H, m, CH-phenyl), 6.17 (1H, m, H l’-uridine), 5.71 (1H, 
m, H2-uridine), 4.36 (1H, m, H2’-uridine), 4.34 (1H, m, H3’-uridine), 4.18 (2H, m, 
CH2-ethyl), 4.14 (2H, m, H5’-uridine), 3.89 (1H, m, CH-a), 3.78 (3H, s, CH30 -  
phenyl), 1.75 (1H, m, CH-lateral chain), 1.57 (2H, m, CH2-lateral chain), 1.26 (3H, m, 
CH3-lateral chain), 0.97 (3H, m, CH3-lateral chain), 0.90 (3H, m, CH3-ethyl); 6 C dept 
(d4-CU3OU): 142.95, 142.67 (1C, C6 -uridine), 122.83, 122.77, 122.63, 122.56 (2C, 
CH-phenyl), 116.16, 116.12 (2C, CH-phenyl), 104.18, 104.08 (1C, C5-uridine), 92.52 
(1C, C4’-uridine), 91.78 (1C, C l ’-uridine), 74.44, 74.37 (1C, C3’-uridine), 74.19, 
74.12 (1C, C2’-uridine), 69.33, 69.26 (1C, C5’-uridine), 62.81, 62.76, 62.47 (1C, 
CH2-ethyl), 56.52 (1C, CH30-phenyl), 55.08, 54.93 (1C, CHa), 45.16, 44.56 (1C, 
CH2-lateral chain), 44.46, 43.99 (1C, CH3-phenyl), 26.25, 26.05, 25.82 (1C, CH2- 
lateral chain), 23.71, 23.61, 23.54 (1C, CH3, lateral chain), 22.90, 22.41, 21.98 (1C, 
CH3, lateral chain), 14.90 (1C, CH3-ethyl).
MS (ES) m/e: 635.1 (M Na\ 100%); Accurate mass: C21H34N7O10NaP required 
635.1852, found 635.1843.
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Synthesis of 4’-azidouridine 5’-0-[/J-naphthyl(benzyl-L-alaninyl)] phosphate
(174)
NH
V ° x  ,NH
3 OH OH
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 200 mg, 0.701 
mmol), ‘BuMgCl (1.40 mL of solution 1M in THF, 1.40 mmol) and /3- 
naphthyl(benzyl-L-alaninyl) phosphorochloridate (94, 1.40 mL of solution 1M in 
THF, 1.40 mmol). The crude product was purified by column chromatography, using 
as eluent CHCl3/MeOH (95:5) then a preparative HPLC. The pure product was a 
white solid (20 mg, 5%).
6 P (^-C H 3OH): 3.78, 3.36; 6 „ (^-C H 3OH): 7.82 (1H, d, H6 -uridine, J= 7.5 Hz), 7.50 
(1H, m, CH-naphthyl), 7.38-7.20 (11H, m, CH-naphthyl, CH-phenyl), 6.03 (1H, m, 
H I’-uridine, J= 4.3 Hz), 5.81 (1H, d, H5-uridine, J= 7.5 Hz), 5.01 (2H, m, CH2- 
benzyl), 4.27 (1H, m, H3’-cytidine), 4.24-4.17 (4H, m, H2’-cytidine, H5’-cytidine, 
CHa), 1.39 (3H, d, CH3-alanine, J= 7.2 Hz).
MS (ES) m/e: 675.2 (MNa+, 100%); Accurate mass: C29H29N6O10NaP required
675.1580, found 675.1583.
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Synthesis of 4’-azido-uridine 5’-0-[a-naphthyl(benzyl-L-alaninyl)] phosphate
(173)
NH
13 OH OH
Prepared according to Standard Procedure D, from 4 ’-azidouridine (24, 200 mg, 0.701 
mmol), ‘BuMgCl (1.4 mL of solution 1M in THF, 1.402 mmol) and a- 
naphthyl(benzyl-L-alaninyl) phosphorochloridate (93, 1.4 mL of solution 1M in THF, 
1.402 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5) then a preparative TLC using as eluent CHCl3/MeOH 
(9:1). The pure product was a white solid (40 mg, 9%).
6 P (<i4-CH3OH): 3.94, 3.76; 6 „ (tf4-CH3OH): 8.18 (1H, m, CH-naphthyl), 7.90 (1H, m, 
CH-naphthyl), 7.72 (1H, m, H6 -uridine), 7.57-7.30 (11H, m, CH-naphthyl, CH- 
phenyl), 6.11 (1H, m, H l’-uridine), 5.50 (1H, m, H5-uridine), 5.11 (2H, m, CH2- 
benzyl), 4.37 (1H, m, H3’-uridine), 4.31-4.19 (3H, m, H2’-uridine, H5’-uridine), 4.11 
(1H, m, CHa), 1.35 (3H, d, CH3-alanine, 7= 7.2 Hz).
MS (ES) m/e: 675.1 (MNa+, 100%); Accurate mass: C29H29N6O10P required 675.1575, 
found 675.1571.
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Synthesis of 4,-azido-uridine 5’-0-[8-quinolinyl(benzyl-L-alaninyl)] phosphate
(179)
N NH
OH OH
Prepared according to Standard Procedure C2, from 2’,3’-O,0-cycIopentylidene-4’- 
azidouridine (145, 200 mg, 0.570 mmol), ‘BuMgCl (1.42 mL, 1M solution in THF,
1.42 mmol) and the crude of the synthesis of 8 -quinolinyl(benzyl-L-alaninyl) 
phosphorochloridate (181, 1.42 mL of solution 1M in THF, 1.42 mmol). The solvent 
was removed under reduced pressure and the obtained crude without further 
purification was dissolved in a solution 80% of HCOOH in water for 3 hours. The 
solvent was removed under reduced pressure and the obtained crude product was 
purified by column chromatography using as eluent CHCl3/MeOH 85:15 and 
preparative HPLC. The pure product was a white solid (12 mg, 3%).
6 P (^-C H 3OH): 4.01, 3.95; 6 „ (^-C H 3OH): 8.93 (1H, m, CH-quinolinyl), 8.37 (1H, 
CH-quinolinyl), 7.80 (1H, m, H6 -uridine), 7.76-7.69 (1H, m, CH-quinolinyl), 7.64-
7.54 (3H, m, CH-quinolinyl, CH-phenyl), 7.43-7.31 (5H, 1 CH-quinolinyl, CH- 
phenyl), 6.15 (1H, m, H l’-uridine), 5.66-5.54 (1H, m, H5-uridine), 5.29 (2H, m, CH2- 
benzyl), 4.42 (1H, m, H3’-uridine), 4.36-4.27 (3H, m, H2’-uridine, H5’-uridine), 4.11 
(1H, m, CHa), 1.37 (3H, d, CH3-alanine, J= 7.2 Hz).
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Synthesis of 4’-azido-uridine 5’ -0-[phenyl(butyl-L-alaninyl)] phosphate (121)
NH
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidouridine (24, 300 mg, 0.986 
mmol), ‘BuMgCl (2.46 mL 1M solution of THF, 2.46 mmol) and phenyl(butyl-L- 
alaninyl) phosphorochloridate (59, 2.46 mL of solution 1M in THF, 2.46 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5), followed by a preparative TLC using as eluent CHCl3/MeOH (85:15). The 
pure product was a white solid (17 mg, 3%).
6 P (^-C H 3OH): 4.91, 4.35; 6 H (^-C H 3OH): 7.65 (1H, m, H6 -cytidine, J= 8.1 Hz), 
7.46-7.22 (5H, m, CH-phenyl), 6.16 (1H, m, H l’-cytidine, J= 3.6 Hz), 5.72 (1H, m, 
H5-cytidine, 7= 8.1 Hz), 4.39-4.27 (2H, m, H2’-cytidine, H3’-cytidine), 4.24-4.09 
(5H, m, CHa, H5’-cytidine, CH2-butyl), 1.67-1.59 (3H, m, CH3-alanine), 1.48-1.30 
(4H, m, CH2-butyl), 0.95 (3H, m, CH3-butyl); 6 C dept (^-C H 3OH): 143.60, 142.98 
(1C, C6 -uridine), 131.57, 131.32 (2C, CH-phenyl), 121.72, 121.65 (2C, CH-phenyl), 
104.04 (1C, C5-cytidine), 92.68-92.38 (1C, C l’-uridine), 74.25, 74.08 (1C, C3’- 
uridine), 73.95, 73.78 (1C, C2’-uridine), 71.77 (1C, CH2-butyl), 69.30 (1C, C5’- 
uridine), 6 8 . 8 6  (1C, CH2-butyl), 52.12, 51.90 (1C, CH-a), 32.15 (1C, CH2-butyl),
20.92, 20.83 (1C, CH3-Iateral chain), 20.71 (1C, CH2-butyl), 14.41 (1C, CH3-butyl).
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Synthesis of 2’, 3 ’-0,0-cyclopentylidene-4 ’-azidouridine 5’-0-[a-
naphthyl(benzyl-cyclopentylglycinyl)] phosphate
Prepared according to Standard Procedure C2, from 
2’,3’-0,O-cyclopentylidene-4’-azidouridine (145, 
200 mg, 0.569 mmol), ‘BuMgCl (1.42 mL, 1M 
solution in THF, 1.42 mmol) and a- 
naphthyl(benzyl-cyclopentylglycinyl) 
phosphorochloridate (169, 1.4 mL of solution 1M in 
THF, 1.423 mmol). The crude product was purified 
by column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white
SP (^-C H 3OH): 2.80; 6„ (^-C H 3OH): 8.32 (1H, d, H6-uridine, J= 7.8 Hz), 8.21 (1H, 
s, CH-naphthyl), 7.78 (1H, d, CH-naphthyl, J= 7.2 Hz), 7.66 (1H, m, CH-naphthyl), 
7.51-7.27 (9H, m, CH-naphthyl, CH-phenyl), 5.93 (1H, d, H l’-uridine, J= 14.0 Hz), 
5.56 (1H, m, H5-uridine, J= 7.8 Hz), 5.12 (2H, m, CH2-benzyl), 5.04-4.88 (2H, m, 
H2’-uridine, H3’-uridine), 4.31-4.23 (2H, m, H5’-uridine), 2.22-2.03 (8H, m, CH2- 
cyclopentyl), 1.68-1.18 (8H, m, CH2-cyclopentyl).
O'"" O 
/ • NH
L A ,f  V ° > ' NH N' -O
N3 CL .0
solid (430 mg, quantitative).
Synthesis of 4’-azido-uridine 5’-(9-[a-naphthyl(benzyl-cyclopentylglycinyl)]
phosphate (175)
NH
3 OH OH
Prepared according to Standard Procedure C3, from 2 ’,3’-0,0-cyclopentylidene-4’- 
azidouridine (510 mg, 0.567 mmol), and 10 mL of a solution 80% of HCOOH in 
water. The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white solid (250 mg, 64%).
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SP (</4-CH3OH): 3.10, 3.06; 6„ M rCH3OH): 8.21 (1H, m, H6-uridine), 7.89 (1H, m, 
CH-naphthyl), 7.72 (1H, t, CH-naphthyl, J= 10.2 Hz), 7.66 (1H, m, CH-naphthyl), 
7.57-7.27 (9H, m, CH-naphthyl, CH-phenyl), 6.12 (1H, d, H l ’-uridine, J= 6.7 Hz),
5.43 (1H, m, H5-uridine), 5.14 (2H, m, CH2-benzyl), 4.37-4.21 (2H, m, H2’-uridine, 
H3’-uridine, H5’-uridine), 2.21-1.98 (4H, m, CH2-cyclopentyl), 1.87-1.46 (8H, m, 
CH2-cyclopentyl).
MS (ES) m/e: 715.1 (MNa+, 100%); Accurate mass: C32H33N6O 10NaP required 
715.1893, found 715.1898.
Synthesis of 2’, 3,-0^0-cyclopentylidene-4,-azidouridine 5’-0-[a-naphthyl(ethyl- 
cyclopentylglycinyl)] phosphate
Prepared according to Standard Procedure C2, from 
2 ’, 3’-0,0-cyclopentylidene-4’-azidouridine (145, 
200 mg, 0.986 mmol), ‘BuMgCl (1.42 mL, 1M 
solution in THF, 1.42 mmol) and a-naphthyl(ethyl- 
cyclopentylglycinyl) phosphorochloridate (170, 1.42 
mL of solution 1M in THF, 1.42 mmol). The crude 
product was purified by column chromatography, 
using as eluent CHCl3/MeOH (95:5). The pure 
product was a white solid (510 mg, quantitative).
d P (^-C H 3OH): 3.00; dH M rCH3OH): 8.22 (1H, t, H6-uridine, J= 6.9 Hz), 7.85 (1H, 
m, CH-naphthyl), 7.70-7.39 (6H, m, CH-naphthyl), 5.96 (1H, m, H l’-uridine), 5.56 
(1H, m, H5-uridine), 4.97-4.94 (2H, m, H2’-uridine, H3’-uridine), 4.36-4.32 (2H, m, 
H5’-uridine), 4.14 (2H, m, CH2-ethyI), 2.17-2.00 (8H, m, CH2-cyclopentyl), 1.77-1.59 
(8H, m, 4 CH2-cyclopentyl), 1.22 (3H, m, CH3-ethyl).
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Synthesis of 4’-azidouridine 5 ’ -0-[a-naphthyl(ethy 1-cyclopentylglyciny 1)]
phosphate (170)
NH
1 3  OH OH
Prepared according to Standard Procedure C3, from 2 ’, 3’-0,O-cyclopentylidene-4’- 
azidouridine 5’-0-[a-naphthyl(ethyl-cyclopentylglycinyl)] phosphate (510 mg, 0.732 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5). 
The pure product was a white solid (250 mg, 54%).
SP (</4-CH3OH): 3.23, 3.15; 6„ (^-C H 3OH): 8.21 (1H, d, H6-uridine, J= 7.5 Hz), 7.90 
(1H, m, CH-naphthyl), 7.72 (1H, t, CH-naphthyl, J= 8.9 Hz), 7.60-7.41 (5H, m, CH- 
naphthyl), 6.14 (1H, m, H l’-uridine), 5.46 (1H, m, H5-uridine, J= 15 Hz), 4.97-4.24 
(4H, m, H2’-uridine, H3’-uridine, H5’-uridine), 4.20-4.13 (2H, m, CH2-ethyl), 2.20-
1.96 (8H, m, CH2-cyclopenty 1), 1.24 (3H, CH3-ethyl).
MS (ES) m/e: 653.1 (MNa+, 100%); Accurate mass: C27H31N6O10NaP required 
653.1737, found 653.1721.
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Synthesis of 2 ’ ,3 ’ -(?,0-cy clopenty lidene-4 ’-azidour idine 5’-0-[a-naphthyl(benzyl-
D-alaninyl)] phosphate
Prepared according to Standard Procedure C2, from 
2 ’ ,3 ’ -O, O-cyclopentylidene-4’ -azidouridine (145,
200 mg, 0.569 mmol), ‘BuMgCl (1.42 mL, 1M 
solution in THF, 1.42 mmol) and a- 
naphthyl(benzyl-D-alaninyl) phosphorochloridate 
(178, 1.42 mL of solution 1M in THF, 1.42 mmol). 
The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (234 mg, 
61%).
6P (^-C H 3OH): 3.67, 3.47; 6„ (^-C H 3OH): 8.04 (1H, m, CH-naphthyl), 7.76-7.73 
(2H, m, CH-naphthyl, H6-uridine), 7.57-7.10 (10H, m, CH-naphthyl, CH-phenyl), 
5.79 (1H, m, H l’-uridine), 5.45 (1H, m, H5-uridine), 4.99 (2H, m, CH2-benzyl), 4.95 
(1H, m, H2’-uridine), 4.91 (1H, m, H3’-uridine), 4.18-4.10 (1H, m, H5’-uridine), 
4.02-3.96 (1H, m, CHa), 2.03-1.93 (2H, m, CH2-cyclopentyl), 1.62-1.57 (6H, m, CH2- 
cyclopentyl), 1.23 (3H, m, CH3-alanine).
Synthesis of 4’-azidouridine 5’ -0-[ a-naphthyl(benzyl-D-alaninyl)] phosphate
(172)
- A A
13 OH OH
Prepared according to Standard Procedure C3, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-0-[a-naphthyl(benzyl-D-alaninyl)] phosphate (234 mg, 0.347 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by
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column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (80 mg, 35%).
5 P (J4-CH3OH): 3.80, 3.60; 6„ (d4-CH3OH): 8.19 (1H, m, CH-naphthyl), 7.90 (1H, m, 
CH-naphthyl), 7.73 (1H, m, H6-uridine), 7.59-7.42 (10H, m, CH-naphthyl, CH- 
phenyl), 6.12 (1H, m, H I’-uridine), 5.51 (1H, m, H5-uridine), 4.97 (2H, m, CH2- 
benzyl), 4.40-3.99 (5H, m, H2’-uridine, H3’-uridine, CHa, H5’-uridine), 1.22 (3H, m, 
CH3-alanine); 6C (^-C H 3OH): 174.62 (1C, C=0 ester), 165.75, 165.69 (1C, C4- 
uridine), 152.10 (1C, C2-uridine), 147.76 (1C, C-naphthyl), 142.50, 142.17 (1C, C6- 
uridine), 137.11 (1C, C-phenyl), 136.33 (1C, C-naphthyl), 129.60, 129.58 (2C, CH- 
naphthyl), 129.37, 129.34, 129.28 (1C, CH-phenyl), 129.05, 128.98 (2C, CH- 
naphthyl), 127.98, 127.94 (2C, CH-naphthyl), 127.74, 127.67 (2C, CH-phenyl),
126.55 (1C, CH-naphthyl), 126.29, 126.23 (1C, CH-naphthyl), 122.66, 122.47 (2C, 
CH-phenyl), 103.60, 103.57 (1C, C5-uridine), 98.68, 98.60 (1C, C4’-uridine), 92.27, 
92.22 (1C, C l ’-uridine), 79.48 (1C, C3’-uridine), 73.74, 73.69, 73.54 (1C, C2’- 
uridine), 68.60, 68.56 (1C, CH2-benzyl), 68.16, 68.09, 67.94 (1C, C5’-uridine), 51.81, 
51.71 (1C, CHa), 20.39, 20.34, 20.25 (1C, CH3-alanine).
MS (ES) m/e: 675.2 (M N a\ 100%); Accurate mass: QgH^NgO^NaP required
675.1580, found 675.1594.
Synthesis of 2,,3,-(2,0-cyclopentylidene-4’-azidouridine 5’-0 -[a - 
naphthyl(isopropyl-D-alaninyl)] phosphate
Prepared according to Standard Procedure C2, from 
2 ’,3’-<9,0-cyclopentylidene-4’-azidouridine (145, 
200 mg, 0.569 mmol), ‘BuMgCl (1.42 mL, 1M 
solution in THF, 1.42 mmol) and a- 
naphthyl(isopropoxy-D-alaninyl) 
phosphorochloridate (171, 1.42 mL of solution 1M 
in THF, 1.42 mmol). The crude product was purified 
by column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white solid (150 mg of, 39%).
6 P (^-C H 3OH): 3.70, 3.61; SH (^-CH 3OH): 8.07 (1H, m, CH-naphthyl), 7.78-7.76 
(2H, m, CH-naphthyl, H6-uridine), 7.61-7.29 (5H, m, CH-naphthyl), 5.83 (1H, m, 
H I’-uridine), 5.47 (1H, m, H5-uridine), 4.88 (1H, m, H2’-uridine), 4.85-4.77 (2H, m,
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H3’-uridine, CH-isopropyl), 4.21-4.17 (1H, m, H5’-uridine), 3.92-3.87 (1H, m, CHa), 
2.05-1.97 (2H, m, CH2-cyclopentyI), 1.64-1.58 (6H, m, CH2-cyclopentyI), 1.21 (3H, 
m, CH3-alanine), 1.11-1.05 (6H, m , CH3-isopropyl).
Synthesis of 4’-azidouridine 5 ’ -<9-[ a-naphthyl(isopropyl-D-alaninyl)] phosphate
h. NH
Na OH OH
Prepared according to Standard Procedure C3, from 2 \3  ’-O,O-cyclopentylidene-4’- 
azidouridine 5’-0-[a-naphthyl(isopropyl-D-alaninyl)] phosphate (150 mg, 0.224 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent CHCl3/MeOH (8:2). The pure 
product was a white solid (50 mg, 37 %).
d P (^-C H 3OH): 3.73, 3.60; 6„ (^-C H 3OH): 8.20 (1H, m, CH-naphthyl), 7.92 (1H, m, 
CH-naphthyl), 7.73 (1H, m, H6-uridine), 7.57-7.41 (6H, m, CH-naphthyl), 6.12 (1H, 
m, H l’-uridine), 5.51 (1H, m, H5-uridine), 4.97 (1H, m, CH-isopropyl), 4.37 (1H, m, 
H2’-uridine), 4.35-4.21 (3H, m, H3’-uridine, H5’-uridine), 3.99 (1H, m CHa), 1.38-
1.33 (3H, m, CH3-alanine), 1.30-1.19 (6H, CH3-isopropyl); 6 C (rf4-CH3OH): 174.33 
(1C, C =0 ester), 165.71 (1C, C4-uridine), 152.21, 151.12 (1C, C2-uridine), 147.87, 
147.82 (1C, C-naphthyl), 142.55, 142.27 (1C, C6-uridine), 136.37, 136.35 (2C, C- 
naphthyl), 129.05, 128.99 (1C, CH-naphthyl), 127.98, 127.96 (1C, CH-naphthyl), 
127.71, 127.65 (1C, CH-naphthyl), 126.55 (1C, CH-naphthyl), 126.28, 126.22 (1C, 
CH-naphthyl), 122.67, 122.51 (1C, CH-naphthyl), 116.32, 116.30, 116.11, 116.09 
(1H, CH-naphthyl), 103.59 (1C, C5-uridine), 98.69, 98.61 (1C, C4’-uridine), 92.29, 
92.21 (1C, C l ’-uridine), 79.48 (1C, C3’-uridine), 73.78, 73.69, 73.63 (1C, C2’- 
uridine), 70.38, 70.34 (1C, CH-isopropyl), 69.08, 68.77, 68.73 (1C, C5’-uridine),
51.93, 51.77 (1C, CHa), 21.99, 21.95, 21.91 (2C, CH3-isopropyl) 20.53, 20.48, 20.39,
20.33 (1C, CH3-alanine).
MS (ES) m/e: 627.2 (MNa+, 100%); Accurate mass: C25H29N6O10NaP required
627.1580, found 627.1584.
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Synthesis of 2’ ,3 ’-0 ,O cy clopenty lidene-4 ’-azidour idine 5’-6L[phenyl(benzyl-
Prepared according to Standard Procedure C2, from 
2 ’,3’-0,0-cyclopentylidene-4’-azidouridine (145, 150 
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(benzyl-glycinyl) 
phosphorochloridate (133, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white 
solid (173 mg, 62%).
6 P (^-CH 3OH): 3.17, 3.02; 6 H ( ^ C H 3OH): 7.63 (1H, d, H6-uridine, J= 8.0 Hz), 7.37- 
7.34 (7H, m, CH-phenyl, CH-benzyl), 7.24-7.19 (3H, m, CH-phenyl), 5.98 (1H, m, 
H l’-uridine), 5.68 (1H, m, H5-uridine, J= 8.0 Hz), 5.18 (2H, s, CH2-benzyl), 5.02 
(1H, m, H2’-uridine), 4.97 (1H, m, H3’-uridine), 4.30-4.25 (2H, m, H5’-uridine), 3.83 
(2H, d, CH2-glycine), 2.20-2.11 (2H, m, CH2-cyclopentyl), 1.80-1.73 (6H, m, CH2- 
cyclopentyl).
glycinyl)] phosphate
n'A
rV°yNH
O* o
Synthesis of 4’-azidouridine 5 ’-0-[phenyl(benzyl-glycinyl)] phosphate (153)
NH
OH OH
Prepared according to Standard Procedure C3, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5 ’-<9-[phenyl(benzyl-glycinyl)] phosphate (173 mg, 0.264 mmol), and 10 
mL of a solution 80% of HCOOH in water. The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a white 
solid (70 mg, 43%).
6 P 04-CH3OH): 3.53, 3.28; 6„ (^-CH 3OH): 7.63 (1H, m, H6-uridine), 7.36 (6H, m, 
CH-phenyl, CH-benzyl), 7.34-7.19 (4H, m, CH-phenyl, CH-benzyl), 6.15 (1H, m,
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H I’-uridine), 5.69 (1H, m, H5-uridine), 5.18 (2H, s, CH2-benzyl), 4.39-418 (4H, m, 
H2’-uridine, H3’-uridine, H5’-uridine), 3.83 (2H, d, CH2-glycine).
MS (ES) m/e: 611.0 (MNa+, 100%); Accurate mass: C24H25N6O10NaP required 
611.1271, found 611.1267.
Anal. Calc, for N6O10P: C 48.98%, H 4.28%, N 14.28%. Found: C 48.69%, H 
3.91%, N 14.30%.
Synthesis of 2’,3’-Cf,0-cyclopentylidene-4,-azidouridine 5’-0-[phenyl(benzyl-L- 
valinyl)] phosphate
Prepared according to Standard Procedure C2, from 
2 ’,3’-0,0-cyclopentylidene-4’-azidouridine (145, 150 
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(benzyl-L-valinyl) 
phosphorochloridate (134, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent 
CHCyMeOH (95:5). The pure product was a white 
solid (173 mg, 58%).
SP (</4-CH3OH): 3.96, 3.81; 6„ (^-C H 3OH): 7.62 (1H, d, H6-uridine, J= 6.1 Hz), 7.39- 
7.32 (7H, m, CH-phenyl, CH-benzyl), 7.24-7.18 (3H, m, CH-phenyl, CH-phenyl),
5.96 (1H, m, H l’-uridine), 5.68 (1H, m, H5-uridine, J= 6.1 Hz), 5.18-5.11 (3H, m, 
CH2-benzyl, H2’-uridine), 4.98 (1H, m, H3’-uridine), 4.29-4.20 (2H, m, H5’-uridine),
3.76 (1H, m, CHa), 2.19-2.05 (3H, m, CH2-cyclopenthyl, CH-lateral chain), 1.78-1.73 
(6H, m, CH2-cyclopentyl), 0.92-0.86 (6H, m, CH3-lateral chain).
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Synthesis of 4’-azidouridine 5’-0-[phenyl(benzyl-L-valinyl)] phosphate (154)
NH
'3 OH OH
Prepared according to Standard Procedure C3, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(benzyl-L-valinyl)] phosphate (173 mg, 0.248 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (70 mg, 55%).
6P (d4-CU3OU): 4.45, 4.14; 6„ (^-C H 3OH): 7.62 (1H, m, H6-uridine, J= 6.8 Hz), 
7.39-7.32 (7H, m, CH-phenyl, CH-benzyl), 7.24-7.18 (3H, m, CH-phenyl, CH- 
phenyl), 6.14 (1H, m, H l’-uridine), 5.68 (1H, m, H5-uridine, J= 6.8 Hz), 5.19-5.10 
(2H, m, CH2-benzyl), 4.37-4.30 (2H, m, H2’-uridine, H3’-uridine), 4.22-4.14 (2H, m, 
H5’-uridine), 3.76 (1H, m, CHa), 2.07 (1H, m, CH-lateral chain), 0.90 (3H, t, CH3- 
valine, J -  8.6 Hz), 0.84 (3H, t, 3 CH3-lateral chain, J -  7.8 Hz).
MS (ES) m/e: 653.0 (MNa+, 100%); Accurate mass: C27H31N6O10NaP required 
653.1754, found 653.1737.
Synthesis of 2’,3’-0,(?-cyclopentylidene-4’-azidouridine 5’-0-[phenyl(methyl-L-
alaninyl)] phosphate
NH
Prepared according to the standard procedure 1, from 
2’,3’-<9,0-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), 'BuMgCl (0.85 mL, 1M solution in 
THF, 0.854 mmol) and phenyl(methyl-L-alaninyl) 
phosphorochloridate (128, 0.85 mL of solution 1M in 
THF, 0.854 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a a white solid (156 mg, 61%).
o
HN 
O ^ N
o
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6 P (^-C H 3OH): 3.14, 3.04; 6„ (^-C H 3OH): 7.66 (1H, t, H6-uridine), 7.35 (2H, t, CH- 
phenyl), 7.28-7.19 (3H, m, CH-phenyl), 5.97 (1H, m, H l’-uridine), 5.70 (1H, m, H5- 
uridine), 5.12-5.04 (2H, m, H2’-uridine, H3’-uridine), 4.31-4.27 (2H, m, H5’-uridine),
4.01 (1H, m, CHa), 3.70 (3H, d, CH3-methyl), 2.21-2.11 (2H, m, CH2-cyclopentyl), 
1.79-1.73 (6H, m, CH2-cyclopentyl), 1.37 (3H, t, CH3-alanine, J -  9.5 Hz).
Synthesis of 4 ’-azidouridine 5’-0'[phenyl(m ethyl-L-alaninyl) phosphate (148)
Prepared according to the standard procedure 2, from 2’,3’-O,0-cyclopentylidene-4’- 
azidouridine 5’-<9-[phenyl(methyl-L-alaninyl)] phosphate (135 mg, 0.222 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (65 mg, 54%).
SP (<VCH3OH): 3.50, 3.31; 6„ (^-CH 3OH): 7.65 (1H, m, H6-uridine), 7.38 (2H, m, 
CH-phenyl), 7.28-7.20 (3H, m, CH-phenyl), 6.15 (1H, m, H l’-uridine), 5.72 (1H, m, 
H5-uridine), 4.42-4.36 (2H, m, H2’-uridine, H3’-uridine), 4.26-4.18 (2H, m, H5’- 
uridine), 4.00 (1H, q, CHa), 3.70 (3H, d, CH3-methyl), 1.35 (3H, dd, CH3-alanine).
MS (ES) m/e: 549.0 (MNa+, 100%); Accurate mass: CjgH^NgO^NaP required
549.1 111, found 549.1124.
Anal. Calc, for C ^ H ^ O ^ P :  C 43.35%, H 4.40%, N 15.97%. Found: C 43.22%, H 
4.38%, N 15.45%.
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J
Synthesis of 2 ’ ,3 ’ - 0,O-cyclopentylidene-4 ’-azidouridine 5 ’ -(7-[pheny l(ethyl-L-
alaninyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-O,0-cyclopentylidene-4’-azidouridine (145, 150 
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethyl-L-alaninyl) 
phosphorochloridate (129, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (135 mg,
52%).
rv ■^  o" 'o
N,
" A
>w NH
5 P (^-C H 3OH): 3.18, 3.08; 6 H (^-C H 3OH): 7.65 (1H, d, H6-uridine, J= 7.9 Hz), 7.36 
(2H, m, CH-phenyl), 7.28-7.19 (3H, m, CH-phenyl), 6.00 (1H, dd, H l’-uridine), 5.69 
(1H, dd, H5-uridine, J= 7.9 Hz), 5.03 (2H, m, H2’-uridine, H3’-uridine), 4.30-4.26 
(2H, m, H5’-uridine), 4.18-4.13 (1H, m, CH2-ethyl), 3.98 (1H, m, CHa), 2.21-2.08 
(2H, m, CH2-cyclopentyl), 1.83-1.74 (6H, m, CH2-cyclopentyl), 1.26 (3H, m, CH3- 
ethyl), 1.25 (3H, m, CH3-alanine).
Synthesis of 4’-azidouridine 5 ’-0-[phenyl(ethyl-L-alaninyl)] phosphate (149)
Prepared according to the standard procedure 2, from 2’,3’-0,O-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(ethyl-L-alaninyl)] phosphate (135 mg, 0.222 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (65 mg, 54%).
6 P (d4-CH3OH): 3.56, 3.35; 6„ (^-C H 3OH): 7.65 (1H, m, H6-uridine), 7.37 (2H, m, 
CH-phenyl), 7.29-7.21 (3H, m, CH-phenyl), 6.17 (1H, m, H l’-uridine), 5.70 (1H, m, 
H5-uridine), 4.41-4.35 (2H, m, H2’-uridine, H3’-uridine), 4.26-4.15 (4H, m, H5’-
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uridine, CH2-ethyl), 3.97 (1H, m, CHa), 1.35 (3H, m, CH3-ethyl), 1.26 (3H, m, CH3- 
alanine).
MS (ES) m/e: 563.0 (MNa+, 100%); Accurate mass: C20H25N6O10NaP required 
563.1257, found 563.1267.
Anal. Calc, for Q qH ^ N A oP: C 44.45%, H 4.66%, N 15.55%. Found: C 44.90%, H 
4.07%, N 15.75%.
rv -O o  
N3
NH Or'N
Synthesis of 2,,3,-0 J>(9-cyclopentylidene-4’-azidouridine 5’-0-[phenyl(isopropyI- 
L-alaninyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,O-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(isopropyl-L-alaninyl) 
phosphorochloridate (130, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (171 mg, 
64%).
b v (</4-CH3OH): 3.22, 3.19; 6 H (^-C H 3OH): 7.65 (1H, d, H6-uridine, J= 7.3 Hz), 7.35 
(2H, d, CH-phenyl), 7.28-7.19 (3H, m, CH-phenyl), 5.97 (1H, dd, H l’-uridine), 5.70 
(1H, m, H5-uridine), 5.12-4.97 (3H, m, H2’-uridine, H3’-uridine, CH-isopropyl), 
4.30-4.26 (2H, m, H5’-uridine), 3.95 (1H, m CHa), 2.21-2.10 (2H, m, CH2- 
cyclopentyl), 1.79-1.73 (6H, m, CH2-cyclopentyl), 1.36 (3H, d, CH3-alanine, J= 7.2 
Hz), 1.24 (6H, d, CH3-isopropyI, J= 5.6 Hz).
o
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Synthesis of 4’-azidouridine 5’-0-[phenyl(isopropyl-L-alaninyl)] phosphate (150)
Prepared according to the standard procedure 2, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(isopropyl-L-alaninyl)] phosphate (171 mg, 0.275 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (144 mg, 94%).
6 P (^-C H 3OH): 3.59, 3.38; 6„ (^-C H 3OH): 7.64 (1H, dd, H6-uridine), 7.37 (2H, d, 
CH-phenyl), 7.28-7.22 (3H, m, CH-phenyl), 6.15 (1H, dd, H l’-uridine), 5.70 (1H, dd, 
H5-uridine), 5.00 (1H, q, CH-isopropyl), 4.40-4.35 (2H, m, H2’-uridine, H3’-uridine), 
4.24-4.18 (2H, m, H5’-uridine), 3.94 (1H, q, CHa), 1.34 (3H, dd, CH3-alanine), 1.24 
(6H, m, CH3-isopropyl).
MS (ES) m/e: 577.1 (MNa+, 100%); Accurate mass: QjH^NgOjoNaP required
577.1424, found 577.1427.
Anal. Calc, for C ^ N A o P :  C 45.49%, H 4.91%, N 15.16%. Found: C 45.57%, H 
4.91%, N 15.34%.
Synthesis of 2’,3,-0,0-cycIopentylidene-4’-azidouridine 5’-0-[phenyl(terM)utyl-
L-alaninyl)] phosphate
67%).
o
). nhfY V N H  O^NW O'V .0
N
Prepared according to the standard procedure 1, from 
2’,3’-<9,0-cycIopentyIidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(tert-butyl-L-alaninyl) 
phosphorochloridate (131, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (180 mg,
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6 P (</4-CH3OH): 3.22, 3.19; 6„ (^-C H 3OH): 7.65 (1H, m, H6-uridine), 7.36 (2H, m, 
CH-phenyl), 7.27-7.18 (3H, m, CH-phenyl), 5.80 (1H, m, H l’-uridine), 5.67 (1H, m, 
H5-uridine), 5.03-5.00 (2H, m, H2’-uridine, H3’-uridine), 4.31-4.26 (2H, m, H5’- 
uridine), 3.86 (1H, m CHa), 2.21-2.10 (2H, m, CH2-cyclopentyl), 1.79-1.46 (6H, m, 
CH2-cyclopentyl), 1.46 (9H, s, CH3-terf-butyl), 1.34 (3H, d, CH3-alanine, J= 6.6 Hz).
Synthesis of 4’-azidouridine 5’-CL[phenyl(te/*-butyl-L-aIaninyl)] phosphate
Prepared according to the standard procedure 2, from 2’,3’-O,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(terf-butyl-L-alaninyl)] phosphate (180 mg, 0.283 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (90 mg, 56%).
6 P (J4-CH3OH): 3.63, 3.59; 6„ (d4-CU3OU): 7.65 (1H, m, H6-uridine), 7.37 (2H, m, 
CH-phenyl), 7.28-7.20 (3H, m, CH-phenyl), 6.14 (1H, m, H l’-uridine), 5.71 (1H, m, 
H5-uridine), 4.41-4.34 (2H, m, H2’-uridine, H3’-uridine), 4.24-4.19 (2H, m, H5’- 
uridine), 3.87-3.84 (1H, m, CHa), 1.46 (9H, s, CH3-terf-butyl), 1.32 (3H, d, CH3- 
alanine, J= 7.4 Hz).
MS (ES) m/e: 591.1 (MNa+, 100%); Accurate mass: C^H^NgOjoNaP required 
591.1586, found 591.1580.
Anal. Calc, for Q o H ^ O ^ :  C 46.48%, H 5.14%, N 14.78%. Found: C 46.70%, H 
4.98%, N 14.53%.
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Synthesis of 2,,3’-0,0-cyclopentylidene-4,-azidouridine 5’-0-[phenyl(benzyl-L-
alaninyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,O-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(benzyl-L-alaninyl) 
phosphorochloridate (132, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (140 mg, 
49%).
6 P (<4-CH3OH): 3.17, 3.02; 6„ (^-C H 3OH): 7.49 (1H, d, H6-uridine, J= 7.9 Hz), 7.22 
(6H, m, CH-phenyl, CH-benzyl), 7.13-7.02 (4H, m, CH-phenyl, CH-benzyl), 5.85 
(1H, m, H l’-uridine), 5.54 (1H, m, H5-uridine, J= 7.9 Hz), 5.03 (3H, m, CH2-benzyl, 
H2’-uridine), 4.87 (1H, m, H3’-uridine), 4.13-4.10 (2H, m, H5’-uridine), 3.94 (1H, m, 
CHa), 2.14-1.97 (2H, m, CH2-cyclopentyl), 1.65-1.59 (6H, m, CH2-cyclopentyl), 1.25 
(3H, m, CH3-alanine).
Synthesis of 4’-azidouridine 5 ’-0-[phenyl(benzyl-L-alaninyl)] phosphate (152)
Prepared according to the standard procedure 2, from 2’,3’-0,O-cyclopentylidene-4’- 
azidouridine 5 ’-0-[phenyl(benzyl-L-alaninyl)] phosphate (140 mg, 0.209 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (70 mg, 55%).
5 P (J4-CH3OH): 3.53, 3.28; 6H (^-CH 3OH): 7.61 (1H, m, H6-uridine), 7.36 (6H, m, 
CH-phenyl, CH-benzyl), 7.31-7.19 (4H, m, CH-phenyl, CH-benzyl), 6.13 (1H, m,
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H l’-uridine), 5.68 (1H, m, H5-uridine), 5.15 (2H, s, CH2-benzyl), 4.36 (2H, m, H2’- 
uridine, H3’-uridine), 4.21-4.14 (2H, m, H5’-uridine), 4.05 (1H, m, CHa), 1.37 (3H, 
m, CH3-alanine).
MS (ES) m/e: 625.0 (MNa+, 100%); Accurate mass: C25H27N60 1oNaP required 
625.1426, found 625.1424.
Anal. Calc, for Q sH ^ O joP: C 49.84%, H 4.52%, N 13.95%. Found: C 49.91%, H 
4.51%, N 13.66%.
uJ
X
N?
o
HN 
O ^ N  
O
NH ° r s J ^
Synthesis of 2,,3’-0^0-cyclopentylidene-4’-azidouridine 5’-O-[phenyl(ethyl-a,a- 
dimethylglycinyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,0-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethyl-a,a- 
dimethylglycinyl) phosphorochloridate (136, 0.85 mL of 
solution 1M in THF, 0.85 mmol). The crude product was 
purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white solid
(179 mg, 67%).
6 P (rf4-CH3OH): 1.68, 1.58; 6„ (4,-CH3OH): 7.66 (1H, dd, H6-uridine), 7.37-7.35 (2H, 
m, CH-phenyl), 7.27 (2H, b, CH-phenyl), 7.20 (1H, b, CH-phenyl), 5.98 (1H, b, H l’- 
uridine), 5.68 (1H, dd, H5-uridine), 5.14-5.01 (2H, m, H2’-uridine, H3’-uridine), 4.28 
(2H, b, H5’-uridine), 4.17 (2H, q, CH2-ethyl, J= 7.1 Hz), 2.21-2.12 (2H, m, CH2- 
cyclopentyl), 1.79-1.73 (6H, m, CH2-cyclopentyl), 1.50 (6H, d, CH3-lateral chain), 
1.26 (3H, t, CH3-ethyl, J= 7.1 Hz).
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Synthesis of 4’-azidouridine 5’-0-[phenyl(ethyl-<x,a-dimethylglycinyl)]
phosphate (156)
Prepared according to the standard procedure 2, from 2’,3’-<2,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(ethyl-a,a-dimethylglycinyl)] phosphate (179 mg, 0.288 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent CHCl3/MeOH (8:2). The pure 
product was a white solid (144 mg, 90%).
6 P (^-C H 3OH): 1.90, 1.87; 6„ (^-C H 3OH): 7.64 (1H, dd, H6-uridine), 7.39-7.35 (2H, 
m, CH-phenyl), 7.26 (2H, d, CH-phenyl), 7.20 (1H, d, CH-phenyl), 6.14 (1H, d, H l’- 
uridine, J= 2.6 Hz), 5.67 (1H, dd, H5-uridine), 4.40-4.37 (2H, m, H2’-uridine, H3’- 
uridine), 4.33 (2H, br, H5’-uridine), 4.23-4.15 (1H, m, CH2-ethyl), 1.49 (6H, d, CH3- 
lateral chain), 1.27 (3H, t, CH3-ethyl).
MS (ES) m/e: 577.1 (M Na\ 100%); Accurate mass: C2iH27N6O10NaP required
577.1424, found 577.1431.
Anal. Calc, for Q jH ^N A oP: C 45.49, H 4.91%, N 15.16%. Found: C 45.45%, H 
5.09%, N 14.74%.
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Synthesis of 2’,3 ’-<9,0-cyclopentylidene-4 ’-azidouridine 5’-0-[phenyl(benzyl- 
a,a-dim ethylglycinyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,<2-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(benzyl-a,a- 
dimethylglycinyl) phosphorochloridate (155, 0.85 mL of 
solution 1M in THF, 0.85 mmol). The crude product was 
purified by column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white solid 
(148 mg, 51%).
d P (</4-CH3OH): 1.72, 1.63; d H M rCH3OH): 7.62 (1H, dd, H6-uridine), 7.37-7.31 (7H, 
m, CH-phenyl, CH-benzyl), 7.23-7.18 (3H, m, CH-phenyl), 5.96 (1H, b, H l’-uridine), 
5.67 (1H, dd, H5-uridine), 5.15 (2H, dd, CH2-benzyl), 5.11-4.94 (2H, m, H2’-uridine, 
H3’-uridine), 4.22 (2H, dd, H5’-uridine), 2.27-2.11 (2H, m, CH2-cyclopentyl), 1.77-
1.72 (6H, m, CH2-cyclopentyl), 1.52 (6H, s, CH3-lateral chain).
Synthesis of 4’-azidouridine 5’-CL[phenyl(benzyl-cr,a-dimethylglycinyl)]
phosphate (135)
Prepared according to the standard procedure 2, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(benzyl-a,a-dimethylglycinyl)] phosphate (148 mg, 0.217 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent CHCl3/MeOH (8:2). The pure 
product was a white solid (110 mg, 82%).
8 P (d4-CH3OH): 1.86, 1.83; d H (</,-CH3OH): 7.60 (1H, dd, H6-uridine), 7.36-7.32 (7H, 
m, 2 CH-phenyl, 5 CH-benzyl), 7.24-7.17 (3H, m, 3 CH-phenyl), 6.12 (1H, dd, H l’-
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uridine), 5.65 (1H, dd, H5-uridine), 5.15 (2H, dd, CH2-benzyl), 4.38-4.29 (2H, m, 
H2’-uridine, H3’-uridine), 4.19-4.16 (2H, dd, H5’-uridine), 1.50 (6H, s, 2 CH3-lateral 
chain).
MS (ES) m/e: 639.1 (MNa+, 100%); Accurate mass: QsH^NgO^NaP required
639.1580, found 639.1574.
Anal. Calc, for Q 6H29N6O10P: C 50.65, H 4.74%, N 13.63%. Found: C 50.64%, H 
4.86%, N 13.12%.
Synthesis of 2’,3’-0,6Lcyclopentylidene-4’-azidouridine 5’-0-[phenyl(ethyl-L- 
phenylalaninyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,0-cyclopenthylidene-4’-azidouridine (145, 150 
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethyl-L-phenylalaninyl) 
phosphorochloridate (138, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (190 mg, 
65%).
SP (^-C H 3OH): 3.07, 2.72; 6 H M rCH3OH): 7.59 (1H, dd, H6-uridine), 7.32-7.09 
(10H, m, CH-phenyl, CH-lateral chain), 5.95 (1H, dd, H l’-uridine), 5.68 (1H, dd, H5- 
uridine), 5.07-4.91 (2H, m, H2’-uridine, H3’-uridine), 4.15-4.08 (3H, m, H5’-uridine, 
CHa), 3.90-3.88 (2H, m, CH2-ethyl), 3.07 (1H, q, CH2-lateral chain), 2.94 (1H, q, 
CH2-lateral chain), 2.20-2.10 (2H, m, CH2-cyclopentyl), 1.78-1.73 (6H, m, CH2- 
cyclopentyl), 1.18 (3H, m, CH3-ethyl).
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Synthesis of 4’-azidouridine 5’-<9-[phenyl(ethyl-L-phenylalaninyI)] phosphate
(158)
HN
OH OH
Prepared according to the standard procedure 2, from 2 ’,3’-(9,O-cy cl opentyli dene-4 
azidouridine 5’-0-[phenyl(ethyl-L-phenylalaninyl)] phosphate (190 mg, 0.278 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (152 mg, 88%).
6 P (^-C H 3OH): 3.28, 3.06; 6„ (^-C H 3OH): 7.55 (1H, dd, H6-uridine), 7.34-7.07 
(10H, m, CH-phenyl, CH-lateral chain), 6.14 (1H, dd, H l’-uridine), 5.70 (1H, dd, H5- 
uridine), 4.27-4.23 (2H, m, H2’-uridine, H3’-uridine), 4.15-4.00 (3H, m, H5’-uridine, 
CHa), 3.81-3.78 (2H, m, CH2-ethyl), 3.10 (1H, q, CH2-lateral chain), 2.89 (1H, q, 
CH2-lateral chain), 1.20 (3H, m, CH3-ethyl).
MS (ES) m/e: 639.0 (MNa+, 100%); Accurate mass: C26H29N6O10NaP required
639.1580, found 639.1594.
Anal. Calc, for C y y ^ O jo P : C 50.65%, H 4.74%, N 13.63%. Found: C 50.61%, H 
4.55%, N 13.51%.
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Synthesis of 2’,3,-0,0-cyclopentylidene-4,-azidouridine 5’-0-[phenyl(benzyl-L- 
phenylalaninyl)] phosphate
Prepared according to the standard procedure 1, from 
2’,3’-0,O-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in
THF, 0.85 mmol) and phenyl(benzyl-L-phenylalaninyl)
phosphorochloridate (137, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (163 mg, 
51%).
5 P 04-CH3OH): 2.98, 2.69; 6„ (^-CH 3OH): 7.53 (1H, dd, H6-uridine), 7.38-6.96 
(15H, m, CH-phenyl, CH-lateral chain, CH-benzyl), 5.93 (1H, dd, H l’-uridine), 5.65 
(1H, dd, H5-uridine), 5.10 (2H, m, CH2benzyl), 5.04-4.87 (2H, m, H2’-uridine, H3’- 
uridine), 4.17-4.07 (3H, m, H5’-uridine, CHa), 3.07 (1H, m, CH2-lateral chain), 2.85
(1H, m, CH2-lateral chain), 2.22-2.07 (2H, m, CH2-cyclopentyl), 1.88-1.71 (6H, m,
CH2-cyclopentyl).
Synthesis of 4 ’-azidouridine 5’-0-[phenyl(benzyl-L-phenylalaniny!)] phosphate
(157)
HN
OH OH
Prepared according to the standard procedure 2, from 2 ’,3’-0,O-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(benzyl-L-phenylalaninyl)] phosphate (163 mg, 0.219 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent CHCl3/MeOH (8:2). The pure 
product was a white solid (130 mg, 87%).
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dP (^-C H 3OH): 3.21, 3.02; 6 H (^-C H 3OH): 7.51 (1H, dd, H6-uridine), 7.32-7.23 (6H, 
m, CH-phenyl, CH-lateral chain, CH-benzyl), 7.18-7.03 (9H, m, CH-phenyl, CH- 
lateral chain, CH-benzyl), 6.14 (1H, dd, H I’-uridine), 5.64 (1H, dd, H5-uridine), 5.16- 
5.09 (4H, m, H2’-uridine, H3’-uridine, CH2benzyl), 4.24-4.12 (3H, m, H5’-uridine, 
CHa), 3.09 (1H, m, CH2-lateral chain), 2.91-2.87 (1H, m, CH2-lateral chain).
MS (ES) m/e: 701.1 (MNa+, 100%); Accurate mass: QjH^NgO^NaP required
701.1737, found 701.1732.
Anal. Calc, for Q jH ,,N 6O10P: C 54.87%, H 4.60%, N 12.38%. Found: C 54.87%, H 
4.60%, N 12.45%.
Synthesis of 2’,3,-0,0-cyclopentylidene-4,-azidouridine 5’-0-[phenyI(ethyl-L- 
leucinyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,O-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethoxy-L-leucinyl) 
phosphorochloridate (139, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (135 mg, 
48%).
d P (<4-CH3OH): 3.44, 3.22; d H (^-C H 3OH): 7.65 (1H, dd, H6-uridine), 7.35 (2H, d, 
CH-phenyl), 7.27-7.19 (3H, m, CH-phenyl), 5.98 (1H, d, H l’-uridine), 5.69 (1H, dd, 
H5-uridine), 5.12-5.00 (2H, m, H2’-uridine, H3’-uridine), 4.30-4.22 (2H, m, H5’- 
uridine), 4.16-4.13 (2H, m, CH2-ethyl), 3.90 (1H, m, CHa), 2.21-2.08 (2H, m, CH2- 
cyclopentyl), 1.79-1.73 (6H, m, CH2-cyclopentyl), 1.62-1.52 (3H, m CH-lateral chain, 
CH2-lateral chain), 1.25 (3H, m, CH3-ethyl), 0.89 (3H, d, CH3-lateral chain, J -  6.6 
Hz), 0.84 (3H, d, CH3-lateral chain, J= 6.0 Hz).
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Synthesis of 4’-azidouridine 5 ’ -0-[phenyl(ethyl-L-leucinyl)] phosphate (159)
HN
OH OH
Prepared according to the standard procedure 2, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(ethyl-L-Ieucinyl)] phosphate (135 mg, 0.208 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (11 lmg, 91%).
6 P (^-C H 3OH): 3.83, 3.47; 6„ (</4-CH3OH): 7.64 (1H, dd, H6-uridine), 7.36 (2H, t, 2 
CH-phenyl), 7.25-7.20 (3H, m, CH-phenyl), 6.16 (1H, d, H l’-uridine), 5.72 (1H, dd, 
H5-uridine), 4.40-4.35 (2H, m, H2’-uridine, H3’-uridine), 4.22 (2H, b, H5’-uridine), 
4.18-4.11 (2H, m, CH2-ethyl), 3.90 (1H, b, CHa), 1.54 (3H, m CH-lateral chain, CH2- 
lateral chain), 1.27-1.19 (3H, m, CH3-ethyl), 0.86 (3H, t, CH3-lateral chain), 0.80 (3H, 
t, CH3-lateral chain).
MS (ES) m/e: 605.1 (MNa+, 100%); Accurate mass: C^H^NgOjoNaP required
605.1737, found 605.1733.
Anal. Calc, for C ^ U ^ O ^ P :  C 47.42%, H 5.36%, N 14.43%. Found: C 47.43%, H 
5.26%, N 14.40%.
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Synthesis of 2’,3,-0^0-cyclopentylidene-4’-azidouridine 5’-6L[phenyl(ethyl-L-
prolinyl)] phosphate
Prepared according to the standard procedure 1, from 
2’,3’-0,0-cyclopentylidene-4’-azidouridine (145, 150 mg, 
0.427 mmol), 'BuMgCl (0.85 mL, 1M solution in THF, 
0.85 mmol) and phenyl(ethyl-L-prolinyl) 
phosphorochloridate (140, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (121 mg, 45%). 
dp (^-C H 3OH): 1.58, 1.38; 6„ (^-C H 3OH): 77.66 (1H, dd, H6-uridine), 7.38 (2H, t, 2 
CH-phenyl), 7.30-7.20 (3H, m, CH-phenyl), 5.95 (1H, dd, H l’-uridine), 5.69 (1H, dd, 
H5-uridine), 5.14 (2H, d, H2’-uridine, J= 6.2 Hz), 5.00 (1H, d, H3’-uridine, J= 5.3 
Hz), 4.30 (2H, m, H5’-uridine), 4.19-4.13 (2H, m, CH2-ethyl), 3.40 (1H, t, CHa), 
2.26-2.17 (2H, m, CH2-cyclopentyl), 2.12-1.99 (6H, m CH2-proline), 1.79-1.73 (6H, 
m, CH2-cyclopentyl), 1.26 (3H, m, CH3-ethyl).
o
Synthesis of 4’-azidouridine 5’-0-[phenyl(ethyl-L-prolinyl) phosphate (160)
HN
OH OH
Prepared according to the standard procedure 2, from 2 ’,3’-0,<9-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(ethyl-L-prolinyl)] phosphate (121 mg, 0.190 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (101 mg, 94%).
6 P (^-C H 3OH): 1.60, 1.25; dH (^-CH 3OH): 7.65 (1H, dd, H6-uridine), 7.39 (2H, t, 
CH-phenyl), 7.30-7.23 (3H, m, CH-phenyl), 6.12 (1H, dd, H l’-uridine), 5.71 (1H, dd, 
H5-uridine), 4.39-4.29 (2H, m, H2’-uridine, H3’-uridine), 4.25-4.13 (4H, m, H5’-
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uridine, CH2-ethyl), 3.42 (1H, m, CHa), 2.23-2.17 (2H, m, CH2-proline), 2.02-1.84 
(4H, m CH2-proline), 1.28 (3H, m, CH3-ethyl).
MS (ES) m/e: 589.1 (MNa+, 100%); Accurate mass: C22H27N6O10NaP required
589.1424, found 589.1416.
Anal. Calc, for C22H27N6O10P: C 46.65, H 4.80%, N 14.84%. Found: C 46.32%, H 
4.86%, N 14.51%.
Synthesis of 2’,3’-0,O-cycIopentylidene-4’-azidouridine 5’-<?-[phenyl(ethyl-L- 
methioninyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-<9,0-cyclopentylidene-4,-azidouridine (145, 150
mg, 0.427 mmol), 'BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethyl-L-methioninyl) 
phosphorochloridate (141, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (187 mg,
65%).
5 P (^-C H 3OH): 3.34, 3.21; 6„ (^-C H 3OH): 7.65 (1H, t, H6-uridine), 7.37 (2H, m, 
CH-phenyl), 7.29-7.19 (3H, m, CH-phenyl), 5.97 (1H, d, H l’-uridine), 5.70 (1H, dd, 
H5-uridine), 5.12-5.02 (2H, m, H2’-uridine, H3’-uridine), 4.30-4.26 (2H, m, H5’- 
uridine), 4.19-4.15 (2H, m, CH2-ethyl), 4.07 (1H, m, CHa), 2.60-2.46 (2H, m, CH2- 
lateral chain), 2.21-2.07 (2H, m, CH2-cyclopentyl), 2.03 (3H, d, CH3-lateral chain, J=
8.3 Hz), 1.94-1.85 (2H, m, CH2-lateral chain), 1.79-1.74 (6H, m, CH2-cyclopentyl), 
1.26 (3H, m, CH3-ethyl).
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Synthesis of 4’-azidouridine 5’-0-[phenyl(ethyI-L- methioninyl)] phosphate (161)
HN
OH OH
Prepared according to the standard procedure 2, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-0-[phenyl(ethyl-L-methioninyl)] phosphate (187 mg, 0.280 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (133 mg, 79%).
6 P (^-CH 3OH): 3.81, 3.48; 6„ (^-CH 3OH): 7.65 (1H, t, H6-uridine), 7.38 (2H, d, 
CH-phenyl), 7.30-7.21 (3H, m, CH-phenyl), 6.15 (1H, dd, H l’-uridine), 5.72 (1H, dd, 
H5-uridine), 4.41-4.35 (2H, m, H2’-uridine, H3’-uridine), 4.27-4.16 (4H, m, H5’- 
uridine, CH2-ethyl), 4.08 (1H, t, CHa), 2.53 (2H, m, CH2-lateral chain), 2.03 (3H, d, 
CH3-lateral chain, J= 15.3 Hz), 1.88-1.84 (2H, m, CH2-lateral chain), 1.31 (3H, m, 
CH3-ethyl).
MS (ES) m/e: 563.0 (MNa+, 100%); Accurate mass: QoH^NgOjoNaP required 
563.1257, found 563.1267.
Anal. Calc, for Q oH ^ N A qP: C 44.45%, H 4.66%, N 15.55%. Found: C 44.90%, H 
4.07%, N 15.75%.
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J
Cr<s'o' O r ' No
N3
Synthesis of 2’,3’-(7,CLcyclopentylidene-4,-azidouridine 5’-CL[phenyl(ethyl-,/V- 
methyl-glycinyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-O,0-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethyl-L- A/-methyl- 
glycinyl) phosphorochloridate (143, 0.85 mL of solution 
1M in THF, 0.85 mmol). The crude product was purified 
by column chromatography, using as eluent 
CHCl3/MeOH (95:5). The pure product was a white solid 
(172 mg, 66%).
SP (^-C H 3OH): 3.36, 3.29; 6„ (d4-CU3OU): 7.74 (1H, dd, H6-uridine), 7.45-7.42 (2H, 
m, CH-phenyl), 7.34-7.28 (3H, m, CH-phenyl), 6.04 (1H, d, H l’-uridine, J= 1.1 Hz),
5.77 (1H, dd, H5-uridine), 5.20-5.07 (2H, m, H2’-uridine, H3’-uridine), 4.41 (1H, dd, 
H5’-uridine), 4.36 (1H, dd, H5’-uridine), 4.28-4.26 (2H, m, CH2-ethyl), 3.88 (1H, m, 
CH2-glycine), 3.42 (1H, m, CH2-glycine), 2.90 (3H, s, CH3-N), 2.27-2.18 (2H, m, 
CH2-cyclopentyl), 1.86-1.80 (6H, m, CH2-cyclopentyl), 1.34 (3H, m, CH3-ethyl).
Synthesis of 4’-azidouridine 5’-0-[phenyl(ethyl-iV-methyl-glycinyl)] phosphate
(163)
O
r v  p  
0 * 0
Nj
OH OH
Prepared according to the standard procedure 2, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5 ’-0-[phenyl(ethyI-A^-methyI-glycinyl)] phosphate (172 mg, 0.284 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent CHCl3/MeOH (8:2). The pure 
product was a white solid (135 mg, 88%).
SP (^-C H 3OH): 5.12, 4.93; 6H (^-CH3OH): 7.66 (1H, dd, H6-uridine), 7.42-7.38 (2H, 
m, CH-phenyl), 7.27-7.22 (3H, m, CH-phenyl), 6.15 (1H, d, H l’-uridine, J= 2.1 Hz),
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5.70 (1H, dd, H5-uridine), 4.42-4.29 (3H, m, H2’-uridine, H3’-uridine, H5’-uridine),
4.26-4.17 (3H, m, H5’-uridine, CH2-ethyl), 4.00 (1H, m, CH2-glycine), 3.80 (1H, m, 
CH2-glycine), 2.83 (3H, d, CH3-N), 1.28 (3H, t, CH3-ethyl, J= 5.0 Hz).
Anal. Calc, for QoH^NgO^P: C 44.45%, H 4.66%, N 15.55%. Found: C 44.60%, H 
4.90%, N 15.54%.
V  o - J
Synthesis of 2’,3’-(7,(7-cyclopentylidene-4’-azidouridine 5’-0-[phenyl(diethyI-L- 
aspartyl)] phosphate
Prepared according to the standard procedure 1, from 
2 ’,3’-0,0-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(diethyl-L-aspartyl) 
phosphorochloridate (144, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (197 mg,
66%).
d P (^-C H 3OH): 3.24, 3.22; 6„ (</4-CH3OH): 7.65 (1H, d, H6-uridine, J= 7.6 Hz), 7.36 
(2H, d, CH-phenyl), 7.27-7.19 (3H, m, CH-phenyl), 5.98 (1H, d, H l’-uridine), 5.70 
(1H, dd, H5-uridine), 5.13-5.00 (2H, m, H2’-uridine, H3’-uridine), 4.29-4.25 (2H, m, 
H5’-uridine), 4.18-4.11 (4H, m, CH2-ethyl, CH2-ethyl lateral chain), 3.99-3.97 (1H, m, 
CHa), 2.48-2.35 (2H, m, CH2-lateral chain), 2.21-2.10 (4H, m, CH2-cyclopentyl, CH2- 
lateral chain), 1.79-1.73 (6H, m, CH2-cyclopentyl), 1.28-1.21 (6H, m, CH3-ethyl 
lateral chain, CH3-ethyl).
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Synthesis of 4’-azidouridine 5’-0-[phenyl(diethyl-L-aspartyl)] phosphate (164)
HN
V 0'  -NH
OH OH
Prepared according to the standard procedure 2, from 2’,3’-0,O-cyclopenthylidene-4’- 
azidouridine 5’-0-[phenyl(diethyl-L-aspartyl)] phosphate (197 mg, 0.284 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (168 mg, 94%).
6 P (<4-CH3OH): 3.66, 3.39; 6 H (d4-CH3OH): 7.60 (1H, dd, H6-uridine), 7.35 (2H, m, 
CH-phenyl), 7.26-7.19 (3H, m, CH-phenyl), 6.12 (1H, d, H l’-uridine), 5.72 (1H, dd, 
H5-uridine), 4.40-4.32 (2H, m, H2’-uridine, H3’-uridine), 4.29-4.08 (6H, m, H5’- 
uridine, CH2-ethyl, CH2-ethyl lateral chain), 4.01-3.94 (1H, m, CHa), 2.42-2.16 (2H, 
m, CH2-lateral chain), 2.10-1.82 (2H, m, CH2-lateral chain), 1.28-1.22 (6H, m, CH3- 
ethyl lateral chain, CH3-ethyl).
Anal. Calc, for C^H^NA oP: C 46.01, H 4.99%, N 13.41%. Found: C 46.15%, H 
5.02%, N 13.62%.
Synthesis of 2’,3’-0,0-cyclopentylidene-4,-azidouridine 5’-0-[phenyl(ethyl-/S- 
alaninyl)] phosphate
Prepared according to the standard procedure 1, from 
2’,3’-0,0-cyclopentylidene-4’-azidouridine (145, 150
mg, 0.427 mmol), ‘BuMgCl (0.85 mL, 1M solution in 
THF, 0.85 mmol) and phenyl(ethyl-jS-alaninyl) 
phosphorochloridate (142, 0.85 mL of solution 1M in 
THF, 0.85 mmol). The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (165 mg,
63%).
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d P (^-C H 3OH): 3.50, 3.44; d H (^-CH 3OH): 7.70 (1H, dd, H6-uridine), 7.44-7.42 (2H, 
m, CH-phenyl), 7.33-7.26 (3H, m, CH-phenyl), 6.03 (1H, dd, H l’-uridine), 5.78 (1H, 
dd, H5-uridine), 5.11-5.09 (2H, m, H2’-uridine, H3’-uridine), 4.33 (2H, b, H5’- 
uridine), 4.20 (1H, q, CH2-ethyl, J= 6.2 Hz), 3.35 (1H, t, CH2a), 2.60 (1H, b, CH2£),
2.26-2.20 (2H, m, CH2-cyclopentyl), 1.86-1.80 (6H, m, CH2-cyclopentyl), 1.32 (3H, t, 
CH3-ethyl, J= 6.2 Hz).
Synthesis of 4’-azidouridine 5’>0>[phenyl(ethyl-^>alaninyl)] phosphate (162)
HN
OH OH
Prepared according to the standard procedure 2, from 2’,3’-0,0-cyclopentylidene-4’- 
azidouridine 5’-<9-[phenyl(ethyl-y3-alaninyl)] phosphate (165 mg, 0.272 mmol), and 
10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent CHCl3/MeOH (8:2). The pure product was a 
white solid (127 mg, 86%).
5 P (^-C H 3OH): 3.33, 3.27; d„ (^-CH 3OH): 7.62 (1H, dd, H6-uridine), 7.38 (2H, t, 
CH-phenyl), 7.26-7.20 (3H, m, CH-phenyl), 6.12 (1H, d, H l’-uridine, J= 3.2 Hz),
5.72 (1H, dd, H5-uridine), 4.39-4.34 (2H, m, H2’-uridine, H3’-uridine), 4.23-4.11 
(4H, m, H5’-uridine, CH2-ethyl), 3.27 (1H, m, CH2a), 2.54 (1H, br, CH2p), 1.25 (3H, 
m, CH3-ethyl).
MS (ES) m/e: 563.0 (M Na\ 100%); Accurate mass: QoH^NgO^NaP required 
563.1267, found 563.1279.
Anal. Calc, for QoH^NgO^P: C 44.45%, H 4.66%, N 15.55%. Found: C 44.24%, H 
4.87%, N 15.58%.
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Synthesis of 4’-ethynyluridine 5’-0-[phenyl(benzyl-D-alaninyl)] phosphate (180)
NH
/// OH OH
Prepared according to Standard Procedure D, from 4 ’-ethynyluridine (25, 150 mg, 
0.559 mmol), ‘BuMgCl (1.12 mL of solution 1M in THF, 1.12 mmol) and 
phenyl(benzyl-D-alaninyl) phosphorochloridate (115, 1.1 mL of solution 1M in THF, 
1.12 mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (90:10) then a preparative TLC using as eluent CHCl3/MeOH 
(9:1). The pure product was a white solid (100 mg, 17%).
6 P (</<-CH3OH): 4.80, 4.14; 6„ (4,-CH3OH): 7.55 (1H, m, H6-uridine), 7.35 (7H, m, 
CH-phenyl, CH-benzyl), 7.23 (3H, m, CH-phenyl, CH-benzyl), 6.00 (1H, m, H l’- 
uridine), 5.65 (1H, m, H2-uridine), 5.16 (2H, s, CH2-benzyl), 4.32 (1H, m, H3’- 
cytidine), 4.28 (1H, m, H2’-cytidine), 4.15 (2H, m, H5’-cytidine), 4.05 (1H, m, CHa), 
3.18 (1H, CH-ethynyl), 1.36 (3H, m, CH3-alanine); 5C (^-CH 3OH): 175.33, 175.28, 
175.08, 175.01 (1C, C=0 ester), 166.37 (1C, C4-uridine), 152.68, 152.58, 152.39, 
152.32 (1C, C2-uridine), 143.13, 143.06 (1C, C6-uridine), 137.62, 137.55 (1C, C- 
phenyl), 131.30, 131.27 (2C, CH-phenyl), 130.01 (2C, 2 CH-benzyl), 129.78, 129.76,
129.71 (2C, 2 CH-phenyl), 127.42 (1C, C-ethynyl), 126.77 (1C, C-benzyl), 124.24, 
124.01 (2C, 2 CH-benzyl), 121.91, 121.85 (1C, CH-benzyl) 121.77, 121.70 (1C, CH- 
phenyl), 103.87, 103.82 (1C, C5-uridine), 99.11, 98.98 (1C, C4’-uridine), 91.97, 
91.41 (1C, C l ’-uridine), 74.55, 74.44 (1C, C3’-uridine), 72.40, 71.99 (1C, C2’- 
uridine), 70.32, 70.25 (1C, CH-ethynyl), 69.62, 69.56 (1C, CH2-benzyl), 68.53, 68.45 
(1C, C5’-uridine), 52.17, 51.89 (1C, CHa), 20.87, 20.78, 20.68 (1C, CH3-lateral 
chain).
MS (ES) m/e: 608.1 (MNa+, 100%); Accurate mass: C ^H ^N ^oN aP  required 
608.1410, found 608.14.
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7.8 Synthesis of 4’-azidoadenosine.
Synthesis of S’-deoxy-S’-iodoadenosine (182)9
Iodine (35.43 g, 0.140 mol) and triphenylphosphine (36.80 g,
NH-
0.140 mol) were added to a solution of adenosine (181, 25 g,
<" 1  J
o
OH OH
0.093 mol) in pyridine (200 mL). After 2 hours a saturated 
solution of NasS20 3 was added; the solvent was removed under 
reduced pressure and the yellow solid was purified by column 
chromatography using as eluent CHCl3/MeOH 9:1. The 
obtained product (60 g, >100 %) was pure enough for the following reaction.
8 h M t(CH3)2SO): 8.82 (1H, s, NH26-adenosine), 8.59 (1H, s, H2-adenosine), 8.36 
(1H, s, H8-adenosine), 5.95 (1H, d, H l’-adenosine, J= 5.6 Hz), 4.75 (1H, t, H2’- 
adenosine), 4.16 (1H, t, H3’-adenosine), 4.01 (1H, m, H4’-adenosine), 3.60 (1H, m, 
H5’-adenosine), 3.46 (1H, m, H5’-adenosine).
Synthesis of l-(5-deoxy-/5-D-glycero-pent-4-enofuranosyl)-adenine (183)
tBuOK (47.0 g, 0.418 mol) was added to a solution of 5 ’-
NH2
deoxy-5’-iodoadenosine (182, 35.0 g, 0.093 mol) in pyridine
'/  " " T i N
(200 mL), and the reaction stirred for 1 hour at 80 °C. The
OH OH
<" JL J
solvent was removed under reduced pressure and the black 
solid was purified by column chromatography using as eluent a 
mixture of CHCl3/MeOH 9:1, then 8:2 and 7:3. The product 
was obtained as brown solid (18.5 g, 80%)
5h (d6-(CH3)2SO): 8.37 (1H, s, H2-adenosine), 8.16 (1H, s, H8-adenosine), 7.32 (2H, 
s, NH26-adenosine), 6.16 (1H, d, H l’-adenosine, J= 5.3 Hz), 5.73 (1H, s, OH2’- 
adenosine), 5.58 (1H, s, OH3’-adenosine), 4.83 (1H, t, H2’-adenosine), 4.73 (1H, t, 
H3’-adenosine), 4.31 (1H, s, H5’-adenosine), 4.21 (1H, s, H5’-adenosine).
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Synthesis of 4,-azido-5,-deoxy-5,iodoadenosine (184)
Sodium azide (11.73 g, 180.4 mmol) was added to a solution
7 H> of ICl (14.65 g, 90.2 mol) in DMF (50 mL) and stirred at 30 
,n ^ A n
/  ti r* ° c  for 20 minutes. Then a solution of l-(5-deoxy-/J-D-< ' j  j
1—1 .0.
N3
glycero-pent-4-enofuranosyl)-adenine (183, 9.0 g, 36.1 mmol) 
in DMF (200 mL) was added dropwise in 30 minutes. After 1 
OH OH hour a saturated solution of NasS20 3 was added; the solvent
was removed under reduced pressure, the solid was dissolved in MeOH, the 
precipitate was removed buy filtration. The solvent was removed under reduced 
pressure and the yellow solid was purified by column chromatography using as eluent 
CHCl3/MeOH 9:1. The desire product was obtained as a yellow solid (19 g, >100).
6„ (^-C H 3OH): 8.86 (1H, s, H2-adenosine), 8.78 (1H, s, H8-adenosine), 6.26 (1H, d, 
H l’-adenosine, J= 5.1 Hz), 5.28 (1H, m, H2’-adenosine), 4.73 (1H, t, H3’-adenosine),
3.71 (1H, s, H5’-adenosine), 3.68 (1H, s, H5’-adenosine); 8C (<4-CH3OH): 157.39 
(1C, C4-adenosine), 154.17 (1C, C2-adenosine), 153.80 (1C, C8-adenosine), 150.68 
(1C, C6-adenosine), 120.70 (1C, C5-adenosine), 98.77 (1C, C4’-adenosine), 91.22 
(1C, C l ’-adenosine), 75.30 (1C, C3’adenosine), 73.98 (1C, C2’-adenosine), 9.61 (1C, 
C5’-adenosine).
Synthesis of #VV*-dibenzoyl, 2 ’ ,3 ’-0 ,0 -dibenzoyl-4 ’ -azido-5 ’ -deoxy-5 ’ -
iodoadenosine (185)
To a solution of 4’-azido-5’-deoxy-5’-iodoadenosine (184,
N(Bz)2
19.0 g, 45.0 mmol) in pyridine (200 mL), benzoyl chloride 
(10.5 mL, 180 mmol) was added. After 15 hours the solvent 
was removed under reduce pressure and the dark solid 
obtained was purified by column chromatography using as 
eluent EtOAc/Hexane 3:7. The desire product was obtained 
as a yellow solid (8.5 g, 35%).
5„ (^-C H 3OH): 8.76 (1H, s, H2-adenosine), 8.67 (1H, s, H8-adenosine), 8.06-7.86 
(10H, m, CH-benzoyl), 7.63-7.40 (10H, m, CH-benzoyl), 6.88 (1H, d, H3’-adenosine, 
J= 3.0 Hz), 6.60-6.59 (2H, m, H2’-adenosine, H I’-adenosine), 3.93 (1H, m, H5’- 
adenosine).
N
N
O
OBz OBz
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Synthesis of 4 ’ -azidoadenosine (27)
N
N
HO O
OH OH
To a solution of 4-N,N-dibenzoyl, 2 ’,3’-0,O-dibenzoyl-4’-azido-5’-deoxy-5’-iodo- 
adenosine (185, 2.20 g, 2.64 mmol) in CH2C12 saturated with 1% of water (20 mL), 
85% MCPBA (meta-chloro-perbenzoic acid, 3.63 g, 15.84 mmol) was added and the 
reaction stirred at 40°C for 1 hour. EtOAc was added and then washed with a 
saturated solution of NasS20 3. The organic layer was dried using M gS04 then the 
solvent was removed under reduced pressure. The yellow solid was dissolved in 6 mL 
of a solution IN of MeONa in MeOH for 1 hour. The product (200 mg, 24%) was 
obtained after purification by column chromatography using as eluent a CHCl3/MeOH 
9:1 with 1% o fN H ^ H ^ ..
6 h (d4-CH3OH): 8.31 (1H, s, H2-adenosine), 8.19 (1H, s, H8-adenosine), 6.25 (1H, d, 
H l’-adenosine, J -  6.4 Hz), 5.00 (1H, t, H2’-adenosine), 4.53 (1H, d, H3’-adenosine),
3.77 (1H, d, H5’-adenosine, J= 12.2 Hz), 3.60 (1H, d, H5’-adenosine, J= 12.2 Hz).
MS (ES) m/e: 331.1 (MNa+, 100%); Accurate mass: C10H12N8O4Na required 
331.0879, found 331.0886.
Synthesis of 2 ’ ,3 '-tert-butyldimethylsily 1-5 ’ -deoxy-5 ’ -iodoadenosine (189)
Iodine (14.22 g, 56.1 mmol) and triphenylphosphine (14.22 g,
56.1 mmol) were added to a solution of adenosine (181, 10.0 g, 
37.4 mmol) in pyridine (45 mL). After 2 hours tert- 
butyldimethyl silyl chloride (24.54 g, 149.6 mmol) and 
imidazole (20.36 g, 299.2 mmol) were added at 0 °C. After 30 
minutes the reaction was slowly warmed at room temperature 
and stirred for 15 hours. The solvent was removed under 
reduced pressure and the crude product was purified by column 
chromatography using as eluent a mixture of EtOAc/Hexane in gradient: 1:9, 8:2, 7:3, 
65:35, 50:50 and 6:4. The pure product (10 g, 44%) was a white solid.
N
N
O
01
- S i
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6 „ (CDCI3): 8.38 (1H, s, H2-adenosine), 7.92 (1H, s, H 8 -adenosine), 5.87 (1H, d, 
H l’-adenosine, J= 5.2 Hz), 5.25 (2H, NH26 -adenosine), 5.23 (1H, t, H2’-adenosine),
4.42 (1H, m, H3’-adenosine), 4.16 (1H, m, H4’-adenosine), 3.73 (1H, m, H5’- 
adenosine), 3.41 (1H, m, H5’-adenosine), 1.00 (9H, s, CH3-terf-butyl), 0.81 (9H, s, 
CH3-terr-butyl), 0.21 (3H, s, CH3-silyl), 0.16 (3H, s, CH 3-silyl), -0.10 (3H, s, CH3- 
silyl), -0.27 (3H, s, CH3-silyl); 6 C (CDC13): 154.55 (1C, C4-adenosine), 151.91 (1C, 
CH2-adenosine), 148.68 (1C, C6 -adenosine), 140.07 (1C, C 8 -adenosine), 119.91 (1C, 
C5-adenosine), 89.16 (1C, C l ’-adeonsine), 83.67 (1C, C 4’-adesonie), 74.22 (1C, C2’- 
adenosine), 72.33 (1C, C3’-adenosine), 61.60 (1C, C 5’-adenosine), 25.11, 24.92, 
24.73, 24.61 (6 C, 6  CH3-terf-butyl), 17.09 (1C, C-tert-butyl), 16.92 (1C, C-tert-butyl), 
-5.63 (2C, 2 CH3-silyl), -6.10 (2C, 2 CH3-silyl).
NH
N
N
O
O Ox 
- S i -  SiIX
Synthesis of 2 ’ ,3 ’-terf- buty ldimethy lsily 1- l-(5-deoxy-/3-D-glycero-pent-4-
enofuranosyl)-adenine (190)10
tBuOK (0.627 g, 4.95 mmol) was added to a solution of 2 ’,3’- 
rm-butyldimethylsilyl-5’-deoxy-5’-iodoadenosine (189, 1.0 g, 
1.65 mmol) in pyridine (15 mL), and the reaction stirred for 3
hour at room temperature. The solvent was removed under
reduced pressure and the solid was purified by column 
chromatography using as eluent a mixture of EtOAc/Hexane in 
gradient: 7:3, 65:35, 50:50, then 8:2 and 7:3. The pure product 
was obtained as a white solid (700 mg, 89%)
S„ (CDC13): 8.22 (1H, s, H2-adenosine), 7.72 (1H, s, H 8 -adenosine), 5.96 (1H, d, 
H l’-adenosine, J= 6.2 Hz), 5.52 (2H, s, NH26 -adenosine), 4.92 (1H, m, H2’- 
adenosine), 4.44 (1H, d, H3’-adenosine, J= 4.2 Hz), 4.37 (1H, d, H5’-adenosine, /=
2.3 Hz), 4.13 (1H, d, H5’-adenosine, J= 2.3 Hz), 0.80 (9H, s, CH3-terr-butyI), 0.61
(9H, s, CH3-tert-butyl), 0.00 (3H, s, CH3-silyl), -0.22 (3H, s, CH3-silyl), -0.45 (3H, s, 
CH3-silyl), -0.27 (3H, s, CH3-silyl); 6 C (CDC13): 160.70 (1C, C4’-adenosine), 155.53 
(1C, C4-adenosine), 153.36 (1C, C2-adenosine), 150.08 (1C, C6 -adenosine), 140.05 
(1C, C8 -adenosine), 120.62 (1C, C5-adenosine), 89.27 (1C, C l ’-adeonsine), 86.79 
(2C, C5’-adesonie), 74.41 (1C, C2’-adenosine), 72.33 (1C, C3’-adenosine), 25.82, 
25.71, 25.61 (6 C, CH3-terf-butyl), 18.23 (1C, C-tert-butyl), 17.88 (1C, C-terf-butyl), - 
4.65 (2C, CH3-silyl), -5.37 (2C, CH3-silyl).
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Synthesis of A6-terf- butanoyl-2 ’ ,3 ’ -tert-buty ldimethy lsily 1- l-(5-deoxy-/?-D-glycero- 
pent-4-enofuranosyl)-adenine (193)10
q  To a solution of 2’,3’-terf-butyldimethylsilyl-l-(5-deoxy- 
y3-D-glycero-pent-4-enofuranosyl)-adenine (190, 3.6 g, 
7.53 mmol) in anhydrous DCM (145 mL), tBuOCl (tert- 
butanoyl chloride, 1.86 mL, 15.10 mmol) and 
diisopropylethylamine (2.63 mL, 15.10 mmol), were added 
and the reaction stirred for 3 hours at room temperature. 
The reaction was washed three times with a saturated 
solution of NaHC03. The organic layer was dried with 
M gS04 and the solvent was removed under reduced pressure. The cured was purified 
by column chromatography using as eluent a mixture of EtOAc and Hexane in 
gradient: 1:10, 1:5, 1:1. The pure compound was obtained as a white solid (4.0 g, 
95%).
5„ (CDC13): 8.62 (1H, s, H2-adenosine), 8.42 (1H, s, NH6-adenosine), 7.90 (1H, s, 
H8-adenosine), 6.02 (1H, d, H I’-adenosine, J= 6.2 Hz), 4.91 (1H, m, H2’-adenosine),
4.42 (1H, d, H3’-adenosine, 7= 4.2 Hz), 4.38 (1H, d, H5’-adenosine, J= 2.3 Hz), 4.15 
(1H, d, H5’-adenosine, J= 2.3 Hz), 1.26 (9H, s, CH3-terf-butanoyl), 0.80 (9H, s, CH3- 
tert-butyl), 0.60 (9H, s, CH3-terf-butyl), 0.00 (3H, s, CH3-silyl), -0.22 (3H, s, CH3- 
silyl), -0.47 (3H, s, CH3-silyl); 6 C (CDC13): 175.65 (1C, C=0-terf-butanoyl), 160.52 
(1C, C4’-adenosine), 152.94 (1C, C2-adenosine), 151.64 (1C, C4-adenosine), 149.81
(1C, C6-adenosine), 142.02 (1C, C8-adenosine), 123.53 (1C, C5-adenosine), 89.31
(1C, C l’-adeonsine), 87.10 (2C, C5’-adesonie), 74.52 (1C, C2’-adenosine), 72.27
(1C, C3’-adenosine), 40.54 (1C, C-terf-butanoyl), 27.17 (3C, CH3-ter/-butyl), 25.79
(3C, CH3-rm-butyl), 25.59 (3C, CH3-terf-butanoyl), 18.21 (1C, C-tert-butyl), 17.84 
(1C, C-tert-butyl), -4.63 (2C, CH3-silyl), -5.35 (2C, CH3-silyl).
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Synthesis of N6-^rt-butanoyl-2,,3,-te/t-butyldimethylsilyl-4’,5,epoxyadenosine
6N-ter/-butanoyl-2’,3’-terf-butyldimethylsilyl-l-(5-deoxy-
adenosine), 8.07 (1H, s, H8-adenosine), 6.11 (1H, d, H l’- 
adenosine, J= 5.2 Hz), 4.94 (1H, m, H2’-adenosine), 4.12 (1H, d, H3’-adenosine, J= 
3.8 Hz), 3.10 (1H, d, H5’-adenosine, J= 3.5 Hz), 2.94 (1H, d, H5’-adenosine, J= 3.5
0.33 (3H, s, CH3-silyl).
Synthesis of iV‘-tert-butanoyl-2,,3,-te/t-butyldimethylsilyl-4,-azidoadenosine (194)
To a solution of 6N-terf-butanoyl-2’,3’-te/t-
emulsion formed was filtrated on celite pad and the solution was washed three times 
with a saturated solution of NaHC03. The organic layer was dried with M gS04. The 
solvent was removed under reduced pressure and the crude product was purified by 
column chromatography using as eluent a mixture of EtOAc/Hexane in gradient: 
50:50 and 70:30. The pure product was obtained as a white solid (1.6 g, 52%).
5„ (CDC13): 8.58 (1H, s, H2-adenosine), 8.50 (1H, s, NH6-adenosine), 7.91 (1H, s, 
H8-adenosine), 6.26 (1H, m, OH5’-adenosine), 5.84 (1H, d, H I’-adenosine, J= 7.9
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5„ (CDC13): 8.70 (1H, s, H2-adenosine), 8.07 (1H, s, NH6-
^-D-glycero-pent-4-enofuranosyl)-adenine (193, 2.0 g, 
3.56 mmol) was added to 110 mL of a 0.1 solution of 
DMDO (dimethoxydioxirane) in acetone. The reaction was 
stirred for 15 minutes at room temperature, then the solvent 
was removed under reduced pressure to give a white 
product (2 g, 100%).
Hz), 1.31 (9H, s, CH3-terf-butanoyl), 0.85 (9H, s, CH3-rm-butyl), 0.71 (9H, s, CH- 
tert-butyl), 0.03 (3H, s, CH3-silyl), 0.00 (3H, s, CH3-silyl), -0.14 (3H, s, CH3-silyl),
O butyldimethylsilyl-4’,5’epoxyadenosine (3.09 g, 5.34 
mmol) in anhydrous DCM (200 mL), TBSN3 {tert-butyl 
azido silane, 2.10 mL, 16.02 mmol) and SnCl4 (tin 
chloride, 3.4 mL, 16.02 mmol) were added at -78 °C. 
The reaction was stirred for 30 minutes then, it was 
slowly wormed at room temperature and stirred for 
other 30 minutes. A saturated solution of NaHC03 was 
added until the reaction reached pH 7. The a white
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Hz), 5.08 (1H, m, H2’-adenosine), 4.22 (1H, d, H3’-adenosine, J= 4.4 Hz), 3.64 (1H,
m, H5’-adenosine), 3.31 (1H, m, H5’-adenosine), 1.24 (9H, s, CH3-tert-butanoyl),
Synthesis of A^-terf-butanoyl-4’-azidoadenosine (195)
To a solution of 6N-ter/-butanoyl-2’,3’-terf-
column chromatography using as eluent a mixture of CHCl3/MeOH 85:15. The pure 
product was obtained as a white solid (1.15 g, 76%).
adenosine, J= 4.7 Hz), 5.82 (1H, d, OH3’-adenosine, J= 5.96 Hz), 5.65 (1H, m, OH5’- 
adenosine), 4.94 (1H, m, H2’-adenosine), 4.48 (1H, m, H3’-adenosine), 3.67 (1H, m, 
H5’-adenosine), 3.51 (1H, m, H5’-adenosine), 1.33 (9H, s, CH3-te/t-butanoyl); 8C (d6- 
(CH3)2SO): 176.29 (1C, C=0-terf-butanoyl), 152.09 (1C, C2-adenosine), 151.68 (1C, 
C4-adenosine), 150.66 (1C, C6-adenosine), 142.96 (1C, C8-adenosine), 125.88 (1C, 
C5-adenosine), 99.90 (1C, C4’-adenosine), 87.77 (1C, C l’-adeonsine), 72.56 (1C, 
C2’-adenosine), 72.51 (1C, C3’-adenosine), 64.13 (1C, C5’-adenosine), 26.87 (3C, 
CH3-terr-butanoyl).
O
butyldimethylsilyl-4’-azidoadenosine (194, 2.8 g, 4.52 
mmol) in THF (30 mL), a 1M solution of TBAF (tetra- 
butyl ammonium fluoride, 9.0 mL, 9.0 mmol) was 
added and the reaction stirred at room temperature for 
one hour. The solvent was removed under reduced 
pressure to give a yellow oil that was purified by
OH OH
8„ (d6-(CH3)2SO): 10.23 (1H, s, NH6-adenosine), 8.77 (1H, s, H2-adenosine), 8.74 
(1H, s, H8-adenosine), 6.33 (1H, d, H l’-adenosine, J= 6.1 Hz), 5.97 (1H, d, OH2’-
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Synthesis of A*-te/t-butanoyl-2’,3’-(?,0-cyclopentylidene-4’-azidoadenosine (196)
A solution of 6N-ter/-butanoyl-4’-azidoadenosine (195, 
°  1.6 g, 4.08 mmol), and p -TSA (1.16 g, 6.12 mmol) in
HN *i 1,1-dimethoxycyclopentane (15 mL) was stirred at
\  | | room temperature for 4 hours. The solvent was
ni^ n removed and the cured was purified by column 
chromatography using as eluent a mixture of 
CHCl3/MeOH 9:1. The pure product was obtained as a 
yellow solid (1.1 g, 52%).
8„ (CDC13): 8.63 (1H, s, NH6-adenosine), 8.62 (1H, s, H2-adenosine), 8.14 (1H, s, 
H8-adenosine), 6.18 (1H, d, H I’-adenosine, 7= 4.5 Hz), 5.23 (1H, m, H2’-adenosine), 
5.02 (1H, d, H3’-adenosine, 7= 5.8 Hz), 3.75 (1H, d, H5’-adenosine, 7= 8.7 Hz), 3.57 
(1H, m, H5’-adenosine, 7= 8.7 Hz), 2.14-2.04 (2H, m, CH2-cyclopentyl), 1.86-1.61 
(6H, m, CH2-cyclopentyl), 1.32 (9H, s, CH3-terf-butyl); 6C (^ (C H ^ S O ): 175.78 (1C, 
C=0-terf-butanoyl), 152.60 (1C, C2-adenosine), 150.31 (1C, C4-adenosine), 150.25 
(1C, C6-adenosine), 148.04 (1C, C8-adenosine), 124.88 (1C, C5-adenosine), 123.92 
(1C, C-cyclopentyl), 103.75 (1C, C4’-adenosine), 92.84 (1C, C l ’-adeonsine), 84.09 
(1C, C2’-adenosine), 83.26 (1C, C3’-adenosine), 65.74 (1C, C5’-adenosine), 36.81 
(1C, CH2-cyclopentyl), 36.14 (1C, CH2-cyclopentyl), 29.61 (1C, C-terf-butanoyl),
26.14 (1C, CH2-cyclopentyl), 25.21 (1C, CH2-cycIopentyl).
Synthesis of 2’,3’-0,0-cyclopentylidene-4,-azidoadenosine (196)
rf-tert- butanoyl-2’ ,3 ’ ■-O, O-cyclopentylidene-4’ - 
azidoadenosine (195, 1.12 g, 2.44 mmol) was solubelized in 
v a solution of MeOH saturated with NH3. The solution was
N sealed at room temperature for 15 hours. The solvent was
HO \  „
removed under reduced pressure and the crude product was 
.0 purified by column chromatography using as eluent a
mixture of CHCl3/MeOH in gradient: 100:0, 98:2 and 
90:10. The pure product was obtained as a white solid (0.8 mg, 67%).
6h (CDC13): 8.44 (1H, s, H2-adenosine), 8.00 (1H, s, H8-adenosine), 6.23 (1H, d, 
H l’-adenosine, 7= 5.1 Hz), 6.20 (2H, s, NH2-adenosine), 5.46 (1H, m, H2’- 
adenosine), 5.21 (1H, d, H3’-adenosine, 7= 5.6 Hz), 3.99 (1H, d, H5’-adenosine, 7=
.a
n 3^
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12.3 Hz), 3.75 (1H, d, H5’-adenosine, J= 12.3 Hz), 2.39-2.22 (2H, m, CH2- 
cyclopentyl), 2.00-1.85 (6H, m, CH2-cyclopentyl); 6C {d6-{CH3)2SO): 156.19 (1C, C4- 
adenosine), 152.67 (1C, C2-adenosine), 148.14 (1C, C6-adenosine), 140.38 (1C, C8- 
adenosine), 124.76 (1C, C5-adenosine), 121.14 (1C, C-cyclopentyl), 100.29 (1C, C4’- 
adenosine), 93.37 (1C, C l’-adeonsine), 83.08 (1C, C2’-adenosine), 82.95 (1C, C3’- 
adenosine), 66.13 (1C, C5’-adenosine), 36.91 (1C, CH2-cyclopentyl), 36.51 (1C, CH2- 
cyclopentyl), 23.77 (1C, CH2-cyclopentyl), 23.25 (1C, CH2-cyclopentyl).
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7.9 Synthesis of 4’-azidoadenosine phosphoramidates.
Synthesis of 4’-azidoadenosine 5’-0-[a-naphthyl(benzyl-L-alaninyl)] phosphate
(202)
NH
N
N
O
OH OH
Prepared according to Standard Procedure C, from 4 ’-azidoadenosine (27, 165.6 mg, 
0.054 mmol), ‘BuMgCl (1.34 mL 1M solution of THF, 1.34 mmol) and a-naphthyl 
(benzyl-L-alaninyl) phosphorochloridate (93, 1.34 mL of solution 1M in THF, 1.34 
mmol). The crude product was purified by column chromatography, using as eluent 
CHCl3/MeOH (85:15), a preparative HPLC. The pure product was a white solid (20 
mg, 6%).
6 P (^-C H 3OH): 3.71, 3.67; SH M rCH3OH): 8.26 (1H, d, H2-adenosine), 8.17 (1H, s, 
H8-adenosine), 8.17 (1H, s, CH-naphthyl), 7.88 (1H, d, CH-naphthyl, J= 7.9 Hz), 
7.69 (1H, m, CH-naphthyl), 7.53-7.43 (4H, m, CH-naphthyl, CH-phenyl), 7.38-7.25 
(5H, CH-naphthyl, CH-phenyl), 6.28 (1H, d, H l’-adenosine, J= 5.1 Hz), 5.05 (2H, m, 
CH2-benzyl), 4.95 (1H, m, H2’-adenosine), 4.70 (1H, d, H3’-adenosine, J= 5.4 Hz), 
4.40 (2H, m, H5’-adenosine), 4.05 (1H, m, CHa), 1.28 (3H, m ,CH3-alanine).
MS (ES) m/e: 698.1 (MNa+, 100%); Accurate mass: Q oH^NqOvNu required 
698.1853, found 698.1852.
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Synthesis of 2’, 3’-O,0-cyclopentylidene-4’-azidoadenosine 5’-0-[a-
naphthyl(ethy 1-L-alaninyl) ] phosphate
Prepared according to Standard Procedure C2,
J from 2’, 3’-0,0-cyclopentylidene-4’-
NH2
. 1 azidoadenosine (196, 150 mg, 0.40 mmol),
J  A O / / S i  N 
// \ ^ 0  NH \  A  j  ‘BuMgCl (1.00 mL, 1M solution in THF, 1.00 
II j  Np' N
mmol) and a-naphthyl(ethyl-L-alaninyl)
/ w .0
phosphorochloridate (200, 1.00 mL of solution 
1M in THF, 1.00 mmol). The crude product was 
purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was a white solid (250 mg, 92%).
6 P (CDC13): 2.74; 6„ (CDC13): 8.19 (1H, s, H2-adenosine), 7.91 (1H, m, CH- 
naphthyl), 7.83 (1H, s, H8-adenosine), 7.80 (1H, d, CH-naphthyl, J= 4.85 Hz), 7.52 
(1H, d, CH-naphthyl, J= 8.2 Hz), 7.44-7.29 (3H, m, CH-naphthyl), 7.42-7.21 (1H, m, 
CH-naphthyl), 6.17 (1H, d, H I’-adenosine, J -  2.3 Hz), 6.03 (1H, s, NH26-adenosine), 
5.06 (1H, m, H2’-adenosine), 4.96 (1H, d, H3’-adenosine, J= 6.5 Hz), 4.35, 4.25 (2H, 
m, NH-alanine, H5’-adenosine), 4.22 (1H, m, H5’-adenosine), 4.00-3.91 (3H, m, 
CHa, CH2-ethyl), 2.18-2.03 (2H, m, CH2-cyclopentyl), 1.67-1.60 (6H, m, CH2- 
cyclopentyl), 1.23 (3H, d, CH3-alanine), 1.08 (3H, CH3-ethyl).
Synthesis of 4’-azidoadenosine 5 ’-0-[a-naphthyl(ethyl-L-alaninyl)] phosphate
(203)
Prepared according to Standard Procedure C3, from 2 ’, 3’-0,0-cyclopentylidene-4’- 
azidoadenosine 5 ’-0-[a-naphthyl(ethyl-L-alaninyl)] phosphate (250 mg, 0.369 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5). 
The pure product was a white solid (100 mg, 51%).
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dP (^-C H 3OH): 3.72, 3.68; 6„ (<2,-CH3OH): 8.27 (1H, s, H2-adenosine), 8.13 (1H, s, 
H8-adenosine), 8.07 (1H, m, CH-naphthyl), 7.83 (1H, m, CH-naphthyl), 7.66 (1H, m, 
CH-naphthyl), 7.52-7.43 (3H, m, CH-naphthyl), 7.38-7.32 (1H, m, CH-naphthyl), 
6.30 (1H, d, H l’-adenosine, J= 5.1 Hz), 4.97 (1H, m, H2’-adenosine), 4.75 (1H, d, 
H3’-adenosine, J= 5.5 Hz), 4.43 (1H, m, H5’-adenosine), 4.36 (1H, m, H5’- 
adenosine), 4.06-3.89 (2H, m, CH2-ethyl), 3.73 (1H, m, CHa), 1.27 (3H, m, CH3- 
alanine), 1.14 (3H, CH3-ethyl); 6 C (^-CH 3OH): 175.03, 175.00 (1C, C=0-ethyl), 
157.11 (1C, C4-adenosine), 153.74 (1C, C2-adenosine), 150.64 (1C, C6-adenosine), 
147.80, 147.74 (1C, C-naphthyl), 141.73 (1C, C8-adenosine), 136.26, 136.21 (1C, C- 
naphthyl), 128.90, 128.83 (1C, CH-naphthyl), 127.82, 127.78 (1C, CH-naphthyl), 
127.72, 127.67 (1C, C-naphthyl), 127.54, 127.47 (1C, CH-naphthyl), 126.44, 126.40 
(1C, CH-naphthyl), 126.09, 126.03 (1C, CH-naphthyl), 122.61, 122.53 (1C, CH- 
naphthyl), 120.69 (1C, C5-adenosine), 116.11, 116.09 (1C, CH-naphthyl), 99.18,
99.10 (1C, C4’-adenosine), 91.14 (1C, C l’-adeonsine), 74.05, 74.00 (1C, C2’- 
adenosine), 73.96, 73.89 (1C, C3’-adenosine), 68.99, 68.80, 68.76 (1C, C5’- 
adenosine), 62.46, 62.40 (1C, CH2-ethyl), 51.68 (1C, CHa), 20.56, 20.51, 20.37, 
20.31 (1C, CH3-alanine), 14.41 (1C, CH3-ethyl).
MS (ES) m/e: 636.1 (MNa+, 100%); Accurate mass: C^H^NjOgNaP required 
636.1696, found 636.1682.
Synthesis of 2’, 3’-0^-cyclopentylidene-4’-azidoadenosine 5’-0-[a-naphthyl(ferf- 
butyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure C2, 
from 2’, 3’-O,0-cyclopentylidene-4’- 
azidoadenosine (196, 150 mg, 0.40 mmol), 
‘BuMgCl (1.00 mL, 1M solution in THF, 1.00 
mmol) and a-naphthyl(rm-butyl-L-alaninyl) 
phosphorochloridate (201, 1.00 mL of solution 
1M in THF, 1.00 mmol). The crude product was 
purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was a white solid (220 mg, 77%).
6P (CDC13): 2.96; 6„ (CDCI3): 8.17 (1H, s, H2-adenosine), 8.05 (1H, m, CH- 
naphthyl), 7.82 (1H, s, H8-adenosine), 7.72-7.65 (2H, m, CH-naphthyl), 7.54-7.44
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(2H, CH-naphthyl), 7.42-7.21 (2H, m, CH-naphthyl), 6.47 (1H, s, NH26-adenosine),
6.14 (1H, d, H I’-adenosine), 4.97 (2H, m, H2’-adenosine, H3’-adenosine), 4.61 (1H, 
m, NH-alanine), 4.30 (1H, m, H5’-adenosine), 4.19 (1H, m, H5’-adenosine), 3.94 
(1H, m, CHa), 2.13-2.01 (2H, m, CH2-cyclopentyl), 1.65-1.56 (6H, m, CH2- 
cyclopentyl), 1.36 (9H, CH3-terf-butyl), 1.23 (3H, m, CH3-alanine).
Synthesis of 4’-azidoadenosine 5’-0-[a-naphthyl(terM)utyl-L-alaninyl)]
phosphate (204)
Prepared according to Standard Procedure C3, from 2’, 3’-0,O-cyclopentylidene-4’- 
azidoadenosine 5’-0-[a-naphthyl(terf-butyl-L-alaninyl)] phosphate (220 mg, 0.308 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5). 
The pure product was a white solid (100 mg, 51%).
SP (<i4-CH3OH): 3.85, 3.73; 6H M rCH3OH): 8.25 (1H, s, H2-adenosine), 8.21 (1H, s, 
H8-adenosine), 8.10 (1H, m, CH-naphthyl), 7.84 (1H, m, CH-naphthyl), 7.64 (1H, m, 
CH-naphthyl), 7.51-7.48 (2H, m, CH-naphthyl), 7.45-7.32 (2H, m, CH-naphthyl),
6.29 (1H, d, H l’-adenosine, J= 5.1 Hz), 4.96 (1H, m, H2’-adenosine), 4.72 (1H, d, 
H3’-adenosine, J= 5.54 Hz), 4.42 (1H, m, H5’-adenosine), 4.36 (1H, m, H5’- 
adenosine), 3.85 (1H, m, CHa), 1.35 (9H, s, CH3-terf-butyl), 1.25 (3H, d, CH3- 
alanine, J= 6.3 Hz); 8C (^-C H 3OH): 174.30, 174.26 (1C, C=0-terr-butyl), 157.22 
(1C, C4-adenosine), 153.92 (1C, C2-adenosine), 150.67 (1C, C6-adenosine), 147.82, 
147.76 (1C, C-naphthyl), 141.64 (1C, C8-adenosine), 136.23 (1C, C-naphthyl), 
128.90, 128.84 (1C, CH-naphthyl), 127.81, 127.77 (2C, CH-naphthyl), 127.72, 127.67 
(1C, C-naphthyl), 127.53, 127.46 (2C, CH-naphthyl), 126.08, 126.02 (1C, CH- 
naphthyl), 122.67, 122.58 (1C, CH-naphthyl), 120.70 (1C, C5-adenosine), 99.18,
99.10 (1C, C4’-adenosine), 91.09, 90.91 (1C, C l ’-adeonsine), 82.83, 82.71 (1C, C- 
tert-butyl), 74.04 (1C, C2’-adenosine), 73.97, 73.92 (1C, C3’-adenosine), 68.91,
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68.87 (1C, C5’-adenosine), 52.29 (1C, CHa), 28.25, 28.21, 28.18 (3C, CH3-tert- 
butyl), 20.78, 20.73, 20.55, 20.49 (1C, CH3-alanine).
MS (ES) m/e: 664.4 (MNa+, 100%); Accurate mass: C^H^NgOgNaP required 
664.2009, found 664.2015.
Synthesis of 2’, 3’-0,0-cyclopentylidene-4’-azidoadenosine 5’-0-[phenyl(benzyl- 
L-alaninyl)] phosphate
Prepared according to Standard Procedure C2, 
from 2’, 3’-0,0-cyclopentylidene-4’- 
azidoadenosine (196, 150 mg, 0.40 mmol), 
‘BuMgCl (1.00 mL, 1M solution in THF, 1.00 
mmol) and phenyl(benzyl-L-alaninyl)
phosphorochloridate (132, 1.00 mL of solution 1M 
in THF, 1.00 mmol). The crude product was 
purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was 
a white solid (200 mg, 72%).
SP (CDC13): 2.28; 6„ (CDC13): 8.22 (1H, s, H2-adenosine), 7.90 (1H, s, H8- 
adenosine), 7.27-7.19 (6H, m, 1 CH-phenyl, CH-benzyl), 7.13-7.10 (2H, m, CH- 
phenyl), 7.97-6.98 (2H, m, 2 CH-phenyl), 6.33 (1H, s, H I’-adenosine), 6.20 (1H, s, 
NH26-adenosine), 5.12-4.98 (4H, CH2-benzyl, H2’-adenosine, H3’-adenosine), 4.42 
(2H, m, NH-alanine), 4.23 (1H, m, H5’-adenosine), 4.13 (1H, m, H5’-adenosine),
3.98 (1H, m, CHa), 2.16-2.03 (2H, m, CH2-cyclopentyl), 1.68-1.62 (6H, m, CH2-
cyclopentyl), 1.25 (3H, d, CH3-alanine, J -  6.9 Hz).
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Synthesis of 4’-azidoadenosine 5’-0-[phenyl(benzyl-L-alaninyl)] phosphate (206)
Prepared according to Standard Procedure C3, from 2’, 3 ’-0,O-cyclopentylidene-4’- 
azidoadenosine 5’-0-[phenyl(benzyl-L-alaninyl)] phosphate (200 mg, 0.290 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent for the first CHCl3/MeOH (95:5). The pure 
product was a white solid (100 mg, 55%).
5P (^-CH 3OH): 3.38. 3.21; 6„ (^-CH 3OH): 8.30 (1H, s, H2-adenosine), 8.21 (1H, s, 
H8-adenosine), 7.44-7.33 (1H, m, CH-phenyl), 7.32-7.28 (7H, m, CH-phenyl, CH- 
benzyl), 7.25-7.15 (2H, m, CH-phenyl), 6.30 (1H, d, H l’-adenosine, J= 5.1 Hz), 5.12 
(2H, m, CH2-benzyl), 4.96 (1H, m, H2’-adenosine), 4.68 (1H, d, H3’-adenosine, J=
5.4 Hz), 4.32 (1H, m, H5’-adenosine), 4.23 (1H, m, H5’-adenosine), 3.92 (1H, m, 
CHa), 1.28 (3H, m, CH3-alanine); 6C (J4-CH3OH): 171.76 (1C, C=0-benzyl), 157.41 
(1C, C4-adenosine), 154.14 (1C, C2-adenosine), 151.89 (1C, C6-adenosine), 150.70 
(1C, C-phenyl), 141.47 (1C, C8-adenosine), 137.23 (1C, C-benzyl), 130.75 (2C, 2 
CH-phenyl), 129.73 (2C, CH-benzyl), 129.63, 129.56 (2C, CH-benzyl), 129.29 (1C, 
CH-benzyl), 126.25 (1C, CH-phenyl), 121.39, 121.35 (2C, CH-phenyl), 120.56 (1C, 
C5-adenosine), 99.16 (1C, C4’-adenosine), 90.89 (1C, C l’-adeonsine), 74.19 (1C, 
C2’-adenosine), 73.95 (1C, C3’-adenosine), 68.54, 68.50 (1C, C5’-adenosine), 67.98 
(1C, CH2-benzyl), 51.69 (1C, CHa), 20.23, 20.17 (1C, CH3-alanine).
MS (ES) m/e: 648.1 (MNa+, 100%); Accurate mass: C^H^NgOgNaP required 
648.1696, found 648.1696.
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Synthesis of 2’, 3’-CM?-cyclopentylidene-4’-azidoadenosine 5’-0-[phenyl(ethyl-L-
alaninyl)] phosphate
Prepared according to Standard Procedure C2,
r V '
uJ NH, from 2’, 3’-0,O-cyclopentylidene-4’-
N
Ox NH N
O' O
N
azidoadenosine (196, 150 mg, 0.40 mmol),
X JN
3 ° ^ °
5
‘BuMgCl (1.00 mL, 1M solution in THF, 1.00 
mmol) and phenyl(ethyl-L-alaninyl)
phosphorochloridate (129, 1.00 mL of solution 1M 
in THF, 1.00 mmol). The crude product was 
purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was a white solid (210 mg, 84%).
SP (CDC13): 2.34; 6h (CDC13): 8.31 (1H, s, H2-adenosine), 7.97 (1H, s, H8- 
adenosine), 7.23-7.22 (2H, m, CH-phenyl), 7.12-7.09 (3H, m, CH-phenyl), 6.31 (1H, 
d, H I’-adenosine, J= 2.2 Hz), 6.23 (1H, s, NH26-adenosine), 5.24 (1H, m, H2’- 
adenosine), 5.14 (1H, d, H3’-adenosine, J= 6.3 Hz), 4.35-4.30 (2H, m, NH-alanine, 
H5’-adenosine), 4.28-4.22 (1H, m, H5’-adenosine), 4.15-4.11 (2H, m, CH2-ethyl), 
3.99 (1H, m, CHa), 2.26-2.14 (2H, m, CH2-cyclopentyl), 1.76-1.69 (6H, m, CH2- 
cyclopentyl), 1.33 (3H, CH3-ethyl), 1.23 (3H, d, CH3-alanine).
Synthesis of 4’-azido-adenosine 5’-0>[phenyl(ethyl-L-alaninyl)] phosphate (207)
Prepared according to Standard Procedure C3, from 2’, 3’-0,O-cyclopentylidyn-4’- 
azido-adenosine 5’-0-[phenyl(ethyl-L-alaninyI)] phosphate (210 mg, 0.335 mmol), 
and 10 mL of a solution 80% of HCOOH in water. The crude product was purified by 
column chromatography, using as eluent for the first CHCl3/MeOH (95:5). The pure 
product was a white solid (100 mg, 48%).
8 P (^-C H 3OH): 3.44. 3.28; 8H (^-CH3OH): 8.27 (1H, s, H2-adenosine), 8.18 (1H, s, 
H8-adenosine), 7.36-7.28 (2H, m, CH-phenyl), 7.16-7.11 (3H, m, CH-phenyl), 6.38
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(1H, d, H l’-adenosine, J= 5.0 Hz), 4.96 (1H, m, H2’-adenosine), 4.75 (1H, d, H3’- 
adenosine, 7= 5.3 Hz), 4.35 (1H, m, H5’-adenosine), 4.25 (1H, m, H5’-adenosine), 
4.15 (2H, m, CH2-ethyl), 3.76 (1H, m, CHa), 1.27 (3H, d, CH3-ethyl, J= 7.2 Hz), 1.22 
(3H, m, CH3-alanine); 6C (^-CH 3QH): 172.78 (1C, C=0-ethyl), 157.38 (1C, C4- 
adenosine), 154.10 (1C, C2-adenosine), 151.99 (1C, C6-adenosine), 150.78 (1C, C- 
phenyl), 141.50 (1C, C8-adenosine), 130.76 (2C, CH-phenyl), 126.26 (1C, CH- 
phenyl), 121.36, 121.32 (2C, CH-phenyl), 120.62 (1C, C5-adenosine), 99.19, 99.11 
(1C, C4’-adenosine), 90.89 (1C, C l’-adeonsine), 74.20 (1C, C2’-adenosine), 73.96 
(1C, C3’-adenosine), 68.53, 68.49 (1C, C5’-adenosine), 62.42 (1C, CH2-ethyl), 51.61 
(1C, CHa), 20.30, 20.24 (1C, CH3-alanine), 14.47 (1C, CH3-alanine).
MS (ES) m/e: 586.4 (MNa+, 100%); Accurate mass: C2,H26N90 8NaP required 
586.1540, found 586.1544.
Synthesis of 2’, 3’-0,0>cyclopentylidyn-4’-azidoadenosine 5’-0-[phenyl(terf- 
butyl-L-alaninyl)] phosphate (208)
Prepared according to Standard Procedure C2, from 
2’, 3’-0,0-cyclopentylidene-4’-azidoadenosine 
(196, 150 mg, 0.40 mmol), ‘BuMgCl (1.00 mL, 1M 
solution in THF, 1.00 mmol) and phenyl(terf-butyl- 
L-alaninyl) phosphorochloridate (131, 1.00 mL of 
solution 1M in THF, 1.00 mmol). The crude 
product was purified by column chromatography, 
using as eluent CHCl3/MeOH (95:5). The pure 
product was a white solid (210 mg, 71%).
8 P (CDC13): 2.43; 8„ (CDC13): 8.28 (1H, s, H2-adenosine), 7.97 (1H, s, H8- 
adenosine), 7.27-7.00 (5H, m, CH-phenyl), 6.55 (1H, s, NH26-adenosine), 5.77 (1H, 
m, H I’-adenosine), 5.17 (1H, m, H2’-adenosine), 5.16 (1H, d, H3’-adenosine, J= 2.1 
Hz), 3.98 (1H, m, NH-alanine), 4.29 (1H, m, H5’-adenosine), 4.20 (1H, m, H5’- 
adenosine), 3.88 (1H, m, CHa), 2.21-2.09 (2H, m, CH2-cyclopentyl), 1.76-1.63 (6H, 
m, CH2-cyclopentyl), 1.37 (9H, CH3-terf-buthyl), 1.26 (3H, d, CH3-alanine, J= 7.0 
Hz).
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Synthesis of 4’-azidoadenosine 5’-0-[phenyl(ter*-butyl-L-alaninyl)] phosphate
(208)
Prepared according to Standard Procedure C3, from 2’, 3’-0,0-cyclopentylidene-4’- 
azidoadenosine 5’-C>-[phenyl(terr-butyl-L-alaninyl)] phosphate (210 mg, 0.356 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5). 
The pure product was a white solid (100 mg, 47%).
6 P (^-CH 3OH): 3.42; 8 H (^-C H 3OH): 8.29 (1H, s, H2-adenosine), 8.21 (1H, s, H8- 
adenosine), 7.32-7.29 (2H, m, CH-phenyl), 7.19-7.14 (3H, m, CH-phenyl), 6.33 (1H, 
d, H I’-adenosine, J= 5.1 Hz), 4.97 (1H, m, H2’-adenosine), 4.72 (1H, d, H3’- 
adenosine, J= 5.45 Hz), 4.36 (1H, m, H5’-adenosine), 4.27 (1H, m, H5’-adenosine), 
3.77 (1H, m, CHa), 1.42 (9H, s, CH3-te/*-butyl), 1.25 (3H, d, CH3-alanine); 6C (d4- 
CH3OH): 174.29, 174.25 (1C, C=0-terr-butyl), 157.39 (1C, C4-adenosine), 154.13 
(1C, C2-adenosine), 152.00, 151.95 (1C, C6-adenosine), 150.77 (1C, C-phenyl), 
141.62, 141.49 (1C, C8-adenosine), 130.81, 130.78 (2C, CH-phenyl), 126.24 (1C, 
CH-phenyl), 121.38, 121.34 (2C, CH-phenyl), 120.64 (1C, C5-adenosine), 99.21, 
99.13 (1C, C4’-adenosine), 90.99, 90.91 (1C, C l’-adeonsine), 82.75 (1C, C-tert- 
butyl), 74.24 (1C, C2’-adenosine), 74.06, 74.01 (1C, C3’-adenosine), 68.84, 68.65, 
68.61 (1C, C5’-adenosine), 52.24, 52.12 (1C, CHa), 28.27, 28.15 (3C, CH3-tert- 
butyl), 20.77, 20.72, 20.53, 20.47 (1C, CH3-alanine).
MS (ES) m/e: 614.4 (MNa+, 100%); Accurate mass: C23H30N9O8NaP required 
614.1853, found 614.1839.
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7.10 Synthesis of 2’-methylnucleosides.
Synthesis of l-hydroxy-l,2-benzoiodoxol-3 (lH)-one 1-oxide11
Potassium bromate (19g, 113.8 mmol) was added over 30 minutes to a
68° C for 3.6 hours, then cooled in an ice-bath for 5 minutes and filtered. The 
resulting solid was washed with water (250 mL), ethanol (2 x 20 mL) and diethyl 
ether (3 x 20 mL). The desire product (17.7 g, 74%) was used without further 
purification in the next step.
Synthesis of 1,1,1-triacetoxy-l, 1-dihydro- l,2-benziodoxol-3(lH)-one12
To a solution of crude 1-Hydroxy-l,2-benzoiodoxol-3 (lH)-one 1-
o
oxide (17.7 g, 63 mmol) in acetic anhydride (88 mL, 897.4 mmol),
in an ice-water bath, filtered and washed with anhydrous diethyl ether (5 x 25 mL). 
The product was isolated as a white fine powder (12.0 g, 45%).
phenyl), 2.02 (9H, s, CH3-acethyl).
Synthesis of a-D-l,3,5-tri-benzoyl-2-ketoribofuranose (210)13
To a solution of 1,1,1-triacetoxy-1,1-dihydro-1,2-benziodoxol-
mmol) at 0 °C. The mixture was allowed to room temperature and stirred for 12 hours. 
The solvent was removed under reduced pressure and the residue triturated with 
diethyl ether (100 mL). The solid was filtrated trough MgS04 pad. The solvent was 
stirred with an equal volume of a solution of Na2S20 3 (12.5 g) in 100 mL of a 
saturated solution of NaHC03.The organic layer was separated, washed with brine and
suspension of 2-iodobenzoic acid (21.16 g, 85.32 mmol) in 0.73 M 
aqueous sulphuric acid (182 mL) at 55 °C stirred with an overhead 
stirrer. Once the addition was complete the reaction was then stirred at
was added /?-TSA (0.11 g, 0.58 mmol) and the flask equipped with a 
drying tube. The reaction was stirred at 80 °C for 3 hours then cooled
6„ (CDC13): 8.32 (2H, m, CH-phenyl), 8.09 (1H, m, CH-phenyl), 7.28 (1H, m, CH-
3(lH)-one (7.13 g, 16.8 mmol) in anhydrous DCM (50 mL), 
was added 1,3,5-tri-benzoyl-a-D-ribofuranose (5.0 g, 11.2
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dried over MgS04. The solvent was removed under vacuum. The product was isolated 
as a white foam (4.9 g, 95%).
6 h (CDCI3): 8.37-7.92 (6H, m, CH-benzoyl), 7.56-7.45 (3H, m, CH-benzoyl), 7.41-
7.29 (6H, m, CH-benzoyl), 6.13 (1H, s, Hl-ribofuranose), 5.80 (1H, d, H3- 
ribofuranose, J -  8.8 Hz), 4.97 (1H, m, H4-ribofuranose), 4.75 (1H, m, H5- 
ribofuranose), 4.57 (1H, m, H5-ribofuranose); 6C (CDC13): 201.31 (1C, C=0 
ketoribofuranose), 166.00 (1C, C=0 benzoyl), 165.45 (1C, C=0 benzoyl), 165.27 
(1C, C =0 benzoyl), 134.09 (1C, CH-benzoyl), 133.94 (1C, CH-benzoyl), 133.34 (1C, 
CH-benzoyl), 130.55 (3C, C-benzoyl), 130.34 (3C, CH-benzoyl), 129.84 (3C, CH- 
benzoyl), 128.67 (2C, C-benzoyl), 128.54 (1C, C-benzoyl), 128.30 (3C, CH-benzoyl), 
91.44 (1C, Cl-ribofuranose), 78.13 (1C, C3-ribofuranose), 72.09 (1C, C4- 
ribofuranose), 63.23 (1C, C5-ribofuranose).
Synthesis of ^2 -m ethy l-1,3,5-tri-benzoyl-a-D-ribofuranose and /?-2-methyl- 
2,3,5-tri-benzoyl-D-ribofuranose (211/212)14
TiCl4 (5.2 mL, 47.57 mmol) was added
BzO —I n
OH |> \  dropwise to anhydrous diethyl ester
OBz OBz OBz OH (140 mL) at -78 °C, followed by the
addition of a solution 3.0 M of methyl magnesium bromide in diethyl ether (15.86 
mL, 47.57 mmol). The reaction was allowed to -10° C and a solution of a-D-l,3,5-tri- 
benzoyl-2-ketoribofuranose (210, 5.28 g, 11.89 mmol) in diethyl ether (13 mL). After 
three hours the reaction was quenched with 60 mL of water. The water layer was 
separated and extracted with diethyl ether (3 x 50 mL). The combined organic layer 
was dried trough MgS04 and purified by column chromatography in gradient starting 
with a mixture of hexane/ethyl acetate 5:2 then 5:2.5 and 5:3.
The product was obtained as mixture of two compounds as a white solid (4.0 g, 70%).
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Synthesis of /3-2-methyl-1,2,3,5-tetra-benzoyl-a-D-ribofuranose (213)14
To a solution of dimethylaminopyridine (1.02 g, 8.40 mmol)
followed by the addition of a solution of /8-2-methyl-1,3,5-tri-benzoyl-a-D- 
ribofuranose and /3-2-methyl-2,3,5-tri-benzoyl-a-D-ribofuranose (211/212, 4.0 g, 8.40 
mmol) in anhydours DCM (22 mL). After 4 hours at room temperature the reaction 
was poured into 250 mL of diethyl ether and washed with a solution 1 N of HC1 (3 x 
75 mL) followed by a saturated solution of NaHC03. The organic layer was dried 
trough M gS04, the solvent was removed under reduced pressure and the syrup 
obtained was purified by column chromatography using as eluent a mixture of 
hexane/ethyl acetate 4:1. The product was obtained as a white solid (2.0 g, 41%).
6„ (CDC13): 8.12-8.02 (8H, m, CH-benzoyl), 7.61-7.58 (4H, m, CH-benzoyl), 7.49- 
7.39 (8H, m, CH-benzoyl), 5.97 (1H, d, Hl-ribofuranose), 4.68-4.55 (2H, m, H3- 
ribofuranose, H4-ribofuranose), 4.62 (1H, m, H5-ribofuranose), 4.10 (1H, m, H5- 
ribofuranose), 1.96 (3H, s, CH3-2-methyl-ribofuranose); 8C (CDC13): 166.03 (1C, 
C=0 benzoyl), 165.41(1C, C =0 benzoyl), 164.77 (1C, C=0 benzoyl), 164.51 (1C, 
C=0 benzoyl), 134.50 (2C, CH-benzoyl), 133.67 (2C, CH-benzoyl), 133.62 (2C, CH- 
benzoyl), 133.25 (2C, CH-benzoyl), 130.53 (1C, C-benzoyl), 130.07 (4C, CH- 
benzoyl), 129.89 (4C, CH-benzoyl), 129.75 (1C, C-benzoyl), 129.70 (1C, C-benzoyl), 
129.43 (1C, C-benzoyl), 128.54 (4C, CH-benzoyl), 93.85 (1C, Cl-ribofuranose), 
86.69 (1C, C2-ribofuranose), 77.39 (1C, C3-ribofuranose), 75.14 (1C, C4- 
ribofuranose), 63.83 (1C, C5-ribofuranose), 18.40 (1C, CH3-2-methy-lribofuranose).
Synthesis of /V*-te/t-butanoyI adenine (217)
To a solution of adenine (216, 2.0 g, 14.80 mmol) in anhydrous
O
II DCM (200 mL), was added tert-butanoyl chloride (3.6 mL, 29.9 
HN mmol), followed by the addition of diisopropyl-ethylamine (5.1 mL,
The solvent was removed under reduced pressure and the obtained solid was purified 
with column chromatography using as eluent a mixture of CHCl3/MeOH 8.2. The pure 
produce was obtained as a white solid (2.6 g, 80%).
and triethylamine (13 mL, 177 mmol) in anhydrous DCM (90 
mL), was added benzoyl chloride (1.90 mL, 16.80 mmol)OBz OBz
29.6 mmol). After 4 hours the reaction was washed with a saturated 
solution of NaHCQ3. The organic layer was dries trough MgSQ4.
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8„ (76-DMSO): 12.20 (1H, NH7-adenine), 10.54 (1H, NH6-adenine), 8.66 (1H, s, H8- 
adenine), 8.44 (1H, s, H2-adenine), 1.32 (9H, s, CH3-terf-butanoyl).
Synthesis of N*-tert-butanoyl -P-2’-methyl-2’,3’,5’-tribenzoyl-adenosine (214)
To a solution of N6-fert-butanoyl adenine (217, 700 g,
O
II 1.206 mmol), /8-2-methyl-1,2,3,5-tetra-benzoyl-a-D-
I I ribofuranose (213, 291 mg, 1.327 mmol) and 7,11-
\  II I diazabicyclo[5.4.0]undec-ll-ene (0.55 mL, 3.618
_ _ mmol) in acetonitrile (14 mL) at 0 °C, trimethyl-silyl-
BZO— ' .0.
triflate (0.88 mL, 4.824 mmol) was added dropwise 
OBz OBz then heated at 85 °C. After 5 hours the reaction the 
reaction was cooled at room temperature and a saturated solution of NaHC03 was 
added. The resulting solution was washed with CHC13 (3 x 50 mL). The organic layer 
was dried trough MgS04. The solvent was removed and the resulting solid was 
purified by column chromatography in gradient starting from a mixture of ethyl 
acetate/hexane 7:3 then only ethyl acetate. The product was obtained as a white solid 
(400 mg, 49%).
8h (CDC13): 8.99 (1H, s, H8-adenosine), 8.78 (1H, s, H2-adenosine), 8.05 (2H, d, CH- 
benzoyl, J= 7.9 Hz), 7.98 (2H, d, CH-benzoyl, 7= 7.9 Hz), 7.91 (2H, d, CH-benzoyl, 
J= 7.8 Hz), 7.51-7.44 (2H, m, CH-benzoyl), 7.38-7.24 (7H, m, CH-benzoyl), 6.77 
(1H, s, H I’-adenosine), 6.16 (1H, d, H3’-adenosine, J= 5.8 Hz), 4.88-4.84 (2H, m, 
H5’-adenosine), 4.68 (1H, m, H4’-adenosine), 1.53 (3H, s, CH3-2’-adenosine), 1.33 
(9H, s, CH3-rm-butanoyl); 5 C (CDC13): 176.26 (1C, C=0-terf-butanoyl), 166.32 (1C, 
C=0 benzoyl), 165.27(1C, C =0 benzoyl), 165.15 (1C, C=0 benzoyl), 152.93 (1C, 
C2-adenosine), 151.42 (1C, C6-adenosine), 150.04 (1C, C4-adenosine), 141.88 (1C, 
C8-adenosine), 133.83 (2C, CH-benzoyl), 133.52 (2C, CH-benzoyl), 133.35 (2C, CH- 
benzoyl), 130.22 (3C, CH-benzoyl), 129.89 (3C, CH-benzoyl), 129.43 (1C, C- 
benzoyl), 129.39 (1C, C-benzoyl), 128.62 (1C, C-benzoyl), 128.33 (3C, CH-benzoyl),
123.14 (1C, C5-adenosine), 88.85 (1C, C l’-adenosine), 84.85 (1C, C2’-adenosine), 
80.12 (1C, C3’-adenosine), 75.80 (1C, C4’-adenosine), 63.50 (1C, C5’-adenosine),
18.10 (1C, CH3-2-ribofuranose).
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Synthesis of /8-2’-methyl-adenosine (215)15
NH
N
<N
HO
OH OH
N6-rm-butanoyl-j8-2’-methyl-2’,3’,5’-tribenzoyladenosine (214, 400 mg, 0.590 
mmol) was added to a solution of MeOH saturated with ammonia, and stirred at room 
temperature. After 12 hours the solvent was removed and the obtained solid was 
purified by column chromatography in gradient starting with a mixture of 
CHCl3/MeOH 9:1 then 8:2. The pure product was obtained as a white solid (120 mg, 
72%).
8H (d6-DMSO): 8.47 (1H, s, H8-adenosine), 8.15 (1H, s, H2-adenosine), 7.30 (1H, s, 
NH26-adenosine), 5.95 (1H, s, H l’-adenosine), 5.25-5.21 (3H, m, OH5’-adenosine, 
OH3’-adenosine, OH2’-adenosine), 4.12-4.05 (1H, d, H3’-adenosine, 7= 8.6 Hz), 3.91 
(1H, m, H4’-adenosine), 3.84 (1H, m, H5’-adenosine), 3.70 (1H, m, H5’-adenosine), 
0.77 (3H, s, CH32’-adenosine); 5 C (d6-DMSO): 156.02 (1C, C6-adenosine), 152.53
(1C, C2-adenosine), 149.01 (1C, C4-adenosine), 138.68 (1C, C8-adenosine), 118.67
(1C, C5-adenosine), 90.78 (1C, C l ’-adenosine), 82.52 (1C, C4’-adenosine), 78.46
(1C, C2’-adenosine), 71.63 (1C, C3’-adenosine), 59.47 (1C, C5’-adenosine), 19.83
(1C, CH3-2’-adenosine).
Anal. Calc, for CnH15N50 4: C 46.97%, H 5.38%, N 24.90%. Found: C 46.67%, H 
5.22%, N 24.20%.
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HO-i ,Q,
Synthesis of A^-te/t-butanoyl-/?-2’-methyl-adenosine (218)
To a solution of N6-terr-butanoyl-/J-2’-methyl-2’,3’,5’-
O
U tribenzoyl-adenosine (214, 740 mg, 1.093 mmol) in
HNM ' pyridine (6 mL) and EtOH (3 mL), a solution of NaOH 1
/ /  Ti N\  H A M was added dropwise. After 30 minutes at room
N N
temperature DOWEX resin was added to reach neutral
pH. The resin was filtered and washed with a solution of 
OH OH pyridine/HzO 4:1. The solvent was removed and the 
obtained brown oil was dissolved in diethyl ether and washed with H20 . The water 
layer was dryness in vacuo to yield a yellow foam of the desire compound (320 mg, 
80%).
5 H(d6-DMSO): 12.23 (1H, s, NH6-adenosine), 8.82 (1H, s, H8-adenosine), 8.71 (1H, 
s, H2-adenosine), 6.09 (1H, s, H l’-adenosine), 5.32-5.22 (3H, m, OH5’-adenosine, 
OH3’-adenosine, OH2’-adenosine), 3.92-3.71 (4H, d, H3’-adenosine, H4’-adenosine, 
2 H5’-adenosine), 1.28 (9H, s, 3 CH3-terf-butanoyll), 0.80 (3H, s, CH3-2’-adenosine).
Synthesis of 2’,3,-0/?-cyclopentyl- A<-terf-butanoyl-/J-2,-methyl-adenosine (219)
To a solution of N6-terf-butanoyl-/8-2’-methyl-adenosine 
j? (218, 320 mg, 0.87 mmol) in 1,1-dimethoxypentane (5
mL), was added /?-TSA (250 mg, 1,314 mmol) at 40° C. 
\  11 I After three hours the reaction was cooled down at room
temperature and a saturated solution of NaHC03 was 
added. The solvent was removed and the brown solid 
was purified by column chromatography in gradient
HO-^ ,Q.
starting from a mixture of CHCl3/MeOH 9:1 then 85:15 
and at the end 8:2. The product was isolated as a white solid (200 mg, 53%).
SH (CDC13): 11.71 (1H, s, NH6-adenosine), 8.31 (1H, s, H8-adenosine), 7.92 (1H, s, 
H2-adenosine), 6.17 (1H, s, H I’-adenosine), 4.75 (1H, s, H3’-adenosine), 4.42 (1H, s, 
H4’-adenosine), 4.07 (1H, d, H5’-adenosine, J= 12.75), 3.84 (1H, d, H5’-adenosine, 
J= 12.75 Hz), 2.05-2.00 (2H, m, CH2-cyclopentyl), 1.74-1.63 (6H, 3 CH2- 
cyclopentyl), 1.40 (9H, s, 3 CH3-terf-butanoyl), 1.24 (3H, s, CH3-2’-adenosine); 6C 
(CDC13): 162.39 (1C, C=0 terf-butanoyl), 156.12 (1C, C6-adenosine), 152.56 (1C, 
C2-adenosine), 148.83 (1C, C4-adenosine), 140.01 (1C, C8-adenosine), 123.12 (1C,
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C5-adenosine), 120.72 (1C, C-cyclopentyl), 97.57 (1C, C l ’-adenosine), 90.54 (1C, 
C2’-adenosine), 86.18 (1C, C3’-adenosine), 85.60 (1C, C4’-adenosine), 62.57 (1C, 
C5’-adenosine), 40.02 (1C, C-terf-butanoyl), 37.46 (2C, CH2-cyclopentyl), 27.37 (3C, 
3 CH3-terf-butanoyl), 23.65 (1C, CH2-cyclopentyl), 23.05 (1C, CH2-cyclopentyl), 
19.08 (1C, CH3-2’-adenosine).
S y n t h e s i s  o f  2 , , 3 , - 0 , 0 - c y c l o p e n t y l - / 3 - 2 , - m e t h y l - a d e n o s i n e  ( 2 2 0 )
2’,3’-0,0-cyclopentyl-N6-terf-butanoyl-/J-2’-methyl-
NH2
adenosine (219, 200 mg, 0.464 mmol) was added to a
-JL ^  solution of MeOH saturated with ammonia, and stirred at 
N N
HO—i c\ room temperature. After 12 hours the solvent was removed
and the obtained solid was purified by column
chromatography in gradient starting with a mixture of
CHCl3/MeOH 98:2 then 9:1. The pure product was obtained 
as a white solid (120 mg, 75%).
6 h (CDC13): 8.26 (1H, s, H8-adenosine), 7.92 (1H, s, H2-adenosine), 6.58 (2H, s, 
NH26-adenosine), 6.15 (1H, s, H I’-adenosine), 4.70 (1H, s, H3’-adenosine), 4.36 (1H, 
s, H4’-adenosine), 4.02 (1H, d, H5’-adenosine, J= 12.75), 3.81 (1H, d, H5’-adenosine, 
J= 12.75 Hz), 2.01-1.99 (2H, m, CH2-cyclopentyl), 1.80-1.66 (6H, 3 CH2-
cyclopentyl), 1.07 (3H, s, CH3-2’-adenosine); 6c(CDC13): 156.25 (1C, C6-adenosine), 
152.66 (1C, C2-adenosine), 148.82 (1C, C4-adenosine), 139.83 (1C, C8-adenosine), 
123.06 (1C, C5-adenosine), 120.59 (1C, C-cyclopentyl), 96.95 (1C, C l’-adenosine), 
90.50 (1C, C2’-adenosine), 85.44 (1C, C3’-adenosine), 84.44 (1C, C4’-adenosine), 
62.41 (1C, C5’-adenosine), 37.48 (2C, CH2-cyclopentyl), 23.60 (1C, CH2-
cyclopentyl), 23.04 (1C, CH2-cyclopentyl), 19.03 (1C, CH3-2’-adenosine).
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Synthesis of 2,,3,,5’-tribenzoyl-/8-2’-methyl- A^-acetyl-guanosine (229)16
To a solution of N2-acetylguanine (228, 2.0 g, 10.34
II mmol), in pyridine (10 mL), was added 1,1,1,3,3,3-
NH O
hexamethyldisilazane (35 mL) and the reaction 
N H stirred for 45 minutes at 130° C. The solvent was
y  removed with high vacuum under argon. The solid
obtained was dissolved in para-xylene (100 mL), 
and ^-2-methyl-1,2,3,5-tetra-benzoyl-a-D-ribofuranose (213, 2.0 g, 3.45 mmol) was 
added, followed by addition of TMS-triflate (1.87 mL, 10.34 mmol). The reaction was 
refluxed at 140° C for 5 hours. The reaction was washed with a saturated solution of 
NaHC03. The aqueous layer was extracted with CHC13 (3 x 100 mL). The combined 
organic layer was dried trough MgS04, the solvent was removed under reduced 
pressure and the resulting solid was purified by column chromatography using as 
eluent a mixture of CHCl3/MeOH 98:2. The desire product was yielded as a white 
solid (1.4 g, 63%).
8„ (d6-DMSO): 12.37 (1H, s, NHl-guanosine), 11.96 (1H, s, NH2-guanosine), 8.50 
(1H, s, H8-guanosine), 8.26-8.22 (4H, m, 4 CH-benzyol), 8.06 (2H, d, 2 CH-benzyol, 
J= 7.6 Hz), 7.98-7.82 (3H, m, 3 CH-benzyol), 7.73 (4H, m, CH-benzoyl), 7.60 (2H, 
m, 2 CH-benzoyl), 6.79 (1H, s, H l’-guanosine), 6.08 (1H, s, H3’-guanosine), 5.08-
5.03 (3H, m, H4’-guanosine, H5’guanosine), 2.50 (3H, s, CH3-acetyl), 1.83 (3H, 
CH32 ’ -guanosine).
Synthesis of /?-2’-methylguanosine (226)16
O
N NH
<"
N
HO
OH OH
N2-acetyl-/J-2’-methyl-2’,3’,5’-tribenzoyI-guanosine (229, 1.42 g, 2.18 mmol) was 
added to a solution of MeOH saturated with ammonia, and stirred at room 
temperature. After 12 hours the solvent was removed and the obtained solid was 
purified by column chromatography using as eluent a mixture of CHCl3/MeOH 8:2. 
The pure product was obtained as a white solid (570 mg, 87%).
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8h (dfg-DMSO): 10.52 (1H, s, NHl-guanosine), 8.48 (1H, s, H8-guanosine), 6.52 (2H, 
s, NH22-guanosine), 5.73 (1H, s, H l’-guanosine), 5.24 (1H, d, OH3’-guanosine, J=
6.3 Hz), 5.11 (1H, m, OH5’-guanosine), 5.03 (1H, s, OH2’-guanosine), 3.97 (1H, m, 
H3’-guanosine), 3.85-3.79 (2H, m, H4’, H5’-guanosine), 3.66 (1H, d, H5’-guanosine, 
J= 12.2 Hz), 0.81 (3H, s, CH3-2’-guanosine); 8C (^-DMSO): 156.72 (1C, C6- 
guanosine), 153.68 (1C, C2-guanosine), 150.77 (1C, C4-guanosine), 135.07 (1C, C8- 
guanosine), 116.38 (1C, C5-guanosine), 90.10 (1C, C l ’-guanosine), 82.30 (1C, C3’- 
guanosine), 78.52 (1C, C2’-guanosine), 71.63 (1C, C4’-guanosine), 59.40 (1C, C5’- 
guanosine), 19.96 (1C, CH3-2’-guanosine).
MS (ES) m/e: 320.2 (MNa+, 100%); Accurate mass: CnH^NsOsNa required 
320.0968, found 320.0971.
a x
nh2
°x°
Synthesis 2 ’ ,3 ’ -<9,CMsopropy 1-fi-2’-methyl-guanosine (230)
^  To a solution of /J-2’-methyl-adenosine (226. 565 mg,
1,90 mmol) in anhydrous acetone (35 mL), perchloric 
acid (0.30 mL) was added dropwise at room 
HO—i n  temperature. After 2 hours a saturated solution of
NH40H  was added to reach neutral pH. The solvent was 
removed and the resulting solid was purified by column 
chromatography using as eluent a solution of CHCl3/MeOH 92:8.
The desire product was obtained as a white solid (210 mg, 33%).
8 h (4;-DMSO): 10.63 (1H, s, NHl-guanosine), 7,92 (1H, s, H8-guanosine), 6.45 (2H, 
s, NH22-guanosine), 6.02 (1H, s, H l’-guanosine), 5.21 (1H, t, OH5’-guanosine, J -  5.0 
Hz), 4.59 (1H, s, H3’-guanosine), 4.17 (1H, s, H4’-guanosine), 3.71 (1H, d, H5’- 
guanosine, J= 7.7 Hz), 3.66 (1H, d, H5’-guanosine, J= 7.7 Hz), 1.54 (3H, s, CH3- 
isopropylidine), 1.38 (3H, s, CH3-isopropylidine), 1.16 (3H, s, CH3-2’-guanosine).
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7.11 Synthesis of 2’-methyladenosine phosphoramidates.
Synthesis of 2 \  3,-0,(?-cycIopentylidene-/J-2,-methyladenosine 5’-0- 
[phenyl(benzyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure C2,
9 from 2’, 3’-0,0-cyclopentylidene-/3-2’-methyladenosine (230, 40 mg, 0.115 mmol),U NH2^  ‘BuMgCl (0.35 mL, 1M solution in THF, 0.345
NH ^  ^  mmol) and a-naphthyl(benzyl-L-alaninyl)
/ '  p' N N
phosphorochloridate (93, 0.35 mL of solution 1M
in THF, 0.345 mmol). The crude product was 
O ^ O
purified by column chromatography, using as 
'— ' eluent CHCl3/MeOH (95:5). The pure product
was a white solid (20 mg, 24%).
6 P (d4-CH3OH): 4.34, 4.18; 6„ (^-CH3OH): 8.50 (1H, s, H2-adenosine), 8.17 (1H, s, 
H8-adenosine), 7.90 (1H, m, CH-naphthyl), 7.71 (1H, m, CH-naphthyl), 7.69 (1H, 
CH-benzyl), 7.55-7.50 (3H, m, CH-naphthyl, CH-benzyl), 7.42-7.27 (6H, m, CH- 
naphthyl, CH-benzyl), 6.25 (1H, d, H l’-adenosine), 5.10 (2H, s, CH2-benzyl), 4.61 
(1H, m, H3’-adenosine), 4.41 (1H, m, H4’-adenosine), 4.15 (1H, m, CHa), 3.95 (1H, 
m, H5’-adenosine, J= 12.2 Hz), 3.85 (1H, m, H5’-adenosine, J= 12.2 Hz), 2.12-2.03 
(2H, m, CH2-cyclopentyl), 1.79-1.72 (6H, m, CH2-cyclopentyl), 1.37 (3H, d, CH3- 
alanine, J= 7.2 Hz), 0.89 (3H, s, CH3-2’-adenosine).
Synthesis of /?-2’-methyladenosine 5’-0-[a-naphthyl(benzyl-L-alaninyl)]
phosphate (222)
NH,
^  0 </Ox NH ^
p' N N
OH OH
Prepared according to Standard Procedure C3, from 2’, 3’-0,<2-cyclopentylidene-/J- 
2’-methyladenosine 5’-0-[a-naphthyl(benzyl-L-alaninyl)] phosphate (30 mg, 0.036
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mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5) 
followed by a semi-preparative HPLC. The pure product was a white solid (5 mg, 
21%).
6P (</4-CH3OH): 4.25, 4.14; d H (^-CH 3OH): 8.04-7.95 (3H, m, H2-adenosine, H8- 
adenosine, CH-naphthyl), 7.68 (1H, m, CH-naphthyl), 7.48 (1H, m, CH-naphthyl), 
7.32-7.23 (3H, m, CH-naphthyl, CH-benzyl), 7.16 (1H, m, CH-naphthyl), 7.05 (6H, 
m, CH-naphthyl, CH-benzyl), 5.88 (1H, d, H l’-adenosine, J= 2.9 Hz), 4.85-4.65 (2H, 
m, CH2-benzyl), 4.37-4.35 (2H, d, H3’-adenosine, H4’-adenosine), 4.06 (2H, m, H5’- 
adenosine), 3.88-3.83 (1H, m, CHa), 1.35 (3H, m, CH3-alanine), 0.88 (3H, s, CH3-2’- 
adenosine).
MS (ES) m/e: 671.2 (MNa+, 100%); Accurate mass: QjH^NgOgNaP required 
671.1990, found 671.1995.
Synthesis of 2’, 3,-0,0-cyclopentylidene-j8-2,-methyladenosine 5’-0-  
[phenyl(ethyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure C2, 
from 2’, 3’-0,0-cyclopentylidene-)8-2’- 
methyladenosine (230, 60 mg, 0.172 mmol), 
lBuMgCl (0.5 mL, 1M solution in THF, 0.519 
mmol) and a-naphthyl(ethyl-L-alaninyl) 
phosphorochloridate (200, 0.5 mL of solution 1M 
in THF, 0.519 mmol). The crude product was 
purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was a white solid (30 mg, 26%).
5 P 04-CH3OH): 4.31, 4.26; d„ (^-C H 3OH): 8.19 (1H, s, H2-adenosine), 8.10 (1H, s, 
H8-adenosine), 7.88 (1H, m, CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.57-7.52 
(4H, m, CH-naphthyl), 7.45-7.43 (1H, m, CH-naphthyl), 6.26 (1H, m, H l’-adenosine), 
4.56-4.42 (4H, m, H4’-adenosine, H3’-adenosine, 2 H5’-adenosine), 4.08 (3H, m, 
CHa, CH2-ethyl), 2.21-2.09 (2H, m, CH2-cyclopentyl), 1.76-1.71 (6H, m, CH2- 
cyclopentyl), 1.35 (3H, d, CH3-alanine, J= 6.9 Hz), 1.25 (3H, m, CH3-ethyl), 0.95 
(3H, s, CH32’-adenosine).
NH
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Synthesis of /7-2’-methyladenosine 5’-0-[a-naphthyl(ethyl-L-alaninyl)]
phosphate (223)
OH OH
Prepared according to Standard Procedure C3, from 2 ’, 3’-0,0-cyclopentylidene-^- 
2 ’-methyladenosine 5’-0-[a-naphthyl(ethyl-L-alaninyl)] phosphate (30 mg, 0.036 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5) 
followed by a semi-preparative HPLC. The pure product was a a white solid (4 mg, 
19%).
d P (rf4-CH3OH): 4.23, 4.20; 6 H (</4-CH3OH): 8.24-8.19 (3H, m, H2-adenosine, H8- 
adenosine, CH-naphthyl), 7.90 (1H, m, CH-naphthyl), 7.63 (1H, CH-naphthyl), 7.53 
(4H, m, CH-naphthyl), 7.41 (1H, m, CH-naphthyl), 6.12 (1H, d, H l’-adenosine, J= 
2.1 Hz), 4.61-4.59 (2H, d, H3’-adenosine, H4’-adenosine), 4.30 (1H, m, H5’- 
adenosine), 4.02-3.99 (3H, m, CHa, CHr ethyl), 1.37 (3H, m, CH3-alanine), 1.27 (3H, 
m, CH3-ethyl), 0.95 (3H, s, CH3-2’-adenosine).
MS (ES) m/e: 609.2 (MNa+, 100%); Accurate mass: C26H31N60 8NaP required 
609.1846, found 609.1839.
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Synthesis of 2’, 3,-0,O-cyclopentylidene-/J-2,-methyladenosine 5’-0-[phenyl(te/t-
butyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure C2, 
from 2’, 3’-0,0-cyclopentylidene-^-2’- 
methyladenosine (230, 60 mg, 0.172 mmol), 
'BuMgCl (0.51 mL, 1M solution in THF, 0.51 
mmol) and a-naphthyl(terr-butyl-L-alaninyl) 
phosphorochloridate (201, 0.5 mL of solution 1M 
in THF, 0.519 mmol). The crude product was 
purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was a white solid (27 mg, 22%).
6 P (^-CH3OH): 4.37, 4.28; 6H (^-CH3OH): 8.21 (1H, s, H2-adenosine), 8.13 (1H, s, 
H8-adenosine), 7.85 (1H, m, CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.57-7.52 
(4H, m, CH-naphthyl), 7.43-7.41 (1H, m, CH-naphthyl), 6.25 (1H, m, H I’-adenosine), 
4.55-4.40 (4H, m, H4’-adenosine, H3’-adenosine, 2 H5’-adenosine), 4.05 (1H, m, 
CHa), 2.20-2.12 (2H, m, CH2-cyclopentyl), 1.79-1.69 (6H, m, CH2-cyclopentyl), 1.36 
(9H, CH3-terf-butyl), 1.25 (3H, d, CH3-alanine, /=  6.9 Hz), 0.%  (3H, s, CH3-2’- 
adenosine).
Synthesis of /5-2,-methyladenosine 5’-6L[a-naphthyl(terMmtyl-L-alaninyl)]
phosphate (224)
OH OH
Prepared according to Standard Procedure C3, from 2’, 3’-O,0-cyclopentylidene-/?- 
2’-methyladenosine 5’-0-[a-naphthyl(terf-butyl-L-alaninyl)] phosphate (27 mg, 0.039 
mmol), and 10 mL of a solution 80% of HCOOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (95:5) 
followed by a semi-preparative HPLC. The pure product was a white solid (10 mg, 
41%).
269
Plinio Perrone Chapter Seven
6P (<i4-CH3OH): 4.20, 4.08; d H (d4-CH3OH): 8.20-8.15 (3H, m, H2-adenosine, H8- 
adenosine, CH-naphthyl), 7.81 (1H, m, CH-naphthyl), 7.60 (1H, CH-naphthyl), 7.54 
(4H, m, CH-naphthyl), 7.39 (1H, m, CH-naphthyl), 6.15 (1H, d, H I’-adenosine), 4.63- 
4.57 (2H, d, H3’-adenosine, H4’-adenosine), 4.31 (1H, m, H5’-adenosine), 4.00-3.97 
(1H, m, CHa), 1.39 (9H, CH3-terM>utyl), 1.27 (3H, m, CH3-alanine), 0.97 (3H, s, 
CH3-2’-adenosine).
270
Plinio Perrone Chapter Seven
7.12 Synthesis of 2’-methylguanosine phosphoramidates.
NH,
Synthesis of 2’, 3’-0,0-isopropylidyn-/5-2’-methylguanosine 5’-0-[a- 
naphthyl(benzyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure 
C2, from 2’, 3’-O,0-isopropylidene-)6-2’- 
methylguanosine (230, 170 mg, 0.503
mmol), 'BuMgCl (1.0 mL, 1M solution in 
THF, 1.006 mmol) and a-naphthyl(benzyl- 
L-alaninyl) phosphorochloridate (93, 1.0 mL 
of solution 1M in THF, 1.006 mmol). The 
crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (95:5). The pure product was a white 
solid (70 mg, 19%).
SP (^-C H 3OH): 4.53, 4.40; 6 H (^-CH3OH): 8.28 (1H, s, H8-guanosine), 7.84 (1H, m, 
CH-naphthyl), 7.77-7.71 (1H, m, CH-benzyl), 7.55-7.49 (4H, m, CH-naphthyl, CH- 
benzyl), 7.44-7.29 (6H, m, CH-naphthyl, CH-benzyl), 6.06 (1H, d, H l’-guanosine),
5.10 (2H, s, CH2-benzyl), 4.59 (1H, m, H3’-guanosine), 4.52-4.45 (1H, m, H4’- 
guanosine), 4.34 (2H, H5’guanosine), 4.14 (1H, m, CHa), 1.59 (3H, d, CH3- 
isopropylidene, J -  10.4 Hz), 1.37 (6H, d, CH3-alanine, CH3-isopropylidene), 0.99 
(3H, d, CH3-2’-guanosine, J= 20.11 Hz).
Synthesis of /?-2’-methylguanosine 5’-0-Ia-naphthyl(benzyl-L-alaninyl)]
phosphate (233)
°V NH nX  A
oA 0 NH,
OH OH
Prepared according to Standard Procedure C4, from 2’, 3’-O,0-isopropylidene-/J-2’- 
methyl-guanosine 5 ’-0-[a-naphthyl(benzyl-L-alaninyl)] phosphate (70 mg, 0.098
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mmol), and 10 mL of a solution 60% of CH3COOH in water at 90 °C for 15 hours. 
The crude product was purified by column chromatography, using as eluent for the 
first CHCl3/MeOH (85:5) followed by a semi-preparative HPLC. The pure product 
was a white solid (12 mg, 18%).
5 P (^-C H 3OH): 4.25, 4.14; dH (^-CH3OH): 8.17 (1H, m, H8-guanosine), 7.88 (1H, 
m, CH-naphthyl), 7.79 (1H, m, CH-naphthyl), 7.53 (2H, m, CH-naphthyl, CH- 
benzyl), 7.42-7.40 (1H, m, CH-naphthyl), 7.36-7.21 (7H, m, CH-naphthyl, CH- 
benzyl), 6.05 (1H, d, H l’-guanosine, J= 8.4 Hz), 5.15-4.90 (2H, m, CH2-benzyl), 
4.58-4.49 (2H, d, H3’-guanosine, H4’-guanosine), 4.44-4.34 (2H, m, H5’-guanosine), 
4.17-4.11 (1H, m, CHa), 1.37 (3H, m, CH3-alanine), 1.00 (3H, s, CH3-2’-guanosine). 
MS (ES) m/e: 687.2 (MNa+, 100%); Accurate mass: QjH^NgC^NaP required 
687.1954, found 687.1944.
Synthesis of 2’, 3’-0,O-isopropylidene-/?-2’-methylguanosine 5’-0-[phenyl(ethyl- 
L-alaninyl)] phosphate
Prepared according to Standard Procedure 
C2, from 2’, 3’-0,0-isopropylidene-/?-2’- 
methylguanosine (230, 220 mg, 0.652 
mmol), ‘BuMgCl (1.3 mL, 1M solution in 
THF, 1.30 mmol) and a-naphthyl(ethyl-L- 
alaninyl) phosphorochloridate (207, 1.3 mL 
of solution 1M in THF, 1.30 mmol). The 
crude product was purified by column chromatography, using as eluent CHCl3/MeOH 
(95:5). The pure product was a white solid (35 mg, 9%).
d P (<^-CH3OH): 4.41, 4.32; d H (^-C H 3OH): 8.18 (1H, s, H8-guanosine), 7.88 (1H, m, 
CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.59-7.52 (4H, m, CH-naphthyl), 7.46-
7.42 (1H, m, CH-naphthyl), 6.08 (1H, d, H l’-guanosine), 4.62-4.40 (4H, m, H3’- 
guanosine, H4’-guanosine, H5’guanosine), 4.11-4.09 (3H, m, CHa, CH2-ethyl), 1.59 
(3H, d, CH3-isopropylidene, J= 13.2 Hz), 1.37 (6H, m, CH3-alanine, CH3- 
isopropylidene), 1.20 (3H, m, CH3-ethyl), 1.00 (3H, m, CH3-2’-guanosine).
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Synthesis of /?-2’-methyl-guanosine 5’-0-[a-naphthyl(ethyl-L-alaninyl)]
phosphate (234)
OH OH
Prepared according to Standard Procedure C4, from 2’, 3’-0,CMsopropylidene-/2-2’- 
methylguanosine 5’-0-[a-naphthyl(ethyl-L-alaninyl)] phosphate (35 mg, 0.054 
mmol), and 10 mL of a solution 60% of CH3COOH in water at 90 °C for 15 hours. 
The crude product was purified by column chromatography, using as eluent for the 
first CHCl3/MeOH (85:5) followed by a semi-preparative HPLC. The pure product 
was a white solid (10 mg, 31%).
dP (<i4-CH3OH): 4.25, 4.14; 6H (^-CH 3OH): 8.18 (1H, m, H8-guanosine), 7.87 (1H, 
m, CH-naphthyl), 7.71 (1H, m, CH-naphthyl), 7.53 (4H, m, CH-naphthyl), 7.51-7.40 
(1H, m, CH-naphthyl), 5.93 (1H, d, H l’-guanosine), 4.62-4.57 (2H, m, H3’- 
guanosine, H4’-guanosine), 4.24 (2H, m, H5’guanosine), 4.03-3.98 (3H, m, CHa, 
CH2-ethyl), 1.31 (3H, d, CH3-alanine, J= 7.9 Hz), 1.15 (3H, m, CH3-ethyl), 1.00 (3H, 
m, CH3-2’-guanosine).
MS (ES) m/e: 625.3 (MNa+, 100%); Accurate mass: C26H31N60 9NaP required 
625.1795, found 6251788.
Anal. Calc, for C ^ N ^ P :  C 51.83%, H 5.19%, N 13.95%. Found: C 51.86%, H 
5.10%, N 12.04%.
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Synthesis of 2’, 3’-0,O-isopropylidene-/J-2’-methylguanosine 5’-0-[phenyl(terf-
butyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure 
C2, from 2’, 3’-0,0-isopropylidene-/£-2’- 
methylguanosine (230, 120 mg, 0.355 
mmol), ‘BuMgCl (0.70 mL, 1M solution in 
THF, 0.711 mmol) and a-naphthyl(terf- 
butyl-L-alaninyl) phosphorochloridate (208, 
0.70 mL of solution 1M in THF,
0.711mmol). The crude product was purified by column chromatography, using as 
eluent CHCl3/MeOH (95:5). The pure product was a white solid (24 mg, 10%).
6 P (^-CH3OH): 4.41, 4.32; S„ (rf4-CH3OH): 8.20 (1H, s, H8-guanosine), 7.89 (1H, m, 
CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.59-7.54 (4H, m, CH-naphthyl), 7.49-
7.42 (1H, m, CH-naphthyl), 6.07 (1H, d, H l’-guanosine), 4.62-4.40 (4H, m, H3’- 
guanosine, H4’-guanosine, 2 H5’guanosine), 3.99-3.86 (1H, m, CHa), 1.58 (3H, d, 
CH3-isoprpylidene, J= 13.7 Hz), 1.44 (9H, s, CH3-terr-butyl), 1.38-1.34 (6H, m, CH3- 
alanine, CH3-isopropylidene), 1.01 (3H, m, CH32’-guanosine).
NH
NH
Synthesis of /J-2’-methylguanosine 5’-0-[a-naphthyl(te/?-butyl-L-alaninyl)]
phosphate (235)
O^T o
OH OH
Prepared according to Standard Procedure C4, from 2 ’, 3’-0,O-isopropylidene-/3-2’- 
methylguanosine 5’-0-[a-naphthyl(ter/-butyl-L-alaninyl)] phosphate (24 mg, 0.036 
mmol), and 10 mL of a solution 60% of CH3COOH in water. The crude product was 
purified by column chromatography, using as eluent for the first CHCl3/MeOH (85:5) 
followed by a semi-preparative HPLC. The pure product was a white solid (4 mg, 
17%).
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5P (^-C H 3OH): 4.23, 4.10; S„ (^-C H 3OH): 8.20 (1H, m, H8-guanosine), 7.85 (1H, 
m, CH-naphthyl), 7.67 (1H, m, CH-naphthyl), 7.57 (4H, m, CH-naphthyl), 7.53-7.43 
(1H, m, CH-naphthyl), 6.00 (1H, d, H l’-guanosine), 4.61-4.55 (2H, m, H3’- 
guanosine, H4’-guanosine), 4.25 (2H, m, H5’guanosine), 4.00-3.97 (1H, m, CHa),
1.47 (9H, s, CHr fm-butyl), 1.36 (3H, m, CH3-alanine), 1.00 (3H, m, CH32’- 
guanosine).
Synthesis of 2’, 3’-0,0-isopropylidene-/?-2’-methylguanosine 5’-0- 
[phenyl(benzyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure C2, 
from 2’, 3’-0,0-isopropylidene-jS-2’- 
methylguanosine (230, 120 mg, 0.355 mmol), 
‘BuMgCl (1.0 mL, 1M solution in THF, 1.07 
mmol) and phenyl(benzoxy-L-alaninyl) 
phosphorochloridate (132, 1.0 mL of solution 
1M in THF, 1.07 mmol). The crude product 
was purified by column chromatography, 
using as eluent CHCl3/MeOH (9:1) followed by semi-preparative HPLC. The pure 
product was a white solid (40 mg, 17%).
d P (^-CH 3OH): 4.63, 4.37; 6H (^-CH3OH): 7.85 (1H, d, H8-guanosine, J= 5.7 Hz),
7.36-7.34 (5H, m, CH-phenyl, CH-benzyl), 7.33-7.26 (5H, m, CH-benzyl, CH- 
phenyl), 6.02 (1H, d, H l’-guanosine, J= 11.4 Hz), 5.16 (2H, s, CH2-benzyl), 4.67 (1H, 
d, H3’-guanosine, J= 1.1 Hz), 4.54-4.43 (1H, m, H4’-guanosine), 4.31 (2H, 
H5’guanosine), 4.10 (1H, m, CHa), 1.61 (3H, s, CH3-isopropylidene), 1.53 (3H, s, 
CH3-isopropylidene), 1.39 (3H, d, CH3-alanine, J= 8.4 Hz), 1.00 (3H, s, CH3-2’- 
guanosine).
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Synthesis of /?-2’-methylguanosine 5’-0-[phenyl (benzyl-L-alaninyl)] phosphate
(238)
Prepared according to Standard Procedure C4, from 2’, 3’-0,0-isopropylidene-/J-2’- 
methylguanosine 5’-0-[phenyl(benzyl-L-alaninyl)] phosphate (40 mg, 0.061 mmol), 
and 10 mL of a solution 60% of CH3COOH in water at 90° C for 15 hours. The crude 
product was purified by column chromatography, using as eluent for the first 
CHCl3/MeOH (85:5) followed by a semi-preparative HPLC. The pure product was a 
white solid (15 mg, 40%).
6 P (^-CH 3OH): 4.27, 4.10; 6„ (^-CH3OH): 7.92 (1H, d, H8-guanosine, J= 8.3 Hz),
7.37-7.29 (5H, m, CH-phenyl, CH-benzyl), 7.25-7.18 (5H, m, CH-benzyl, CH- 
phenyl), 5.96 (1H, d, H l’-guanosine, J= 2.3 Hz), 5.15 (2H, s, CH2-benzyl), 4.43-4.35 
(2H, m, H3’-guanosine, H4’-guanosine), 4.33-4.28 (1H, m, H5’-guanosine), 4.24-4.19 
(1H, m, H5’-guanosine), 4.08-3.93 (1H, m, CHa), 1.35 (3H, m, CH3-alanine), 1.24 
(3H, s, CH3-2’-guanosine).
Synthesis of 2’, 3,-0,0-isopropyIidene-/?-2,-methylguanosine 5’-0-[a-naphthyl 
(methyl-L-alaninyl)] phosphate
of solution 1M in THF, 0.96 mmol). The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (97:3). The pure product was a white 
solid (26 mg, 11%).
OH OH
Prepared according to Standard Procedure 
C2, from 2’, 3’-0,<9-isopropylidene-/?-2’- 
methyl-guanosine (230, 130 mg, 0.385 
mmol), ‘BuMgCl (0.96 mL, 1M solution in 
THF, 0.96 mmol) and a-naphthyl(methyl-L- 
alaninyl) phosphorochloridate (231, 0.96 mL
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6 P (^-CH 3OH): 4.51, 4.45; d H MrCH3OH): 8.21 (1H, d, H8-guanosine, 7= 7.5 Hz),
7.91-7.89 (1H, m, CH-naphthyl), 7.73 (1H, m, CH-naphthyl), 7.58-7.53 (4H, m, CH- 
naphthyl), 7.48-7.45 (1H, m, CH-naphthyl), 6.09 (1H, d, H l’-guanosine, 7= 7.4 Hz), 
4.63 (1H, d, H3’-guanosine, 7= 3.0 Hz), 4.57-4.53 (1H, m, H4’-guanosine), 4.43-4.41 
(2H, m, H5’guanosine), 4.12-4.05 (1H, m, CHa), 3.62 (3H, d, CH3-methyl, 7= 10.1 
Hz), 1.59 (3H, d, CH3-isopropylidene, 7= 7.9 Hz), 1.40 (3H, d, CH3-alanine, 7= 3.4 
Hz), 1.35 (3H, d, CH3-isopropylidene, 7= 7.2 Hz), 1.05 (3H, d, CH3-2’-guanosine, 7=
7.0 Hz).
Synthesis of /S-2’-methylguanosine 5’-0 -[a -naphthyl(methyl-L-alaninyl)]
phosphate (236)
Prepared according to Standard Procedure C4, from 2’, 3’-0,0-isopropylidene-/3-2’- 
methylguanosine 5’-0-[a-naphthyl(methyl-L-alaninyl)] phosphate (26 mg, 0.041 
mmol), and 10 mL of a solution 60% of CH3COOH in water at 90° C for 15 hours. 
The crude product was purified by column chromatography, using as eluent for the 
first CHCl3/MeOH (92:8). The pure product was a white solid (4 mg, 17%). 
d P (^-CH3OH): 4.35, 4.26; dH (^-CH 3OH): 8.20 (1H, d, H8-guanosine, 7= 5.8 Hz),
7.91-7.87 (2H, m, CH-naphthyl), 7.70 (1H, m, CH-naphthyl), 7.58-7.52 (3H, m, CH- 
naphthyl), 7.50-7.41 (1H, m, CH-naphthyl), 5.93 (1H, s, H l’-guanosine), 4.58-4.56 
(2H, m, H3’-guanosine, H4’-guanosine), 4.29-4.21 (2H, m, H5’guanosine), 4.06-4.03 
(1H, m, CHa), 3.56 (3H, d, CH3-methyl, 7= 1.7 Hz), 1.31 (3H, d, CH3-alanine, 7= 7.4 
Hz), 1.00 (3H, d, CH3-2’-guanosine, 7= 12.4 Hz).
OH OH
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Synthesis of 2’, 3,-0/Msopropylidene-/J-2,-methylguanosine 5’-0-
[phenyl(methyl-L-alaninyl)] phosphate
Prepared according to Standard Procedure C2,
O"" O
N from 2’, 3’-0,O-isopropylidene-/?-2’-
O // NH
On NH ^  methylguanosine (230, 140 mg, 0.415 mmol),
O' No —| 0  'BuMgCl (1.04 mL, 1M solution in THF, 1.04
> |r mmol) and phenyl(methyl-L-alaninyl)
phosphorochloridate (128, 1.04 mL of
solution 1M in THF, 1.04 mmol). The crude product was purified by column 
chromatography, using as eluent CHCl3/MeOH (97:3). The pure product was a white 
solid (21 mg, 9%).
dP (^-CH 3OH): 4.09, 3.91; 6„ (d4-CU3OU): 7.88, 7.80 (1H, d, H8-guanosine), 7.41- 
7.35 (2H, m, CH-phenyl), 7.30-7.20 (3H, m, CH-phenyl), 6.14 (1H, d, H l’-guanosine, 
J= 11.8 Hz), 4.69 (1H, d, H3’-guanosine, J= 2.9 Hz), 4.49-4.39 (3H, m, H4’- 
guanosine, H5’guanosine), 4.04-3.99 (1H, m, CHa), 3.70 (3H, d, CH3-methyl, J=
12.7 Hz), 1.63 (3H, d, CH3-isopropylidene, J -  2.3 Hz), 1.44 (3H, d, CH3-alanine, J=
3.1 Hz), 1.41 (3H, d, CH3-isopropylidene, J -  6.8 Hz), 1.10 (3H, d, CH3-2’-guanosine, 
J= 6.5 Hz).
Synthesis of /?-2’-methylguanosine 5’-0-[phenyl(methyl-L-alaninyl)] phosphate
(239)
OH OH
Prepared according to Standard Procedure C4, from 2’, 3’-0,6Msopropylidene-/3-2’- 
methylguanosine 5’-0-[phenyl(methyl-L-alaninyl)] phosphate (21 mg, 0.036 mmol), 
and 10 mL of a solution 60% of CH3COOH in water at 90° C for 15 hours. The crude 
product was purified by column chromatography, using as eluent for the first 
CHCI3/MeOH (92:8). The pure product was a white solid (7 mg, 36%).
6P (J4-CH3OH): 4.15, 3.90; dH (^-CH3OH): 8.96 (1H, br, H8-guanosine), 7.40-7.35 
(2H, m, CH-phenyl), 7.29-7.20 (3H, m, CH-phenyl), 6.08 (1H, d, H l’-guanosine, J=
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8.5 Hz), 4.55-4.49 (2H, m, H3’-guanosine, H4’-guanosine), 4.26 (1H, m, 
H5’guanosine), 4.17-4.11 (1H, m, H5’-guanosine), 4.00-3.97 (1H, m, CHa), 3.73 
(3H, d, CH3-methyl, J= 11.1 Hz), 1.36 (3H, d, CH3-alanine, 7= 7.1 Hz), 1.14 (3H, d, 
CH3-2’-guanosine, J= 4.9 Hz).
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